0000885725-24-000068.txt : 20240801 0000885725-24-000068.hdr.sgml : 20240801 20240801161614 ACCESSION NUMBER: 0000885725-24-000068 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240801 DATE AS OF CHANGE: 20240801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 241166927 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 10-Q 1 bsx-20240630.htm 10-Q bsx-20240630
000088572512/312024Q2falseP1YP2Y727iso4217:USDxbrli:sharesxbrli:sharesiso4217:USDxbrli:pureiso4217:HKDxbrli:sharesutr:Rateiso4217:EURbsx:derivative_instrumentbsx:reportablesegmentsbsx:business00008857252024-01-012024-06-300000885725us-gaap:CommonStockMember2024-01-012024-06-300000885725bsx:SeniorNotedue2027Member2024-01-012024-06-3000008857252024-07-3000008857252024-04-012024-06-3000008857252023-04-012023-06-3000008857252023-01-012023-06-3000008857252024-06-3000008857252023-12-310000885725us-gaap:CommonStockMember2024-06-300000885725us-gaap:PreferredStockMember2024-03-310000885725us-gaap:PreferredStockMember2023-03-310000885725us-gaap:PreferredStockMember2023-12-310000885725us-gaap:PreferredStockMember2022-12-310000885725us-gaap:PreferredStockMember2024-04-012024-06-300000885725us-gaap:PreferredStockMember2023-04-012023-06-300000885725us-gaap:PreferredStockMember2024-01-012024-06-300000885725us-gaap:PreferredStockMember2023-01-012023-06-300000885725us-gaap:PreferredStockMember2024-06-300000885725us-gaap:PreferredStockMember2023-06-300000885725us-gaap:CommonStockMember2024-03-310000885725us-gaap:CommonStockMember2023-03-3100008857252022-12-310000885725us-gaap:CommonStockMember2024-04-012024-06-300000885725us-gaap:CommonStockMember2023-04-012023-06-300000885725us-gaap:CommonStockMember2024-01-012024-06-300000885725us-gaap:CommonStockMember2023-01-012023-06-300000885725us-gaap:CommonStockMember2023-06-3000008857252023-06-300000885725us-gaap:CommonStockMember2023-12-310000885725us-gaap:CommonStockMember2022-12-310000885725us-gaap:TreasuryStockCommonMember2024-03-310000885725us-gaap:TreasuryStockCommonMember2023-03-310000885725us-gaap:TreasuryStockCommonMember2023-12-310000885725us-gaap:TreasuryStockCommonMember2022-12-310000885725us-gaap:TreasuryStockCommonMember2024-04-012024-06-300000885725us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000885725us-gaap:TreasuryStockCommonMember2024-01-012024-06-300000885725us-gaap:TreasuryStockCommonMember2023-01-012023-06-300000885725us-gaap:TreasuryStockCommonMember2024-06-300000885725us-gaap:TreasuryStockCommonMember2023-06-300000885725us-gaap:AdditionalPaidInCapitalMember2024-03-310000885725us-gaap:AdditionalPaidInCapitalMember2023-03-310000885725us-gaap:AdditionalPaidInCapitalMember2023-12-310000885725us-gaap:AdditionalPaidInCapitalMember2022-12-310000885725us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000885725us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000885725us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300000885725us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300000885725us-gaap:AdditionalPaidInCapitalMember2024-06-300000885725us-gaap:AdditionalPaidInCapitalMember2023-06-300000885725us-gaap:RetainedEarningsMember2024-03-310000885725us-gaap:RetainedEarningsMember2023-03-310000885725us-gaap:RetainedEarningsMember2023-12-310000885725us-gaap:RetainedEarningsMember2022-12-310000885725us-gaap:RetainedEarningsMember2024-04-012024-06-300000885725us-gaap:RetainedEarningsMember2023-04-012023-06-300000885725us-gaap:RetainedEarningsMember2024-01-012024-06-300000885725us-gaap:RetainedEarningsMember2023-01-012023-06-300000885725us-gaap:RetainedEarningsMember2024-06-300000885725us-gaap:RetainedEarningsMember2023-06-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000885725us-gaap:NoncontrollingInterestMember2024-03-310000885725us-gaap:NoncontrollingInterestMember2023-03-310000885725us-gaap:NoncontrollingInterestMember2023-12-310000885725us-gaap:NoncontrollingInterestMember2022-12-310000885725us-gaap:NoncontrollingInterestMember2024-04-012024-06-300000885725us-gaap:NoncontrollingInterestMember2023-04-012023-06-300000885725us-gaap:NoncontrollingInterestMember2024-01-012024-06-300000885725us-gaap:NoncontrollingInterestMember2023-01-012023-06-300000885725us-gaap:NoncontrollingInterestMember2024-06-300000885725us-gaap:NoncontrollingInterestMember2023-06-300000885725bsx:SilkMedicalMember2024-06-180000885725bsx:SilkMedicalMember2024-06-182024-06-180000885725bsx:AxonicsMember2024-01-080000885725bsx:AxonicsMember2024-01-082024-01-080000885725bsx:ApolloMember2023-04-040000885725bsx:ApolloMember2023-04-042023-04-040000885725bsx:AcotecMember2023-02-200000885725bsx:AcotecMember2023-02-202023-02-200000885725bsx:AcotecMember2024-01-012024-06-300000885725bsx:ApolloMember2024-01-012024-06-300000885725bsx:AcotecMember2024-06-300000885725bsx:ApolloMember2024-06-300000885725bsx:AcotecMember2023-02-200000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:AcotecMember2024-06-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:AcotecMember2024-01-012024-06-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:AcotecMembersrt:WeightedAverageMember2024-06-300000885725bsx:AcotecMemberus-gaap:CustomerRelationshipsMember2024-06-300000885725bsx:AcotecMemberus-gaap:CustomerRelationshipsMember2024-01-012024-06-300000885725bsx:AcotecMemberus-gaap:CustomerRelationshipsMembersrt:WeightedAverageMember2024-06-300000885725bsx:AcotecMemberus-gaap:OtherIntangibleAssetsMember2024-06-300000885725bsx:AcotecMemberus-gaap:OtherIntangibleAssetsMember2024-01-012024-06-300000885725bsx:AcotecMemberus-gaap:OtherIntangibleAssetsMembersrt:WeightedAverageMember2024-06-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:ApolloMember2024-06-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:ApolloMember2024-01-012024-06-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:ApolloMembersrt:WeightedAverageMember2024-06-300000885725bsx:ApolloMemberus-gaap:CustomerRelationshipsMember2024-06-300000885725bsx:ApolloMemberus-gaap:CustomerRelationshipsMember2024-01-012024-06-300000885725bsx:ApolloMemberus-gaap:CustomerRelationshipsMembersrt:WeightedAverageMember2024-06-300000885725bsx:AllBusinessAcquisitionsMember2024-06-300000885725bsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-06-300000885725srt:MinimumMemberbsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-06-300000885725bsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMember2024-06-300000885725bsx:RevenueBasedPaymentsMembersrt:WeightedAverageMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-06-300000885725us-gaap:TechnologyBasedIntangibleAssetsMember2024-06-300000885725us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000885725us-gaap:PatentsMember2024-06-300000885725us-gaap:PatentsMember2023-12-310000885725us-gaap:OtherIntangibleAssetsMember2024-06-300000885725us-gaap:OtherIntangibleAssetsMember2023-12-310000885725us-gaap:GoodwillMember2024-06-300000885725us-gaap:GoodwillMember2023-12-310000885725us-gaap:InProcessResearchAndDevelopmentMember2024-06-300000885725us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2024-06-300000885725us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000885725bsx:MedsurgMember2023-12-310000885725bsx:CardiovascularMember2023-12-310000885725bsx:MedsurgMember2024-01-012024-06-300000885725bsx:CardiovascularMember2024-01-012024-06-300000885725bsx:MedsurgMember2024-06-300000885725bsx:CardiovascularMember2024-06-300000885725bsx:December2027NotesMember2023-12-310000885725bsx:December2027NotesMember2024-06-300000885725us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-01-012024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberbsx:ForeigncurrencydenominatedindebtMember2024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberbsx:ForeigncurrencydenominatedindebtMember2023-12-310000885725us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-06-300000885725us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-06-300000885725us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-06-300000885725srt:MinimumMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembersrt:MaximumMember2024-01-012024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-04-012024-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2024-04-012024-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberbsx:ForeigncurrencydenominatedindebtMember2024-04-012024-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-04-012024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2023-04-012023-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2023-04-012023-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberbsx:ForeigncurrencydenominatedindebtMember2023-04-012023-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2023-04-012023-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-01-012024-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberbsx:ForeigncurrencydenominatedindebtMember2024-01-012024-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2023-01-012023-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberbsx:ForeigncurrencydenominatedindebtMember2023-01-012023-06-300000885725us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2023-01-012023-06-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2024-04-012024-06-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-06-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-06-300000885725us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-06-300000885725us-gaap:InterestExpenseMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2024-06-300000885725us-gaap:InterestExpenseMemberus-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-06-300000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2024-04-012024-06-300000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2023-04-012023-06-300000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2024-01-012024-06-300000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2023-01-012023-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMember2024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMember2024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000885725us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-06-300000885725us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2024-06-300000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-06-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-06-300000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-06-300000885725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000885725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000885725us-gaap:FairValueMeasurementsRecurringMember2024-06-300000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310000885725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000885725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000885725us-gaap:FairValueMeasurementsRecurringMember2023-12-310000885725us-gaap:FairValueInputsLevel3Member2024-06-300000885725bsx:LicensingarrangementassetsMember2024-06-300000885725bsx:LicensingarrangementassetsMembersrt:WeightedAverageMember2024-06-300000885725bsx:LicensingarrangementliabilitiesMembersrt:MinimumMember2024-06-300000885725bsx:LicensingarrangementliabilitiesMembersrt:MaximumMember2024-06-300000885725bsx:LicensingarrangementliabilitiesMembersrt:WeightedAverageMember2024-06-300000885725bsx:LicensingarrangementassetsMember2024-01-012024-06-300000885725bsx:LicensingarrangementliabilitiesMember2024-01-012024-06-300000885725bsx:March2025NotesMember2024-06-300000885725bsx:March2025NotesMember2023-12-310000885725bsx:June2025NotesMember2024-06-300000885725bsx:June2025NotesMember2023-12-310000885725bsx:March2026NotesMember2024-06-300000885725bsx:March2026NotesMember2023-12-310000885725bsx:March2028SeniorNotesMember2024-06-300000885725bsx:March2028SeniorNotesMember2023-12-310000885725bsx:March2028NotesMember2024-06-300000885725bsx:March2028NotesMember2023-12-310000885725bsx:March2029NotesMember2024-06-300000885725bsx:March2029NotesMember2023-12-310000885725bsx:March2029EuroSeniorNotesMember2024-06-300000885725bsx:March2029EuroSeniorNotesMember2023-12-310000885725bsx:June2030NotesMember2024-06-300000885725bsx:June2030NotesMember2023-12-310000885725bsx:March2031NotesMember2024-06-300000885725bsx:March2031NotesMember2023-12-310000885725bsx:March2032EuroSeniorNotesMember2024-06-300000885725bsx:March2032EuroSeniorNotesMember2023-12-310000885725bsx:March2034NotesMember2024-06-300000885725bsx:March2034NotesMember2023-12-310000885725bsx:November2035NotesMember2024-06-300000885725bsx:November2035NotesMember2023-12-310000885725bsx:March2039NotesMember2024-06-300000885725bsx:March2039NotesMember2023-12-310000885725bsx:January2040NotesMember2024-06-300000885725bsx:January2040NotesMember2023-12-310000885725bsx:March2049NotesMember2024-06-300000885725bsx:March2049NotesMember2023-12-310000885725us-gaap:SeniorNotesMember2024-06-300000885725us-gaap:SeniorNotesMember2023-12-310000885725us-gaap:CapitalLeaseObligationsMember2024-06-300000885725us-gaap:CapitalLeaseObligationsMember2023-12-310000885725bsx:November2035NotesMemberbsx:CreditRatingAOrA3OrHigherMember2024-06-300000885725us-gaap:RevolvingCreditFacilityMember2021-05-100000885725us-gaap:RevolvingCreditFacilityMember2023-12-310000885725us-gaap:RevolvingCreditFacilityMember2024-06-300000885725bsx:CurrentRequirementMember2024-06-300000885725bsx:ActualCovenantMember2024-06-300000885725bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember2024-06-300000885725bsx:RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember2024-06-300000885725bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember2024-06-300000885725bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember2024-06-300000885725bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember2024-06-300000885725bsx:RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember2024-06-300000885725us-gaap:CommercialPaperMember2024-06-300000885725us-gaap:CommercialPaperMember2023-12-310000885725bsx:TheOfferingAggregatePrincipalAmountMember2024-02-220000885725bsx:March2029EuroSeniorNotesMember2024-02-220000885725bsx:March2032EuroSeniorNotesMember2024-02-220000885725bsx:March2024NotesMember2024-06-300000885725bsx:AMSEuropeMember2024-01-012024-06-300000885725bsx:EuroDenominatedFactoringArrangementsMember2024-06-300000885725bsx:EuroDenominatedFactoringArrangementsMember2024-01-012024-06-300000885725bsx:EuroDenominatedFactoringArrangementsMember2023-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2024-01-012024-03-310000885725bsx:YenDenominatedFactoringArrangementsMember2024-06-300000885725bsx:YenDenominatedFactoringArrangementsMember2024-01-012024-06-300000885725bsx:YenDenominatedFactoringArrangementsMember2023-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2024-01-012024-03-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2024-06-300000885725bsx:RenminbiDenominatedFactoringArrangementsMember2024-01-012024-06-300000885725bsx:RenminbiDenominatedFactoringArrangementsMember2023-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2024-01-012024-03-3100008857252024-03-3100008857252023-03-3100008857252023-01-312023-01-3100008857252024-06-0500008857252024-05-220000885725bsx:A550MCPSSeriesAMember2020-05-270000885725bsx:A550MCPSSeriesAMember2020-05-272020-05-270000885725bsx:A550MCPSSeriesAMember2023-06-010000885725us-gaap:EmployeeStockOptionMember2024-04-012024-06-300000885725us-gaap:EmployeeStockOptionMember2023-04-012023-06-300000885725us-gaap:EmployeeStockOptionMember2024-01-012024-06-300000885725us-gaap:EmployeeStockOptionMember2023-01-012023-06-300000885725bsx:A550MCPSSeriesAMember2024-04-012024-06-300000885725bsx:A550MCPSSeriesAMember2023-04-012023-06-300000885725bsx:A550MCPSSeriesAMember2024-01-012024-06-300000885725bsx:A550MCPSSeriesAMember2023-01-012023-06-3000008857252020-12-140000885725bsx:MedsurgMember2024-04-012024-06-300000885725bsx:MedsurgMember2023-04-012023-06-300000885725bsx:MedsurgMember2023-01-012023-06-300000885725bsx:CardiovascularMember2024-04-012024-06-300000885725bsx:CardiovascularMember2023-04-012023-06-300000885725bsx:CardiovascularMember2023-01-012023-06-300000885725bsx:BSXReportableSegmentsMember2024-04-012024-06-300000885725bsx:BSXReportableSegmentsMember2023-04-012023-06-300000885725bsx:BSXReportableSegmentsMember2024-01-012024-06-300000885725bsx:BSXReportableSegmentsMember2023-01-012023-06-300000885725bsx:TotalAllocatedToReportableSegmentsMember2024-04-012024-06-300000885725bsx:TotalAllocatedToReportableSegmentsMember2023-04-012023-06-300000885725bsx:TotalAllocatedToReportableSegmentsMember2024-01-012024-06-300000885725bsx:TotalAllocatedToReportableSegmentsMember2023-01-012023-06-300000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2024-04-012024-06-300000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2023-04-012023-06-300000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2024-01-012024-06-300000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2023-01-012023-06-300000885725bsx:SpecialChargesMember2024-04-012024-06-300000885725bsx:SpecialChargesMember2023-04-012023-06-300000885725bsx:SpecialChargesMember2024-01-012024-06-300000885725bsx:SpecialChargesMember2023-01-012023-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2024-04-012024-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2024-04-012024-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMember2024-04-012024-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2023-04-012023-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2023-04-012023-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMember2023-04-012023-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2024-04-012024-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:NonUsMember2024-04-012024-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2024-04-012024-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2023-04-012023-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:NonUsMember2023-04-012023-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-04-012023-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2024-04-012024-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMemberus-gaap:NonUsMember2024-04-012024-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMember2024-04-012024-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2023-04-012023-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMemberus-gaap:NonUsMember2023-04-012023-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMember2023-04-012023-06-300000885725country:USbsx:MedsurgMember2024-04-012024-06-300000885725us-gaap:NonUsMemberbsx:MedsurgMember2024-04-012024-06-300000885725country:USbsx:MedsurgMember2023-04-012023-06-300000885725us-gaap:NonUsMemberbsx:MedsurgMember2023-04-012023-06-300000885725country:USbsx:InterventionalCardiologyTherapiesMember2024-04-012024-06-300000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2024-04-012024-06-300000885725bsx:InterventionalCardiologyTherapiesMember2024-04-012024-06-300000885725country:USbsx:InterventionalCardiologyTherapiesMember2023-04-012023-06-300000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2023-04-012023-06-300000885725bsx:InterventionalCardiologyTherapiesMember2023-04-012023-06-300000885725country:USbsx:WatchmanMember2024-04-012024-06-300000885725us-gaap:NonUsMemberbsx:WatchmanMember2024-04-012024-06-300000885725bsx:WatchmanMember2024-04-012024-06-300000885725country:USbsx:WatchmanMember2023-04-012023-06-300000885725us-gaap:NonUsMemberbsx:WatchmanMember2023-04-012023-06-300000885725bsx:WatchmanMember2023-04-012023-06-300000885725bsx:CardiacRhythmManagementMembercountry:US2024-04-012024-06-300000885725bsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2024-04-012024-06-300000885725bsx:CardiacRhythmManagementMember2024-04-012024-06-300000885725bsx:CardiacRhythmManagementMembercountry:US2023-04-012023-06-300000885725bsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2023-04-012023-06-300000885725bsx:CardiacRhythmManagementMember2023-04-012023-06-300000885725bsx:ElectrophysiologyEPMembercountry:US2024-04-012024-06-300000885725bsx:ElectrophysiologyEPMemberus-gaap:NonUsMember2024-04-012024-06-300000885725bsx:ElectrophysiologyEPMember2024-04-012024-06-300000885725bsx:ElectrophysiologyEPMembercountry:US2023-04-012023-06-300000885725bsx:ElectrophysiologyEPMemberus-gaap:NonUsMember2023-04-012023-06-300000885725bsx:ElectrophysiologyEPMember2023-04-012023-06-300000885725bsx:GlobalCardiologyReportingUnitMembercountry:US2024-04-012024-06-300000885725bsx:GlobalCardiologyReportingUnitMemberus-gaap:NonUsMember2024-04-012024-06-300000885725bsx:GlobalCardiologyReportingUnitMember2024-04-012024-06-300000885725bsx:GlobalCardiologyReportingUnitMembercountry:US2023-04-012023-06-300000885725bsx:GlobalCardiologyReportingUnitMemberus-gaap:NonUsMember2023-04-012023-06-300000885725bsx:GlobalCardiologyReportingUnitMember2023-04-012023-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2024-04-012024-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:NonUsMember2024-04-012024-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2024-04-012024-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2023-04-012023-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:NonUsMember2023-04-012023-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2023-04-012023-06-300000885725bsx:CardiovascularMembercountry:US2024-04-012024-06-300000885725bsx:CardiovascularMemberus-gaap:NonUsMember2024-04-012024-06-300000885725bsx:CardiovascularMembercountry:US2023-04-012023-06-300000885725bsx:CardiovascularMemberus-gaap:NonUsMember2023-04-012023-06-300000885725country:US2024-04-012024-06-300000885725us-gaap:NonUsMember2024-04-012024-06-300000885725country:US2023-04-012023-06-300000885725us-gaap:NonUsMember2023-04-012023-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2024-01-012024-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2024-01-012024-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMember2024-01-012024-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2023-01-012023-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2023-01-012023-06-300000885725bsx:GlobalEndoscopyEndoReportingUnitMember2023-01-012023-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2024-01-012024-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:NonUsMember2024-01-012024-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2024-01-012024-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2023-01-012023-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:NonUsMember2023-01-012023-06-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-01-012023-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2024-01-012024-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMemberus-gaap:NonUsMember2024-01-012024-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMember2024-01-012024-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2023-01-012023-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMemberus-gaap:NonUsMember2023-01-012023-06-300000885725bsx:GlobalNeuromodulationNmReportingUnitMember2023-01-012023-06-300000885725country:USbsx:MedsurgMember2024-01-012024-06-300000885725us-gaap:NonUsMemberbsx:MedsurgMember2024-01-012024-06-300000885725country:USbsx:MedsurgMember2023-01-012023-06-300000885725us-gaap:NonUsMemberbsx:MedsurgMember2023-01-012023-06-300000885725country:USbsx:InterventionalCardiologyTherapiesMember2024-01-012024-06-300000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2024-01-012024-06-300000885725bsx:InterventionalCardiologyTherapiesMember2024-01-012024-06-300000885725country:USbsx:InterventionalCardiologyTherapiesMember2023-01-012023-06-300000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2023-01-012023-06-300000885725bsx:InterventionalCardiologyTherapiesMember2023-01-012023-06-300000885725country:USbsx:WatchmanMember2024-01-012024-06-300000885725us-gaap:NonUsMemberbsx:WatchmanMember2024-01-012024-06-300000885725bsx:WatchmanMember2024-01-012024-06-300000885725country:USbsx:WatchmanMember2023-01-012023-06-300000885725us-gaap:NonUsMemberbsx:WatchmanMember2023-01-012023-06-300000885725bsx:WatchmanMember2023-01-012023-06-300000885725bsx:CardiacRhythmManagementMembercountry:US2024-01-012024-06-300000885725bsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2024-01-012024-06-300000885725bsx:CardiacRhythmManagementMember2024-01-012024-06-300000885725bsx:CardiacRhythmManagementMembercountry:US2023-01-012023-06-300000885725bsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2023-01-012023-06-300000885725bsx:CardiacRhythmManagementMember2023-01-012023-06-300000885725bsx:ElectrophysiologyEPMembercountry:US2024-01-012024-06-300000885725bsx:ElectrophysiologyEPMemberus-gaap:NonUsMember2024-01-012024-06-300000885725bsx:ElectrophysiologyEPMember2024-01-012024-06-300000885725bsx:ElectrophysiologyEPMembercountry:US2023-01-012023-06-300000885725bsx:ElectrophysiologyEPMemberus-gaap:NonUsMember2023-01-012023-06-300000885725bsx:ElectrophysiologyEPMember2023-01-012023-06-300000885725bsx:GlobalCardiologyReportingUnitMembercountry:US2024-01-012024-06-300000885725bsx:GlobalCardiologyReportingUnitMemberus-gaap:NonUsMember2024-01-012024-06-300000885725bsx:GlobalCardiologyReportingUnitMember2024-01-012024-06-300000885725bsx:GlobalCardiologyReportingUnitMembercountry:US2023-01-012023-06-300000885725bsx:GlobalCardiologyReportingUnitMemberus-gaap:NonUsMember2023-01-012023-06-300000885725bsx:GlobalCardiologyReportingUnitMember2023-01-012023-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2024-01-012024-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:NonUsMember2024-01-012024-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2024-01-012024-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2023-01-012023-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:NonUsMember2023-01-012023-06-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2023-01-012023-06-300000885725bsx:CardiovascularMembercountry:US2024-01-012024-06-300000885725bsx:CardiovascularMemberus-gaap:NonUsMember2024-01-012024-06-300000885725bsx:CardiovascularMembercountry:US2023-01-012023-06-300000885725bsx:CardiovascularMemberus-gaap:NonUsMember2023-01-012023-06-300000885725country:US2024-01-012024-06-300000885725us-gaap:NonUsMember2024-01-012024-06-300000885725country:US2023-01-012023-06-300000885725us-gaap:NonUsMember2023-01-012023-06-300000885725country:USbsx:BSXReportableSegmentsMember2024-04-012024-06-300000885725country:USbsx:BSXReportableSegmentsMember2023-04-012023-06-300000885725country:USbsx:BSXReportableSegmentsMember2024-01-012024-06-300000885725country:USbsx:BSXReportableSegmentsMember2023-01-012023-06-300000885725us-gaap:EMEAMemberbsx:BSXReportableSegmentsMember2024-04-012024-06-300000885725us-gaap:EMEAMemberbsx:BSXReportableSegmentsMember2023-04-012023-06-300000885725us-gaap:EMEAMemberbsx:BSXReportableSegmentsMember2024-01-012024-06-300000885725us-gaap:EMEAMemberbsx:BSXReportableSegmentsMember2023-01-012023-06-300000885725srt:AsiaPacificMemberbsx:BSXReportableSegmentsMember2024-04-012024-06-300000885725srt:AsiaPacificMemberbsx:BSXReportableSegmentsMember2023-04-012023-06-300000885725srt:AsiaPacificMemberbsx:BSXReportableSegmentsMember2024-01-012024-06-300000885725srt:AsiaPacificMemberbsx:BSXReportableSegmentsMember2023-01-012023-06-300000885725bsx:LatinAmericaandCanadaMemberbsx:BSXReportableSegmentsMember2024-04-012024-06-300000885725bsx:LatinAmericaandCanadaMemberbsx:BSXReportableSegmentsMember2023-04-012023-06-300000885725bsx:LatinAmericaandCanadaMemberbsx:BSXReportableSegmentsMember2024-01-012024-06-300000885725bsx:LatinAmericaandCanadaMemberbsx:BSXReportableSegmentsMember2023-01-012023-06-300000885725bsx:EmergingMarketsMember2024-04-012024-06-300000885725bsx:EmergingMarketsMember2023-04-012023-06-300000885725bsx:EmergingMarketsMember2024-01-012024-06-300000885725bsx:EmergingMarketsMember2023-01-012023-06-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-04-012024-06-300000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-04-012024-06-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-06-300000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-04-012023-06-300000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-04-012023-06-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-06-300000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-06-300000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-06-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-06-300000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-06-300000885725bsx:JosephM.FitzgeraldMember2024-04-012024-06-300000885725bsx:RuleTradingArrangementCommonStockMemberbsx:JosephM.FitzgeraldMember2024-06-300000885725bsx:JosephM.FitzgeraldMemberbsx:RuleTradingArrangementStockAppreciationRightMember2024-06-300000885725bsx:VanceRBrownMember2024-04-012024-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2024
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 1-11083
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware04-2695240
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
    300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234
        (Address of Principal Executive Offices)                        (Zip Code)
508 683-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
The number of shares outstanding of Common Stock, $0.01 par value per share, as of July 30, 2024 was 1,472,626,135.


TABLE OF CONTENTS
  Page No.
 
   
   
 
   
 
   
 
   
 
   
   
   
   
   
   
 
2

PART I
FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

Three Months Ended
June 30,
Six Months Ended
June 30,
(in millions, except per share data)2024202320242023
Net sales$4,120 $3,599 $7,977 $6,988 
Cost of products sold1,270 1,058 2,479 2,098 
Gross profit2,850 2,542 5,498 4,891 
Operating expenses:
Selling, general and administrative expenses1,446 1,354 2,810 2,570 
Research and development expenses383 359 749 695 
Royalty expense9 12 19 23 
Amortization expense213 210 427 412 
Intangible asset impairment charges276 57 276 57 
Contingent consideration net expense (benefit)2 19 18 31 
Restructuring net charges (credits)1 16 5 36 
 2,330 2,028 4,303 3,825 
Operating income (loss)520 514 1,195 1,066 
Other income (expense):
Interest expense(77)(70)(146)(135)
Other, net(23)(18)(21)(61)
Income (loss) before income taxes420 426 1,028 870 
Income tax expense (benefit)98 156 213 287 
Net income (loss)322 270 815 584 
Preferred stock dividends (9) (23)
Net income (loss) attributable to noncontrolling interests(2) (4) 
Net income (loss) attributable to Boston Scientific common stockholders$324 $261 $819 $561 
Net income (loss) per common share — basic$0.22 $0.18 $0.56 $0.39 
Net income (loss) per common share — diluted$0.22 $0.18 $0.55 $0.39 
Weighted-average shares outstanding
Basic1,470.6 1,446.2 1,469.5 1,441.0 
Diluted1,484.2 1,456.2 1,483.0 1,451.1 

Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
3

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

Three Months Ended
June 30,
Six Months Ended
June 30,
(in millions)2024202320242023
Net income (loss)$322 $270 $815 $584 
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment45 15 102 (28)
Net change in derivative financial instruments(16)15 6 (28)
Net change in defined benefit pensions and other items0 0 0 (5)
Other comprehensive income (loss)30 30 108 (61)
Comprehensive income (loss)$352 $300 $924 $523 
Net income (loss) attributable to noncontrolling interests(2) (4) 
Other comprehensive income (loss) attributable to noncontrolling interests(1) (6) 
Comprehensive income (loss) attributable to noncontrolling interests(4) (10) 
Comprehensive income attributable to Boston Scientific common stockholders$356 $300 $933 $523 



































Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
4

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
 As of
(in millions, except share and per share data)June 30, 2024December 31, 2023
ASSETS  
Current assets:  
Cash and cash equivalents$2,913 $865 
Trade accounts receivable, net2,400 2,228 
Inventories2,608 2,484 
Prepaid income taxes315 315 
Other current assets756 621 
Total current assets8,991 6,514 
Property, plant and equipment, net2,951 2,859 
Goodwill14,397 14,387 
Other intangible assets, net5,417 6,003 
Deferred tax assets3,801 3,841 
Other long-term assets1,551 1,531 
TOTAL ASSETS$37,108 $35,136 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
Current liabilities:  
Current debt obligations$1,580 $531 
Accounts payable906 942 
Accrued expenses2,320 2,646 
Other current liabilities770 814 
Total current liabilities5,576 4,933 
Long-term debt8,991 8,571 
Deferred income taxes132 134 
Other long-term liabilities1,800 1,967 
Commitments and contingencies
Stockholders’ equity  
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of June 30, 2024 and December 31, 2023
  
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,734,329,744 shares as of June 30, 2024 and 1,729,000,224 shares as of December 31, 2023
17 17 
Treasury stock, at cost - 263,289,848 shares as of June 30, 2024 and December 31, 2023
(2,251)(2,251)
Additional paid-in capital20,803 20,647 
Retained earnings1,639 819 
Accumulated other comprehensive income (loss), net of tax164 49 
Total stockholders’ equity20,371 19,282 
Noncontrolling interests238 248 
Total equity20,609 19,530 
TOTAL LIABILITIES AND EQUITY$37,108 $35,136 



Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
5

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)
Three Months Ended
June 30,
Six Months Ended
June 30,
(in millions, except share data)2024202320242023
Preferred stock shares issued
   Beginning 10,062,500  10,062,500 
Conversion of mandatory convertible preferred stock to common stock (10,062,500) (10,062,500)
   Ending    
Common stock shares issued
   Beginning1,733,293,885 1,700,828,873 1,729,000,224 1,696,633,993 
Impact of stock-based compensation plans1,035,859 1,144,366 5,329,520 5,339,246 
Conversion of mandatory convertible preferred stock to common stock 23,982,902  23,982,902 
   Ending1,734,329,744 1,725,956,141 1,734,329,744 1,725,956,141 
Preferred stock
   Beginning$ $0 $ $0 
Conversion of mandatory convertible preferred stock to common stock (0) (0)
   Ending$ $ $ $ 
Common stock
   Beginning$17 $17 $17 $17 
Impact of stock-based compensation plans0 0 0 0 
Conversion of mandatory convertible preferred stock to common stock 0  0 
   Ending$17 $17 $17 $17 
Treasury stock
Beginning$(2,251)$(2,251)$(2,251)$(2,251)
Repurchase of common stock    
Ending$(2,251)$(2,251)$(2,251)$(2,251)
Additional paid-in capital
Beginning$20,713 $20,356 $20,647 $20,289 
Impact of stock-based compensation plans90 85 156 153 
Ending$20,803 $20,441 $20,803 $20,441 
Retained earnings/(Accumulated deficit)
Beginning$1,314 $(450)$819 $(750)
Net income (loss)322 270 815 584 
Net (income) loss attributable to noncontrolling interests2  4  
Preferred stock dividends (9) (23)
Ending$1,639 $(189)$1,639 $(189)
Accumulated other comprehensive income (loss), net of tax
Beginning$132 $178 $49 $269 
Changes in other comprehensive income (loss)31 30 114 (61)
Ending$164 $208 $164 $208 
Total stockholders' equity$20,371 $18,226 $20,371 $18,226 
Noncontrolling interests
Beginning$242 $259 $248 $ 
Net income (loss) attributable to noncontrolling interests(2) (4) 
Changes in other comprehensive income (loss)(1) (6) 
Changes to noncontrolling ownership interest   259 
Ending$238 $259 $238 $259 
Total equity$20,609 $18,485 $20,609 $18,485 



Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
6

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Six Months Ended June 30,
(in millions)20242023
Net income (loss)$815 $584 
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Depreciation and amortization615 583 
Deferred and prepaid income taxes21 (45)
Stock-based compensation expense129 115 
Goodwill and other intangible asset impairment charges276 57 
Net loss (gain) on investments and notes receivable46 35 
Contingent consideration net expense (benefit)18 31 
Inventory step-up amortization 3 
Other, net8 23 
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable(228)(161)
Inventories(219)(399)
Other assets(126)(55)
Accounts payable, accrued expenses and other liabilities(379)78 
Cash provided by (used for) operating activities977 848 
Investing activities:  
Purchases of property, plant and equipment and internal use software(334)(254)
Proceeds from sale of property, plant and equipment1 3 
Payments for acquisitions of businesses, net of cash acquired(95)(1,018)
Payments for investments and acquisitions of certain technologies, net of investment proceeds(139)(73)
Proceeds from royalty rights11 16 
Proceeds from settlements of hedge contracts 2 
Cash provided by (used for) investing activities(556)(1,324)
Financing activities:  
Payment of contingent consideration previously established in purchase accounting(34)(39)
Payments for royalty rights(15)(34)
Payments for finance leases(25) 
Payments on short-term borrowings(504) 
Net increase (decrease) in commercial paper 37 
Proceeds from long-term borrowings, net of debt issuance costs2,145  
Cash dividends paid on preferred stock (28)
Cash used to net share settle employee equity awards(80)(52)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans106 90 
Cash provided by (used for) financing activities1,593 (26)
Effect of foreign exchange rates on cash(8)(3)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents2,006 (506)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period1,055 1,126 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$3,062 $620 





Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
7

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(SUPPLEMENTAL INFORMATION)

Six Months Ended June 30,
(in millions)20242023
Supplemental Information
Stock-based compensation expense$129 $115 
Non-cash impact of transferred royalty rights(11)(16)

As of June 30,
Reconciliation to amounts within the unaudited consolidated balance sheets:20242023
Cash and cash equivalents$2,913 $426 
Restricted cash and restricted cash equivalents included in Other current assets
75 135 
Restricted cash equivalents included in Other long-term assets
74 60 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$3,062 $620 

























Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
8

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A – BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation.

Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

Subsequent Events

We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure within our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.

Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note H – Commitments and Contingencies for further details.

NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.

On June 18, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Silk Road Medical, Inc. (Silk Road Medical), a publicly traded medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is $27.50 in cash per share, or approximately $1.260 billion for 100% of the fully diluted equity. The transaction is expected to be completed in the second half of 2024, subject to customary closing conditions. The Silk Road Medical business will be integrated into our Peripheral Interventions division.

On January 8, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $71.00 in cash per share, or approximately $3.670 billion for 100% of the fully diluted equity. On April 3, 2024, we and Axonics each received a request for additional information (Second Request) from the United States Federal Trade Commission (FTC) in connection with the FTC's review of the transaction. The issuance of the Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), until 30 days after both we and Axonics have substantially complied with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. We and Axonics are responding to the Second Request and continue to work cooperatively with the FTC in its review. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. The Axonics business will be integrated into our Urology division.
9


2023 Acquisitions

On April 4, 2023, we completed our acquisition of 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The transaction consisted of an upfront cash payment of $636 million, net of cash acquired. The Apollo business is being integrated into our Endoscopy division.

On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases. We consolidated this majority stake investment in Acotec based on the conclusion we control the entity, and recorded a noncontrolling interest for the portion we do not own. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.

Purchase Price Allocation

We accounted for these transactions as business combinations in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805). The final purchase prices were comprised of the amounts presented below:

(in millions)
Acotec(1)
Apollo
Payment for acquisition, net of cash acquired(2)
$381 $636 
$381 $636 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction
(2) Related to Acotec, represents our majority stake investment

We recorded the assets acquired, liabilities assumed and specific to Acotec, the noncontrolling interest, at their respective fair values as of the closing date of the transaction. The final purchase price allocations were comprised of the components presented below, with the excess of the purchase price over the fair value of net assets acquired recorded to goodwill:

(in millions)AcotecApollo
Goodwill$337 $378 
Amortizable intangible assets334 248 
Other assets acquired93 50 
Liabilities assumed(48)(33)
Net deferred tax liabilities(76)(5)
Fair value of noncontrolling interest(259) 
$381 $636 

The fair value of Acotec's noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented in Stockholders' equity within our accompanying unaudited consolidated balance sheets. Goodwill was primarily established for Acotec due to opportunities for collaboration in research and development, manufacturing and commercial strategies, and for Apollo, due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.

10

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Acotec:
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
Apollo:
Amortizable intangible assets:
Technology-related$222 1112%
Customer relationships26 1112%
$248 
Contingent Consideration
Changes in the fair value of our contingent consideration liability during the first six months of 2024 associated with prior period acquisitions were as follows:

(in millions)
Balance as of December 31, 2023$404 
Amount recorded related to current year acquisitions29 
Contingent consideration net expense (benefit)18 
Contingent consideration payments and other adjustments(158)
Balance as of June 30, 2024$293 

The payments made during the first six months of 2024 primarily related to our acquisition of Farapulse, Inc. (Farapulse) following the achievement of revenue-based earnouts as a result of over-performance. The maximum amount we could be required to pay for certain contingent consideration is not determinable as it is uncapped and based on a percent of certain sales. As of June 30, 2024, the fair value of such uncapped contingent consideration is estimated at $163 million. As of June 30, 2024, the maximum amount that we could be required to pay under our other contingent consideration arrangements (undiscounted) is approximately $320 million. Refer to Note B – Acquisitions and Strategic Investments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of June 30, 2024Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Revenue-based Payments and Milestones$293 millionDiscounted Cash FlowDiscount Rate6%-15%7%
Probability of Payment90%-100%99%
Projected Year of Payment2024-20292027
(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
11


Projected contingent payment amounts related to our revenue-based payments and milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of June 30, 2024.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)June 30, 2024December 31, 2023
Equity method investments$207 $219 
Measurement alternative investments(1, 2)
243 194 
$450 $413 
(1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2) Includes publicly-held securities and convertible notes measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.

These investments are classified as Other long-term assets within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies.

As of June 30, 2024, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $233 million, which represents amortizable intangible assets, in-process research and development (IPR&D), goodwill and deferred tax liabilities.

NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
As of June 30, 2024As of December 31, 2023
(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs
Technology-related$12,846 $(8,372)$13,207 $(8,101)
Patents476 (380)480 (387)
Other intangible assets2,188 (1,555)2,130 (1,500)
Amortizable intangible assets$15,510 $(10,307)$15,817 $(9,988)
    
Goodwill$24,297 $(9,900)$24,287 $(9,900)
IPR&D$94 $54 
Technology-related120 120 
Indefinite-lived intangible assets$214 $174 
12


The following represents a roll-forward of our goodwill balance by reportable segment:
(in millions)MedSurgCardiovascularTotal
As of December 31, 2023$5,347 $9,041 $14,387 
Goodwill acquired24 46 71 
Impact of foreign currency fluctuations and purchase price and other adjustments(30)(30)(61)
As of June 30, 2024$5,341 $9,057 $14,397 

Goodwill and Other Intangible Asset Impairments

We did not record any goodwill impairment charges in the first six months of 2024 or 2023. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.

We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. We identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, Intangibles - Goodwill and Other (FASB ASC Topic 350), we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components of our Cardiology operating segment into a single Rhythm Management reporting unit.

In the second quarter of 2024, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. For the reporting units tested using the qualitative approach, after assessing the totality of events, it was determined that it was not more likely than not that the fair value of the reporting units was less than their carrying value, and it was not deemed necessary to proceed to the quantitative test. For the reporting units tested using the quantitative approach, we determined that the fair value of the reporting units exceeded the carrying value and concluded that goodwill was not impaired or at risk of impairment.

We recorded Intangible asset impairment charges of $276 million in the second quarter and first six months of 2024 and $57 million in the second quarter and first six months of 2023. The impairment charges recorded in 2024 were associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively. Intangible assets acquired from Cryterion were impaired due to strong commercial adoption of our Farapulse™ Pulsed Field Ablation System and the resulting lower revenue projections and cannibalization of our cryoablation business in major markets like the U.S. Intangible assets acquired from Devoro were impaired following management's decision to cancel the related program in the second quarter of 2024. We calculated the fair value of our Cryterion and Devoro intangible assets as the present value of estimated future cash flows we expect to generate from the assets based on estimates and assumptions about future revenue contributions, cost structures and the remaining useful lives of the assets.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist.

Refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements
13

and Supplementary Data of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments

Risk Management Strategy

Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecasted transactions denominated primarily in euro, Chinese renminbi, Japanese yen, British pound sterling, Australian dollar and Swiss franc. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold within our unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within Accumulated other comprehensive income (loss), net of tax (AOCI) to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities within our unaudited consolidated statements of cash flows.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Chinese renminbi and Japanese yen. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the Foreign currency translation adjustment (CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within Interest expense within our unaudited consolidated statements of operations.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the euro. As of June 30, 2024 and December 31, 2023, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within
14

Other, net within our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net within our accompanying unaudited consolidated statements of operations.

Interest Rate Hedging Instruments

Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of June 30, 2024 or December 31, 2023. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of June 30, 2024 or December 31, 2023. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest-rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of
June 30, 2024December 31, 2023
Forward currency contractsCash flow hedge$1,969 $2,284 
Forward currency contractsNet investment hedge645 333 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,284 3,282 
Total Notional Outstanding$6,895 $6,896 
(1) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.

The remaining time to maturity as of June 30, 2024 is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and two years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 within our accompanying unaudited consolidated statements of operations. Refer to Note M – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss).

15

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended June 30, 2024
Forward currency contracts
Cash flow hedges$31 $(7)$24 Cost of products sold$1,270 $(52)$12 $(41)
Net investment hedges(2)
20 (5)16 Interest expense77 (4)1 (3)
Foreign currency-denominated debt
Net investment hedges(3)
9 (2)7 Other, net23    
Interest rate derivative contracts
Cash flow hedges   Interest expense77 0 (0)0 

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended June 30, 2023
Forward currency contracts
Cash flow hedges$74 $(17)$58 Cost of products sold$1,058 $(55)$12 $(43)
Net investment hedges(2)
22 (5)17 Interest expense70 (2)1 (2)
Foreign currency-denominated debt
Net investment hedges(3)
1  1 Other, net18    
Interest rate derivative contracts
Cash flow hedges   Interest Expense70 1 (0)1 

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Six Months Ended June 30, 2024
Forward currency contracts
Cash flow hedges$108 $(24)$84 Cost of products sold$2,479 $(101)$23 $(79)
Net investment hedges(2)
48 (11)37 Interest expense146 (8)2 (6)
Foreign currency-denominated debt
Net investment hedges(3)
32 (7)25 Other, net21    
Interest rate derivative contracts
Cash flow hedges   Interest expense146 1 (0)1 

16

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Six Months Ended June 30, 2023
Forward currency contracts
Cash flow hedges$87 $(20)$67 Cost of products sold$2,098 $(125)$28 $(97)
Net investment hedges(2)
28 (6)22 Interest expense135 (5)1 (4)
Foreign currency-denominated debt
Net investment hedges(3)
(18)4 (14)Other, net61    
Interest rate derivative contracts
Cash flow hedges   Interest expense135 1 (0)1 
(1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.

As of June 30, 2024, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Designated Hedging Instrument
Forward currency contractsCash flow hedgeCost of products sold$163 
Forward currency contractsNet investment hedgeInterest expense11 
Interest rate derivative contractsCash flow hedgeInterest expense(1)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
Location on Unaudited Consolidated Statements of OperationsThree Months Ended June 30,Six Months Ended June 30,
(in millions)2024202320242023
Net gain (loss) on currency hedge contractsOther, net$30 $11 $45 $2 
Net gain (loss) on currency transaction exposuresOther, net(31)(20)(51)(26)
Net currency exchange gain (loss)$(1)$(9)$(6)$(24)

17

Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:

 
Location on Unaudited Consolidated Balance Sheets(1)
As of
(in millions)June 30, 2024December 31, 2023
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$236 $140 
Forward currency contractsOther long-term assets46 107 
  282 246 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets31 20 
Total Derivative and Nonderivative Assets $313 $266 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$3 $15 
Forward currency contractsOther long-term liabilities0 9 
Foreign currency-denominated debt(2)
Long-term debt957 988 
  960 1,012 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities14 38 
Total Derivative and Nonderivative Liabilities $974 $1,050 
(1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
18

Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 June 30, 2024December 31, 2023
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$2,153 $ $ $2,153 $454 $ $ $454 
Publicly-held equity securities19   19 18   18 
Hedging instruments 313  313  266  266 
Licensing arrangements  51 51   77 77 
 $2,173 $313 $51 $2,536 $472 $266 $77 $816 
Liabilities        
Hedging instruments$ $974 $ $974 $ $1,050 $ $1,050 
Contingent consideration liability  293 293   404 404 
Licensing arrangements  60 60   90 90 
 $ $974 $353 $1,327 $ $1,050 $494 $1,545 

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents or Other current assets within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies. In addition to $2.153 billion invested in money market funds and time deposits as of June 30, 2024 and $454 million as of December 31, 2023, we held $793 million in interest-bearing and non-interest-bearing bank accounts as of June 30, 2024 and $411 million as of December 31, 2023.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability. In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We maintain a financial asset and associated liability for our licensing arrangements measured at fair value within our unaudited consolidated balance sheets in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Refer to Note D – Hedging Activities and Fair Value Measurements to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our licensing arrangements recognized within our accompanying unaudited consolidated balance sheet as of June 30, 2024 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of June 30, 2024Valuation TechniqueUnobservable InputRange
Weighted Average (1)
Financial Asset$51 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2024-20252025
Financial Liability$60 millionDiscounted Cash FlowDiscount Rate12 %-15%13%
Projected Year of Payment2024-20262025
(1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

19

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2023$77 
Proceeds from royalty rights(21)
Fair value adjustment (expense) benefit(5)
Balance as of June 30, 2024$51 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2023$90 
Payments for royalty rights(26)
Fair value adjustment expense (benefit)(4)
Balance as of June 30, 2024$60 

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations, excluding finance leases, was $10.073 billion as of June 30, 2024 and $8.735 billion as of December 31, 2023. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.

20

NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of $10.571 billion as of June 30, 2024 and $9.102 billion as of December 31, 2023, with current obligations of $1.580 billion as of June 30, 2024 and $531 million as of December 31, 2023. The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)Issuance DateMaturity DateAs of
Coupon Rate(1)
June 30,
2024
December 31,
2023
March 2025 Senior Notes(3)
March 2022March 2025 1,105 0.750%
June 2025 Senior NotesMay 2020June 2025 500 1.900%
March 2026 Senior NotesFebruary 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027963 995 0.625%
March 2028 Senior Notes(3)
March 2022March 2028802 829 1.375%
March 2028 Senior NotesFebruary 2018March 2028344 344 4.000%
March 2029 Senior NotesFebruary 2019March 2029272 272 4.000%
March 2029 Senior Notes(3)
February 2024March 2029802  3.375%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031802 829 1.625%
March 2032 Senior Notes(3)
February 2024March 20321,337  3.500%
March 2034 Senior Notes(3)
March 2022March 2034535 553 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.500%
March 2039 Senior NotesFebruary 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior NotesFebruary 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2024 - 2049(77)(65)
Finance Lease ObligationVarious4 5 
Long-term debt$8,991 $8,571 
(1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of June 30, 2024 and December 31, 2023, respectively.

Revolving Credit Facility

On May 10, 2021, we entered into a $2.750 billion revolving credit facility (as amended, supplemented or otherwise modified from time to time, the 2021 Revolving Credit Facility) with a global syndicate of commercial banks. On May 10, 2024, we entered into a third amendment to the 2021 Revolving Credit Facility credit agreement, which provided for, among other things, an extension of the scheduled maturity date to May 10, 2029, an amendment of the Ratings based pricing grid of the Applicable Margin, each as defined in the credit agreement, and reset the applicable date for purposes of determining the amounts of restructuring charges and restructuring-related expenses that may be excluded from consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the credit agreement, for purposes of our maximum leverage ratio covenant, from December 31, 2022 to March 31, 2024, as further discussed under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. We had no amounts outstanding under the 2021 Revolving Credit Facility as of June 30, 2024 or December 31, 2023.

21

Financial Covenant

As of June 30, 2024, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
Covenant RequirementActual
 as of June 30, 2024as of June 30, 2024
Maximum permitted leverage ratio(1)
3.75 times1.97 times
(1) Ratio of total debt to deemed consolidated EBITDA, as defined by the 2021 Revolving Credit Facility credit agreement, as amended.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The credit agreement provides for higher leverage ratios, at our election, for the period following a Qualified Acquisition, as defined by the agreement, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have elected to designate the Axonics acquisition as a Qualified Acquisition under the credit agreement, and upon closing, will increase the maximum permitted leverage ratio at that time. The agreement also provides for an exclusion of any debt incurred to fund a Qualified Acquisition, until the earlier of the acquisition close date or date of abandonment, termination or expiration of the acquisition agreement. As of June 30, 2024, we excluded from our leverage ratio calculation $2.120 billion of debt incurred in connection with the Axonics acquisition.

The financial covenant requirement, as amended on May 10, 2024, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions related to restructuring charges and restructuring-related expenses from December 31, 2022 to March 31, 2024. Permitted exclusions include up to $500 million in cash and non-cash restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of June 30, 2024, we had $453 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of June 30, 2024, we had $1.448 billion of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of June 30, 2024 or December 31, 2023.

Senior Notes

We had senior notes outstanding of $10.633 billion as of June 30, 2024 and $9.136 billion as of December 31, 2023. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (refer to Other Arrangements below).

In February 2024, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €2.000 billion in aggregate principal amount of euro-denominated senior notes comprised of €750 million of 3.375% Senior Notes due 2029 and €1.250 billion of 3.500% Senior Notes due 2032 (collectively, the 2024 Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the 2024 Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations.
22

AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $2.145 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering of the 2024 Eurobonds to fund the repayment at maturity of our 3.450% Senior Notes due March 2024 and to pay accrued and unpaid interest with respect to such notes. Additionally, we plan to use the remaining net proceeds from the Offering to fund a portion of the purchase price of the Axonics acquisition and to pay related fees and expenses, and for general corporate purposes. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. If (i) the Axonics acquisition is not consummated on or before the later of (x) January 8, 2025 (as such date may be extended in accordance with the merger agreement to no later than January 8, 2026) and (y) the date that is five business days after any later date to which we and Axonics may agree to extend the "Outside Date" in the merger agreement or (ii) AMS Europe notifies the trustee that we will not pursue consummation of the Axonics Acquisition, AMS Europe will be required to redeem each series of the notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of such series of notes, plus accrued and unpaid interest, if any, to, but excluding, the date on which the notes will be redeemed. Refer to Note B – Acquisitions and Strategic Investments for more information on the Axonics acquisition.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
Factoring ArrangementsAs of June 30, 2024As of December 31, 2023
Amount
De-recognized
Weighted Average
Interest Rate
Amount
De-recognized
Weighted Average
Interest Rate
Euro denominated$187 5.3 %$206 5.1 %
Yen denominated187 0.8 %214 0.6 %
Renminbi denominated
26 1.7 %14 2.9 %

Other Contractual Obligations and Commitments

We had outstanding letters of credit of $189 million as of June 30, 2024 and $174 million as of December 31, 2023, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of June 30, 2024 and December 31, 2023 we had not recognized a related liability for our outstanding letters of credit within our accompanying unaudited consolidated balance sheets.

We have a supplier financing program offered primarily in the U.S. that enables our suppliers to opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within Accounts Payable within our unaudited consolidated balance sheets and were $131 million as of June 30, 2024 and $152 million as of December 31, 2023.

Refer to Note E – Contractual Obligations and Commitments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.

23

NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions within our accompanying unaudited consolidated balance sheets are as follows:

Trade accounts receivable, net
 As of
(in millions)June 30, 2024December 31, 2023
Trade accounts receivable$2,505 $2,338 
Allowance for credit losses(105)(110)
 $2,400 $2,228 

The following is a roll forward of our Allowance for credit losses:
Three Months Ended June 30,Six Months Ended
June 30,
(in millions)2024202320242023
Beginning balance$109 $118 $110 $109 
Credit loss expense12 19 21 35 
Write-offs(16)(10)(26)(16)
Ending balance$105 $127 $105 $127 

Inventories
 As of
(in millions)June 30, 2024December 31, 2023
Finished goods$1,558 $1,537 
Work-in-process201 174 
Raw materials849 773 
 $2,608 $2,484 
Other current assets
 As of
(in millions)June 30, 2024December 31, 2023
Restricted cash and restricted cash equivalents$75 $130 
Derivative assets267 159 
Licensing arrangements38 47 
Other376 285 
 $756 $621 
24


Property, plant and equipment, net
 As of
(in millions)June 30, 2024December 31, 2023
Land$140 $140 
Buildings and improvements1,876 1,843 
Equipment, furniture and fixtures3,598 3,503 
Capital in progress897 857 
 6,512 6,343 
Less: accumulated depreciation3,561 3,484 
 $2,951 $2,859 

Depreciation expense was $98 million for the second quarter of 2024, $88 million for the second quarter of 2023, $188 million for the first six months of 2024 and $170 million for the first six months of 2023.

Other long-term assets

 As of
(in millions)June 30, 2024December 31, 2023
Restricted cash equivalents$74 $60 
Operating lease right-of-use assets416 439 
Derivative assets46 107 
Investments450 413 
Licensing arrangements13 30 
Indemnification asset172 176 
Other381 306 
 $1,551 $1,531 
Accrued expenses
 As of
(in millions)June 30, 2024December 31, 2023
Legal reserves$118 $206 
Payroll and related liabilities948 1,051 
Rebates412 389 
Contingent consideration175 304 
Other667 696 
 $2,320 $2,646 

Other current liabilities
 As of
(in millions)June 30, 2024December 31, 2023
Deferred revenue$284 $266 
Licensing arrangements40 49 
Taxes payable224 220 
Other222 278 
 $770 $814 
25


Other long-term liabilities
 As of
(in millions)June 30, 2024December 31, 2023
Accrued income taxes$356 $470 
Legal reserves133 172 
Contingent consideration118 100 
Licensing arrangements20 41 
Operating lease liabilities365 390 
Deferred revenue316 311 
Other491 484 
 $1,800 $1,967 

NOTE G – INCOME TAXES

Our effective tax rate from continuing operations is presented below:
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Effective tax rate from continuing operations23.4 %36.6 %20.7 %32.9 %

Our reported tax rate is affected by recurring items such as the amount of our earnings subject to differing tax rates in foreign jurisdictions and the impact of certain receipts and charges that are taxed at rates that differ from our effective tax rate.

The primary reasons for the difference between the statutory rate and our reported tax rate in the second quarter and first six months of 2024 relate to certain charges for acquisition expenses, as well as certain benefits for intangible asset impairment charges and integration costs, and discrete benefits primarily related to stock-based compensation. In the second quarter and first six months of 2023, the primary difference between the statutory tax rate and our reported tax rate relates to acquisition-related charges, as well as certain benefits for integration costs, and discrete tax items primarily related to unrecognized tax benefits.

As of June 30, 2024, we had $478 million of gross unrecognized tax benefits, of which a net $406 million, if recognized, would affect our effective tax rate. As of December 31, 2023, we had $467 million of gross unrecognized tax benefits, of which a net $395 million, if recognized, would affect our effective tax rate. The change in gross unrecognized tax benefit is primarily related to current year accruals for reserves and audits.

It is reasonably possible that within the next 12 months, we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $9 million.

26

NOTE H – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. For additional information, refer to Note I – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations.

Our accrual for legal matters that are probable and estimable was $251 million as of June 30, 2024 and $377 million as of December 31, 2023 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund, which is included in restricted cash and restricted cash equivalents in Other current assets of $75 million as of June 30, 2024 and $130 million as of December 31, 2023. Refer to Note F – Supplemental Balance Sheet Information for additional information. We did not record any litigation-related net charges during the second quarter and first six months of 2024 or 2023.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or
27

otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against the Company in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT filed a motion seeking prejudgment interest and enhanced damages. The Company filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial. On June 5, 2024, the Court granted the Company’s motion for judgment as a matter of law of no willful infringement, but otherwise denied the Company’s motions. The Court also denied UT’s motion for enhanced damages, awarded approximately $7.4 million in pre-judgment interest, and awarded post-judgment interest. On July 3, 2024, UT and the Company each filed a notice of appeal.

Product Liability Litigation

Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand.

We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims, which we continue to vigorously contest. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission issued its decision on May 22, 2024, holding that BSB and a former employee should be held liable and setting a fine of $17 million. The Commission held that the three other current or former Company employees should be acquitted. BSB has filed a motion to clarify the proper calculation of the fine and, to the extent
28

any fine is upheld, the Company intends to appeal the decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.

Like many healthcare companies, the Company receives inquiries and has ongoing discussions with governmental agencies with respect to the Company’s operations, such as the Securities and Exchange Commission (SEC), the Department of Justice (DOJ) and foreign regulators, including its operations in Vietnam with respect to alleged Foreign Corrupt Practices Act (FCPA) violations the Company received in March 2022. The Company has received related subpoenas for documents from the DOJ and the SEC with respect to the Vietnam matter, and is cooperating with the government while investigating these allegations. From time to time, the Company also self-discloses potential concerns to regulators. In the course of Vietnam-related discussions with the DOJ and SEC, the Company has disclosed that it is investigating other potential concerns in Vietnam and other countries.

From time to time, the Company also receives U.S.-based subpoenas and DOJ Civil Investigative Demands (CID), including the following matters: in April 2023, the Company received a DOJ subpoena that seeks documents and information related to its ambulatory electrocardiography monitoring business; in December 2023, the Company received a DOJ CID related to the provision of peripheral intervention services through office-based labs. The Company is cooperating with the DOJ in these matters.

Other Proceedings

On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Union Asset Management Holding AG as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. On October 23, 2023, the Company reached an agreement in principle with the lead plaintiff to settle the case. The Court granted the motion for preliminary approval of the proposed settlement on December 27, 2023, and approved the settlement and dismissed the case on April 23, 2024.

On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to Section 220 of the Delaware General Corporation Law, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On April 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa. On May 8, 2023, the Court stayed the case until the conclusion of the consolidated class action case. On October 18, 2023, Frank Tripson filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware against the Company, Michael F. Mahoney, Daniel J. Brennan, Joseph M. Fitzgerald, Shawn McCarthy, Kevin Ballinger, Ian Meredith, Susan Vissers Lisa, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P. MacMillan, David Roux, John E. Sununu, and Ellen M. Zane. On December 15, 2023, the Court stayed that case until March 31, 2024. On March 26, 2024, the Company reached an agreement in principle with all of the plaintiffs to resolve the matters.





29

NOTE I – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses.

On June 1, 2023, (the Mandatory Conversion Date), all outstanding shares of MCPS automatically converted into shares of common stock. The conversion rate for each share of MCPS was 2.3834 shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS.

Refer to Note J – Stockholders' Equity to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for information on the pertinent rights and privileges of our outstanding common stock.
NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING

Three Months Ended June 30,Six Months Ended June 30,
(in millions)2024202320242023
Weighted average shares outstanding — basic1,470.6 1,446.2 1,469.5 1,441.0 
Net effect of common stock equivalents13.6 10.1 13.5 10.1 
Weighted average shares outstanding - diluted1,484.2 1,456.2 1,483.0 1,451.1 

The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:
Three Months Ended June 30,Six Months Ended June 30,
(in millions)2024202320242023
Stock options outstanding(1)
0
MCPS(2)
1620
(1)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2)    Represents common stock issuable upon the conversion of MCPS. Refer to Note I – Stockholders' Equity for additional information.

We base Net income (loss) per common share - diluted upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and, prior to the Mandatory Conversion Date, our MCPS, from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.

30

For the second quarter and first six months of 2023, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income (loss) was reduced by cumulative Preferred stock dividends, as presented within our accompanying unaudited consolidated statements of operations, for purposes of calculating Net income attributable to Boston Scientific common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.

We issued approximately one million shares of our common stock in the second quarter of 2024, approximately five million shares in the first six months of 2024, approximately 25 million shares in the second quarter of 2023 and approximately 29 million shares in the first six months of 2023. Shares were issued following the exercise of stock options, vesting of restricted stock units or purchases under our employee stock purchase plan and, specific to 2023, following the automatic conversion of the MCPS. We did not repurchase any shares of our common stock in the first six months of 2024 or 2023. On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of June 30, 2024, we had the full amount remaining available under the authorization.

NOTE K – SEGMENT REPORTING

We aggregate our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. Refer to Note L – Revenue for net sales by reportable segment presented in accordance with GAAP.

31

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation.

Three Months Ended
June 30,
Six Months Ended
June 30,
Net Sales2024202320242023
MedSurg$1,480 $1,346$2,882 $2,611
Cardiovascular2,632 2,2045,058 4,275
Total net sales of reportable segments4,112 3,5497,939 6,886
Impact of foreign currency fluctuations8 5137 102
$4,120 $3,599$7,977 $6,988
Income (loss) before income taxes
MedSurg$511 $458$986 $867
Cardiovascular761 5821,414 1,135
Total operating income of reportable segments1,272 1,0402,400 2,002
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(153)(75)(268)(173)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(386)(241)(510)(351)
Amortization expense(213)(210)(427)(412)
Operating income (loss)520 5141,195 1,066
Other income (expense), net(100)(88)(167)(195)
Income (loss) before income taxes$420 $426$1,028 $870

Three Months Ended June 30,Six Months Ended
June 30,
Operating income margin of reportable segments2024202320242023
MedSurg34.6 %34.0 %34.2 %33.2 %
Cardiovascular28.9 %26.4 %28.0 %26.6 %


32

NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.

Three Months Ended June 30,
20242023
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$415 $261 $676 $384 $246 $631 
Urology363 162 525 340 146 485 
Neuromodulation214 68 282 183 61 244 
MedSurg992 491 1,483 907 453 1,360 
   Interventional Cardiology Therapies201 464 665 189 440 629 
   Watchman342 36 379 286 30 317 
   Cardiac Rhythm Management352 224 576 356 209 566 
    Electrophysiology271 157 428 85 108 193 
Cardiology1,166 881 2,047 917 787 1,704 
Peripheral Interventions308 281 590 285 250 535 
Cardiovascular1,474 1,163 2,637 1,202 1,037 2,239 
Total Net Sales$2,466 $1,654 $4,120 $2,110 $1,490 $3,599 

Six Months Ended June 30,
20242023
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$810 $508 $1,318 $735 $472 $1,207 
Urology719 319 1,038 666 289 954 
Neuromodulation405 134 539 356 123 478 
MedSurg1,933 961 2,895 1,757 883 2,640 
   Interventional Cardiology Therapies396 921 1,316 372 848 1,220 
   Watchman653 70 723 552 55 607 
   Cardiac Rhythm Management706 446 1,151 702 412 1,114 
    Electrophysiology429 300 729 170 199 370 
Cardiology2,183 1,736 3,919 1,796 1,514 3,310 
Peripheral Interventions608 555 1,163 560 478 1,039 
Cardiovascular2,791 2,291 5,082 2,356 1,993 4,349 
Total Net Sales$4,724 $3,252 $7,977 $4,113 $2,876 $6,988 

Refer to Note K - Segment Reporting for information on our reportable segments.

33

Three Months Ended June 30,Six Months Ended June 30,
Geographic Regions2024202320242023
U.S.$2,466 $2,110 $4,724 $4,113 
Europe, Middle East and Africa822 723 1,625 1,435 
Asia-Pacific670 626 1,317 1,174 
Latin America and Canada162 140 311 267 
Total Net Sales$4,120 $3,599 $7,977 $6,988 
Emerging Markets(1)
$680 $592 $1,328 $1,121 
(1) Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $599 million as of June 30, 2024 and $577 million as of December 31, 2023. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $59 million in the second quarter and $120 million in the first six months of 2024 that was included in the above contract liability balance as of December 31, 2023. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

For additional information on variable consideration, refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K.

NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax attributable to Boston Scientific common stockholders:
(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of March 31, 2024$(34)$175 $(8)$132 
Other comprehensive income (loss) before reclassifications50 24 0 75 
(Income) loss amounts reclassified from accumulated other comprehensive income(3)(40)(0)(44)
Total other comprehensive income (loss)47 (16)0 31 
Balance as of June 30, 2024$13 $159 $(8)$164 

34

(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of March 31, 2023$(43)$225 $(4)$178 
Other comprehensive income (loss) before reclassifications17 58  74 
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(42)(0)(44)
Total other comprehensive income (loss)15 15 (0)30 
Balance as of June 30, 2023$(28)$241 $(4)$208 

(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2023$(96)$154 $(8)$49 
Other comprehensive income (loss) before reclassifications115 84 0 199 
(Income) loss amounts reclassified from accumulated other comprehensive income(6)(78)(0)(84)
Total other comprehensive income (loss)108 6 0 114 
Balance as of June 30, 2024$13 $159 $(8)$164 

(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(24)67 (5)39 
(Income) loss amounts reclassified from accumulated other comprehensive income(4)(95)(1)(100)
Total other comprehensive income (loss)(28)(28)(5)(61)
Balance as of June 30, 2023$(28)$241 $(4)$208 

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustment and our cash flow hedges recorded in Net change in derivative financial instruments.

NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first six months of 2024, we implemented the following standard on a prospective basis, which did not have a material impact on our unaudited consolidated financial statements:

ASC Update No. 2022-03

ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities.
35


Standards to be Implemented

In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. As this accounting standard update impacts disclosures only, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. As this accounting standard update impacts disclosures only, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.

36

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 40 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high performance solutions to address unmet patient needs and reduce the cost of health care. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.

Financial Summary

Three Months Ended June 30, 2024

Our net sales for the second quarter of 2024 were $4.120 billion, compared to $3.599 billion for the second quarter of 2023. This increase of $521 million, or 14.5 percent, included operational1 net sales growth of 16.1 percent and the negative impact of 160 basis points from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 14.7 percent and the positive impact of 140 basis points from our majority stake investment in Acotec Scientific Holdings Limited (Acotec) and the acquisitions of Relievant Medsystems, Inc. (Relievant) and the endoluminal vacuum therapy portfolio of B. Braun Medical Inc. (Braun) during the first and fourth quarters of 2023 and first quarter of 2024, respectively, for which there is less than a full period of comparable net sales. The increase in our net sales was primarily driven by strong commercial execution across our businesses, led by the rapid adoption of our Farapulse Pulsed Field Ablation System following U.S. launch in early 2024. Refer to Quarterly Results and Business Overview for a discussion of our net sales by business.

Our reported net income attributable to Boston Scientific common stockholders for the second quarter of 2024 was $324 million, or $0.22 per diluted share. Our reported results for the second quarter of 2024 included certain charges and/or credits totaling $589 million (after-tax), or $0.40 per diluted share. Excluding these items, adjusted net income attributable to Boston Scientific common stockholders3 was $914 million, or $0.62 per diluted share.

Our reported net income attributable to Boston Scientific common stockholders for the second quarter of 2023 was $261 million, or $0.18 per diluted share. Our reported results for the second quarter of 2023 included certain charges and/or credits totaling $516 million (after-tax), or $0.35 per diluted share. Excluding these items, adjusted net income attributable to Boston Scientific common stockholders3 was $777 million, or $0.53 per diluted share.















1Operational net sales growth excludes the impact of foreign currency fluctuations.
2Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
3Adjusted measures, including operational and organic net sales growth and adjusted net income attributable to Boston Scientific common stockholders, exclude certain items required by generally accepted accounting principles in the United States (GAAP), are not prepared in accordance with GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures.
37

The following is a reconciliation of our results of operations prepared in accordance with GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:
 Three Months Ended June 30, 2024
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per Share
Reported$420 $98 $322 $ $(2)$324 $0.22 
Non-GAAP adjustments:
Amortization expense213 29 184 — 182 0.12 
Goodwill and other intangible asset impairment charges276 332432430.16 
Acquisition/divestiture-related net charges (credits)49 1138380.03 
Restructuring and restructuring-related net charges (credits)50 744440.03 
Investment portfolio net losses (gains) and impairments31 329290.02 
European Union (EU) Medical device regulation (MDR) implementation costs12 210100.01 
Deferred tax expenses (benefits)— (44)44440.03 
Adjusted$1,051 $138 $913 $ $(0)$914 $0.62 

 Three Months Ended June 30, 2023
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common Stockholders
Impact per Share(4)
Reported$426 $156 $270 $(9)$ $261 $0.18 
Non-GAAP adjustments:
Amortization expense210 28 182 — — 182 0.12 
Goodwill and other intangible asset impairment charges57 54 — — 54 0.04 
Acquisition/divestiture-related net charges (credits)118 (57)175 — — 175 0.12 
Restructuring and restructuring-related net charges (credits)42 35 — — 35 0.02 
Investment portfolio net losses (gains) and impairments(2)(6)— — 0.00 
European Union (EU) Medical device regulation (MDR) implementation costs20 17 — — 17 0.01 
Deferred tax expenses (benefits)— (47)47 — — 47 0.03 
Discrete tax items— (1)— — 0.00 
Adjusted$871 $86 $786 $(9)$ $777 $0.53 



4 For the three months ended June 30, 2023, the effect of assuming the conversion of our 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of Net income (loss) per common share - diluted earnings per share (EPS). Accordingly, GAAP Net income (loss) and Adjusted net income were reduced by cumulative Preferred stock dividends, as presented within our unaudited consolidated statements of operations, for purposes of calculating GAAP Net income attributable to Boston Scientific common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.
38

Six Months Ended June 30, 2024

Our net sales for the first six months of 2024 were $7.977 billion, compared to $6.988 billion for the first six months of 2023. This increase of $988 million, or 14.1 percent, included operational1 net sales growth of 15.5 percent and the negative impact of 140 basis points from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 13.9 percent and the positive impact of 160 basis points from our majority stake investment in Acotec and the acquisitions of Apollo Endosurgery, Inc. (Apollo), Relievant and the endoluminal vacuum therapy portfolio of Braun during the first, second and fourth quarters of 2023 and first quarter of 2024, respectively, for which there is less than a full period of comparable sales. The increase in our net sales was primarily driven by strong commercial execution across our businesses, led by the rapid adoption of our Farapulse Pulsed Field Ablation System following U.S. launch in early 2024. Refer to Quarterly Results and Business Overview for a discussion of our net sales by business.

Our reported net income attributable to Boston Scientific common stockholders for the first six months of 2024 was $819 million, or $0.55 per diluted share. Our reported results for the first six months of 2024 included certain charges and/or credits totaling $926 million (after-tax), or $0.62 per diluted share. Excluding these items, adjusted net income attributable to Boston Scientific common stockholders3 for the first six months of 2024 was $1.745 billion, or $1.18 per diluted share.

Our reported net income attributable to Boston Scientific common stockholders for the first six months of 2023 was $561 million, or $0.39 per diluted share. Our reported results for the first six months of 2023 included certain charges and/or credits totaling $889 million (after-tax), or $0.61 per diluted share. Excluding these items, adjusted net income attributable to Boston Scientific common stockholders3 for the first six months of 2023 was $1.449 billion, or $1.00 per diluted share.































1Operational net sales growth excludes the impact of foreign currency fluctuations.
2Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
3Adjusted measures, including operational and organic net sales growth and adjusted net income attributable to Boston Scientific common stockholders, exclude certain items required by generally accepted accounting principles in the United States (GAAP), are not prepared in accordance with GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures.
39


The following is a reconciliation of our results of operations prepared in accordance with GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:

Six Months Ended June 30, 2024
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per Share
Reported$1,028 $213 $815 $ $(4)$819 $0.55 
Non-GAAP adjustments:
Amortization expense427 58 369 — 364 0.25 
Goodwill and other intangible asset impairment charges276 33 243 — — 243 0.16 
Acquisition/divestiture-related net charges (credits)112 (2)115 — — 115 0.08 
Restructuring and restructuring-related net charges (credits)97 13 84 — — 84 0.06 
Investment portfolio net losses (gains) and impairments18 (0)18 — — 18 0.01 
European Union (EU) Medical device regulation (MDR) implementation costs26 22 — — 22 0.01 
Deferred tax expenses (benefits)— (81)81 — — 81 0.05 
Adjusted$1,983 $237 $1,746 $ $1 $1,745 $1.18 

Six Months Ended June 30, 2023
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common Stockholders
Impact per Share(4)
Reported$870 $287 $584 $(23)$ $561 $0.39 
Non-GAAP adjustments:
Amortization expense412 56 357 — — 357 0.25 
Goodwill and other intangible asset impairment charges57 54 — — 54 0.04 
Acquisition/divestiture-related net charges (credits)178 (64)242 — — 242 0.17 
Restructuring and restructuring-related net charges (credits)86 14 71 — — 71 0.05 
Investment portfolio net losses (gains) and impairments19 (2)20 — — 20 0.01 
European Union (EU) Medical device regulation (MDR) implementation costs36 31 — — 31 0.02 
Deferred tax expenses (benefits)— (88)88 — — 88 0.06 
Discrete tax items— (26)26 — — 26 0.02 
Adjusted$1,659 $186 $1,472 $(23)$ $1,449 $1.00 

(4) For the first six months ended June 30, 2023, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of Net income (loss) per common share - diluted EPS. Accordingly, GAAP Net income (loss) and Adjusted net income were reduced by cumulative Preferred stock dividends, as presented within our unaudited consolidated statements of operations, for purposes of calculating GAAP Net income attributable to Boston Scientific common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.
40




Quarterly Results and Business Overview

The following section describes our net sales and results of operations by reportable segment and business. For additional information on our businesses and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K.
 Three Months Ended June 30,
(in millions)20242023Increase/(Decrease)
Endoscopy
$676 $631 7.1%
Urology525 485 8.2%
Neuromodulation
282 244 15.5%
MedSurg1,483 1,360 9.0%
Cardiology2,047 1,704 20.1%
Peripheral Interventions
590 535 10.2%
Cardiovascular2,637 2,239 17.8%
Net Sales$4,120 $3,599 14.5%
Six Months Ended June 30,
(in millions)20242023Increase/(Decrease)
Endoscopy
$1,318 $1,207 9.2%
Urology1,038 954 8.7%
Neuromodulation
539 478 12.6%
MedSurg2,895 2,640 9.6%
Cardiology3,919 3,310 18.4%
Peripheral Interventions
1,163 1,039 12.0%
Cardiovascular5,082 4,349 16.9%
Net Sales$7,977 $6,988 14.1%

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less-invasive technologies. Net sales of Endoscopy products of $676 million during the second quarter and $1.318 billion during the first six months of 2024 represented 16 percent and 17 percent of our consolidated net sales, respectively. Endoscopy net sales increased $45 million, or 7.1 percent, during the second quarter and $111 million, or 9.2 percent, during the first six months of 2024, compared to the prior year periods. During the second quarter of 2024, this increase included operational net sales growth of 8.4 percent and a negative impact of 130 basis points from foreign currency fluctuations, compared to the prior year period. During the first six months of 2024, this increase included operational net sales growth of 10.2 percent and a negative impact of 100 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth included organic net sales growth of 7.9 percent during the second quarter of 2024 and 8.8 percent for the first six months of 2024, and the positive impact of 50 and 140 basis points, respectively, from our acquisition of Apollo and divestiture of our pathology business in the second quarter of 2023, and our acquisition of the endoluminal vacuum therapy portfolio of Braun in the first quarter of 2024. Organic net sales growth in both periods was primarily driven by our biliary franchise led by our AXIOS Stent and Delivery System and our endoluminal surgery franchise.
41


Urology

Our Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Net sales of Urology products of $525 million during the second quarter and $1.038 billion during the first six months of 2024 represented 13 percent of our consolidated net sales in both periods. Urology net sales increased $40 million, or 8.2 percent, during the second quarter and $83 million, or 8.7 percent, during the first six months of 2024, compared to the prior year periods. During the second quarter of 2024, this increase included operational net sales growth of 9.1 percent and a negative impact of 90 basis points from foreign currency fluctuations, compared to the prior year period. During the first six months of 2024, this increase included operational net sales growth of 9.5 percent and a negative impact of 70 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth in both periods was primarily driven by our stone management franchise, led by our Lumenis Pulse™ Holmium Laser Systems with MOSES™ Technology, as well as our core stone and prosthetic urology franchises.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Net sales of Neuromodulation products of $282 million during the second quarter and $539 million during the first six months of 2024 represented 7 percent of our consolidated net sales in both periods. Neuromodulation net sales increased $38 million, or 15.5 percent during the second quarter and $60 million, or 12.6 percent during the first six months of 2024, compared to the prior year periods. During the second quarter of 2024, this increase included operational net sales growth of 16.2 percent and a negative impact of 70 basis points from foreign currency fluctuations, compared to the prior year period. During the first six months of 2024, this increase included operational net sales growth of 13.1 percent and a negative impact of 50 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth included organic net sales growth of 3.7 percent during the second quarter of 2024 and 1.2 percent during the first six months of 2024, and the positive impact of 1,250 and 1,180 basis points, respectively, from our acquisition of Relievant in the fourth quarter of 2023. Organic net sales growth in the second quarter of 2024 was primarily driven by improved performance in our U.S. pain franchise from our radiofrequency ablation portfolio. Organic net sales growth in the first six months of 2024 was primarily driven by improved performance in our U.S. pain franchise from our radiofrequency ablation portfolio and our deep brain stimulation franchise.

Cardiovascular

Cardiology

Our Cardiology business develops and manufactures devices and medical technologies for diagnosing and treating a variety of diseases and abnormalities of the heart. Net sales of Cardiology products of $2.047 billion during the second quarter and $3.919 billion for the first six months of 2024 represented 50 percent and 49 percent of our consolidated net sales, respectively. Cardiology net sales increased $343 million, or 20.1 percent, during the second quarter and $609 million, or 18.4 percent, during the first six months of 2024, compared to the prior year periods. During the second quarter of 2024, this increase included operational net sales growth of 22.0 percent and a negative impact of 190 basis points from foreign currency fluctuations, compared to the prior year period. During the first six months of 2024, this increase included operational net sales growth of 20.0 percent and a negative impact of 160 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth in both periods was primarily driven by growth of our electrophysiology business, led by our Farapulse™ Pulsed Field Ablation System, continued market penetration of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN FLX™ LAAC Device and our WATCHMAN FLX™ Pro LAAC Device, as well as our access solutions portfolio and our percutaneous coronary intervention guidance franchises.

42


Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Net sales of Peripheral Interventions products of $590 million during the second quarter and $1.163 billion for the first six months of 2024 represented 14 percent and 15 percent of our consolidated net sales, respectively. Peripheral Interventions net sales increased $55 million, or 10.2 percent, during the second quarter and $125 million, or 12.0 percent, during the first six months of 2024, compared to the prior year periods. During the second quarter of 2024, this increase included operational net sales growth of 12.3 percent and a negative impact of 210 basis points from foreign currency fluctuations, compared to the prior year period. During the first six months of 2024, this increase included operational net sales growth of 14.1 percent and a negative impact of 210 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth included organic net sales growth of 9.4 percent during the second quarter of 2024 and 10.4 percent during the first six months of 2024, and the positive impact of 280 and 370 basis points, respectively, from our majority stake investment in Acotec which we acquired in the first quarter of 2023. Organic net sales growth in both periods was primarily driven by our interventional oncology franchise led by our Therasphere™ Y-90 Radioactive Glass Microspheres and EMBOLD™ Fibered Coil, as well as our drug-eluting portfolio within our vascular franchise led by our Ranger™ Drug Coated Balloon.

Emerging Markets

As part of our strategic imperative to drive global expansion, we are seeking to grow net sales and market share by expanding our global presence, including in Emerging Markets. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.

Our Emerging Markets' net sales represented 16 percent and 17 percent of our consolidated net sales during the second quarter and first six months of 2024, respectively, and 16 percent during the second quarter and first six months of 2023. During the second quarter of 2024, our Emerging Markets net sales grew 14.8 percent on a reported basis, which included operational net sales growth of 19.3 percent and a negative impact of 460 basis points from foreign currency fluctuations, compared to the prior year period. During the first six months of 2024, our Emerging Markets net sales grew 18.5 percent on a reported basis, which included operational net sales growth of 23.5 percent and a negative impact of 500 basis points from foreign currency fluctuations, compared to the prior year period. Operational growth in both periods was driven primarily by growth in China, fueled by the breadth of our portfolio and focus on innovation and strong commercial execution.

Economic Environment

Our business has been impacted by global supply chain disruptions, which have continued to improve in recent quarters, however challenges still exist. We have experienced, and may continue to experience, increases in cost and limited availability of certain raw materials, components, and other inputs necessary to manufacture and distribute our products due to constraints and continued inflation within the global supply chain, as well as increases in wage costs and the cost and time to distribute our products. Uncertainty around inflationary pressures, interest rates, monetary policy and changes in tax laws could potentially cause new, or exacerbate existing, economic challenges that we may face, including the impact of foreign currency fluctuations on our results of operations, or result in an economic downtown or recession, which could negatively impact our business operations and results. Existing and future potential geopolitical dynamics, including matters related to the Russia/Ukraine war, Israel/Hamas war, as well as tension in the Taiwan strait, may create economic, supply chain, energy, and other challenges, including disruptions to business operations, which impact, and may in the future negatively impact, our business. In particular, international conflicts could create instability, have and may further result in sanctions, tariffs, and other measures that restrict international trade and may negatively affect our business operations and results.

43

Gross Profit

Our Gross profit was $2.850 billion for the second quarter of 2024, $2.542 billion for the second quarter of 2023, $5.498 billion for the first six months of 2024 and $4.891 billion for the first six months of 2023. The following is a reconciliation of our gross profit margin and a description of the drivers of the changes from period to period:
Percentage of Net Sales
Three MonthsSix Months
Gross profit margin - period ended June 30, 202370.6%70.0%
Sales pricing, volume and mix(0.3)0.4
Net impact of foreign currency fluctuations0.20.0
All other, including inventory charges and other period expenses(1.3)(1.4)
Gross profit margin - period ended June 30, 202469.2%68.9%

The primary factors contributing to the decrease in our gross profit margin in the second quarter of 2024, as compared to the same period in the prior year, were inventory charges, including related to the POLARx™ cryoablation system given the strong commercial adoption of our Farapulse™ Pulsed Field Ablation System in the U.S., and other period expenses. These impacts were partially offset by favorable foreign currency fluctuations. The decrease in our gross profit margin in the first six months of 2024, as compared to the same period in the prior year, resulted primarily from inventory charges, including related to the POLARx™ cryoablation system given the strong commercial adoption of our Farapulse™ Pulsed Field Ablation System, and other period expenses, partially offset by increased sales of higher margin products.

Operating Expenses

The following table provides a summary of our key operating expenses:
 Three Months Ended June 30,Six Months Ended June 30,
 2024202320242023
(in millions)$% of Net Sales$% of Net Sales$% of Net Sales$% of Net Sales
Selling, general and administrative expenses$1,446 35.1 %$1,354 37.6 %$2,810 35.2 %$2,570 36.8 %
Research and development expenses383 9.3 %359 10.0 %749 9.4 %695 10.0 %

Selling, General and Administrative expenses (SG&A Expenses)

During the second quarter of 2024, SG&A expenses increased $92 million, or 7 percent, compared to the prior year period and were 250 basis points lower as a percentage of net sales. During the first six months of 2024, SG&A expenses increased $241 million, or 9 percent, compared to the prior year period and were 160 basis points lower as a percentage of net sales. The increase in SG&A expenses in both periods was primarily due to higher selling costs driven by higher global net sales and costs to support recent and upcoming product launches, including the Farapulse™ Pulsed Field Ablation System.

Research and Development expenses (R&D Expenses)

We remain committed to advancing medical technologies and investing in meaningful R&D projects across our businesses. During the second quarter of 2024, R&D expenses increased $24 million, or 7 percent, compared to the prior year period and were 70 basis points lower as a percentage of net sales. During the first six months of 2024, R&D expenses increased $53 million, or 8 percent, compared to the prior year period, and were 60 basis points lower as a percentage of net sales. R&D expenses increased in both periods as a result of investments across our businesses in order to maintain a pipeline of new products that we believe will contribute to profitable sales growth.

44

Other Operating Expenses

The following provides a summary of certain of our other operating expenses, which are excluded by management for purposes of evaluating operating performance; refer to Additional Information for a further description.

Amortization Expense

During the second quarter of 2024, Amortization expense increased $3 million, or 2 percent, compared to the prior year period. In the first six months of 2024, Amortization expense increased $14 million, or 3 percent, compared to the prior year period. The increase in Amortization expense during both periods was driven by the addition of amortizable intangible assets associated with our recent acquisitions.

Intangible Asset Impairment Charges

We recorded Intangible asset impairment charges of $276 million in the second quarter and first six months of 2024 and $57 million in the second quarter and first six months of 2023. The impairment charges recorded in 2024 were associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively. Intangible assets acquired from Cryterion were impaired due to strong commercial adoption of our Farapulse™ Pulsed Field Ablation System and the resulting lower revenue projections and cannibalization of our cryoablation business in major markets like the U.S. Intangible assets acquired from Devoro were impaired following management's decision to cancel the related program in the second quarter of 2024. Refer to Note C – Goodwill and Other Intangible Assets to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q and Critical Accounting Policies and Estimates contained in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of our most recent Annual Report on Form 10-K for additional details and a discussion of key assumptions used in our intangible asset impairment testing and future events that could have a negative impact on the recoverability of our intangible assets.

Contingent Consideration Net Expense (Benefit)

To recognize changes in the fair value of our contingent consideration liability, we recorded net charges of $2 million in the second quarter of 2024, $19 million in the second quarter of 2023, $18 million in the first six months of 2024 and $31 million in the first six months of 2023. The net charges recorded in the second quarter and first six months of 2024 related to an increase in expected payments for achievement of revenue-based earn outs as a result of over-performance. In addition, we made payments of $133 million and $73 million associated with prior acquisitions during the first six months of 2024 and 2023, respectively, following the achievement of revenue-based earnouts. Refer to Note B – Acquisitions and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for additional details related to our contingent consideration arrangements.

Restructuring and Restructuring-related Net Charges (Credits)

On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan). The 2023 Restructuring Plan will advance our Global Supply Chain Optimization strategy, which is intended to simplify our manufacturing and distribution network by transferring certain production lines among facilities and drive operational efficiencies and resiliency. Key activities under the 2023 Restructuring Plan will also include optimizing certain functional capabilities to achieve cost synergies and better support business growth. For more information, refer to 2023 Restructuring Plan contained in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of our most recent Annual Report on Form 10-K.

Pursuant to the 2023 Restructuring Plan, we recorded restructuring charges in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations of $1 million and $5 million in the second quarter and first six months of 2024, respectively. The restructuring reserve balance was $29 million as of June 30, 2024. In addition, we recorded restructuring-related charges of $49 million and $92 million in the second quarter and first six months of 2024, respectively, primarily within Cost of products sold and SG&A Expenses. During the second quarter and first six months of 2023, we recorded restructuring charges of $16 million and $36 million, respectively, and restructuring-related charges of $26 million and $50 million, respectively, and the restructuring reserve balance as of December 31, 2023 was $41 million.

45

Litigation-related Net Charges (Credits)

We did not record any litigation-related net charges (credits) during the second quarter and first six months of 2024 or 2023. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within SG&A expenses.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation, and therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with the financial covenant required by our credit arrangements. Refer to Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for discussion of our material legal proceedings.

Interest Expense
The following table provides a summary of our Interest expense and average borrowing rate:
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Interest expense (in millions)
$(77)$(70)$(146)$(135)
Average borrowing rate2.8 %2.9 %2.8 %2.8 %

Interest expense increased during the second quarter and first six months of 2024 compared to the prior year period primarily due to increased debt from the registered public offering of €2.000 billion in aggregate principal amount of euro-denominated senior notes during the first quarter of 2024. Our average borrowing rate remained relatively flat during the second quarter and first six months of 2024 compared to the prior year period. Refer to Liquidity and Capital Resources and Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for more information regarding our debt obligations.

Tax Rate

Our effective tax rate from continuing operations is presented below:
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Effective tax rate from continuing operations23.4 %36.6 %20.7 %32.9 %

Our reported tax rate is affected by recurring items such as the amount of our earnings subject to differing tax rates in foreign jurisdictions and the impact of certain receipts and charges that are taxed at rates that differ from our effective tax rate.

The primary reasons for the difference between the statutory rate and our reported tax rate in the second quarter and first six months of 2024 relate to certain charges for acquisition expenses, as well as certain benefits for intangible asset impairment charges and integration costs, and discrete benefits primarily related to stock-based compensation. In the second quarter and first six months of 2023, the primary difference between the statutory tax rate and our reported tax rate relates to acquisition-related charges, as well as certain benefits for integration costs, and discrete tax items primarily related to unrecognized tax benefits.

Effective January 1, 2024, many countries where we do business, including the United Kingdom, Japan, South Korea, Canada and many EU member states, adopted a global minimum effective tax rate of 15% based on the Pillar Two framework issued by the Organization for Economic Cooperation and Development (OECD). Other countries where we do business are also actively considering adopting the framework or are in various stages of enacting the framework into their country’s laws. While the Company continues to monitor legislative adoption of the Pillar Two rules by country, as well as for additional guidance from the OECD, there is significant uncertainty that exists regarding the interpretation of the detailed Pillar Two rules, whether such rules will be implemented consistently across taxing jurisdictions, how such rules interact with existing national tax laws and whether such rules are consistent with existing tax treaty obligations. Although the current impact of the adoption of a global minimum effective tax on our financial statements is not material, it is possible that the final adoption, implementation, and
46

interpretation of Pillar Two across all jurisdictions where we do business could have a material adverse impact on our financial position, results of operations, and cash flows.

Our operations presently benefit from various tax provisions of the Tax Cuts and Jobs act which are set to expire in 2025. If future legislation is unable to extend or modify these provisions, this could have a material adverse impact on our overall effective tax rate, financial condition, results of operations, and cash flows.

Critical Accounting Policies and Estimates

Our financial results are affected by the selection and application of accounting policies and methods. During the second quarter and first six months of 2024, there were no material changes to the application of critical accounting policies previously disclosed in our most recent Annual Report on Form 10-K.

Liquidity and Capital Resources

Based on our current business plan, we believe our existing balance of Cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, service and repay our existing debt and fund possible acquisitions for the next 12 months and for the foreseeable future.

As of June 30, 2024, we had $2.913 billion of unrestricted Cash and cash equivalents on hand, including approximately $83 million held by Acotec, a less than wholly owned entity of which we acquired a majority stake investment during the first quarter of 2023. The balance is comprised of $2.153 billion invested in money market funds and time deposits and $793 million in interest bearing and non-interest-bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn at market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer.

In 2021, we entered into our $2.750 billion revolving credit facility (as amended, supplemented or otherwise modified from time to time, the 2021 Revolving Credit Facility) with a global syndicate of commercial banks. On May 10, 2024, we entered into a third amendment to the 2021 Revolving Credit Facility credit agreement, which provided for, among other things, an extension of the scheduled maturity date to May 10, 2029, an amendment of the Ratings based pricing grid of the Applicable Margin, each as defined in the credit agreement, and reset the applicable date for purposes of determining the amounts of restructuring charges and restructuring-related expenses that may be excluded from consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the credit agreement, for purposes of our maximum leverage ratio covenant, from December 31, 2022 to March 31, 2024, as further discussed under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the 2021 Revolving Credit Facility or our commercial paper program as of June 30, 2024, resulting in an additional $2.750 billion of available liquidity.

For additional details related to our debt obligations, including our financial covenant requirement, refer to Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q.

The following provides a summary and description of our net cash inflows (outflows):
Six Months Ended June 30,
(in millions)20242023
Cash provided by (used for) operating activities$977 $848 
Cash provided by (used for) investing activities(556)(1,324)
Cash provided by (used for) financing activities1,593 (26)

Operating Activities

During the first six months of 2024, cash provided by (used for) operating activities increased $130 million compared to the prior year period primarily due to comparatively higher sales, operating income and slower inventory buildup due to improved macroeconomic supply chain conditions, offset by higher income tax and employee related payments.

47

Investing Activities

During the first six months of 2024, cash provided by (used for) investing activities included purchases of property, plant and equipment and internal use software of $334 million as well as payments for investments and acquisitions of certain technologies, net of investment proceeds of $139 million. During the first six months of 2023, cash used for investing activities included cash payments of $1.018 billion, net of cash acquired, for the acquisition of Apollo and a majority stake investment in Acotec, as well as purchases of property, plant and equipment and internal use software of $254 million. For more information on our acquisitions, refer to Note B – Acquisitions and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q.

Financing Activities

During the first six months of 2024, cash provided by (used for) financing activities included a registered public offering (the Offering) of €2.000 billion in aggregate principal amount of euro-denominated senior notes (the 2024 Eurobonds). The Offering resulted in cash proceeds of $2.145 billion, net of investor discounts and issuance costs. We used the net proceeds from the Offering of the 2024 Eurobonds to fund the repayment at maturity of our 3.450% Senior Notes due March 2024 and to pay accrued and unpaid interest with respect to such notes. Additionally, we plan to use the remaining net proceeds from the Offering to fund a portion of the purchase price of our announced agreement to acquire Axonics, Inc. (Axonics) and to pay related fees and expenses, and for general corporate purposes. If the Axonics acquisition is not consummated by the applicable outside date pursuant to the merger agreement or we choose to not pursue consummation of the acquisition, we will be required to redeem each series of the notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of such series of notes, plus accrued and unpaid interest, if any, to, but excluding, the date on which the notes will be redeemed. For more information, refer to Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q. Cash provided by (used for) financing activities in the first six months of 2023 included proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans of $90 million, cash used to net share settle employee equity awards of $52 million and payments of contingent consideration previously established in purchase accounting of $39 million.

Financial Covenant

As of June 30, 2024, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The credit agreement provides for higher leverage ratios, at our election, for the period following a Qualified Acquisition, as defined by the agreement, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have elected to designate the Axonics acquisition as a Qualified Acquisition under the credit agreement, and upon closing, will increase the maximum permitted leverage ratio at that time. The agreement also provides for an exclusion of any debt incurred to fund a Qualified Acquisition, until the earlier of the acquisition close date or date of abandonment, termination or expiration of the acquisition agreement. As of June 30, 2024, we excluded from our leverage ratio calculation $2.120 billion of debt incurred in connection with the Axonics acquisition. We believe that we have the ability to comply with the financial covenant for the next 12 months.

The financial covenant requirement, as amended on May 10, 2024, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions related to restructuring charges and restructuring-related expenses from December 31, 2022 to March 31, 2024. Permitted exclusions include up to $500 million in cash and non-cash restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of June 30, 2024, we had $453 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of June 30, 2024, we had $1.448 billion of the litigation exclusion remaining.
48

Contractual Obligations and Commitments

On June 18, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Silk Road Medical, Inc. (Silk Road Medical), a publicly traded medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is $27.50 in cash per share, or approximately $1.260 billion. The transaction is expected to be completed in the second half of 2024, subject to customary closing conditions. We plan to fund the acquisition through a mix of cash on hand and commercial paper, if needed. The Silk Road Medical business will be integrated into our Peripheral Interventions division.

On January 8, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Axonics, a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $71.00 in cash per share, or approximately $3.670 billion. On April 3, 2024, we and Axonics each received a request for additional information (Second Request) from the United States Federal Trade Commission (FTC) in connection with the FTC's review of the transaction. The issuance of the Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), until 30 days after both we and Axonics have substantially complied with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. We and Axonics are responding to the Second Request and continue to work cooperatively with the FTC in its review. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. We plan to fund the acquisition through a mix of cash on hand and net proceeds from the Offering. The Axonics business will be integrated into our Urology division.

Certain of our acquisitions involve the payment of contingent consideration. Refer to Note B – Acquisitions and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for further details regarding the estimated potential amount of future contingent consideration we could be required to pay associated with our acquisitions. There have been no other material changes to our contractual obligations and commitments as of June 30, 2024.

Equity

On June 1, 2023, in accordance with the terms of our MCPS, all outstanding shares of MCPS automatically converted into shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. The conversion rate for each share of MCPS was 2.3834 shares of common stock. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS, resulting in the retirement of the annualized approximately $55 million cash dividend payment on the MCPS.

We received $106 million during the first six months of 2024 and $90 million during the first six months of 2023 in proceeds from stock issuances related to our stock option and employee stock purchase plans. Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of our employees.

We did not repurchase any shares of our common stock during the first six months of 2024 or 2023. On December 14, 2020, our Board of Directors approved a new stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of June 30, 2024, we had the full amount remaining available under the authorization.

Legal Matters

For a discussion of our material legal proceedings refer to Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q and Note I – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

49

Recent Accounting Pronouncements
Information regarding new accounting pronouncements implemented since December 31, 2023, and relevant accounting pronouncements to be implemented in the future are included in Note N – New Accounting Pronouncements to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q.

Additional Information

Corporate Responsibility

Our sustainable environmental, social and governance (ESG) practices underpin all aspects of our global business. Our approach is aligned with the United Nations Sustainable Development Goals and our material topics and practices are informed by a broad range of internal and external stakeholders – locally, nationally and globally. Our employees around the world work with suppliers and other organizations that share our commitment to these practices that help address issues related to health inequity, economic disparity, climate change and environmental protection. Our global ESG vision and strategy is led by our ESG Executive Steering Committee and our vice president of ESG, who provides regular updates to our Board of Directors or committees thereof as appropriate. Our ESG team works closely with subject matter experts and key advisors from across the business to implement our ESG practices and determine how we measure and share progress. The importance of our ESG efforts is reinforced by a company wide scorecard that is part of our annual bonus program. For additional information on our sustainability efforts, as well as our Diversity, Equity and Inclusion initiatives, refer to our most recent Annual Report on Form 10-K. For additional information on our annual bonus plan, refer to our Proxy Statement for the 2024 Annual Meeting of Shareholders.
Cybersecurity

We have established controls and procedures to escalate enterprise level issues, including cybersecurity matters, to the appropriate management levels within our organization and our Board of Directors, or members or committees thereof, as appropriate. Under our framework, cybersecurity issues, including those involving vulnerabilities introduced by our use of third-party software, are analyzed by subject matter experts, including a crisis committee as needed in accordance with our incident response plans, for potential financial, operational, and reputational risks, based on, among other factors, the nature of the matter and breadth of impact. Matters determined to present potential material impacts to our financial results, operations, and/or reputation are immediately reported by management to the Board of Directors, or individual members or committees thereof, as appropriate, in accordance with our established escalation framework. In addition, we have established procedures to help ensure that members of management responsible for overseeing the effectiveness of disclosure controls are informed in a timely manner of known cybersecurity risks and incidents that may materially impact our operations and that timely public disclosure is made, as appropriate. For additional information on our risk management, strategy and governance around cybersecurity, refer to Part I, Item 1C. Cybersecurity in our most recent Annual Report on Form 10-K.

Stock Trading Policy

Our directors and executive officers are subject to our Stock Trading Policy, which is designed to facilitate compliance with insider trading laws and governs transactions in our common stock and related derivative securities. Our policy designates certain regular periods, dictated by release of financial results, in which trading is restricted for individuals in information-sensitive positions, including directors and executive officers. In addition, additional periods of trading restriction may be imposed as determined by the President and Chief Executive Officer, General Counsel, or Chief Financial Officer in light of material pending developments. Further, during permitted windows, certain individuals in information-sensitive positions are required to seek pre-clearance for trades from the General Counsel, who assesses whether there are any important pending developments which need to be made public before the individual may participate in the market.

Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our own Stock Trading Policy. A Rule 10b5-1 trading plan is a written document that pre-establishes the amount, prices and dates (or formulas for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of restricted stock units. These plans are entered into at a time when the person is not in possession of material non-public information about the Company. In addition to any plans described in Part II, Item 5 of this Quarterly Report on Form 10-Q, we disclose details regarding individual Rule 10b5-1 trading plans on the Investor Relations section of our website.

50

Use of Non-GAAP Financial Measures

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. Amounts are presented after-tax using our effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, “General Methodology and Use of Estimated Annual Effective Tax Rate.” Please refer to Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission for an explanation of each of these adjustments and the reasons for excluding each item.

The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the relevant sections of this Quarterly Report on Form 10-Q.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

51

Safe Harbor for Forward-Looking Statements

Certain statements that we may make from time to time, including statements contained in this Quarterly Report on Form 10-Q and information incorporated by reference herein, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” “aim,” "goal," "target," "continue," "hope," "may" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

The forward-looking statements in this Quarterly Report on Form 10-Q are based on certain risks and uncertainties, including the risk factors described in Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K and the specific risk factors discussed herein and in connection with forward-looking statements throughout this Quarterly Report on Form 10-Q, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this Quarterly Report on Form 10-Q. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve environmental, social and governance goals and commitments; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, refer to Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A. Risk Factors in subsequent Quarterly Reports on Form 10-Q that we will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this Quarterly Report on Form 10-Q.

The following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements. For further discussion of these and other risk factors, refer to Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K.

Our Business

Risks associated with challenging or uncertain domestic and international economic conditions, including those related to interest rates, inflation, supply chain disruptions and constraints, adverse developments and volatility in the banking industry, currency devaluations or economies entering into periods of recession,

The impact of disruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products,

Labor shortages and the impact of inflation on the cost of raw materials and direct labor,

The impact of any future pandemics or other public health crises on worldwide economies, financial markets, manufacturing and distribution systems, including disruption in the manufacture or supply of certain components, materials or products, and business operations,

The impact of natural disasters, climate change or other catastrophic events on our ability to manufacture, distribute and sell our products,
52


The impact of competitive offerings, value-based procurement practices, government-imposed payback provisions and changes in reimbursement practices and policies on average selling prices for our products,

The ongoing impact on our business of physician alignment to hospitals, governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed,

The performance of, and physician and patient confidence in, our products and technologies or those of our competitors,

The impact and outcome of ongoing and future clinical trials and market studies undertaken by us, our competitors or other third parties or perceived product performance of our or our competitors' products,
 
Variations in clinical results, reliability or product performance of our and our competitors' products,

Our ability to acquire or develop, launch and supply new or next-generation products and technologies worldwide and in line with our commercialization strategies in a timely and successful manner and with respect to our recent acquisitions,

The effect of consolidation and competition in the markets in which we do business or plan to do business,

Our ability to achieve our projected level or mix of product sales, as some of our products are more profitable than others,

Our ability to attract and retain talent, including key personnel associated with acquisitions, and to maintain our corporate culture in a hybrid work environment,

The impact of enhanced requirements to obtain and maintain regulatory approval in the U.S. and around the world, including EU MDR and the associated timing and cost of product approval,
 
The impact of increased pressure on the availability and rate of third-party reimbursement for our products and procedures in the U.S. and around the world, including with respect to the timing and costs of creating and expanding markets for new products and technologies,

The issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission, and

The impact of potential goodwill and intangible asset impairment charges on our results of operations.

Regulatory Compliance, Litigation and Data Protection

The impact of health care policy changes and legislative or regulatory efforts in the U.S., the EU and around the world to modify product approval or reimbursement processes, including a trend toward demonstrating clinical outcomes, comparative effectiveness and cost efficiency, as well as the impact of other health care reform legislation,

Risks associated with our regulatory compliance and quality systems and activities in the U.S., the EU and around the world, including meeting regulatory standards applicable to manufacturing and quality processes,

The effect of global legal, regulatory or market responses to climate change and sustainability matters, including increased compliance burdens and costs to meet regulatory obligations,

Our ability to minimize or avoid future field actions or FDA warning letters, or similar actions by regulatory agencies around the world, relating to our products and processes and the ongoing inherent risk of potential physician advisories related to our or our competitors' products,

The impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes, economic pressures or otherwise, including under U.S. Anti-Kickback Statute, U.S. False Claims Act and similar laws in other jurisdictions, U.S. Foreign Corrupt Practices Act (FCPA) and similar laws in other jurisdictions, and U.S. and foreign export control, trade embargo and customs laws,
53


Costs and risks associated with current and future asserted litigation,

The effect of our litigation and risk management practices, including self-insurance and compliance activities on our loss contingencies, legal provisions and cash flows,
 
The impact of, diversion of management attention as a result of, and costs to cooperate with, litigate and/or resolve governmental investigations and our class action, product liability, contract and other legal proceedings,

The possibility of failure to protect our intellectual property rights and the outcome of patent litigation,

Our ability to secure our information technology and operational technology systems that support our business operations and protect our data integrity and products from a cyber-attack, other breach or other malicious actors that may have a material adverse effect on our business, reputation or results of operations including increased risks as an indirect result of the ongoing Russia/Ukraine war and Israel/Hamas war, and

The potential impact to internal control over financial reporting relating to potential restrictions to access to consigned inventory at customer locations for our inventory count procedures.

Innovation and Certain Growth Initiatives

The timing, size and nature of our strategic growth initiatives and market opportunities, including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunities,

Our ability to complete planned clinical trials successfully, obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates, including the successful completion of projects from in-process research and development,

Our ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable net sales growth opportunities as well as to maintain the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologies,

Our ability to develop, manufacture and market new products and technologies successfully and in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete,

Our ability to execute appropriate decisions to discontinue, write-down or reduce the funding of any of our research and development projects, including projects from in-process research and development from our acquisitions, in our growth adjacencies or otherwise,

Our dependence on acquisitions, alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions, alliances and investments, and

The potential failure to successfully integrate, collaborate or realize the expected benefits, including cost synergies, from strategic acquisitions, alliances and investments we have consummated or may consummate in the future.

International Markets

Our dependency on international net sales to achieve growth, and our ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete, including through investments in China and other Emerging Markets countries,

The timing and collectability of customer payments, as well as our ability to continue factoring customer receivables where we have factoring arrangements, or to enter new factoring arrangements with favorable terms,

54

The impact on pricing due to national and regional tenders, including value-based procurement practices and government-imposed payback provisions,

Geopolitical and economic conditions, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, tariffs and other protectionist measures,

The impact of the Russia/Ukraine war, Israel/Hamas war and tension in the Taiwan strait, and related, downstream effects thereof, including disruptions to operations or the impact of sanctions on U.S. manufacturers doing business in these regions,

Protection of our intellectual property,

Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including FCPA, EU MDR and similar laws in other jurisdictions,

Our ability to comply with U.S. and foreign export control, trade embargo and customs laws,

The impact of significant developments or uncertainties stemming from changes in the U.S. government following the 2024 presidential and congressional elections, including changes in U.S. trade policies, tariffs and the reaction of other countries thereto, particularly China, and

The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, operating expenses and resulting profit margins.

Liquidity

Our ability to generate sufficient cash flow to fund operations, capital expenditures, global expansion initiatives, any litigation settlements and judgments, share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and financial covenant compliance,

Our ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to us,

The unfavorable resolution of open tax matters, exposure to additional tax liabilities and the impact of changes in U.S. and international tax laws,

The unfavorable resolution of open litigation matters, exposure to additional loss contingencies and legal provisions,

The impact of examinations and assessments by domestic and international taxing authorities on our tax provisions, financial condition or results of operations,

The possibility of counterparty default on our derivative financial instruments, and

Our ability to collect outstanding and future receivables and/or sell receivables under our factoring programs.

Cost Reduction and Optimization Initiatives

Risks associated with changes made or expected to be made to our organizational and operational structure, pursuant to our restructuring plans as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs, and

Business disruption and employee distraction as we execute our global compliance program, restructuring and optimization plans and any divestitures of assets or businesses and implement our other strategic and cost reduction initiatives.
55

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.

Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily European manufacturing operations) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $5.898 billion as of June 30, 2024 and $5.899 billion as of December 31, 2023. A ten percent appreciation in the U.S. dollar’s value relative to the hedged currencies would increase the derivative instruments’ fair value by $256 million as of June 30, 2024 compared to $236 million as of December 31, 2023. A ten percent depreciation in the U.S. dollar’s value relative to the hedged currencies would decrease the derivative instruments’ fair value by $313 million as of June 30, 2024 compared to $288 million as of December 31, 2023. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impacts on our unaudited consolidated statements of operations.

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of June 30, 2024 or December 31, 2023. As of June 30, 2024, $10.633 billion in aggregate principal amount of our outstanding debt obligations was at fixed interest rates, representing approximately 100 percent of our total debt, on an amortized cost basis. As of June 30, 2024, our outstanding debt obligations at fixed interest rates were comprised of senior notes.

Refer to Note D – Hedging Activities and Fair Value Measurements to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for further information regarding our derivative financial instruments.

56

ITEM 4.CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our President and Chief Executive Officer (CEO) and our Executive Vice President and Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2024 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and ensure that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that, as of June 30, 2024, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

During 2022, we began a multi-year implementation of a new global enterprise resource planning (ERP) system, which will replace our existing system. The implementation is expected to occur in phases over the next several years. The portion of the transition to the new ERP system which we have completed to date resulted in changes in our internal control over financial reporting in 2023. No changes occurred during the first six months of 2024. As future phases are implemented, we expect the changes to have a material impact on our internal controls over financial reporting and we will evaluate whether these process changes necessitate further changes in the design of and testing for effectiveness of internal controls over financial reporting.

57

PART II
OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Refer to Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS

In addition to other information contained elsewhere in this report, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K, which could materially affect our business, financial condition or future results.

ITEM 5. OTHER INFORMATION

(c)

On May 23, 2024, Joseph M. Fitzgerald, our Executive Vice President and Group President, Cardiology, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Fitzgerald’s plan covers the sale of 553,370 shares of our common stock, including 492,532 shares to be acquired upon exercise of stock options. Transactions under Mr. Fitzgerald’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Fitzgerald’s plan will terminate on the earlier of May 20, 2026, or the date all shares subject to the plan have been sold.

ITEM 6. EXHIBITS (* documents filed or furnished with this report; # compensatory plans or arrangements)
3.1
10.1*
22
31.1* 
 
31.2* 
 
32.1* 
 
32.2* 
 
101.SCH*
Inline XBRL Taxonomy Extension Schema Document.
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*
Inline XBRL Taxonomy Extension Label Linkbase Document.
58

101.PRE*
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
59

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on August 1, 2024.

 
BOSTON SCIENTIFIC CORPORATION
 
 By:/s/ Daniel J. Brennan
   
  Name:Daniel J. Brennan
  Title:Executive Vice President and
Chief Financial Officer 
60
EX-10.1 2 ex101-bscthirdamendmentto2.htm EX-10.1 Document
Exhibit 10.1


        Execution Version

THIRD AMENDMENT
THIRD AMENDMENT, dated as of May 10, 2024 (this “Amendment”), to the Credit Agreement, dated as of May 10, 2021 (as amended by that certain Amendment dated as of December 21, 2022 and the Second Amendment, dated as of March 1, 2023, and as further amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among (i) BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Borrower”), (ii) the several banks and other financial institutions from time to time parties thereto (the “Lenders”) and (iii) WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent for the Lenders thereunder (in such capacity, the “Administrative Agent”).
W I T N E S S E T H:
WHEREAS, the Borrower, the Lenders and the Administrative Agent are parties to the Credit Agreement; and
WHEREAS, the Borrower has requested that the Lenders otherwise amend the Credit Agreement to refinance the Borrower’s existing $2,750,000,000 Revolving Credit Commitments as set forth herein; and
WHEREAS, the Lenders and the Administrative Agent are willing to agree to such amendments to the Credit Agreement and such other agreements, subject to the terms and conditions set forth herein;
NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the Borrower, the Lenders and the Administrative Agent hereby agree as follows:
SECTION 1.Defined Terms. Terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.
SECTION 2.Amendments to the Credit Agreement. Subject to the satisfaction of the conditions set forth in Section 3, (i) the Credit Agreement (including the schedules thereto) is hereby amended in accordance with Exhibit A hereto by deleting the stricken text (indicated textually in the same manner as the following example: stricken text) and by inserting the double-underlined text (indicated textually in the same manner as the following example: double-underlined text) and (ii) the Exhibits to the Credit Agreement are hereby amended and restated as set forth in Schedule I hereto.
SECTION 3.Conditions to Effectiveness. This Amendment shall become effective on the date (the “Amendment Effective Date”) on which:
(a)the Borrower, the Administrative Agent and the Lenders shall have executed and delivered to the Administrative Agent this Amendment, with a counterpart for each Lender and original Notes executed by the Borrower (in the case of Revolving Credit Notes, Multicurrency Notes or CAF Advance Notes), in favor of each Lender requesting a Note,
(b) The Administrative Agent shall have received a certificate of the Borrower, dated the Amendment Effective Date, substantially in the form of Exhibit F, with appropriate insertions and


        2




attachments, satisfactory in form and substance to the Administrative Agent, executed by the President or any Vice President and the Secretary or any Assistant Secretary of the Borrower,

(c) The Administrative Agent shall have received an executed legal opinion (addressed to the Administrative Agent and the Lenders) from Shearman & Sterling LLP, counsel for the Borrower, in form and substance reasonably satisfactory to the Administrative Agent. The Borrower hereby requests such counsel to deliver such opinion,

(d) Each of the representations and warranties made by the Borrower in or pursuant to the Loan Documents shall be true and correct in all material respects on and as of the Amendment Effective Date as if made on and as of the Amendment Effective Date,
(e) all accrued fees and reasonable out-of-pocket expenses (including the reasonable fees and expenses of counsel to the Arrangers) of the Arrangers through the Amendment Effective Date invoiced with reasonable detail at least three Business Days prior to the Amendment Effective Date in connection with the Loan Documents shall have been paid; provided that the Arrangers shall have provided an estimate and available reasonable detail five business days prior to the Amendment Effective Date,
(f) The Administrative Agent shall have received an unaudited consolidated balance sheet of the Borrower and its consolidated Subsidiaries and the related unaudited consolidated statements of operations and of cash flows for each fiscal quarter ended after December 31, 2023 (so long as such fiscal quarters have ended at least 40 days prior to the Amendment Effective Date). The Borrower’s filing of any required unaudited financial statements with respect to the Borrower on Form 10-Q will satisfy the requirements under this paragraph,
(g) No Default or Event of Default shall have occurred and be continuing on such date or after giving effect to the Loans requested to be made, or Letters of Credit requested to be issued, and
(i) The Administrative Agent shall have received at least three Business Days prior to the Amendment Effective Date all documentation and other information about the Borrower as has been reasonably requested by the Administrative Agent at least 10 Business Days prior to the Amendment Effective Date that is required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including without limitation the USA PATRIOT Act.
SECTION 4.Foreign Currencies. The parties hereto acknowledge that notwithstanding anything to the contrary set forth in this Amendment, the Suspension of Rights Agreement, dated as of November 30, 2021 and the Suspension of Rights Agreement, dated as of May 10, 2024, between the Borrower and the Administrative Agent remains in full force and effect.

SECTION 5.Representation and Warranties. To induce the Administrative Agent to enter into this Amendment, the Borrower hereby represents and warrants to the Administrative Agent and all of the Lenders as of the Amendment Effective Date that:
(a)Corporate Power; Authorization; Enforceable Obligations.


        3




(i)The Borrower has the corporate power and authority, and the legal right, to make and deliver this Amendment and to perform the Loan Documents, as amended by this Amendment, to which it is a party and has taken all necessary corporate action to authorize the execution, delivery and performance of this Amendment and the performance of the Loan Documents, as so amended, to which it is a party.
(ii)No consent or authorization of, filing with (other than the Borrower’s public filing of the Amendment on Form 8-K, if applicable), or notice to or other act by or in respect of, any Governmental Authority or any other Person is required with respect to the Borrower or any of its Subsidiaries in connection with the execution and delivery of this Amendment or with the performance, validity or enforceability of the Loan Documents, as amended by this Amendment, to which the Borrower is party.
(iii)This Amendment has been duly executed and delivered on behalf of the Borrower.
(iv)This Amendment and each Loan Document, as amended by this Amendment, to which the Borrower is a party constitutes a legal, valid and binding obligation of the Borrower enforceable against the Borrower in accordance with its terms, subject to the effects of bankruptcy, examination, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.
(b)Representations and Warranties. (i) The representations and warranties made by the Borrower in or pursuant to the Loan Documents are true and correct in all material respects on and as of the Amendment Effective Date, after giving effect to the effectiveness of this Amendment, as if made on and as of the Amendment Effective Date and (ii) after giving effect to this Amendment, no Default or Event of Default has occurred and is continuing.
SECTION 6.Payment of Expenses. The Borrower agrees to pay or reimburse the Administrative Agent for all of its reasonable and documented out-of-pocket costs and expenses incurred in connection with this Amendment, any other documents prepared in connection herewith and the transactions contemplated hereby, including, without limitation, the reasonable and documented fees and disbursements of counsel to the Administrative Agent.
SECTION 7.No Other Amendments; Confirmation. Except as expressly amended, modified and supplemented hereby, the provisions of the Credit Agreement and the other Loan Documents are and shall remain in full force and effect.
SECTION 8.Governing Law; Counterparts.
(a)This Amendment and the rights and obligations of the parties hereto and any claim, controversy, dispute, proceeding or cause of action (whether in contract, tort or otherwise and whether at law or in equity) based upon, arising out of or relating to this Amendment and the transactions contemplated hereby shall be governed by, and construed and interpreted in accordance with, the laws of


        4




the State of New York. The provisions of subsections 13.12 and 13.17 of the Credit Agreement are incorporated herein, mutatis mutandis.
(b)This Amendment may be executed by one or more of the parties to this Amendment on any number of separate counterparts (including by facsimile transmission or in electronic (i.e., “pdf” or “tif”) format), and all of said counterparts taken together shall be deemed to constitute one and the same instrument. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to this Amendment shall be deemed to include Electronic Signatures (as defined below), deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be. “Electronic Signatures” means any electronic symbol or process attached to, or associated with, any contract or other record and adopted by a person with the intent to sign, authenticate or accept such contract or record.
SECTION 9.Miscellaneous.
(a)Upon and after the Amendment Effective Date, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Credit Agreement, and each reference in the other Loan Documents to “the Credit Agreement”, “thereunder”, “thereof” or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement as modified hereby.  This Amendment shall constitute a Loan Document.
(b)The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Agent under any of the Loan Documents, nor, except as expressly provided herein, constitute a waiver or amendment of any provision of any of the Loan Documents. It is the intent of the parties hereto, and the parties hereto agree, that this Amendment shall not constitute a novation of the Credit Agreement, any other Loan Document or any of the rights, obligations or liabilities thereunder.



IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective proper and duly authorized officers as of the day and year first above written.
BOSTON SCIENTIFIC CORPORATION


By: /s/ Robert J. Castagna_______________________
Name: Robert J. Castagna
Title: Vice President and Treasurer


Signature Page to Third Amendment to Credit Agreement


WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent and as a Lender


By: /s/ Darin Mullis_______________________
Name: Darin Mullis
Title: Managing Director



BANK OF AMERICA, N.A.    ,
    as a Lender


By: /s/ Darren Merten______________________
Name: Darren Merten
Title: Director



BARCLAYS BANK PLC            ,
    as a Lender


By: /s/ Edward Pan________________________
Name: Edward Pan
Title: Vice President



CITIBANK, N.A.                ,
    as a Lender


By: /s/ Richard Rivera_____________________
Name: Richard Rivera
Title: Vice President



JPMORGAN CHASE BANK, N.A.    ,
    as a Lender


By: /s/ Marcelo Nicolas Osovi Conti__________
Name: Marcelo Nicolas Osovi Conti
Title: Vice President


Signature Page to Third Amendment to Credit Agreement



Signature Page to Third Amendment to Credit Agreement



Société Générale    ,
    as a Lender


By: /s/ Shelly Yu_______________________
Name: Shelly Yu
Title: Director



BNP Paribas    ,
    as a Lender


By: /s/ John Bosco_______________________
Name: John Bosco
Title: Managing Director


By: /s/ Claudia Zarate_____________________
Name: Claudia Zarate
Title: Managing Director



DEUTSCHE BANK AG NEW YORK BRANCH,
    as a Lender


By: /s/ Ming K. Chu_______________________
Name: Ming K. Chu
Title: Director


By: /s/ Marko Lukin _____________________
Name: Marko Lukin
Title: Vice President



GOLDMAN SACHS BANK USA        ,
    as a Lender


By: /s/ Nicholas Merino____________________
Name: Nicholas Merino
Title: Authorized Signatory

Signature Page to Third Amendment to Credit Agreement




Royal Bank of Canada    ,
    as a Lender


By: /s/ Scott MacVicar____________________
Name: Scott MacVicar
Title: Authorized Signatory


STANDARD CHARTERED BANK    ,
    as a Lender


By: /s/ Kristopher Tracy___________________
Name: Kristopher Tracy
Title: Director, Financing Solutions



THE BANK OF NOVA SCOTIA    ,
    as a Lender


By: /s/ Iain Stewart _____________________
Name: Iain Stewart
Title: Managing Director


The Toronto-Dominion Bank, New York Branch    ,
    as a Lender


By: /s/ Mike Tkach__ _____________________
Name: Mike Tkach
Title: Authorized Signatory


MUFG Bank LTD.     ,
    as a Lender


By: /s/ Reema Sharma_____________________
Name: Reema Sharma
Title: Authorized Signatory



Signature Page to Third Amendment to Credit Agreement

            
                                            Exhibit A

AMENDED CREDIT AGREEMENT

[See attached]




                EXHIBIT A

$2,750,000,000
CREDIT AGREEMENT
among
BOSTON SCIENTIFIC CORPORATION,
as Borrower,
The Several Lenders
from Time to Time Parties Hereto,
BANK OF AMERICA, N.A.,
BARCLAYS BANK PLC,
CITIBANK, N.A.,
JPMORGAN CHASE BANK, N.A.,
and
SOCIÉTÉ GÉNÉRALE,
as Documentation Agents,
and
WELLS FARGO BANK, NATIONAL ASSOCIATION,
as Administrative Agent
Dated as of May 10, 2021
____________________________________________________________________________
WELLS FARGO SECURITIES, LLC,
as Joint Lead Arranger and Bookrunner,

BofA SECURITIES, INC.,
BARCLAYS BANK PLC,
CITIBANK, N.A.,
JPMORGAN CHASE BANK, N.A.,
and
SOCIÉTÉ GÉNÉRALE
as Joint Lead Arrangers







TABLE OF CONTENTS
Page
SECTION 1 DEFINITIONS    1
1.1.    Defined Terms    1
1.2.    Other Definitional Provisions    32
1.3.    Rates    32
SECTION 2 AMOUNT AND TERMS OF COMMITMENTS    33
2.1.    Revolving Credit Commitments    33
2.2.    Procedure for Revolving Credit Borrowing    33
2.3.    Reserved    34
2.4.    Reserved    34
2.5.    Fees    34
2.6.    Termination or Reduction of Revolving Credit Commitments    34
2.7.    Repayment of Loans    35
2.8.    CAF Advances    35
2.9.    Procedure for CAF Advance Borrowing    35
2.10.    Repayment of CAF Advances    38
2.11.    Certain Restrictions with Respect to CAF Advances    38
2.12.    Multicurrency Commitments    38
2.13.    Repayment of Multicurrency Loans    38
2.14.    Procedure for Multicurrency Borrowing    39
2.15.    Termination or Reduction of Multicurrency Commitments    39
2.16.    Borrowings of Revolving Credit Loans and Refunding of Loans    39
2.17.    Increase of Revolving Credit Commitments    41
2.18.    Cash Collateral    41
2.19.    Defaulting Lenders    42
2.20.    Extension of Termination Date    44
SECTION 3 CERTAIN PROVISIONS APPLICABLE TO THE LOANS    46
3.1.    Optional and Mandatory Prepayments    46
3.2.    Conversion and Continuation Options    47
3.3.    Minimum Amounts and Maximum Number of Tranches    47
3.4.    Interest Rates and Payment Dates    48
3.5.    Computation of Interest and Fees    48
3.6.    Changed Circumstances    49
3.7.    Pro Rata Treatment and Payments    51
3.8.    Illegality    52
3.9.    Requirements of Law    53
    - i -

    TABLE OF CONTENTS
    (continued)
        Page

3.10.    Taxes    54
3.11.    Indemnity    57
3.12.    Change of Lending Office; Removal of Lender    58
3.13.    Evidence of Debt    58
SECTION 4 LOCAL CURRENCY FACILITIES    59
4.1.    Terms of Local Currency Facilities.    59
4.2.    Reporting of Local Currency Outstandings    60
SECTION 5 LETTERS OF CREDIT    61
5.1.    L/C Commitment    61
5.2.    Procedure for Issuance of Letter of Credit    61
5.3.    Fees and Other Charges    62
5.4.    L/C Participations    63
5.5.    Reimbursement Obligation of the Borrower    63
5.6.    Obligations Absolute    64
5.7.    Letter of Credit Payments    64
5.8.    Applications    64
5.9.    Reimbursement Obligations for Certain Letters of Credit Denominated in Currencies Other Than Dollars    65
5.10.    Replacement of Issuing Lenders    65
SECTION 6 REPRESENTATIONS AND WARRANTIES    65
6.1.    Financial Condition    65
6.2.    Corporate Existence; Compliance with Law    66
6.3.    Corporate Power; Consents and Authorization; Enforceable Obligations    66
6.4.    No Legal Bar    66
6.5.    No Default    67
6.6.    Taxes    67
6.7.    Federal Regulations    67
6.8.    ERISA    67
6.9.    Investment Company Act; Other Regulations    67
6.10.    Purpose of Loans    67
6.11.    Environmental Matters    67
6.12.    Disclosure    68
6.13.    No Change    68
6.14.    No Material Litigation    69
6.15.    Anti-Corruption Laws and Sanctions    69
SECTION 7 CONDITIONS PRECEDENT    69
7.1.    Conditions to Closing    69
    - ii -

    TABLE OF CONTENTS
    (continued)
        Page

7.2.    Conditions to Each Loan and Letter of Credit    70
SECTION 8 AFFIRMATIVE COVENANTS    71
8.1.    Financial Statements    71
8.2.    Certificates; Other Information    72
8.3.    Payment of Obligations    72
8.4.    Conduct of Business and Maintenance of Existence    72
8.5.    Maintenance of Property; Insurance    73
8.6.    Inspection of Property; Books and Records; Discussions    73
8.7.    Notices    73
SECTION 9 NEGATIVE COVENANTS    74
9.1.    Financial Covenant    74
9.2.    Limitation on Liens    74
9.3.    Limitation on Indebtedness pursuant to Receivables Transactions    75
9.4.    Limitation on Fundamental Changes    75
9.5.    Limitation on Indebtedness of Subsidiaries    76
SECTION 10 EVENTS OF DEFAULT    76
SECTION 11 THE AGENTS    78
11.1.    Appointment    78
11.2.    Delegation of Duties    78
11.3.    Exculpatory Provisions    79
11.4.    Reliance by Administrative Agent    79
11.5.    Notice of Default    79
11.6.    Non-Reliance on Administrative Agent and Other Lenders    79
11.7.    Indemnification    80
11.8.    Administrative Agent in Its Individual Capacity    80
11.9.    Successor Administrative Agent    80
11.10.    The Arrangers, the Bookrunner and the Documentation Agents    81
11.11.    Certain ERISA Matters    81
11.12.    Accidental Payments    82
SECTION 12 GUARANTEE    84
12.1.    Guarantee    84
12.2.    No Subrogation    84
12.3.    Amendments, etc. with respect to the Obligations; Waiver of Rights    85
12.4.    Guarantee Absolute and Unconditional    85
12.5.    Reinstatement    86
12.6.    Payments    86
    - iii -

    TABLE OF CONTENTS
    (continued)
        Page

12.7.    “Lenders”    86
SECTION 13 MISCELLANEOUS    87
13.1.    Amendments and Waivers    87
13.2.    Notices    88
13.3.    No Waiver; Cumulative Remedies    90
13.4.    Survival of Representations and Warranties    91
13.5.    Payment of Expenses and Taxes    91
13.6.    Successors and Assigns; Participations and Assignments    91
13.7.    Adjustments; Set-off    94
13.8.    Counterparts    95
13.9.    Severability    95
13.10.    Integration    95
13.11.    GOVERNING LAW    95
13.12.    Submission To Jurisdiction and Waivers    95
13.13.    Acknowledgements    96
13.14.    Confidentiality    96
13.15.    Loan Conversion/Participations    97
13.16.    Judgment    98
13.17.    WAIVERS OF JURY TRIAL    98
13.18.    USA Patriot Act Notice    98
13.19.    No Advisory or Fiduciary Responsibility    99
13.20.    Acknowledgement and Consent to Bail-In of Affected Financial Institutions    99
13.21.    Acknowledgement Regarding Any Supported QFCs    100

SCHEDULES
Schedule I    Names and Commitments of Lenders
Schedule II    Information Concerning Local Currency Loans
Schedule 9.2    Existing Liens
Schedule 9.5    Existing Subsidiary Indebtedness

EXHIBITS
Exhibit A    Form of Revolving Credit Note
Exhibit B    Form of CAF Advance Note
Exhibit C    Form of CAF Advance Request
Exhibit D    Form of CAF Advance Offer
Exhibit E    Form of CAF Advance Confirmation
Exhibit F    Form of Closing Certificate
Exhibit G    Form of Opinion of Counsel to Borrower
Exhibit H    Form of Assignment and Assumption
Exhibit I    Form of Local Currency Facility Addendum
    - iv -

    TABLE OF CONTENTS
    (continued)
        Page

Exhibit J-1 – J-4     U.S. Tax Compliance Certificate
Exhibit K    [Reserved]
Exhibit L    Form of Multicurrency Note
    - v -


CREDIT AGREEMENT, dated as of May 10, 2021, among (i) BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Borrower”), (ii) the several banks and other financial institutions or entities from time to time parties hereto (the “Lenders”), (iii) Bank of America, N.A., Barclays Bank PLC, Citibank, N.A., JPMorgan Chase Bank, N.A. and Société Générale, as Documentation Agents (each, in such capacity, a “Documentation Agent”, and collectively, the “Documentation Agents”) and (iv) WELLS FARGO BANK, NATIONAL ASSOCIATION, as administrative agent for the Lenders hereunder (in such capacity, the “Administrative Agent”).
W I T N E S S E T H:
WHEREAS, the Borrower has requested that the Lenders make Revolving Credit Loans (as defined below), CAF Advances (as defined below), Multicurrency Loans (as defined below) and Local Currency Loans (as defined below) to the Borrower on the terms and conditions set forth herein;
WHEREAS, the Lenders have agreed to make the credit facilities available upon the terms and subject to the conditions set forth herein; and
WHEREAS, the new credit facilities will be used to refinance the existing credit facilities under the Credit Agreement, dated as of December 19, 2018, among the Borrower, the lenders and the administrative agent party thereto (the “Existing Credit Facilities);
NOW, THEREFORE, in consideration of the premises, and of the mutual covenants and agreements herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto hereby agree as follows:
SECTION 1    

DEFINITIONS
1.1.    Defined Terms
.
As used in this Agreement, the following terms shall have the following meanings:
ABR”: for any day, a rate per annum equal to the greatest of (a) the Prime Rate in effect on such day, (b) the NYFRB Rate in effect on such day plus 1/2 of 1% per annum and (c) Adjusted Term SOFR for a one month Interest Period on such day (or if such day is not a Business Day, the immediately preceding Business Day) plus 1% per annum. For purposes hereof: “Prime Rate” shall mean the rate of interest per annum publicly announced from time to time by the Administrative Agent as its prime rate in effect (the Prime Rate not being intended to be the lowest rate of interest charged by the Administrative Agent in connection with extensions of credit to debtors); and “NYFRB Rate” shall mean, for any day, the greater of (a) the Federal Funds Effective Rate in effect on such day and (b) the Overnight Bank Funding Rate in effect on such day (or for any day that is not a Business Day, for the immediately preceding Business Day); provided that if none of such rates are published for any day that is a Business Day, the term “NYFRB Rate” means the rate for a federal funds transaction quoted at 11:00 A.M. on such day received by the Administrative Agent from a Federal funds broker of recognized standing selected by it (it being agreed the Prime Rate and NYFRB Rate will not be less than zero). Any change in the ABR due to a change in the Prime Rate, the NYFRB Rate or Adjusted Term SOFR shall be effective as of the
    - 1 -    


opening of business on the effective day of such change in the Prime Rate, the NYFRB Rate or Adjusted Term SOFR, respectively.
ABR Loans”: Revolving Credit Loans bearing interest based upon the ABR.
Accrued Legal Liabilities”: any cash litigation costs, including judgments, orders, awards, settlements and related legal costs, that are accrued prior to, and unpaid as of, December 31, 2022.
Additional Lender”: as defined in subsection 2.20(c).
Additional Revolving Credit Commitment”: as defined in subsection 2.17.
Adjusted Aggregate Committed Outstandings”: with respect to each Lender, the Aggregate Committed Outstandings of such Lender, plus the amount of any participating interests purchased by such Lender pursuant to subsection 13.15, minus the amount of any participating interests sold by such Lender pursuant to subsection 13.15.
Adjusted Term SOFR” means, for purposes of any calculation, the rate per annum equal to (a) Term SOFR for such calculation plus (b) the Term SOFR Adjustment; provided that if Adjusted Term SOFR as so determined shall ever be less than the Floor, then Adjusted Term SOFR shall be deemed to be the Floor.
Administrative Agent”: as defined in the preamble hereto.
Affected Financial Institution”: (a) any EEA Financial Institution or (b) any UK Financial Institution.
Affiliate”: as to any Person, any other Person (other than a Subsidiary) which, directly or indirectly, is in control of, is controlled by, or is under common control with, such Person. For purposes of this definition, “control” of a Person means the power, directly or indirectly, either to (a) vote 10% or more of the securities having ordinary voting power for the election of directors of such Person or (b) direct or cause the direction of the management and policies of such Person, whether by contract or otherwise.
Agency Fee Letter”: the agency fee letter, dated April 1410, 20212024, between Wells Fargo and the Borrower.
Agent Parties”: as defined in subsection 13.2(c).
Agents”: the collective reference to the Administrative Agent, the Documentation Agents, the Arrangers and the Bookrunner.
Aggregate Exposure Percentage”: as defined in the definition of “Majority Lenders.”
Aggregate Available Multicurrency Commitments”: as at any date of determination with respect to all Multicurrency Lenders, an amount in Dollars equal to the sum of the Available Multicurrency Commitments of all Multicurrency Lenders on such date.
    - 2 -


Aggregate Available Revolving Credit Commitments”: as at any date of determination with respect to all Lenders, an amount in Dollars equal to the sum of the Available Revolving Credit Commitments of all Lenders on such date.
Aggregate Committed Outstandings”: as at any date of determination with respect to any Lender, an amount in Dollars equal to the sum of (a) the Aggregate Revolving Credit Outstandings of such Lender on such date, (b) the Dollar Equivalent of the Aggregate Multicurrency Outstandings of such Lender on such date, and (c) the Dollar Equivalent of the Aggregate Local Currency Outstandings of such Lender on such date.
Aggregate Local Currency Outstandings”: as at any date of determination with respect to any Lender, an amount in the applicable Local Currencies equal to the aggregate unpaid principal amount of such Lender’s Local Currency Loans.
Aggregate Multicurrency Outstandings”: as at any date of determination with respect to any Lender, an amount in the applicable Available Foreign Currencies equal to the aggregate unpaid principal amount of such Lender’s Multicurrency Loans.
Aggregate Revolving Credit Commitments”: the aggregate amount of the Revolving Credit Commitments of all of the Lenders.
Aggregate Revolving Credit Outstandings”: as at any date of determination with respect to any Lender, an amount in Dollars equal to the sum of (a) the aggregate unpaid principal amount of such Lender’s Revolving Credit Loans on such date plus (b) such Lender’s Revolving Credit Commitment Percentage of the L/C Obligations.
Aggregate Total Outstandings”: as at any date of determination with respect to any Lender, an amount in Dollars equal to the sum of (a) the Aggregate Revolving Credit Outstandings of such Lender on such date, (b) the Dollar Equivalent of the aggregate unpaid principal amount of such Lender’s CAF Advances on such date, (c) the Dollar Equivalent of the Aggregate Multicurrency Outstandings of such Lender on such date and (d) the Dollar Equivalent of the Aggregate Local Currency Outstandings of such Lender on such date.
Agreement”: this Credit Agreement, as amended, amended and restated, supplemented or otherwise modified from time to time.
Agreement Currency”: as defined in subsection 13.16(b).
Anti-Corruption Laws”: the United States Foreign Corrupt Practices Act of 1977, as amended, and all similar laws, rules, and regulations of any jurisdiction applicable to the Borrower or its Subsidiaries prohibiting bribery or corruption.
Applicable Margin”: with respect to each day for each Type of Loan, the rate per annum based on the Ratings in effect on such day, as set forth under the relevant column heading below:
    - 3 -


RatingSOFR Loans/
Multicurrency Loans
ABR Loans
Rating I0.680%0.0%
Rating II
0.795%0.0%
Rating III
0.910%0.0%
Rating IIIV
1.015%0.015%
Rating IV
1.100%0.100%
Rating V1.400%0.400%
Applicable Screen Rate”: as defined in the definition of “Impacted Interest Period”.
Application”: an application, in such form as the Issuing Lender may specify from time to time, requesting the Issuing Lender to issue a Letter of Credit.
Arrangers”: Wells Fargo Securities, LLC, BofA Securities, Inc. (or any other registered broker-dealer wholly-owned by Bank of America Corporation to which all or substantially all of Bank of America Corporation’s or any of its subsidiaries’ investment banking, commercial lending services or related businesses may be transferred following the date of this Agreement), Barclays Bank PLC, Citibank, N.A., JPMorgan Chase Bank, N.A. and Société Générale as Joint Lead Arrangers for this Agreement.
Assignee”: as defined in subsection 13.6(c).
Australian Dollar”: the lawful currency of the Commonwealth of Australia.
Available Foreign Currencies”: (a) Euro, Japanese Yen, Australian Dollar, Canadian Dollar, Singapore Dollar, Swiss Franc and Pound Sterling; provided that (i) as of the Second Amendment Effective Date, Japanese Yen, Swiss Franc and Pound Sterling are subject to that certain Suspension of Rights Agreement, dated as of November 30, 2021, between the Borrower and the Administrative Agent and (ii) as of the Third Amendment Effective Date, Canadian Dollar and Singapore Dollar are subject to that certain Suspension of Rights Agreement, dated as of May 10, 2024, between the Borrower and the Administrative Agent and (b) any other available and freely convertible non-Dollar currency selected by the Borrower and approved by the Administrative Agent and the Multicurrency Lenders.
Available Foreign Currency Equivalent”: for any amount of any Available Foreign Currency, at the time of determination thereof, (a) if such amount is expressed in such Available Foreign Currency, such amount and (b) if such amount is expressed in Dollars, the equivalent of such amount in such Available Foreign Currency determined by using the rate of exchange for the purchase of such Available Foreign Currency with Dollars last provided (either by publication or otherwise provided to the Administrative Agent) by the applicable Reuters source on the Business Day (New York City time) immediately preceding the date of determination or if such service ceases to be available or ceases to provide a rate of exchange for the purchase of such Available Foreign Currency with Dollars, as provided by such other publicly available information service which provides that rate of exchange at such time in place of Reuters chosen by the Administrative Agent in its sole discretion (or if such service ceases to be available or ceases to provide such rate of exchange, the equivalent of such amount in Dollars as determined by the Administrative Agent using any method of determination it deems appropriate in its sole discretion).
    - 4 -


Available Multicurrency Commitment”: as at any date of determination with respect to any Multicurrency Lender (after giving effect to the making and payment of any Revolving Credit Loans required to be made on such date pursuant to subsection 2.16), an amount in Dollars equal to the lesser of (a) the excess, if any, of (i) the amount of such Multicurrency Lender’s Multicurrency Commitment in effect on such date over (ii) the Dollar Equivalent of the Aggregate Multicurrency Outstandings of such Multicurrency Lender on such date, and (b) the excess, if any, of (i) the amount of such Lender’s Revolving Credit Commitment in effect on such date over (ii) the Aggregate Committed Outstandings of such Lender on such date.
Available Revolving Credit Commitment”: as at any date of determination with respect to any Lender (after giving effect to the making and payment of any Revolving Credit Loans required to be made on such date pursuant to subsection 2.16), an amount in Dollars equal to the excess, if any, of (a) the amount of such Lender’s Revolving Credit Commitment in effect on such date over (b) the Aggregate Committed Outstandings of such Lender on such date.
Available Tenor” means, as of any date of determination and with respect to any then-current Benchmark for any Currency, as applicable, (a) if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining the length of an interest period pursuant to this Agreement or (b) otherwise, any payment period for interest calculated with reference to such Benchmark (or component thereof) that is or may be used for determining any frequency of making payments of interest calculated with reference to such Benchmark, in each case, as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of “Interest Period” pursuant to Section 3.6(b)(iv).
Bail-In Action”: the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.
Bail-In Legislation”: (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation rule or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).
Bank of America”: Bank of America, N.A.
Bankruptcy Code”: the Bankruptcy Code in Title 11 of the United States Code, as amended, modified, succeeded or replaced from time to time.
Benchmark” means, initially, with respect to any (a) Obligations, interest, fees, commissions or other amounts denominated in, or calculated with respect to, Dollars, the Term SOFR Reference Rate; provided that if a Benchmark Transition Event has occurred with respect to the Term SOFR Reference Rate or then-current Benchmark for Dollars, then “Benchmark” means, with respect to such Obligations, interest, fees, commissions or other amounts, the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section 3.6(b)(i) and (b) Obligations, interest, fees, commissions or other amounts denominated in, or calculated with respect to any Available Foreign Currency, the applicable benchmark rate for Multicurrency Loans denominated
    - 5 -


in such Currency; provided that if a Benchmark Transition Event or an Early Opt-In Election, as applicable, has occurred with respect to the then-current Benchmark for such Currency, then “Benchmark” means, with respect to such Obligations, interest, fees, commissions or other amounts, the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section 3.6(b)(i).
Benchmark Replacement” means, with respect to any Benchmark Transition Event for any then-current Benchmark, the sum of: (a) the alternate benchmark rate that has been selected by the Administrative Agent and the Borrower as the replacement for such Benchmark giving due consideration to (i) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement for such Benchmark for syndicated credit facilities denominated in the applicable Currency at such time and (b) the related Benchmark Replacement Adjustment; provided that, if such Benchmark Replacement as so determined would be less than the Floor, such Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents.
Benchmark Replacement Adjustment”: with respect to any replacement of any then-current Benchmark with an Unadjusted Benchmark Replacement for any applicable Available Tenor, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Administrative Agent and the Borrower giving due consideration to (a) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for syndicated credit facilities at such time denominated in the applicable Currency.
Benchmark Replacement Conforming Changes”: means, with respect to the use or administration of an initial Benchmark or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of “Base Rate”, the definition of “Business Day,” the definition of “London Banking Day,” the definition of “U.S. Government Securities Business Day,” the definition of “Interest Period” or any similar or analogous definition (or the addition of a concept of “interest period”), timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods, the applicability of Section 3.11 and other technical, administrative or operational matters) that the Administrative Agent decides (in consultation with the Borrower) may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent determines that no market practice for the administration of any such rate exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents)..
Benchmark Replacement Date” means the earliest to occur of the following events with respect to the then-current Benchmark for any Currency:
    - 6 -


(a)    in the case of clause (a) or (b) of the definition of “Benchmark Transition Event,” the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof); or
(b)    in the case of clause (c) of the definition of “Benchmark Transition Event,” the first date on which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative; provided that such non-representativeness will be determined by reference to the most recent statement or publication referenced in such clause (c) and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date.
For the avoidance of doubt, the “Benchmark Replacement Date” will be deemed to have occurred in the case of clause (a) or (b) with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).
Benchmark Transition Event” means, with respect to the then-current Benchmark for any Currency, the occurrence of one or more of the following events with respect to such Benchmark:
(a)    a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely; provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof);
(b)    a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Board, the Federal Reserve Bank of New York, the central bank for the Currency applicable to such Benchmark, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof); or
(c)    a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative.
For the avoidance of doubt, a “Benchmark Transition Event” will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).
    - 7 -


Benchmark Transition Start Date” means, with respect to any Benchmark for any Currency, (a) in the case of a Benchmark Transition Event, the earlier of (i) the applicable Benchmark Replacement Date and (ii) if such Benchmark Transition Event is a public statement or publication of information of a prospective event, the 90th day prior to the expected date of such event as of such public statement or publication of information (or if the expected date of such prospective event is fewer than 90 days after such statement or publication, the date of such statement or publication) and (b) in the case of an Early Opt-in Election, the date specified by the Administrative Agent or the Majority Lenders, as applicable, by notice to the Borrower, the Administrative Agent (in the case of such notice by the Majority Lenders) and the Lenders.
Benchmark Unavailability Period” means, with respect to any then-current Benchmark for any Currency, the period (if any) (x) beginning at the time that a Benchmark Replacement Date with respect to such Benchmark pursuant to clauses (a) or (b) of that definition has occurred if, at such time, no Benchmark Replacement has replaced such Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 3.6(b) and (y) ending at the time that a Benchmark Replacement has replaced such Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 3.6(b).
BBSY”: with respect to Australian Dollars for any Interest Period (i) the rate of interest per annum equal to the per annum rate of interest which appears as “BID” on the page designated as “BBSY” on the Reuters Monitor System (or such other comparable page as may, in the reasonable opinion of the Administrative Agent and in consultation with the Borrower, replace such BBSY page on such system for the purpose of displaying the bank bill swap rates) with maturities comparable to such Interest Period at approximately 10:30 am (Sydney, Australia time) on the first day of such Interest Period or (ii) if such rate is not available at such time for any reason, the rate per annum determined by the Administrative Agent as the average of the buying rates quoted to the Administrative Agent at or around 10:30 am (Sydney, Australia time) on the first day of such Interest Period for bills of exchange accepted by leading Australian banks which have a tenor equal to such Interest Period. If any Interest Period is an Impacted Interest Period, then BBSY shall be the Interpolated Rate for such Interest Period. BBSY shall not be less than zero.
Beneficial Ownership Regulation”: 31 C.F.R. § 1010.230.
Benefit Plan”: any of (a) an “employee benefit plan” (as defined in Section 3(3) of ERISA) that is subject to Title I of ERISA, (b) a “plan” as defined in Section 4975 of the Code to which Section 4975 of the Code applies and (c) any Person whose assets include (for purposes of the Plan Asset Regulations or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such “employee benefit plan” or “plan”.
benefited Lender”: as defined in subsection 13.7(a).
Board”: the Board of Governors of the Federal Reserve System.
Bookrunner”: Wells Fargo Securities, LLC as the sole Bookrunner for this Agreement.
Borrower”: as defined in the preamble hereto.
Borrower Materials”: as defined in subsection 8.2.
    - 8 -


Borrowing Date”: any Business Day specified in a notice pursuant to subsection 2.2, 2.9 or 2.14 as a date on which the Borrower requests the Lenders to make Loans hereunder or, with respect to Local Currency Loans, the date on which a Foreign Subsidiary Borrower requests Local Currency Lenders to make Local Currency Loans to such Foreign Subsidiary Borrower pursuant to the Local Currency Facility to which such Foreign Subsidiary Borrower and Local Currency Lenders are parties.
Business”: as defined in subsection 6.11(b).
Business Day”: a day other than a Saturday, Sunday or other day on which commercial banks in New York are authorized or required by law to close; provided that when such term is used for the purpose of determining the date on which the Eurocurrency Base Rate is determined under this Agreement for any Loan denominated in euro for any Interest Period therefor and for purposes of determining the first and last day of any such Interest Period, references in this Agreement to Business Days shall be deemed to be references to Target Operating Days; provided, further,
(a)    if such day relates to any interest rate settings as to a SOFR Loan, any fundings, disbursements, settlements and payments in Dollars in respect of any such SOFR Loan, or any other dealings in Dollars to be carried out pursuant to this Agreement in respect of any such SOFR Loan, means any such day that is also a U.S. Government Securities Business Day;
(b)    if such day relates to any interest rate settings as to a Multicurrency Loan or CAF Advance denominated in a currency other than Dollars or euro, means any such day on which dealings in deposits in the relevant currency are conducted by and between banks in the London or other applicable offshore interbank market for such currency; and
(c)    if such day relates to any fundings, disbursements, settlements and payments in a currency other than Dollars or euro in respect of a Multicurrency Loan or a CAF Advance denominated in a currency other than Dollars or euro, or any other dealings in any currency other than Dollars or euro to be carried out pursuant to this Agreement in respect of any such Multicurrency Loan or CAF Advance (other than any interest rate settings), means any such day on which banks are open for foreign exchange business in the principal financial center of the country of such currency.
CAF Advance”: each competitive advance facility advance made pursuant to subsection 2.8.
CAF Advance Availability Period”: the period from and including the Closing Date to and including the date which is seven days prior to the Termination Date.
CAF Advance Confirmation”: each confirmation by the Borrower of its acceptance of CAF Advance Offers, which confirmation shall be substantially in the form of Exhibit E and shall be delivered to the Administrative Agent by facsimile transmission.
CAF Advance Interest Payment Date”: as to each CAF Advance, each interest payment date specified by the Borrower for such CAF Advance in the related CAF Advance Request.
CAF Advance Maturity Date”: as to any CAF Advance, the date specified by the Borrower pursuant to subsection 2.9(d)(ii) in its acceptance of the related CAF Advance Offer.
CAF Advance Note”: as defined in subsection 3.13(e).
    - 9 -


CAF Advance Offer”: each offer by a Lender to make CAF Advances pursuant to a CAF Advance Request, which offer shall contain the information specified in Exhibit D and shall be delivered to the Administrative Agent by telephone, immediately confirmed by facsimile transmission.
CAF Advance Request”: each request by the Borrower for Lenders to submit bids to make CAF Advances, which request shall contain the information in respect of such requested CAF Advances specified in Exhibit C and shall be delivered to the Administrative Agent in writing, by facsimile transmission, or by telephone, immediately confirmed by facsimile transmission.
Canadian Dollar”: the lawful currency of Canada.
Capital Lease Obligations”: as to any Person, the obligations of such Person to pay rent or other amounts under any lease of (or other arrangement conveying the right to use) real or personal property, or a combination thereof, which obligations are required to be classified and accounted for as capital leases on a balance sheet of such Person under GAAP and, for the purposes of this Agreement, the amount of such obligations at any time shall be the capitalized amount thereof at such time determined in accordance with GAAP.
Capital Stock”: any and all shares, interests, participations or other equivalents (however designated) of capital stock of a corporation, any and all equivalent ownership interests in a Person (other than a corporation) and any and all warrants or options to purchase any of the foregoing.
Cash Collateralize”: to pledge and deposit with or deliver to the Administrative Agent, for the benefit of the Administrative Agent, an Issuing Lender (as applicable) and the Lenders, as collateral for L/C Obligations or obligations of Lenders to fund participations in respect thereof (as the context may require), cash or deposit account balances or, if an Issuing Lender benefiting from such collateral shall agree in its sole discretion, other credit support, in each case pursuant to documentation in form and substance reasonably satisfactory to (a) the Administrative Agent and (b) the Issuing Lender (as applicable). “Cash Collateral” shall have a meaning correlative to the foregoing and shall include the proceeds of such cash collateral and other credit support.
CDOR”: with respect to Canadian Dollars for any Interest Period, the rate per annum, equal to the average of the annual yield rates applicable to Canadian banker’s acceptances at or about 10:00 a.m. (Toronto, Canada time) on the first day of such Interest Period on the “CDOR Page” (or any display substituted therefor) of Reuters Monitor Money Rates Service (or such other page or commercially available source displaying Canadian interbank bid rates for Canadian Dollar bankers’ acceptances as may be designated by the Administrative Agent from time to time in consultation with the Borrower) for a term equivalent to such Interest Period (or if such Interest Period is not equal to a number of months, for a term equivalent to the number of months closest to such Interest Period). If any Interest Period is an Impacted Interest Period, then CDOR shall be the Interpolated Rate for such Interest Period. CDOR shall not be less than zero.
Closing Date”: May 10, 2021.
Code”: the Internal Revenue Code of 1986, as amended from time to time.
Commitment Period”: the period from and including the Closing Date to but excluding the Termination Date or such earlier date on which the Commitments shall terminate as provided herein.
    - 10 -


Commitments”: the collective reference to the Revolving Credit Commitments, Multicurrency Commitments and L/C Commitments.
Committed Outstandings Percentage”: on any date with respect to any Lender, the percentage which the Adjusted Aggregate Committed Outstandings of such Lender constitutes of the Adjusted Aggregate Committed Outstandings of all Lenders.
Commonly Controlled Entity”: an entity, whether or not incorporated, which is under common control with the Borrower within the meaning of Section 4001(a)(14)(A)-(B) of ERISA or is part of a group which includes the Borrower and which is treated as a single employer under Sections 414(b), 414(c), 414(m) and 414(o) of the Code.
Conduit Lender”: any special purpose corporation organized and administered by any Lender for the purpose of making Loans otherwise required to be made by such Lender and designated by such Lender in a written instrument; provided, that the designation by any Lender of a Conduit Lender shall not relieve the designating Lender of any of its obligations to fund a Loan under this Agreement if, for any reason, its Conduit Lender fails to fund any such Loan, and the designating Lender (and not the Conduit Lender) shall have the sole right and responsibility to deliver all consents and waivers required or requested under this Agreement with respect to its Conduit Lender; and provided, further, that no Conduit Lender shall (a) be entitled to receive any greater amount pursuant to subsection 3.9, 3.10, 3.11 or 13.5 than the designating Lender would have been entitled to receive in respect of the extensions of credit made by such Conduit Lender or (b) be deemed to have any Commitment.
Consolidated EBITDA”: of any Person for any period, without duplication, Consolidated Net Income of such Person and its Subsidiaries for such period plus, to the extent reflected as a charge in the statement of such Consolidated Net Income for such period, the sum of:
(a)    income tax expense, including any expenses resulting from income tax disputes with a Governmental Authority,
(b)    Consolidated Interest Expense of such Person and its Subsidiaries, amortization or writeoff of debt discount and debt issuance costs and commissions, discounts and other fees and charges associated with Indebtedness,
(c)    depreciation expense,
(d)    amortization or write-down of intangibles (including, but not limited to, goodwill) and organization costs,
(e)    any extraordinary, unusual or nonrecurring expenses or losses (to the extent any of the foregoing are non-cash items) (including, whether or not otherwise includable as a separate item in the statement of such Consolidated Net Income for such period, losses on sales of assets outside of the ordinary course of business (including as a result of write downs of goodwill or net intangible assets) and including special charges and purchased research and development charges in connection with acquisitions and other strategic alliances, inventory step-up charges, fair value adjustments, and unrealized investment impairments),
(f)    any non-cash stock compensation expense in accordance with GAAP,
    - 11 -


(g)    any cash litigation costs, including judgments, orders, awards, settlements and related legal costs paid during such period (net of any cash litigation or settlement payments received during such period) (“Cash Litigation Payments”), provided that, solely for the purposes of this definition, the aggregate amount of Cash Litigation Payments under this clause (g) since December 31, 2022 shall not exceed $1,000,000,000 plus all Accrued Legal Liabilities as set forth in the financial statements of the Borrower required to be delivered pursuant to Section 8.1 for the period ended December 31, 2022,
(h)    any cash or non-cash charges in respect of restructurings, plant closings, staff reductions, distributor network optimization initiatives, distribution technology optimization initiatives or other similar charges, provided that, solely for the purposes of this definition, the aggregate amount of all charges under this clause (h) shall not exceed $500,000,000 since DecemberMarch 31, 20222024,
(i)    any income or expense associated with business combinations following the adoption of FASB Statement No. 141(R), “Business Combinations - a replacement of FASB Statement No. 141”, which would have been treated as a cost of the acquisition (e.g., as goodwill) under FASB Statement No. 141, “Business Combinations” including income or expense relating to contingent consideration, and
(j)    any Non-Cash Charges, including those attributable to litigation, intangible asset impairment, intellectual property research and development charges;
and minus, to the extent included in the statement of such Consolidated Net Income for such period, the sum of
(a)    interest income (except to the extent deducted in determining Consolidated Interest Expense), and
(b)    any extraordinary, unusual or nonrecurring income or gains (to the extent any of the foregoing are non-cash items) (including, whether or not otherwise includable as a separate item in the statement of such Consolidated Net Income for such period, gains on the sales of assets outside of the ordinary course of business, inventory step-up charges, fair value adjustments, and unrealized investment impairments).
Consolidated Interest Expense”: of any Person for any period, total interest expense of such Person and its Subsidiaries for such period with respect to all outstanding Indebtedness of such Person and its Subsidiaries determined in accordance with GAAP (including, all net costs that are allocable to such period in accordance with GAAP).
Consolidated Leverage Ratio”: as at the last day of any period of four consecutive fiscal quarters of the Borrower, the ratio of (a) Consolidated Total Debt on such day to (b) Consolidated EBITDA of the Borrower and its Subsidiaries for such period.
Consolidated Net Income”: of any Person for any period, the consolidated net income (or loss) of such Person and its Subsidiaries for such period, determined on a consolidated basis in accordance with GAAP plus cash receipts received in connection with litigation related Non-Cash Charges and minus cash payments made in connection with such litigation related Non-Cash Charges.
    - 12 -


Consolidated Tangible Assets”: at any date, Consolidated Total Assets minus (without duplication) the net book value of all assets which would be treated as intangible assets, as determined on a consolidated basis in accordance with GAAP.
Consolidated Total Assets”: at any date, the net book value of all assets of the Borrower and its Subsidiaries as determined on a consolidated basis in accordance with GAAP.
Consolidated Total Debt”: at any date, an amount equal to the aggregate principal amount of all Indebtedness (excluding, for the avoidance of doubt, any operating leases) of the Borrower and its Subsidiaries at such date, determined on a consolidated basis in accordance with GAAP as in effect on the date of this Agreement and with subsection 1.2(e), provided that Indebtedness incurred to prefund a Qualified Acquisition shall not constitute Consolidated Total Debt for purposes of compliance with Section 9.1 until the earlier of (i) the Qualified Acquisition has closed or (ii) the date the consummation of such Qualified Acquisition has been abandoned, terminated or expired pursuant to the terms of the relevant acquisition documentation.
Continuing Directors”: as defined in subsection 10(j).
Contractual Obligation”: as to any Person, any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound.
Conversion Date”: any date on which either (a) an Event of Default under subsection 10(g) has occurred or (b) the Commitments shall have been terminated and/or the Loans shall have been declared immediately due and payable pursuant to Section 10.
Conversion Sharing Percentage”: on any date with respect to any Lender and any Loans of such Lender outstanding in any currency other than Dollars, the percentage of such Loans such that, after giving effect to the conversion of such Loans to Dollars and the purchase and sale by such Lender of participating interests as contemplated by subsection 13.15, the Committed Outstandings Percentage of such Lender will equal such Lender’s Revolving Credit Commitment Percentage on such date (calculated immediately prior to giving effect to any termination or expiration of the Commitments on the Conversion Date).
Converted Loans”: as defined in subsection 13.15(a).
Covered Party”: as defined in subsection 13.21(a).
Currencies” means Dollars and each Available Foreign Currency, and “Currency” means any of such Currencies.
Debtor Relief Laws”: the Bankruptcy Code, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the United States or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally.
Default”: any of the events specified in Section 10, whether or not any requirement for the giving of notice, the lapse of time, or both, or any other condition, has been satisfied.
    - 13 -


Defaulting Lender”: subject to subsection 2.19(b), any Lender that, as reasonably determined by the Administrative Agent, (a) has failed to perform any of its funding obligations hereunder, including in respect of its Loans or participations in respect of Letters of Credit, within two Business Days of the date required to be funded by it hereunder (other than as a result of a good faith dispute with respect to amount), (b) has notified the Borrower, the Administrative Agent or any Lender that it does not intend to comply with its funding obligations or has made a public statement to that effect with respect to its funding obligations hereunder or generally under other agreements in which it commits to extend credit, (c) has failed, within three Business Days after request by the Administrative Agent, to provide a certification in writing from an authorized officer of such Lender that it will comply with its funding obligations (and is financially able to meet such obligations), provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon the Administrative Agent’s receipt of such certification in form and substance satisfactory to it and the Borrower, or (d) has (i) become the subject of a proceeding under any Debtor Relief Law or a Bail-In Action, (ii) had a receiver, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or a custodian appointed for it, or (iii) taken any action in furtherance of, or indicated its consent to, approval of or acquiescence in any such proceeding or appointment; provided that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority as long as such ownership or acquisition interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made by such Lender.
Disposition” or “Dispose”: the sale, transfer, license, lease or other disposition, whether effected pursuant to a Division or otherwise (including any sale and leaseback transaction), of any property by any Person, including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith.
Dividing Person”: as defined in the definition of “Division”.
Division”: the division of assets, liabilities and/or obligations of a Person (the “Dividing Person”) among two or more Persons (whether pursuant to a “plan of division” or similar arrangement), which may or may not include the Dividing Person and pursuant to which the Dividing Person may or may not survive.
Documentation Agents”: Bank of America, N.A., Barclays Bank PLC, Citibank, N.A., JPMorgan Chase Bank, N.A. and Société Générale, as Documentation Agents for this Agreement.
Dollar Equivalent”: at the time of determination thereof, (a) if such amount is expressed in Dollars, such amount, (b) if such amount is expressed in an Available Foreign Currency, the equivalent of such amount in Dollars determined by using the rate of exchange for the purchase of Dollars with such Available Foreign Currency in the London foreign exchange market at or about 11:00 a.m. London time (or New York time, as applicable) on a particular day as displayed by ICE Data Services as the “ask price”, or as displayed on such other information service which publishes that rate of exchange from time to time in place of ICE Data Services (or if such service ceases to be available, the equivalent of such amount in Dollars as determined by the Administrative Agent based on the rate published or quoted by Bloomberg) and (c) if such amount is denominated in any other currency, the equivalent of such amount in Dollars as determined by the Administrative Agent based on the rate published or quoted by Bloomberg.
    - 14 -


Dollars” and “$”: dollars in lawful currency of the United States of America.
Early Opt-in Election”: with respect to any then-current Benchmark (other than any Benchmark in respect of Dollars), the occurrence of:
(1)    (i) a determination by the Administrative Agent or (ii) a notification by the Majority Lenders to the Administrative Agent (with a copy to the Borrower) that the Majority Lenders have determined that syndicated credit facilities being executed at such time, or that include language similar to that contained in this Section are being executed or amended, as applicable, to incorporate or adopt a new benchmark interest rate to replace such Benchmark, and
(2)    (i) the election by the Administrative Agent or (ii) the election by the Majority Lenders to declare that an Early Opt-in Election with respect to such Benchmark has occurred and the provision, as applicable, by the Administrative Agent of written notice of such election to the Borrower and the Lenders or by the Majority Lenders of written notice of such election to the Administrative Agent.

EEA Financial Institution”: (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.
EEA Member Country”: any of the member states of the European Union, Iceland, Liechtenstein, and Norway.
EEA Resolution Authority”: any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.
Environmental Laws”: any and all applicable foreign, Federal, state, local or municipal laws, rules, regulations, statutes, ordinances, codes, decrees or other enforceable requirements or orders of any Governmental Authority or other Requirements of Law regulating, relating to or imposing liability or standards of conduct concerning protection of human health or the environment, as now or may at any time hereafter be in effect.
ERISA”: the Employee Retirement Income Security Act of 1974, as amended from time to time.
Erroneous Payment”: as defined in subsection 11.12(a).
Erroneous Payment Deficiency Assignment”: as defined in subsection 11.12(d)
Erroneous Payment Return Deficiency”: as defined in subsection 11.12(d).
EU Bail-In Legislation Schedule”: the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.
    - 15 -


EURIBOR”: for any Interest Period for each Loan denominated in Euro comprising part of the same borrowing, an interest rate per annum equal to (a) the Euro interbank offered rate administered by the Banking Federation of the European monetary union (or any other person which takes over administration of that rate) for the relevant period displayed on page EURIBOR01 of the Reuters screen at or about 11:00 A.M. (Central European time) two Target Operating Days before the first day of such Interest Period or, if such page or such service shall cease to be available, such other page or such other service for the purpose of displaying an average rate of the Banking Federation of the European monetary union as the Administrative Agent, after consultation with the Lenders and the Borrower, shall reasonably select; provided that any comparable or successor rate shall be applied in a manner consistent with market practice or (b) if no quotation for the Euro for the relevant period is displayed and the Administrative Agent has not selected an alternative service on which a quotation is displayed, the rate per annum determined by the Administrative Agent as the average at which deposits in Euro for delivery on the first day of such Interest Period in same day funds in the approximate amount of the Loan being made, continued or converted and with a term equivalent to such Interest Period are offered to the Administrative Agent’s London branch (or other branch or Affiliate) by leading banks in the European interbank market at or about 11:00 A.M. (Central European time) two Target Operating Days before the first day of such Interest Period. EURIBOR shall not be less than zero. If any Interest Period is an Impacted Interest Period, then EURIBOR shall be the Interpolated Rate for such Interest Period.
Euros”: the single currency of the participating member states of the European monetary union.
Eurocurrency Rate”:
for any Interest Period with respect to a Loan, a rate per annum determined in accordance with the following formula:
Eurocurrency Base Rate
1.00 - Eurocurrency Reserve Requirements
where,
Eurocurrency Base Rate” means (i) with respect to each day during each Interest Period pertaining to a Loan or CAF Advance denominated in Japanese Yen or Swiss Franc, the rate per annum determined by the Administrative Agent to be the rate administered by the ICE Benchmark Administration (or any successor thereto) as the offered rate for deposits in Dollars with a term comparable to such Interest Period appearing on the Reuters Screen LIBOR01 Page at approximately 11:00 A.M., London time, two Business Days prior to the beginning of such Interest Period; provided, however, that if at any time for any reason such offered rate for any such currency does not appear on a Reuters page, “Eurocurrency Base Rate” shall mean, with respect to each day during each Interest Period pertaining to a Loan denominated in such Currency, the rate per annum determined by the Administrative Agent to be the average rate at which the Administrative Agent’s London branch is offered deposits in such currency at or about 11:00 A.M., London time, two Business Days prior to the beginning of such Interest Period in the London interbank market for delivery on the first day of such Interest Period for the number of days comprised therein, (ii) with respect to each day during each Interest Period pertaining to a Multicurrency Loan or CAF Advance denominated in Pounds Sterling, the rate per annum determined by the Administrative Agent to be the offered rate for deposits in the applicable currency with a term comparable to such Interest Period appearing on the Reuters Screen LIBOR01 Page at approximately 11:00 A.M., London time, on the first day of such Interest
    - 16 -


Period; provided, however, that if at any time for any reason such offered rate for Pounds Sterling does not appear on a Reuters page, “Eurocurrency Base Rate” shall mean, with respect to each day during each Interest Period pertaining to a Loan denominated in Pounds Sterling, the rate per annum determined by the Administrative Agent to be the average rate at which the Administrative Agent is offered deposits in Pounds Sterling at or about 11:00 A.M., London time, on the first day of such Interest Period in the London interbank market for delivery on the first day of such Interest Period for the number of days comprised therein, (iii) with respect to each day during each Interest Period pertaining to a Multicurrency Loan or CAF Advance denominated in Euros, EURIBOR, (iv) with respect to each day during each Interest Period pertaining to a Multicurrency Loan or CAF Advance denominated in Australian Dollars, BBSY, (v) with respect to each day during each Interest Period pertaining to a Multicurrency Loan or CAF Advance denominated in Canadian Dollars, CDOR, and (vi) with respect to each day during each Interest Period pertaining to a Multicurrency Loan or CAF Advance denominated in Singapore Dollars, SGD; provided that if any Interest Period with respect to any currency is an Impacted Interest Period, then the Eurocurrency Base Rate shall be the Interpolated Rate with respect to the applicable currency for such Interest Period; and
The Eurocurrency Rate and Eurocurrency Base Rate shall not be less than zero.
Eurocurrency Reserve Requirements”: for any day as applied to a Loan, the aggregate (without duplication) of the rates (expressed as a decimal) of reserve requirements in effect on such day (including, without limitation, basic, supplemental, marginal and emergency reserves) under any regulations of the Board or other Governmental Authority having jurisdiction with respect thereto dealing with reserve requirements prescribed for eurocurrency funding (currently referred to as “Eurocurrency Liabilities” in Regulation D of such Board) maintained by a member bank of such System.
Event of Default”: any of the events specified in Section 10, provided that any requirement for the giving of notice, the lapse of time, or both, or any other condition, has been satisfied.
Exchange Rate”: with respect to any non-Dollar currency on any date, the rate at which such currency may be exchanged into Dollars, as set forth on such date on the relevant Reuters currency page at or about 11:00 A.M., London time, on the date that is (x) in the case of Pounds Sterling and Canadian Dollars, on the date as of which the foreign exchange computation is made and (y) in the case of any other non-Dollar currency, two Business Days prior to the date as of which the foreign exchange computation is made. In the event that such rate does not appear on any Reuters currency page, the “Exchange Rate” with respect to such non-Dollar currency shall be determined by reference to such other publicly available service for displaying exchange rates as may be agreed upon by the Administrative Agent and the Borrower or, in the absence of such agreement, such “Exchange Rate” shall instead be the Administrative Agent’s spot rate of exchange in the interbank market where its foreign currency exchange operations in respect of such non-Dollar currency are then being conducted, at or about 10:00 A.M., London time, on such applicable date for the purchase of Dollars with such non-Dollar currency, for delivery (x) in the case of Pounds Sterling and Canadian Dollars, on such date and (y) in the case of any other non-Dollar currency, two Business Days later; provided, that if at the time of any such determination, no such spot rate can reasonably be quoted, the Administrative Agent may use any reasonable method as it deems applicable to determine such rate, and such determination shall be conclusive absent manifest error. The Administrative Agent shall determine the Exchange Rate as of each Revaluation Date in accordance with the foregoing.
Excluded Taxes”: as defined in subsection 3.10(a).
    - 17 -


Existing Credit Facilities”: as defined in the recitals hereto.
Extensions of Credit”: as to any Lender at any time, (a) an amount equal to the sum of (i) the aggregate principal amount of all Revolving Credit Loans made by such Lender then outstanding and (ii) such Lender’s Revolving Credit Commitment Percentage of the L/C Obligations then outstanding, or (b) the making of any Loan or participation in any Letter of Credit by such Lender, as the context requires.
Extension Request”: a written request from the Borrower to the Administrative Agent requesting an extension of the Termination Date.
Facility Fee Rate”: for each day during each calculation period, (x) until the Third Amendment Effective Date, 0.090% per annum and (y) on and following the Third Amendment Effective Date, the rate per annum based on the Ratings in effect on such day, as set forth below:
RatingFacility
Fee Rate
Rating I
0.0800.070%
Rating II
0.0900.080%
Rating III
0.1100.090%
Rating IV
0.1500.110%
Rating V
0.2250.150%

FATCA”: Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any applicable intergovernmental agreements with respect thereto, any law, regulations, or other official guidance enacted in any other jurisdiction relating to such intergovernmental agreement, and any agreement entered into pursuant to Section 1471(b)(1) of the Code.
Federal Funds Effective Rate”: for any day, the rate calculated by the NYFRB based on such day’s federal funds transactions by depositary institutions (as determined in such manner as the NYFRB shall set forth on its public website from time to time) and published on the next succeeding Business Day by the NYFRB as the federal funds effective rate, provided that if the Federal Funds Effective Rate shall be less than zero, such rate shall be deemed to zero for the purposes of this Agreement.
Fee Commencement Date”: the Closing Date.
Financing Lease”: any lease of property, real or personal, the obligations of the lessee in respect of which are required in accordance with GAAP to be capitalized on a balance sheet of the lessee.
Fixed Rate CAF Advance”: any CAF Advance made pursuant to a Fixed Rate CAF Advance Request.
Fixed Rate CAF Advance Request”: any CAF Advance Request requesting the Lenders to offer to make CAF Advances at a fixed rate (as opposed to a rate composed of the Eurocurrency Rate or Adjusted Term SOFR plus (or minus) a margin).
    - 18 -


Floor” means a rate of interest equal to 0.00%.
Foreign Subsidiary Borrower”: each Subsidiary of the Borrower organized under the laws of a jurisdiction outside the United States that the Borrower designates as a “Foreign Subsidiary Borrower” in a Local Currency Facility Addendum.
Fronting Exposure”: at any time there is a Defaulting Lender with respect to the Issuing Lender, such Defaulting Lender’s Revolving Credit Commitment Percentage of the outstanding L/C Obligations other than L/C Obligations as to which such Defaulting Lender’s participation obligation has been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof.
Funding Commitment Percentage”: as at any date of determination (after giving effect to the making and payment of any Loans made on such date pursuant to subsection 2.16), with respect to any Lender, that percentage which the Available Revolving Credit Commitment of such Lender then constitutes of the Aggregate Available Revolving Credit Commitments.
GAAP”: generally accepted accounting principles in the United States of America consistent with those utilized in preparing the audited financial statements referred to in subsection 6.1.
Governmental Authority”: any nation or government, any state or other political subdivision thereof and any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government.
Guarantee Obligation”: as to any Person (the “guaranteeing person”), any obligation of (a) the guaranteeing person or (b) another Person (including, without limitation, any bank under any letter of credit) to induce the creation of which the guaranteeing person has issued a reimbursement, counterindemnity or similar obligation, in either case guaranteeing or in effect guaranteeing any Indebtedness, leases, dividends or other obligations (the “primary obligations”) of any other unrelated third Person (the “primary obligor”) in any manner, whether directly or indirectly, including, without limitation, any obligation of the guaranteeing person, whether or not contingent, (i) to purchase any such primary obligation or any property constituting direct or indirect security therefor, (ii) to advance or supply funds (1) for the purchase or payment of any such primary obligation or (2) to maintain working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor, (iii) to purchase property, securities or services primarily for the purpose of assuring the owner of any such primary obligation of the ability of the primary obligor to make payment of such primary obligation or (iv) otherwise to assure or hold harmless the owner of any such primary obligation against loss in respect thereof; provided, however, that the term Guarantee Obligation shall not include endorsements of instruments for deposit or collection in the ordinary course of business. The amount of any Guarantee Obligation of any guaranteeing person shall be deemed to be the lower of (a) an amount equal to the stated or determinable amount of the primary obligation in respect of which such Guarantee Obligation is made and (b) the maximum amount for which such guaranteeing person may be liable pursuant to the terms of the instrument embodying such Guarantee Obligation, unless such primary obligation and the maximum amount for which such guaranteeing person may be liable are not stated or determinable, in which case the amount of such Guarantee Obligation shall be such guaranteeing person’s reasonably anticipated liability in respect thereof as determined by the Borrower in good faith.
Hedge Agreements”: all agreements with non-related third parties of the Borrower with respect to any swap, forward, future or derivative transaction or option or similar agreements involving, or settled by reference to, one or more rates, currencies, commodities, equity or debt instruments or securities, or
    - 19 -


economic, financial or pricing indices or measures of economic, financial or pricing risk or value or any similar transaction or any combination of these transactions; provided that no employee benefit plan of the Borrower or any of its Subsidiaries shall be a “Hedge Agreement.”
Impacted Interest Period”: any Interest Period for which the applicable rate or screen used to determine the applicable rate (the “Applicable Screen Rate”) shall not be available at the applicable time for such Interest Period.
Indebtedness”: of any Person at any date, without duplication, (a) all obligations of such Person for borrowed money, (b) all obligations of such Person for the deferred purchase price of property or services (other than current trade liabilities incurred in the ordinary course of such Person’s business and payable in accordance with customary practices and earn-outs and other similar obligations in respect of acquisition and other similar agreements), (c) all obligations of such Person evidenced by notes, bonds, debentures or other similar instruments, (d) all indebtedness created or arising under any conditional sale or other title retention agreement with respect to property acquired by such Person (even though the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such property), (e) all Capital Lease Obligations of such Person, (f) all obligations of such Person, contingent or otherwise, as an account party or applicant under or in respect of acceptances, letters of credit, surety bonds or similar arrangements, (g) the liquidation value of all redeemable preferred Capital Stock of such Person, (h) all indebtedness of such Person, determined in accordance with GAAP, arising out of a Receivables Transaction, (i) all Guarantee Obligations of such Person in respect of obligations of the kind referred to in clauses (a) through (h) above, (j) all obligations of the kind referred to in clauses (a) through (i) above secured by (or for which the holder of such obligation has an existing right, contingent or otherwise, to be secured by) any Lien on property (including accounts and contract rights) owned by such Person, whether or not such Person has assumed or become liable for the payment of such obligation, and (k) for the purposes of subsection 10(f) only, all obligations of such Person in respect of Hedge Agreements. The Indebtedness of any Person shall, for the avoidance of doubt, exclude any operating leases (as defined in GAAP as in effect on the date of this Agreement) and the Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person’s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness expressly provide that such Person is not liable therefor.
indemnified liabilities” as defined in subsection 13.5.
indemnified party: as defined in subsection 13.5.
Information” as defined in subsection 13.14.
Insolvency”: with respect to any Multiemployer Plan, the condition that such Multiemployer Plan is insolvent within the meaning of Section 4245 of ERISA.
Interest Payment Date”: (a) as to any ABR Loan, the last day of each March, June, September and December and the Termination Date, (b) as to any SOFR Loan or Multicurrency Loan having an Interest Period of three months or less, the last day of such Interest Period, and (c) as to any SOFR Loan or Multicurrency Loan having an Interest Period longer than three months, each day which is three months, or a whole multiple thereof, after the first day of such Interest Period and the last day of such Interest Period.
Interest Period”: (a) with respect to any SOFR Loan or Multicurrency Loan:
    - 20 -


(i)    initially, the period commencing on the Borrowing Date or conversion date, as the case may be, with respect to such SOFR Loan or Multicurrency Loan and ending, with respect to such SOFR Loan, one or three months, or with respect to such Multicurrency Loan, one, three or six (or if available to all Lenders, twelve) months thereafter, as selected by the Borrower in its notice of borrowing or notice of conversion or continuation, as the case may be, given with respect thereto; and
(ii)    thereafter, each period commencing on the last day of the next preceding Interest Period applicable to such SOFR Loan or Multicurrency Loan and ending, with respect to such SOFR Loan, one or three months, or with respect to such Multicurrency Loan, one, three or six (or if available to all Lenders, twelve) months thereafter, as selected by the Borrower by irrevocable notice to the Administrative Agent not less than three Business Days prior to the last day of the then current Interest Period with respect thereto;
provided that, all of the foregoing provisions relating to Interest Periods are subject to the following:
(1)    if any Interest Period would otherwise end on a day that is not a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless the result of such extension would be to carry such Interest Period into another calendar month in which event such Interest Period shall end on the immediately preceding Business Day;
(2)    any Interest Period in respect of any Loan made by any Lender that would otherwise extend beyond the Termination Date applicable to such Lender shall end on such Termination Date;
(3)    any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of a calendar month;
(4)    no Multicurrency Loan or CAF Advance denominated in Singapore Dollars shall have an Interest Period of one week or two months;
(5)    for any Interest Period, the durations available above shall only be available in a currency if a rate based on a corresponding duration (one, three, six or twelve months) is available from the applicable Screen Rate for the requested currency at the such time;
(6)    no tenor that has been removed from this definition pursuant to Section 3.6(b)(iv) shall be available for specification in a notice of borrowing or a notice of conversion or continuation, unless such tenor has been reinstated in accordance with Section 3.6(b)(iv), and
(b)    with respect to any Term Rate CAF Advance, the period beginning on the Borrowing Date with respect thereto and ending on the CAF Advance Maturity Date with respect thereto.
    - 21 -


Interpolated Rate”: at any time, for any Interest Period, the rate per annum (rounded to the same number of decimal places as the Applicable Screen Rate) determined by the Administrative Agent (which determination shall be conclusive and binding absent manifest error) to be equal to the rate that results from interpolating on a linear basis between: (a) the Applicable Screen Rate for the longest period for which the Applicable Screen Rate is available) that is shorter than the Impacted Interest Period; and (b) the Applicable Screen Rate for the shortest period (for which that Applicable Screen Rate is available) that exceeds the Impacted Interest Period, in each case, at such time. The Interpolated Rate shall not be less than zero.
Issuing Lender”: Wells Fargo, Bank of America, Barclays Bank PLC, Citibank, N.A., JPMorgan Chase Bank, N.A., Société Générale and each other Lender which agrees to act as Issuing Lender hereunder and which is approved (such approval not to be unreasonably withheld) by the Administrative Agent and the Borrower, in its capacity as issuer of any Letter of Credit.
Issuing Lender Commitment”: as to any Issuing Lender at any time, the amount set forth opposite such Issuing Lender’s name in Schedule I under the heading “Issuing Lender Commitment”, as such amount may be reduced or increased from time to time in accordance with the provisions of this Agreement.
Japanese Yen”: the lawful currency of Japan.
Judgment Currency”: as defined in subsection 13.16(b).
L/C Commitment”: the lesser of (i) $500,000,000 and (ii) the aggregate amount of the Revolving Credit Commitments then in effect (or, if the Revolving Credit Commitments have terminated, the Aggregate Revolving Credit Commitments in effect immediately prior to such termination).
L/C Fee Payment Date”: the last day of each March, June, September and December and the last day of the Commitment Period.
L/C Obligations”: at any time, an amount equal to the sum of (a) the aggregate then undrawn amount of the then outstanding Letters of Credit and (b) the aggregate amount of drawings under Letters of Credit that have not then been reimbursed pursuant to subsection 5.5.
L/C Participants”: the collective reference to all the Lenders other than the Issuing Lender.
Lender Affiliate”: (a) any Affiliate of any Lender, (b) any Person that is administered or managed by any Lender and that is engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business and (c) with respect to any Lender which is a fund that invests in commercial loans and similar extensions of credit, any other fund that invests in commercial loans and similar extensions of credit and is managed or advised by the same investment advisor as such Lender or by an Affiliate of such Lender or investment advisor.
Lenders”: as defined in the preamble hereto together with any affiliate of any such Person through which such Person elects, by notice to the Administrative Agent and the Borrower, to make any Loans available to the Borrower or any Foreign Subsidiary Borrower; provided that, for all purposes of voting or consenting with respect to (a) any amendment, supplementation or modification of any Loan Document, (b) any waiver of any requirements of any Loan Document or any Default or Event of Default and its consequences, or (c) any other matter as to which a Lender may vote or consent pursuant to
    - 22 -


subsection 13.1 of this Agreement, the Lender making such election shall be deemed the “Person” rather than such affiliate, which shall not be entitled to vote or consent; and provided further, that unless the context otherwise requires, each reference herein to the Lenders shall be deemed to include any Conduit Lender.
Lending Office”: with respect to any Lender, the office of such Lender maintaining such Lender’s Extensions of Credit, which office may, to the extent the applicable Lender notifies the Administrative Agent in writing, include an office of any Affiliate of such Lender or any domestic or foreign branch of such Lender or Affiliate.
Letters of Credit”: as defined in subsection 5.1(a).
Lien”: any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge or other security interest or any preference, priority or other security agreement or preferential arrangement of any kind or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement and any Financing Lease having substantially the same economic effect as any of the foregoing but excluding for all purposes hereunder any letter of credit).
Loan”: any Revolving Credit Loan, CAF Advance, Multicurrency Loan or Local Currency Loan, as the case may be.
Loan Documents”: this Agreement, any Notes, the Applications, any Letters of Credit and any document or instrument evidencing or governing any Local Currency Facility.
Loans to be Converted”: as defined in subsection 13.15(a).
Local Currency”: any available and freely convertible non-Dollar currency selected by a Foreign Subsidiary Borrower and approved by the Administrative Agent.
Local Currency Facility”: any Qualified Credit Facility that the Borrower designates as a “Local Currency Facility” pursuant to a Local Currency Facility Addendum.
Local Currency Facility Addendum”: a Local Currency Facility Addendum received by the Administrative Agent, substantially in the form of Exhibit I, and conforming to the requirements of Section 4.
Local Currency Facility Agent”: with respect to each Local Currency Facility, the Local Currency Lender acting as agent for the Local Currency Lenders parties thereto (and, in the case of any Local Currency Facility to which only one Lender is a party, such Lender).
Local Currency Facility Maximum Borrowing Amount”: as defined in subsection 4.1(b).
Local Currency Lender”: any Lender (or, if applicable, any Affiliate, branch or agency thereof) party to a Local Currency Facility.
Local Currency Lender Maximum Borrowing Amount”: as defined in subsection 4.1(b).
Local Currency Loan”: any loan made pursuant to a Local Currency Facility.
    - 23 -


London Banking Day”: any day on which dealings in Dollar deposits are conducted by and between banks in the London interbank eurodollar market.
Majority Lenders”: Lenders whose Aggregate Exposure Percentage in the aggregate is more than 50%. “Aggregate Exposure Percentage”: as at any date of determination with respect to any Lender (a) at any time prior to the termination of the Revolving Credit Commitments, the aggregate Revolving Credit Commitments of such Lender divided by the aggregate Revolving Credit Commitments of all Lenders and (b) at any time after the termination of the Revolving Credit Commitments, the Aggregate Total Outstandings of such Lender divided by the Aggregate Total Outstandings of all Lenders; provided that for purposes of this definition, the Aggregate Exposure Percentage of each Lender shall be adjusted upward or downward so as to give effect to any participations or assignments effected pursuant to subsection 13.15; and provided further that the Revolving Credit Commitment of, and the Aggregate Total Outstandings held or deemed to be held by, any Defaulting Lender shall be excluded for purposes of making a determination of Majority Lenders.
Majority Multicurrency Lenders”: at any time, Multicurrency Lenders the Multicurrency Commitment Percentages of which aggregate more than 50%; provided that the Multicurrency Commitment of, and the Aggregate Multicurrency Outstandings held or deemed to be held by, any Defaulting Lender shall be excluded for purposes of making a determination of Majority Multicurrency Lenders.
Material Adverse Effect”: a material adverse effect on (a) the business, operations, property or condition (financial or otherwise) of the Borrower and its Subsidiaries taken as a whole or (b) the validity or enforceability of this Agreement or any of the other Loan Documents or the rights or remedies of the Administrative Agent or the Lenders hereunder or thereunder.
Materials of Environmental Concern”: any gasoline or petroleum (including crude oil or any fraction thereof) or petroleum products or any hazardous or toxic substances, materials or wastes, defined or regulated as such in or under any Environmental Law, including, without limitation, asbestos, polychlorinated biphenyls and urea-formaldehyde insulation.
Maximum Leverage Ratio”: 3.75 to 1.00; provided that (a) for the four consecutive fiscal quarters ended immediately following the consummation of any Qualified Acquisition (including the fiscal quarter in which such Qualified Acquisition occurs), the Maximum Leverage Ratio shall be 4.75 to 1.00, (b) for the fiscal quarter ended immediately after such four fiscal quarters referred to in clause (a), the Maximum Leverage Ratio shall be 4.50 to 1.00, (c) for the fiscal quarter ended immediately after the fiscal quarter referred to in clause (b), the Maximum Leverage Ratio shall be 4.25 to 1.00 and (d) for the fiscal quarter ended immediately after the fiscal quarter referred to in clause (c), the Maximum Leverage Ratio shall be 4.00 to 1.00 (and, for the avoidance of doubt, for each fiscal quarter ended after the fiscal quarter referred to in clause (d), the Maximum Leverage Ratio shall be 3.75 to 1.00).
Moody’s”: Moody’s Investors Service, Inc. or any successor thereto.
Multicurrency Commitment”: as to any Multicurrency Lender at any time, its obligation to make Multicurrency Loans to the Borrower in an aggregate amount in Available Foreign Currencies the Dollar Equivalent of which does not exceed at any time outstanding the amount set forth opposite such Multicurrency Lender’s name in Schedule I under the heading “Multicurrency Commitment”, as such amount may be reduced from time to time as provided in subsection 2.15 and the other applicable provisions hereof.
    - 24 -


Multicurrency Commitment Percentage”: as to any Multicurrency Lender at any time, the percentage which such Multicurrency Lender’s Multicurrency Commitment at such time constitutes of the aggregate Multicurrency Commitments of all Multicurrency Lenders at such time (or, if the Multicurrency Commitments have terminated or expired, the percentage which (a) the Dollar Equivalent of the Aggregate Multicurrency Outstandings of such Multicurrency Lender at such time constitutes of (b) the Dollar Equivalent of the Aggregate Multicurrency Outstandings of all Multicurrency Lenders at such time).
Multicurrency Lender”: each Lender having an amount greater than zero set forth opposite such Lender’s name in Schedule I under the heading “Multicurrency Commitment.”
Multicurrency Loans”: as defined in subsection 2.12.
Multicurrency Note”: as defined in subsection 3.13(f).
Multicurrency Sublimit”: at any time, the lesser of (i) $800,000,000 and (ii) the aggregate amount of the Revolving Credit Commitments then in effect (or, if the Revolving Credit Commitments have terminated, the aggregate Revolving Credit Commitments in effect immediately prior to such termination).
Multiemployer Plan”: a Plan which is a multiemployer plan as defined in Section 4001(a)(3) of ERISA.
Non-Cash Charges”: (a) losses on asset sales, disposals or abandonments, (b) any impairment charge or asset write-off related to intangible assets, long-lived assets, and investments in debt and equity securities pursuant to GAAP, (c) all losses from investments recorded using the equity method, (d) stock-based awards compensation expense, and (e) other non-cash charges (provided that if any non-cash charges referred to in this clause (e) represent an accrual or reserve for potential cash items in any future period, the cash payment in respect thereof in such future period shall be subtracted from Consolidated EBITDA to such extent, and excluding amortization of a prepaid cash item that was paid in a prior period).
Non-Consenting Lender”: any Lender that does not approve any consent, waiver or amendment that (i) requires the approval of all affected Lenders in accordance with the terms of subsection 13.1 and (ii) has been approved by the Majority Lenders.
Non-Excluded Taxes”: as defined in subsection 3.10(a).
Non-extending Lender”: as defined in subsection 2.20(a).
Non-Multicurrency Lender”: each Revolving Credit Lender which is not a Multicurrency Lender.
Non-U.S. Lender”: a Lender that is not a U.S. Person.
Notes”: the collective reference to any Revolving Credit Notes, any Multicurrency Notes and any CAF Advance Notes.
Notice of Local Currency Outstandings”: with respect to each Local Currency Facility Agreement, a notice from the relevant Local Currency Facility Agent containing the information,
    - 25 -


delivered to the Administrative Agent and any other Person, in the manner and by the time, specified for a Notice of Local Currency Outstandings in Schedule II.
Notice of Multicurrency Loan Borrowing”: with respect to a Multicurrency Loan, a notice from the Borrower containing the information in respect of such Loan, delivered to the Administrative Agent and any other Person, in the manner and by the time, specified for a Notice of Multicurrency Loan Borrowing in respect of the currency of such Loan in Schedule II.
Notice of Multicurrency Loan Continuation”: with respect to a Multicurrency Loan, a notice from the Borrower containing the information in respect of such Loan, delivered to the Person, in the manner and by the time, specified for a Notice of Multicurrency Loan Continuation in respect of the currency of such Loan in Schedule II.
NYFRB”: the Federal Reserve Bank of New York.
Obligations”: collectively, the unpaid principal of and interest on the Loans and all other obligations and liabilities of the Borrower and each Foreign Subsidiary Borrower under this Agreement and any Local Currency Facility and other Loan Documents to which it is a party (including, without limitation, interest accruing at the then applicable rate provided in this Agreement or any other applicable Loan Document after the maturity of the Loans and interest accruing at the then applicable rate provided in this Agreement or any other applicable Loan Document after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, relating to the Borrower or such Foreign Subsidiary Borrower, whether or not a claim for post-filing or post-petition interest is allowed in such proceeding), whether direct or indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred, which may arise under, out of, or in connection with, this Agreement, the Notes, the other Loan Documents, Hedge Agreements entered into with Lenders or any Affiliates of a Lender or any other document made, delivered or given in connection therewith, in each case whether on account of principal, interest, reimbursement obligations, fees, indemnities, costs, expenses or otherwise (including, without limitation, all fees and disbursements of counsel to the Administrative Agent or to the Lenders that are required to be paid by the Borrower or any Foreign Subsidiary Borrower pursuant to the terms of this Agreement or any other Loan Document).
Overnight Bank Funding Rate”: for any day, the rate comprised of both overnight federal funds and overnight Eurodollar borrowings by U.S.-managed banking offices of depository institutions, as such composite rate shall be determined by the NYFRB as set forth on its public website from time to time, and published on the next succeeding Business Day by the NYFRB as an overnight bank funding rate (from and after such date as the NYFRB shall commence to publish such composite rate).
Participant”: as defined in subsection 13.6(b).
Participant Register”: as defined in subsection 13.6(b).
Patriot Act”: as defined in subsection 13.18.
Payment Receipt”: as defined in subsection 11.12(a).
PBGC”: the Pension Benefit Guaranty Corporation established pursuant to Subtitle A of Title IV of ERISA.
    - 26 -


Person”: an individual, partnership, corporation, business trust, joint stock company, trust, unincorporated association, joint venture, Governmental Authority or other entity of whatever nature.
Plan”: at a particular time, any employee benefit plan which is covered by ERISA and in respect of which the Borrower or a Commonly Controlled Entity is (or, if such plan were terminated at such time, would under Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA.
Plan Asset Regulations”: 29 C.F.R. §2510.3-101 , et seq ., as modified by Section 3(42) of ERISA.
Platform”: as defined in subsection 8.2.
Pounds Sterling”: the lawful currency of the United Kingdom of Great Britain and Northern Ireland.
Properties”: as defined in subsection 6.11(a).
PTE”: a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.
Public Lenders”: as defined in subsection 8.2.
QFC Credit Support”: as defined in subsection 13.21.
Qualified Acquisition”: any transaction permitted under this Agreement and consummated on or after the Closing Date, (a) by which the Borrower or any of its Subsidiaries (i) acquires any going concern or business or all or substantially all of the assets of any firm, corporation or limited liability company, or division or business unit thereof, whether through purchase of assets, merger or otherwise or (ii) directly or indirectly acquires at least a majority (in number of votes) of the Capital Stock of a Person if the aggregate amount of Indebtedness incurred by the Borrower and its Subsidiaries to finance the purchase price and other consideration for such transaction, plus the amount of Indebtedness assumed by the Borrower and its Subsidiaries in connection with such transaction, is at least $1,000,000,000 and (b) for which the Borrower notifies the Administrative Agent in writing prior to or promptly upon consummation of such transaction that such transaction shall be a “Qualified Acquisition” for purposes of this Agreement.
Qualified Credit Facility”: a credit facility (a) providing for one or more Local Currency Lenders to make unsecured loans denominated in a Local Currency to a Foreign Subsidiary Borrower, (b) providing for such loans to bear interest at a rate or rates determined by the Borrower and such Local Currency Lender or Local Currency Lenders and (c) otherwise conforming to the requirements of Section 4.
Rating”: the respective rating of each of the Rating Agencies applicable to the long-term senior unsecured non-credit enhanced debt of the Borrower, as announced by the Rating Agencies from time to time.
Rating Agencies”: collectively, Moody’s and S&P.
Rating Category”: each of Rating I, Rating II, Rating III, Rating IV and Rating V.
    - 27 -


Rating I, Rating II, Rating III, Rating IV and Rating V”: the respective Ratings set forth below:
Rating
Category
Moody’sS&P
Rating Igreater than or equal to A2greater than or equal to A
Rating II
greater than or equal to A3greater than or equal to A-
Rating III
greater than or equal to Baa1greater than or equal to BBB+
Rating IIIV
greater than or equal to Baa2greater than or equal to BBB
Rating IVgreater than or equal to Baa3greater than or equal to BBB
Rating V
lower than or equal to Ba1Baa3
lower than or equal to BBB+-
If different Ratings Categories are applicable, the higher Ratings Category shall apply unless one of the two Ratings is two or more levels lower than the other, in which case the Ratings Category shall be the level immediately below that of the higher of the two Ratings.
Receivables”: any accounts receivable of any Person, including, without limitation, any thereof constituting or evidenced by chattel paper, instruments or general intangibles (as defined in the Uniform Commercial Code of the State of New York), and all proceeds thereof and rights (contractual and other) and collateral related thereto.
Receivables Transaction”: any transactions or series of related transactions providing for the financing of Receivables of the Borrower or any of its Subsidiaries.
Register”: as defined in subsection 13.6(d).
Reimbursement Obligation”: the obligation of the Borrower to reimburse the Issuing Lender pursuant to subsection 5.5 for amounts drawn under Letters of Credit.
Related Parties”: with respect to any Person, such Person’s Affiliates and partners, officers, employees, agents and advisors of such Person and such Person’s Affiliates.
Relevant Governmental Body” means (a) with respect to a Benchmark Replacement in respect of Obligations, interest, fees, commissions or other amounts denominated in, or calculated with respect to, Dollars, the Board or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Board or the Federal Reserve Bank of New York, or any successor thereto and (b) with respect to a Benchmark Replacement in respect of Obligations, interest, fees, commissions or other amounts denominated in, or calculated with respect to, any Available Foreign Currency, (i) the central bank for the Currency in which such Obligations, interest, fees, commissions or other amounts are denominated, or calculated with respect to, or any central bank or other supervisor which is responsible for supervising either (A) such Benchmark Replacement or (B) the administrator of such Benchmark Replacement or (ii) any working group or committee officially endorsed or convened by (A) the central bank for the Currency in which such Obligations, interest, fees, commissions or other amounts are denominated, or calculated with respect to, (B) any central bank or other supervisor that is responsible for
    - 28 -


supervising either (1) such Benchmark Replacement or (2) the administrator of such Benchmark Replacement, (C) a group of those central banks or other supervisors or (D) the Financial Stability Board or any part thereof.
Reportable Event”: any of the events set forth in Section 4043(c) of ERISA, other than those events as to which the thirty day notice period is waived under regulations issued under PBGC Reg. § 4043 or which notice is otherwise waived by PBGC.
Requested Local Currency Loans”: as defined in subsection 2.16(b).
Requested Multicurrency Loans”: as defined in subsection 2.16(a).
Requirement of Law”: as to any Person, the Certificate of Incorporation and By-Laws or other organizational or governing documents of such Person, and any law, treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.
Resolution Authority”: an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.
Response Date”: as defined in subsection 2.20(a).
Responsible Officer”: the chief executive officer or the president of the Borrower or, with respect to financial matters, the chief financial officer of the Borrower.
Revaluation Date”: (a) with respect to any Loan, each of the following: (i) each date of a borrowing of a Multicurrency Loan or a Local Currency Loan or the making of a CAF Advance, (ii) each date of a continuation of a Multicurrency Loan pursuant to subsection 3.2 and (iii) such additional dates as the Administrative Agent shall determine or the Majority Lenders shall require; and (b) with respect to any Letter of Credit, each of the following: (i) each date of issuance of a Letter of Credit denominated in a currency other than Dollars, (ii) each date of an amendment of any such Letter of Credit having the effect of increasing the amount thereof (solely with respect to the increased amount), (iii) each date of any payment by the Issuing Lender under any Letter of Credit denominated in a currency other than Dollars and (iv) such additional dates as the Administrative Agent or the Issuing Lender shall determine or the Majority Lenders shall require.
Revolving Credit Commitment”: as to any Lender, the obligation of such Lender to make Revolving Credit Loans to the Borrower hereunder in an aggregate principal amount at any one time outstanding not to exceed the amount set forth opposite such Lender’s name on Schedule I under the heading “Revolving Credit Commitment,” as such amount may be reduced or increased from time to time in accordance with the provisions of this Agreement.
Revolving Credit Commitment Percentage”: as to any Lender at any time, the percentage which such Lender’s Revolving Credit Commitment at such time constitutes of the Aggregate Revolving Credit Commitments at such time (or, if the Revolving Credit Commitments have terminated or expired, the percentage which (a) the Aggregate Revolving Credit Outstandings of such Lender at such time then constitutes of (b) the Aggregate Revolving Credit Outstandings of all Lenders at such time), subject to adjustment as provided in subsection 2.19.
    - 29 -


Revolving Credit Loans”: as defined in subsection 2.1.
Revolving Credit Note”: as defined in subsection 3.13(d).
Revolving Lender”: each Lender that has a Revolving Credit Commitment hereunder or that holds Revolving Credit Loans.
S&P”: Standard & Poor’s Ratings Services or any successor thereto.
Sanctioned Country”: a country or territory which is the subject or target of any Sanctions (as of the Second Amendment Effective Date, the so-called Donetsk People’s Republic, so-called Luhansk People’s Republic, Crimea, Kherson, and Zaporizhzhia regions of Ukraine, Cuba, Iran, North Korea and Syria).
Sanctioned Person”: (a) any Person described or listed in any Sanctions-related executive order or list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, the United Nations Security Council, the European Union, any European Union member state, His Majesty’s Treasury of the United Kingdom or other relevant sanctions authority, (b) any Person operating, organized or resident in a Sanctioned Country or (c) any Person 50 percent or more owned or controlled by any such Person.
Sanctions”: economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State or (b) the United Nations Security Council, the European Union, any European Union member state, His Majesty’s Treasury of the United Kingdom or other relevant sanctions authority.
Second Amendment”: that certain Second Amendment, dated as of March 1, 2023, to this Agreement.
Second Amendment Consenting Lenders”: those Lenders party to the Second Amendment.
Second Amendment Effective Date”: March 1, 2023.
SGD”: with respect to Singapore Dollars for any Interest Period, the rate per annum equal to the rate administered by the Association of Banks in Singapore (or any other person which takes over the administration of that rate) for Singapore Dollars displayed on page SIBOR of the Reuters screen (or any replacement Reuters page which displays that rate) at approximately the Singapore time equivalent of 12:00 p.m. (London time) two Business Days prior to the first day of such Interest Period for a term comparable to such Interest Period. If any Interest Period is an Impacted Interest Period, then SGD shall be the Interpolated Rate for such Interest Period. SGD shall not be less than zero.
Singapore Dollar”: the lawful currency of the Republic of Singapore.
Single Employer Plan”: any Plan that is covered by Title IV of ERISA, but that is not a Multiemployer Plan.
SOFR” means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator.
    - 30 -


SOFR Administrator” means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).
SOFR Loan” means any Loan bearing interest at a rate based on Adjusted Term SOFR other than pursuant to clause (c) of the definition of “ABR”.
Subsidiary”: as to any Person, a corporation, limited liability company, partnership or other entity of which shares of stock or other ownership interests having ordinary voting power (other than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the board of directors or other managers of such corporation, partnership or other entity are at the time owned, or the management of which is otherwise controlled, directly or indirectly through one or more intermediaries, or both, by such Person. Unless otherwise qualified, all references to a “Subsidiary” or to “Subsidiaries” in this Agreement shall refer to a Subsidiary or Subsidiaries of the Borrower.
Supported QFC”: as defined in subsection 13.21.
Swiss Franc”: the lawful currency of the Swiss Confederation.
Target Operating Day”: any day that is not (a) a Saturday or Sunday, (b) Christmas Day or New Year’s Day or (c) any other day on which the Trans-European Real-time Gross Settlement Operating System (or any successor settlement system) is not operating (as determined by the Administrative Agent).
Taxes”: all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments or other charges in the nature of a tax imposed by any Governmental Authority, including any interest additions or penalties applicable thereto.
Term Rate CAF Advance”: any CAF Advance made pursuant to a Term Rate CAF Advance Request.
Term Rate CAF Advance Request”: any CAF Advance Request requesting the Lenders to offer to make CAF Advances at an interest rate equal to (a) in respect of CAF Advances denominated in Dollars, Adjusted Term SOFR plus (or minus) a margin and (b) in respect of CAF Advances denominated in an Available Foreign Currency, the Eurocurrency Rate for the currency of such CAF Advance plus (or minus) a margin.
Term SOFR” means,
(a)    for any calculation with respect to a SOFR Loan, the Term SOFR Reference Rate for a tenor comparable to the applicable Interest Period on the day (such day, the “Periodic Term SOFR Determination Day”) that is two (2) U.S. Government Securities Business Days prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator; provided, however, that if as of 5:00 p.m. (Eastern time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such
    - 31 -


first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such Periodic Term SOFR Determination Day, and
(b)    for any calculation with respect to an ABR Loan on any day, the Term SOFR Reference Rate for a tenor of one month on the day (such day, the “ABR Term SOFR Determination Day”) that is two (2) U.S. Government Securities Business Days prior to such day, as such rate is published by the Term SOFR Administrator; provided, however, that if as of 5:00 p.m. (Eastern time) on any ABR Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such ABR SOFR Determination Day.
Term SOFR Adjustment” means a percentage equal to 0.10% per annum.
Term SOFR Administrator” means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Administrative Agent in its reasonable discretion).
Term SOFR Reference Rate” means the forward-looking term rate based on SOFR.
Termination Date”: the later of (a) May 10, 20262029 and (b) if the maturity date is extended pursuant to subsection 2.20, such extended maturity date as determined pursuant to such subsection; provided, however, that, in each case, if such date is not a Business Day, the Termination Date shall be the next preceding Business Day. For the avoidance of doubt, pursuant to the Second Amendment, clause (a) of the above was extended to May 10, 2027 in respect of the Commitments and Loans of the Second Amendment Consenting Lenders (and may be similarly extended in respect of the Commitments and Loans of other Lenders in accordance with Section 2.20(c)).
“Third Amendment”: that certain Third Amendment, dated as of May 10, 2024, to this Agreement.
“Third Amendment Effective Date”: May 10, 2024.
Tranche”: the collective reference to SOFR Loans or Multicurrency Loans of the same Currency the then current Interest Periods with respect to all of which begin on the same date and end on the same later date (whether or not such Loans shall originally have been made on the same day); Tranches may be identified as “SOFR Tranches” or “Multicurrency Tranches”.
Transactions”: the execution and delivery of this Agreement and the delivery of a notice to terminate the Existing Credit Facilities.
Transferee”: as defined in subsection 13.6(f).
Type”: as to any Revolving Credit Loan, its nature as an ABR Loan or SOFR Loan.
    - 32 -


UK Financial Institutions”: any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended frorm time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.
UK Resolution Authority”: the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.
Unadjusted Benchmark Replacement”: with respect to a given Benchmark Replacement, such Benchmark Replacement excluding the Benchmark Replacement Adjustment for such Benchmark Replacement.
United States”: the United States of America (including the states, commonwealths and territories thereof and the District of Columbia).
U.S. Government Securities Business Day” means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities; provided, that for purposes of notice requirements in Section 2.2, 3.1(a) and 3.2, in each case, such day is also a Business Day.
U.S. Person”: a “United States person” within the meaning of Section 7701(a)(30) of the Code.
U.S. Special Resolution Regimes ”: as defined in subsection 13.21.
U.S. Tax Compliance Certificate”: as defined in subsection 3.10(c)(B)(iii).
Wells Fargo”: Wells Fargo Bank, National Association.
Write-Down and Conversion Powers”: (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.
1.2.    Other Definitional Provisions
.
(a)    Unless otherwise specified therein, all terms defined in this Agreement shall have the defined meanings when used in any Notes or any certificate or other document made or delivered pursuant hereto.
    - 33 -


(b)    As used herein and in any Notes, and any certificate or other document made or delivered pursuant hereto, accounting terms relating to the Borrower and its Subsidiaries not defined in subsection 1.1 and accounting terms partly defined in subsection 1.1, to the extent not defined, shall have the respective meanings given to them under GAAP.
(c)    The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and Section, subsection, Schedule and Exhibit references are to this Agreement unless otherwise specified.
(d)    The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms.
(e)    Computations of amounts and ratios referred to herein shall be made without giving effect to any change in accounting for leases pursuant to GAAP resulting from the implementation of Accounting Standards Update 2016-02, Leases (Topic 842) issued February 2016, as amended from time to time.
1.3.    Rates
. The Administrative Agent does not warrant or accept any responsibility for, and shall not have any liability with respect to, (a) the continuation of, administration of, submission of, calculation of or any other matter related to the Term SOFR Reference Rate, Adjusted Term SOFR, Term SOFR, the Eurocurrency Rate or any other Benchmark, or any component definition thereof or rates referred to in the definition thereof, or with respect to any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or characteristics of any such alternative, successor or replacement rate (including any Benchmark Replacement), as it may or may not be adjusted pursuant to Section 3.6(b), will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, the Term SOFR Reference Rate, Term SOFR, Adjusted Term SOFR, the Eurocurrency Rate, such Benchmark or any other Benchmark prior to its discontinuance or unavailability, or (b) the effect, implementation or composition of any Benchmark Replacement Conforming Changes. The Administrative Agent and its Affiliates or other related entities may engage in transactions that affect the calculation of a Benchmark, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto and such transactions may be adverse to the Borrower. The Administrative Agent may select information sources or services in its reasonable discretion to ascertain any Benchmark, any component definition thereof or rates referred to in the definition thereof, in each case pursuant to the terms of this Agreement, and shall have no liability to the Borrower, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.

SECTION 2    

AMOUNT AND TERMS OF COMMITMENTS
2.1.    Revolving Credit Commitments
    - 34 -


.
(a)    Subject to the terms and conditions hereof, each Revolving Lender severally agrees to make revolving credit loans (“Revolving Credit Loans”) in Dollars to the Borrower from time to time during the Commitment Period so long as after giving effect thereto (i) the Available Revolving Credit Commitment of each Revolving Lender is greater than or equal to zero and (ii) the Aggregate Total Outstandings of all Lenders do not exceed the Aggregate Revolving Credit Commitments. During the Commitment Period, the Borrower may use the Revolving Credit Commitments by borrowing, prepaying the Revolving Credit Loans in whole or in part, and reborrowing, all in accordance with the terms and conditions hereof.
(b)    The Revolving Credit Loans may from time to time be (i) SOFR Loans, (ii) ABR Loans or (iii) a combination thereof, as determined by the Borrower and notified to the Administrative Agent in accordance with subsections 2.2 and 3.2, provided that no Revolving Credit Loan shall be made as a SOFR Loan after the day that is one month prior to the Termination Date.
2.2.    Procedure for Revolving Credit Borrowing
. The Borrower may borrow under the Revolving Credit Commitments during the Commitment Period on any Business Day, provided that the Borrower shall give the Administrative Agent irrevocable notice (which notice must be received by the Administrative Agent prior to (x) with respect to SOFR Loans, 10:00 A.M., New York City time, or (y) with respect to ABR Loans, 1:00 P.M., New York City time: (a) three U.S. Government Securities Business Days prior to the requested Borrowing Date, if all or any part of the requested Revolving Credit Loans are to be initially SOFR Loans or (b) on the requested Borrowing Date, otherwise), in each case specifying (i) the amount to be borrowed, (ii) the requested Borrowing Date, (iii) whether the borrowing is to be of SOFR Loans, ABR Loans or a combination thereof and (iv) if the borrowing is to be entirely or partly of SOFR Loans, the amount of such Type of Loan and the length of the initial Interest Period therefor. Each borrowing under the Revolving Credit Commitments (other than a borrowing under subsections 2.16 and 5.5) shall be in an amount equal to (x) in the case of ABR Loans, $5,000,000 or a whole multiple of $1,000,000 in excess thereof (or, if the Aggregate Available Revolving Credit Commitments are less than $1,000,000, such lesser amount) and (y) in the case of SOFR Loans, $5,000,000 or a whole multiple of $1,000,000 in excess thereof. Upon receipt of any such notice from the Borrower, the Administrative Agent shall promptly notify each Revolving Lender thereof. Prior to (x) with respect to SOFR Loans, 11:00 A.M., New York City time, or (y) with respect to ABR Loans, 2:00 P.M., New York City time, on the Borrowing Date requested by the Borrower, each Revolving Lender will make an amount equal to its Funding Commitment Percentage of the principal amount of the Revolving Credit Loans requested to be made on such Borrowing Date available to the Administrative Agent for the account of the Borrower at the office of the Administrative Agent specified in writing by the Administrative Agent to the Lenders in funds immediately available to the Administrative Agent. Except as otherwise provided in subsection 2.16, such borrowing will then be made available to the Borrower by the Administrative Agent crediting the account of the Borrower with the aggregate of the amounts made available to the Administrative Agent by the Revolving Lenders and in like funds as received by the Administrative Agent.
2.3.    Reserved
.
2.4.    Reserved
    - 35 -


.
2.5.    Fees
.
(a)    Facility Fee. The Borrower agrees to pay to the Administrative Agent for the account of each Revolving Lender a facility fee for the period from and including the Fee Commencement Date to the Termination Date computed at the Facility Fee Rate on the actual daily amount of the Revolving Credit Commitment of such Revolving Lender (regardless of usage and, following terminating the Revolving Credit Commitments, on the actual daily amount of the Aggregate Total Outstandings of such Revolving Lender) during the period for which payment is made, subject to adjustment as provided in subsection 2.19 and payable quarterly in arrears on the last day of each March, June, September and December, subject to the provisions of subsection 3.7, and on the Termination Date or such earlier date on which the Revolving Credit Commitments shall terminate as provided herein, commencing on the first of such dates to occur after the date hereof.
(b)    Agency Fee Letter. The Borrower agrees to pay to the Administrative Agent the fees in the amounts and on the dates set forth in the Agency Fee Letter.
2.6.    Termination or Reduction of Revolving Credit Commitments
. The Borrower shall have the right, upon not less than three Business Days’ notice to the Administrative Agent, to terminate the Revolving Credit Commitments or, from time to time, to reduce the amount of the Revolving Credit Commitments; provided that no such termination or reduction shall be permitted if, after giving effect thereto and to any prepayments of the Loans made on the effective date thereof, either (a) the Aggregate Available Revolving Credit Commitments would not be greater than or equal to zero or (b) the Available Revolving Credit Commitments of any Revolving Lender would not be greater than or equal to zero; provided further that such notice delivered by the Borrower may state that such notice is conditioned upon the effectiveness of other credit facilities, in which case such notice may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified effective date) if such condition is not satisfied. Any such reduction shall be in an amount equal to $5,000,000 or a whole multiple thereof and shall reduce permanently the Revolving Credit Commitments then in effect. The Administrative Agent shall give each Revolving Lender prompt notice of any notice received from the Borrower pursuant to this subsection 2.6.
2.7.    Repayment of Loans
. The Borrower hereby unconditionally promises to pay to the Administrative Agent for the account of each Revolving Lender the then unpaid principal amount of each Revolving Credit Loan of such Lender on the Termination Date (or such earlier date on which the Revolving Credit Loans become due and payable pursuant to Section 10). The Borrower hereby further agrees to pay interest on the unpaid principal amount of the Revolving Credit Loans from time to time outstanding from the date hereof until payment in full thereof at the rates per annum, and on the dates, set forth in subsection 3.4.
2.8.    CAF Advances
. Subject to the terms and conditions of this Agreement, the Borrower may borrow CAF Advances from time to time on any Business Day during the CAF Advance Availability Period. Term Rate CAF Advances may be denominated in Dollars or a lawful eurocurrency that is (x) readily available
    - 36 -


and freely transferable and convertible into dollars, (y) available in the London interbank deposit market and (z) agreed to by the Administrative Agent and the bidding Lender. CAF Advances may be borrowed in amounts such that the amount of Aggregate Total Outstandings of all Lenders at any time shall not exceed the Aggregate Revolving Credit Commitments at such time. Within the limits and on the conditions hereinafter set forth with respect to CAF Advances, the Borrower from time to time may borrow, repay and request new CAF Advances.
2.9.    Procedure for CAF Advance Borrowing
.
(a)    The Borrower shall request CAF Advances by delivering a CAF Advance Request to the Administrative Agent, not later than 11:00 AM (New York City time, or in the case of a Term CAF Advance Request for any non-Dollar currency, London time) five Business Days prior to the proposed Borrowing Date (in the case of a Term Rate CAF Advance Request), and not later than 10:00 AM. (New York City time) one Business Day prior to the proposed Borrowing Date (in the case of a Fixed Rate CAF Advance Request). Each CAF Advance Request in respect of any Borrowing Date may solicit bids for CAF Advances on such Borrowing Date in an aggregate principal amount of $5,000,000 or an integral multiple of $1,000,000 in excess thereof (or, in the case of CAF Advances to be denominated in a currency other than Dollars, an amount in such currency the Dollar Equivalent of which is equal to $5,000,000 or $1,000,000, as the case may be) and having not more than three alternative CAF Advance Maturity Dates. The CAF Advance Maturity Date for each CAF Advance shall be the date set forth therefor in the relevant CAF Advance Request, which date shall be (i) not less than 7 days nor more than 360 days after the Borrowing Date therefor, in the case of a Fixed Rate CAF Advance, (ii) not less than 30 days nor more than 360 days after the Borrowing Date therefor, in the case of a Term Rate CAF Advance and (iii) not later than the Termination Date, in the case of any CAF Advance. The Administrative Agent shall notify each Revolving Lender promptly by facsimile transmission of the contents of each CAF Advance Request received by the Administrative Agent.
(b)    In the case of a Term Rate CAF Advance Request, upon receipt of notice from the Administrative Agent of the contents of such CAF Advance Request, each Revolving Lender may elect, in its sole discretion, to offer irrevocably to make one or more CAF Advances at the applicable Eurocurrency Rate or (in the case of CAF Advances denominated in Dollars, Adjusted Term SOFR) plus (or minus) a margin determined by such Revolving Lender in its sole discretion for each such CAF Advance. Any such irrevocable offer shall be made by delivering a CAF Advance Offer to the Administrative Agent, before 10:30 A.M. (New York City time) on the day that is three Business Days (or, in the case of CAF Advances denominated in Dollars, three U.S. Government Securities Business Days) before the proposed Borrowing Date, setting forth:
(i)    the maximum amount of CAF Advances for each CAF Advance Maturity Date and the aggregate maximum amount of CAF Advances for all CAF Advance Maturity Dates which such Revolving Lender would be willing to make (which amounts may, subject to subsection 2.8, exceed such Lender’s Revolving Credit Commitment); and
(ii)    the margin above or below the applicable Eurocurrency Rate or Adjusted Term SOFR, as applicable, at which such Revolving Lender is willing to make each such CAF Advance.
    - 37 -


The Administrative Agent shall advise the Borrower before 11:00 A.M. (New York City time) on the date which is three Business Days before the proposed Borrowing Date of the contents of each such CAF Advance Offer received by it. If the Administrative Agent, in its capacity as a Revolving Lender, shall elect, in its sole discretion, to make any such CAF Advance Offer, it shall advise the Borrower of the contents of its CAF Advance Offer before 10:15 A.M. (New York City time) on the date which is three Business Days before the proposed Borrowing Date.
(c)    In the case of a Fixed Rate CAF Advance Request, upon receipt of notice from the Administrative Agent of the contents of such CAF Advance Request, each Revolving Lender may elect, in its sole discretion, to offer irrevocably to make one or more CAF Advances at a rate of interest determined by such Revolving Lender in its sole discretion for each such CAF Advance. Any such irrevocable offer shall be made by delivering a CAF Advance Offer to the Administrative Agent before 9:30 A.M. (New York City time) on the Borrowing Date, setting forth:
(i)    the maximum amount of CAF Advances for each CAF Advance Maturity Date, and the aggregate maximum amount for all CAF Advance Maturity Dates, which such Lender would be willing to make (which amounts may, subject to subsection 2.8, exceed such Revolving Lender’s Revolving Credit Commitment); and
(ii)    the rate of interest at which such Revolving Lender is willing to make each such CAF Advance.
The Administrative Agent shall advise the Borrower before 10:00 A.M. (New York City time) on the proposed Borrowing Date of the contents of each such CAF Advance Offer received by it. If the Administrative Agent, in its capacity as a Revolving Lender, shall elect, in its sole discretion, to make any such CAF Advance Offer, it shall advise the Borrower of the contents of its CAF Advance Offer before 9:15 A.M. (New York City time) on the proposed Borrowing Date.
(d)    Before 11:30 A.M. (New York City time, or in the case of a CAF Advance requested by a Term Rate CAF Advance Request for any non-Dollar currency, London time) three Business Days (or in the case of a CAF Advance requested in Dollars, three U.S. Government Securities Business Days) before the proposed Borrowing Date (in the case of CAF Advances requested by a Term Rate CAF Advance Request) and before 10:30 A.M. (New York City time) on the proposed Borrowing Date (in the case of CAF Advances requested by a Fixed Rate CAF Advance Request), the Borrower, in its absolute discretion, shall:
(i)    cancel such CAF Advance Request by giving the Administrative Agent telephone notice to that effect, or
(ii)    by giving telephone notice to the Administrative Agent (immediately confirmed by delivery to the Administrative Agent of a CAF Advance Confirmation by facsimile transmission) (A) subject to the provisions of subsection 2.9(e), accept one or more of the offers made by any Revolving Lender or Revolving Lenders pursuant to subsection 2.9(b) or subsection 2.9(c), as the case may be, and (B) reject any remaining offers made by Revolving Lenders pursuant to subsection 2.9(b) or subsection 2.9(c), as the case may be.
(e)    The Borrower’s acceptance of CAF Advances in response to any CAF Advance Offer shall be subject to the following limitations:
    - 38 -


(i)    the amount of CAF Advances accepted for each CAF Advance Maturity Date specified by any Revolving Lender in its CAF Advance Offer shall not exceed the maximum amount for such CAF Advance Maturity Date specified in such CAF Advance Offer;
(ii)    the aggregate amount of CAF Advances accepted for all CAF Advance Maturity Dates specified by any Revolving Lender in its CAF Advance Offer shall not exceed the aggregate maximum amount specified in such CAF Advance Offer for all such CAF Advance Maturity Dates;
(iii)    the Borrower may not accept offers for CAF Advances for any CAF Advance Maturity Date in an aggregate principal amount in excess of the maximum principal amount requested in the related CAF Advance Request; and
(iv)    if the Borrower accepts any of such offers, it must accept offers based solely upon pricing for each relevant CAF Advance Maturity Date and upon no other criteria whatsoever, and if two or more Revolving Lenders submit offers for any CAF Advance Maturity Date at identical pricing and the Borrower accepts any of such offers but does not wish to (or, by reason of the limitations set forth in subsection 2.8, cannot) borrow the total amount offered by such Revolving Lenders with such identical pricing, the Borrower shall accept offers from all of such Revolving Lenders in amounts allocated among them pro rata according to the amounts offered by such Lenders (with appropriate rounding, in the sole discretion of the Borrower, to assure that each accepted CAF Advance is an integral multiple of $1,000,000 or, in the case of CAF Advances to be denominated in a currency other than Dollars, an amount in such currency the Dollar Equivalent of which is approximately equal to $1,000,000); provided that if the number of Revolving Lenders that submit offers for any CAF Advance Maturity Date at identical pricing is such that, after the Borrower accepts such offers pro rata in accordance with the foregoing provisions of this paragraph, the CAF Advance to be made by any such Revolving Lender would be less than $5,000,000 (or, in the case of CAF Advances to be denominated in a currency other than Dollars, an amount in such currency the Dollar Equivalent of which is approximately equal to $5,000,000) principal amount, the number of such Revolving Lenders shall be reduced by the Administrative Agent by lot until the CAF Advances to be made by each such remaining Revolving Lender would be in a principal amount of $5,000,000 or an integral multiple of $1,000,000 in excess thereof (or, in the case of CAF Advances to be denominated in a currency other than Dollars, an amount in such currency the Dollar Equivalent of which is approximately equal to $5,000,000 or an integral multiple of $1,000,000 in excess thereof).
(f)    If the Borrower notifies the Administrative Agent that a CAF Advance Request is cancelled pursuant to subsection 2.9(d)(i), the Administrative Agent shall give prompt telephonic or written notice thereof to the Revolving Lenders.
(g)    If the Borrower accepts pursuant to subsection 2.9(d)(ii) one or more of the offers made by any Revolving Lender or Revolving Lenders, the Administrative Agent promptly shall notify each Revolving Lender which has made such an offer of (i) the aggregate amount of such CAF Advances to be made on such Borrowing Date for each CAF Advance Maturity Date and (ii) the acceptance or rejection of any offers to make such CAF Advances made by such Revolving Lender. Before 12:00 Noon (New York City time) on the Borrowing Date specified in the applicable CAF Advance Request (in the case of CAF Advances denominated in Dollars) and before the funding time for the relevant currency from time to time specified by the Administrative Agent by notice to the Revolving Lenders (in the case of CAF Advances denominated in any currency other than Dollars), each Revolving Lender whose CAF Advance
    - 39 -


Offer has been accepted shall make available to the Administrative Agent the amount of CAF Advances to be made by such Revolving Lender, in immediately available funds, at the funding office for the relevant currency specified from time to time by the Administrative Agent by notice to the Revolving Lenders. The Administrative Agent will make such funds available to the Borrower as soon as practicable on such date at such office of the Administrative Agent. As soon as practicable after each Borrowing Date, the Administrative Agent shall notify each Revolving Lender of the aggregate amount of CAF Advances advanced on such Borrowing Date and the respective CAF Advance Maturity Dates thereof.
2.10.    Repayment of CAF Advances
. The Borrower hereby unconditionally promises to pay to the Administrative Agent, for the account of each Revolving Lender which has made a CAF Advance, on the applicable CAF Advance Maturity Date the then unpaid principal amount of such CAF Advance. The Borrower shall have the right to prepay any principal amount of any CAF Advance only with the consent of the Revolving Lender to which such CAF Advance is owed. The Borrower hereby further agrees to pay interest on the unpaid principal amount of each CAF Advance from the Borrowing Date to the applicable CAF Advance Maturity Date at the rate of interest specified in the CAF Advance Offer accepted by the Borrower in connection with such CAF Advance (calculated on the basis of a 360-day year for actual days elapsed), payable on each applicable CAF Advance Interest Payment Date.
2.11.    Certain Restrictions with Respect to CAF Advances
. A CAF Advance Request may request offers for CAF Advances to be made on not more than one Borrowing Date and to mature on not more than three CAF Advance Maturity Dates. No CAF Advance Request may be submitted earlier than five Business Days after submission of any other CAF Advance Request.
2.12.    Multicurrency Commitments
. Subject to the terms and conditions hereof, each Multicurrency Lender severally agrees to make revolving credit loans (each, a “Multicurrency Loan”) in any Available Foreign Currency to the Borrower from time to time during the Commitment Period so long as after giving effect thereto (a) the Available Multicurrency Commitment of each Multicurrency Lender is greater than or equal to zero, (b) the aggregate outstanding principal amount of Multicurrency Loans, plus (i) the aggregate outstanding principal amount of Local Currency Loans and (ii) the aggregate outstanding amount of L/C Obligations attributable to Letters of Credit denominated in any currency other than Dollars, does not exceed an amount the Dollar Equivalent of which is the Multicurrency Sublimit and (c) the Aggregate Total Outstandings of all Lenders do not exceed the Aggregate Revolving Credit Commitments. During the Commitment Period, the Borrower may use the Multicurrency Commitments by borrowing, repaying the Multicurrency Loans in whole or in part, and reborrowing, all in accordance with the terms and conditions hereof. Any Multicurrency Lender may cause its Multicurrency Loans to be made by any branch, affiliate or international banking facility of such Multicurrency Lender, provided, that such Multicurrency Lender shall remain responsible for all of its obligations hereunder and no additional taxes, costs or other burdens shall be imposed upon the Borrower or the Administrative Agent as a result thereof.
2.13.    Repayment of Multicurrency Loans
. The Borrower hereby unconditionally promises to pay to the Administrative Agent for the account of each Multicurrency Lender the then unpaid principal amount of each Multicurrency Loan of such Multicurrency Lender on the Termination Date and on such other date(s) and in such other amounts
    - 40 -


as may be required from time to time pursuant to this Agreement. The Borrower hereby further agrees to pay interest on the unpaid principal amount of the Multicurrency Loans advanced to it and from time to time outstanding until payment thereof in full at the rates per annum, and on the dates, set forth in subsection 3.4.
2.14.    Procedure for Multicurrency Borrowing
. The Borrower may request the Multicurrency Lenders to make Multicurrency Loans during the Commitment Period on any Business Day by delivering a Notice of Multicurrency Loan Borrowing. Each borrowing under the Multicurrency Commitments shall be in an amount in an Available Foreign Currency the Dollar Equivalent of which is equal to at least $1,000,000 (or, if the then Aggregate Available Multicurrency Commitments are less than $1,000,000, such lesser amount). Upon receipt of any such Notice of Multicurrency Borrowing from the Borrower, the Administrative Agent shall promptly notify each Multicurrency Lender thereof. Not later than the funding time, on the applicable Borrowing Date, for the relevant Available Foreign Currency specified from time to time by the Administrative Agent by notice to the Borrower and the Multicurrency Lenders each Multicurrency Lender shall make an amount equal to its Multicurrency Commitment Percentage of the principal amount of Multicurrency Loans requested to be made on such Borrowing Date available to the Administrative Agent at the appropriate funding office for the relevant Available Foreign Currency specified from time to time by the Administrative Agent by notice to the Borrower and the Multicurrency Lenders in the relevant Available Foreign Currency and in immediately available funds; provided that, unless and until the Administrative Agent shall otherwise direct, any Multicurrency Lender may provide funds in the then applicable Dollar Equivalent (including an exchange fee and other normal and customary fees for providing this service as determined by the Administrative Agent in its sole discretion) thereof in lieu of the requested currency, so long as the Multicurrency Lender has given reasonable notice to the Administrative Agent of its desire and intent to so provide funds therefor promptly after (but in any event within one hour of) its receipt of any such notice for a Multicurrency Loan. The amounts made available by each Multicurrency Lender will then be made available to the Borrower at such funding office and in like funds as received by the Administrative Agent; provided, in the case of Multicurrency Loans for which any Lender has provided funds in Dollars, the Administrative Agent shall provide such funds to the applicable Borrower in the requested currency.
2.15.    Termination or Reduction of Multicurrency Commitments
. The Borrower shall have the right, upon not less than three Business Days’ notice to the Administrative Agent (which shall give prompt notice thereof to each Multicurrency Lender), to terminate the Multicurrency Commitments or, from time to time, to reduce the amount of the Multicurrency Commitments; provided that no such termination or reduction shall be permitted if, after giving effect thereto and to any prepayments of the Loans made on the effective date thereof, the Available Multicurrency Commitment of any Multicurrency Lender would be less than zero. Any such reduction shall be in an amount equal to U.S. $1,000,000 or a whole multiple of U.S. $100,000 in excess thereof and shall reduce permanently the Multicurrency Commitments then in effect; provided further that such notice delivered by the Borrower may state that such notice is conditioned upon the effectiveness of other credit facilities, in which case such notice may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified effective date) if such condition is not satisfied.
2.16.    Borrowings of Revolving Credit Loans and Refunding of Loans
.
    - 41 -


(a)    If on any Borrowing Date on which the Borrower has requested the Multicurrency Lenders to make Multicurrency Loans (the “Requested Multicurrency Loans”),
(i)    the aggregate principal amount of the Requested Multicurrency Loans exceeds the Aggregate Available Multicurrency Commitments on such Borrowing Date (before giving effect to the making and payment of any Loans required to be made pursuant to this subsection 2.16 on such Borrowing Date) and,
(ii)    the Dollar Equivalent of the amount of such excess is less than or equal to the aggregate Available Revolving Credit Commitments of all Non-Multicurrency Lenders (before giving effect to the making and payment of any Loans pursuant to this subsection 2.16 on such Borrowing Date),
each Non-Multicurrency Lender shall make a Revolving Credit Loan to the Borrower on such Borrowing Date, and the proceeds of such Revolving Credit Loans shall be simultaneously applied to repay outstanding Revolving Credit Loans, Local Currency Loans and/or Multicurrency Loans of the Multicurrency Lenders (as directed by the Borrower) in each case in amounts such that, after giving effect to (1) such borrowings and repayments and (2) the borrowing from the Multicurrency Lenders of the Requested Multicurrency Loans, the Committed Outstanding Percentage of each Lender will equal (as nearly as possible) its Revolving Credit Commitment Percentage. To effect such borrowings and repayments, (x) not later than 12:00 Noon, New York City time, on such Borrowing Date, the proceeds of such Revolving Credit Loans shall be made available by each Non-Multicurrency Lender to the Administrative Agent at its office specified in subsection 13.2 in Dollars and in immediately available funds and the Administrative Agent shall apply the proceeds of such Revolving Credit Loans toward repayment of outstanding Revolving Credit Loans, Multicurrency Loans and/or Local Currency Loans of the Multicurrency Lenders (as directed by the Borrower) and (y) concurrently with the repayment of such Loans on such Borrowing Date, (I) the Multicurrency Lenders shall, in accordance with the applicable provisions hereof, make the Requested Multicurrency Loans in an aggregate amount equal to the amount so requested by the Borrower (but not in any event greater than the Aggregate Available Multicurrency Commitments after giving effect to the making of such repayment of any Loans on such Borrowing Date) and (II) the Borrower shall pay to the Administrative Agent for the account of the Lenders whose Loans to the Borrower are repaid on such Borrowing Date pursuant to this subsection 2.16 all interest accrued on the amounts repaid to the date of repayment, together with any amounts payable pursuant to subsection 3.11 in connection with such repayment.
(b)    Subject to the limitations on borrowings contained in a given Local Currency Facility, if on any Borrowing Date on which a Foreign Subsidiary Borrower has requested Local Currency Lenders to make Local Currency Loans (the “Requested Local Currency Loans”) under a Local Currency Facility to which such Foreign Subsidiary Borrower and Local Currency Lenders are parties, (i) the aggregate principal amount of the Requested Local Currency Loans (A) exceeds the aggregate available amount of the commitments of such Local Currency Lenders under such Local Currency Facility on such Borrowing Date (before giving effect to the making and payment of any Revolving Credit Loans required to be made pursuant to this subsection 2.16 on such Borrowing Date) or (B) together with the aggregate then outstanding principal amount of Multicurrency Loans and the aggregate outstanding amount of L/C Obligations attributable to Letters of Credit denominated in any currency other than Dollars, would exceed an amount of which the Dollar Equivalent is the Multicurrency Sublimit, (ii) after giving effect to the Requested Local Currency Loans, the Dollar Equivalent of the aggregate outstanding principal amount of Local Currency Loans of such Foreign Subsidiary Borrower will be less than or equal to the aggregate commitments of such Local Currency Lenders under such Local Currency Facility and (iii) the
    - 42 -


Dollar Equivalent of the amount of the excess described in clause (i) above is less than or equal to the Aggregate Available Revolving Credit Commitments of all Revolving Lenders other than such Local Currency Lenders (before giving effect to the making and payment of any Revolving Credit Loans pursuant to this subsection 2.16 on such Borrowing Date), each such other Revolving Lender shall make a Revolving Credit Loan to the Borrower, on such Borrowing Date, and the proceeds of such Revolving Credit Loans shall be simultaneously applied to repay outstanding Revolving Credit Loans, Multicurrency Loans and/or Local Currency Loans of such Local Currency Lenders (as directed by the Borrower) in each case in amounts such that, after giving effect to (1) such borrowings and repayments and (2) the borrowing from such Local Currency Lenders of the Requested Local Currency Loans, the Committed Outstandings Percentage of each Lender will equal (as nearly as possible) its Revolving Credit Commitment Percentage and the Dollar Equivalent of the aggregate outstanding principal amount of Multicurrency Loans and Local Currency Loans will not exceed the Multicurrency Sublimit. To effect such borrowings and repayments, (x) not later than 12:00 Noon, New York City time, on such Borrowing Date, the proceeds of such Revolving Credit Loans shall be made available by each such other Revolving Lender to the Administrative Agent at its office specified in subsection 13.2 in Dollars and in immediately available funds and the Administrative Agent shall apply the proceeds of such Revolving Credit Loans toward the repayment of outstanding Revolving Credit Loans, Multicurrency Loans and/or Local Currency Loans of such Local Currency Lenders (as directed by the Borrower) and (y) concurrently with the repayment of such Revolving Credit Loans on such Borrowing Date, (I) such Local Currency Lenders shall, in accordance with the applicable provisions hereof, make the Requested Local Currency Loans in an aggregate amount equal to the amount so requested by such Foreign Subsidiary Borrower and (II) the relevant Foreign Subsidiary Borrower shall pay to the Administrative Agent for the account of the Revolving Lenders whose Loans to such Foreign Subsidiary Borrower are repaid on such Borrowing Date pursuant to this subsection 2.16 all interest accrued on the amounts repaid to the date of repayment, together with any amounts payable pursuant to subsection 3.11 in connection with such repayment.
(c)    If any borrowing of Revolving Credit Loans is required pursuant to this subsection 2.16, the Borrower shall notify the Administrative Agent in the manner provided for Revolving Credit Loans in subsection 2.2, except that the minimum borrowing amounts set forth in subsection 2.2 shall not be applicable to the extent that such minimum borrowing amounts exceed the amounts of Revolving Credit Loans required to be made pursuant to this subsection 2.16.
2.17.    Increase of Revolving Credit Commitments
. The Borrower shall have the right to increase the Revolving Credit Commitments from time to time in an aggregate principal amount not to exceed $500,000,000 upon prior notice to the Administrative Agent and pursuant to procedures established by the Administrative Agent and acceptable to the Borrower. Each such increase (each, an “Additional Revolving Credit Commitment”) shall be in a principal amount of at least $25,000,000, and no such increase shall become effective (i) if a Default or Event of Default then exists or would exist immediately after giving effect thereto and (ii) unless all representations and warranties made by the Borrower required to be made pursuant to subsection 7.2 in this Agreement and the other Loan Documents are true in all material respects as of the date of such increase. Each bank or other financial institution (other than an existing Lender or Lender Affiliate providing any Additional Revolving Credit Commitments) shall be reasonably acceptable to the Administrative Agent and the Borrower and shall be a “Lender” for all purposes under this Agreement. No Lender shall have any obligation to provide any such Additional Revolving Credit Commitments unless and until it shall expressly agree under the applicable procedures to do so, at which time such Lender shall be deemed to have made an Additional Revolving Credit Commitment. The Lenders agree that this Agreement and the other Loan Documents may be amended from time to time with the consent
    - 43 -


of the Administrative Agent and the Borrower to reflect such Additional Revolving Credit Commitments in connection with this subsection 2.17.
2.18.    Cash Collateral
.
(a)    At any time that (i) there shall exist a Defaulting Lender and (ii) the Rating provided by (x) S&P is less than BBB or (y) Moody’s is less than Baa2, within twenty Business Days after receipt of the written request of the Administrative Agent or the Issuing Lender, the Borrower shall deliver to the Administrative Agent Cash Collateral in an amount sufficient to cover all Fronting Exposure (after giving effect to subsection 2.19(a)(iv) and any Cash Collateral provided by the Defaulting Lender); provided however, notwithstanding the foregoing, in lieu of providing Cash Collateral to cover all or a portion of the Fronting Exposure, at any time within twenty Business Days after the receipt of written request of the Administrative Agent or the Issuing Lender, the Borrower (but only to the extent necessary to cover Fronting Exposure which is not covered by Cash Collateral) (i) may request that all or a portion of the Revolving Credit Commitments of such Defaulting Lender be re-allocated to another Lender or Lenders (as acceptable to each Lender in its sole discretion) or (ii) shall have the option to exercise its right to increase the Revolving Credit Commitments under subsection 2.17 by obtaining Additional Revolving Credit Commitments from one or more financial institutions (which may be a Lender) in an amount to cover all or a portion of the Fronting Exposure; provided further that the only limitation applicable to such exercise shall be that the aggregate amount of such increases pursuant to Section 2.17 shall not exceed $500,000,000.
(b)    All Cash Collateral (other than credit support not constituting funds subject to deposit) shall be maintained in blocked, interest bearing deposit accounts at the Administrative Agent. The Borrower, and to the extent provided by any Lender, such Lender, hereby grants to (and subjects to the control of) the Administrative Agent, for the benefit of the Administrative Agent, the Issuing Lender and the Lenders, and agrees to maintain, a first priority security interest in all such cash, deposit accounts and all balances therein, and all other property so provided as collateral pursuant hereto, and in all proceeds of the foregoing, all as security for the obligations to which such Cash Collateral may be applied pursuant to subsection 2.18(c). If at any time the Administrative Agent reasonably determines that Cash Collateral is subject to any right or claim of any Person that is prior to the claim of the Administrative Agent as herein provided, or that the total amount of such Cash Collateral is less than the applicable Fronting Exposure and other obligations secured thereby, the Borrower or the relevant Defaulting Lender will, promptly upon demand by the Administrative Agent, pay or provide to the Administrative Agent additional Cash Collateral in an amount sufficient to eliminate such deficiency.
(c)    Notwithstanding anything to the contrary contained in this Agreement, Cash Collateral provided under any of this subsection 2.18, subsection 5.1 or 2.19 or Section 10 in respect of Letters of Credit shall be held and applied to the satisfaction of the specific L/C Obligations, obligations to fund participations therein (including, as to Cash Collateral provided by a Defaulting Lender, any interest accrued on such obligation) and other obligations for which the Cash Collateral was so provided, prior to any other application of such property as may be provided for herein.
(d)    Cash Collateral (or the appropriate portion thereof) provided to reduce Fronting Exposure or other obligations shall be released promptly following (i) the elimination of the applicable Fronting Exposure or other obligations giving rise thereto (including by the termination of Defaulting Lender status of the applicable Lender (or, as appropriate, its assignee following compliance with subsection 13.6)) or
    - 44 -


(ii) the Administrative Agent’s good faith determination that there exists excess Cash Collateral; provided, however, (x) that Cash Collateral furnished by or on behalf the Borrower shall not be released during the continuance of an Event of Default (and following application as provided in this subsection 2.18 may be otherwise applied in accordance with Section 10), and (y) the Person providing Cash Collateral and the Issuing Lender, as applicable, may agree that Cash Collateral shall not be released but instead held to support Fronting Exposure or other obligations with respect to requested but unfunded extensions of credit.
2.19.    Defaulting Lenders
.
(a)    Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable law:
(i)    That Defaulting Lender’s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in subsection 13.1.
(ii)    Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of that Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Section 10 or otherwise, and including any amounts made available to the Administrative Agent by that Defaulting Lender pursuant to subsection 13.7), shall be applied at such time or times as may be determined by the Administrative Agent as follows: first, to the payment of any amounts owing by that Defaulting Lender to the Administrative Agent hereunder; second, to the payment on a pro rata basis of any amounts owing by that Defaulting Lender to the Issuing Lender hereunder; third, if so determined by the Administrative Agent or requested by the Issuing Lender, to be held as Cash Collateral for future funding obligations of that Defaulting Lender of any participation in any Letter of Credit; fourth, as the Borrower may request (so long as no Event of Default exists), to the funding of any Loan in respect of which that Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; fifth, if so determined by the Administrative Agent and the Borrower, to be held in an interest bearing deposit account and released in order to satisfy obligations of that Defaulting Lender to fund Loans under this Agreement; sixth, to the payment of any amounts owing to the Lenders or the Issuing Lender as a result of any judgment of a court of competent jurisdiction obtained by any Lender or the Issuing Lender against that Defaulting Lender as a result of that Defaulting Lender’s breach of its obligations under this Agreement; seventh, so long as no Event of Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower against that Defaulting Lender as a result of that Defaulting Lender’s breach of its obligations under this Agreement; and eighth, to that Defaulting Lender or as otherwise directed by a court of competent jurisdiction; provided that if (x) such payment is a payment of the principal amount of any Loans or L/C Obligations in respect of which that Defaulting Lender has not fully funded its appropriate share and (y) such Loans or L/C Obligations were made at a time when the conditions set forth in subsection 7.2 were satisfied or waived, such payment shall be applied solely to pay the Loans of, and L/C Obligations owed to, all non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of, or L/C Obligations owed to, that Defaulting Lender. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post Cash Collateral
    - 45 -


pursuant to this subsection 2.19(a)(ii) shall be deemed paid to and redirected by that Defaulting Lender, and each Lender irrevocably consents to the foregoing.
(iii)    That Defaulting Lender (x) shall be entitled to receive any facility fee pursuant to subsection 2.5(a) for any period during which that Lender is a Defaulting Lender only to extent allocable to the sum of (1) the Dollar Equivalent of the principal amount of the Loans funded by it and (2) its Revolving Credit Commitment Percentage of the stated amount of Letters of Credit for which it has provided Cash Collateral pursuant to subsection 2.14, 2.19(a)(ii) or 5.1, as applicable (and the Borrower shall (A) be required to pay to the Issuing Lender, as applicable, the amount of such fee allocable to its Fronting Exposure arising from that Defaulting Lender and (B) not be required to pay the remaining amount of such fee that otherwise would have been required to have been paid to that Defaulting Lender) and (y) shall be limited in its right to receive Letter of Credit fees as provided in subsection 5.3(a).
(iv)    During any period in which there is a Defaulting Lender, for purposes of computing the amount of the obligation of each non-Defaulting Lender to acquire, refinance or fund participations in Letters of Credit pursuant to subsections 5.1 and 5.4(a), the “Revolving Credit Commitment Percentage” of each non-Defaulting Lender shall be computed without giving effect to the Revolving Credit Commitment of that Defaulting Lender; provided, that, (i) each such reallocation shall be given effect only if, at the date the applicable Lender becomes a Defaulting Lender, no Event of Default exists; and (ii) the aggregate obligation of each non-Defaulting Lender to acquire, refinance or fund participations in Letters of Credit shall not exceed the positive difference, if any, of (1) the Revolving Credit Commitment of that non-Defaulting Lender minus (2) the Dollar Equivalent of the principal amount of the Loans of that Lender.
(b)    If the Borrower, the Administrative Agent and the Issuing Lender agree in writing that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any Cash Collateral), that Lender will, to the extent applicable, purchase that portion of outstanding Revolving Credit Loans of the other Lenders or take such other actions as the Administrative Agent may determine to be necessary to cause the Revolving Credit Loans and funded and unfunded participations in Letters of Credit to be held on a pro rata basis by the Revolving Lenders in accordance with their Revolving Credit Commitment Percentages (without giving effect to subsection 2.19(a)(iv)), whereupon that Lender will cease to be a Defaulting Lender; provided that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender’s having been a Defaulting Lender.
(c)    If any Lender is a Defaulting Lender, then the Borrower may, at its sole expense and effort, upon notice to such Defaulting Lender and the Administrative Agent, require such Defaulting Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, subsection 13.6), all of its interests, rights and obligations under this Agreement and the related Loan Documents to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment), provided that:
(i)    the Borrower shall have paid to the Administrative Agent the assignment fee specified in subsection 13.6;
    - 46 -


(ii)    such Defaulting Lender shall have received payment of an amount equal to 100% of the outstanding principal of its Loans, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under subsection 3.11) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts);
(iii)    such assignment does not conflict with applicable laws; and
(iv)    such Defaulting Lender shall not be required to sign and deliver any assignment form in order for such assignment to become effective.
A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply.
2.20.    Extension of Termination Date
.
(a)    The Borrower may, by sending an Extension Request to the Administrative Agent (in which case the Administrative Agent shall promptly deliver a copy to each of the Lenders), at least three months in advance of the Termination Date in effect at such time (including at any time prior thereto on or after any anniversary of the Closing Date), request that the Lenders extend such Termination Date then in effect to the first anniversary of the Termination Date then in effect. Each Lender, acting in its sole discretion, shall, by notice to the Administrative Agent given not later than the date that is the 20th day after the date of the Extension Request, or if such day is not a Business Day, the immediately following Business Day (the “Response Date”) advise the Administrative Agent in writing whether or not such Lender agrees to such extension (each Lender that so advises the Administrative Agent that it will not extend the Termination Date, being referred to herein as a “Non-extending Lender”); provided that any Lender that does not advise the Administrative Agent by the Response Date and any Defaulting Lender shall be deemed to be a Non-extending Lender. The election of any Lender to agree to such extension shall not obligate any other Lender to agree.
(b)    (i) If, on the Response Date, Lenders holding Revolving Credit Commitments that aggregate to 50% or more of the total Revolving Credit Commitments shall not have agreed to extend the Termination Date, then such Termination Date shall not be so extended and the outstanding principal balance of all Loans and other amounts payable hereunder shall be payable on such Termination Date.
(ii)    If (and only if), on the Response Date, Lenders holding Revolving Credit Commitments that aggregate to more than 50% of the total Revolving Credit Commitments shall have agreed to extend the Termination Date, then the Termination Date that shall so have agreed shall be the first anniversary of the current Termination Date (subject to satisfaction of the conditions set forth in subsection 2.20(d)). In the event of such extension, the Revolving Credit Commitment of each Non-extending Lender shall terminate on the Termination Date in effect prior to such extension, all Loans and other amounts payable hereunder to such Non-extending Lenders shall become due and payable on such Termination Date and the total Revolving Credit Commitments of the Lenders hereunder shall be reduced by the Revolving Credit Commitments of the Non-extending Lenders so terminated on such Termination Date.
    - 47 -


(c)    In the event that the conditions of clause (ii) of paragraph (b) above have been satisfied, the Borrower shall have the right on or before the Termination Date in effect prior to the requested extension, at its own expense, to require any Non-extending Lender to transfer and assign without recourse (in accordance with and subject to the restrictions contained in subsection 13.6) all its interests, rights and obligations under this Agreement to one or more banks or other financial institutions identified to the Non-extending Lender, which may include any Lender (each an “Additional Lender”), provided that (w) such Additional Lender, if not already a Lender hereunder, shall be subject to the approval of the Administrative Agent, the Issuing Lender and the Borrower (such approvals not to be unreasonably withheld), (x) such assignment shall become effective as of a date specified by the Borrower (which shall not be later than the Termination Date in effect prior to the requested extension); (y) the Additional Lender shall pay to such Non-extending Lender in immediately available funds on the effective date of such assignment the principal of and interest accrued to the date of payment on the Loans made by it hereunder and all other amounts accrued for its account or owed to it hereunder and (z) such Non-extending Lender shall not be required to sign and deliver any assignment form in order for such assignment to become effective.
(d)    As a condition precedent to each such extension, the Borrower shall deliver to the Administrative Agent a certificate of the Borrower dated as of the Termination Date then in effect signed by a Responsible Officer of the Borrower certifying that, before and after giving effect to such extension, (A) the representations and warranties contained in Section 6 (including subsections 6.13 and 6.14) and the other Loan Documents are true and correct on and as of the Termination Date, and except that for purposes of this subsection 2.20, the representations and warranties contained in subsection 6.1 shall be deemed to refer to the most recent statements furnished pursuant to paragraphs (a) and (b), respectively, of subsection 8.1, and (B) no Default or Event of Default exists. In addition, no such extension of the Revolving Credit Facility shall be effective if on the Termination Date then in effect, the Aggregate Total Outstandings would exceed the Revolving Credit Commitments then being extended.
SECTION 3    

CERTAIN PROVISIONS APPLICABLE TO THE LOANS
3.1.    Optional and Mandatory Prepayments
.
(a)    The Borrower may at any time and from time to time prepay the Loans, in whole or in part, without premium or penalty (other than any amounts payable pursuant to subsection 3.11 if such prepayment is of SOFR Loans and is made on a day other than the last day of the Interest Period with respect thereto), upon at least three U.S. Government Securities Business Days’ irrevocable notice to the Administrative Agent, specifying the date and amount of prepayment and whether the prepayment is of SOFR Loans, ABR Loans or a combination thereof, and, if of a combination thereof, the amount allocable to each; provided further that such notice delivered by the Borrower may state that such notice is conditioned upon the effectiveness of other credit facilities, in which case such notice may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified effective date) if such condition is not satisfied. Upon receipt of any such notice the Administrative Agent shall promptly notify each Lender thereof. If any such notice is given, the amount specified in such notice shall be due and payable on the date specified therein. Partial prepayments of Loans shall be in an aggregate principal amount of at least $1,000,000 or an integral multiple of $100,000 in excess thereof.
    - 48 -


(b)    The Borrower may at any time and from time to time prepay, without premium or penalty (other than any amounts payable pursuant to subsection 3.11 if such prepayment is of Multicurrency Loans and is made on a day other than the last day of the Interest Period with respect thereto), the Multicurrency Loans, in whole or in part, upon at least three Business Days’ irrevocable notice to the Administrative Agent specifying the date and amount of prepayment; provided further that such notice delivered by the Borrower may state that such notice is conditioned upon the effectiveness of other credit facilities, in which case such notice may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified effective date) if such condition is not satisfied. Upon the receipt of any such notice, the Administrative Agent shall promptly notify each Multicurrency Lender thereof. If any such notice is given, the amount specified in such notice shall be due and payable on the date specified therein. Partial prepayments of Multicurrency Loans shall be in an aggregate principal amount the Dollar Equivalent of which is at least $1,000,000 or an integral multiple of $100,000 in excess thereof.
(c)    If at any time during the Commitment Period, for any reason the Aggregate Total Outstandings of all Lenders exceed the Aggregate Revolving Credit Commitments then in effect, the Borrower shall, without notice or demand, immediately prepay the Revolving Credit Loans and/or the Multicurrency Loans in amounts such that the sum of (A) the aggregate principal amount of the Revolving Credit Loans so prepaid and (B) the Dollar Equivalent of the aggregate principal amount of the Multicurrency Loans so prepaid, equals or exceeds the amount of such excess.
(i)    If, at any time during the Commitment Period, for any reason either (1) the Aggregate Total Outstandings of all Multicurrency Lenders exceed the Aggregate Revolving Credit Commitments of the Multicurrency Lenders by 5% or more, (2) the Aggregate Multicurrency Outstandings exceed the aggregate Multicurrency Commitments by 5% or more, (3) the sum of the Aggregate Multicurrency Outstandings plus the Dollar Equivalent of (x) the aggregate outstanding principal amount of Local Currency Loans and (y) the aggregate outstanding amount of L/C Obligations attributable to Letters of Credit denominated in currencies other than Dollars, exceeds the aggregate Multicurrency Commitments by 5% or more or (4) the Dollar Equivalent of all L/C Obligations attributable to Letters of Credit denominated in currencies other than Dollars exceeds, in the aggregate, the Multicurrency Sublimit by 5% or more, the Borrower shall, without notice or demand, immediately prepay the Revolving Credit Loans and/or the Multicurrency Loans and/or Local Currency Loans and/or cash collateralize the L/C Obligations in amounts such that any such excess is eliminated.
(ii)    Each prepayment of Loans pursuant to this subsection 3.1(c) shall be accompanied by the payment of unpaid accrued interest on the principal amount so prepaid and any amounts payable under subsection 3.11 in connection with such prepayment.
(iii)    Notwithstanding the foregoing, mandatory prepayments of Revolving Credit Loans or Multicurrency Loans that would otherwise be required pursuant to this subsection 3.1(c) solely as a result of fluctuations in Exchange Rates from time to time shall only be required to be made pursuant to this subsection 3.1(c) on the last Business Day of each month on the basis of the Exchange Rate in effect on such Business Day.
3.2.    Conversion and Continuation Options
.
    - 49 -


(a)    The Borrower may elect from time to time to convert SOFR Loans to ABR Loans by giving the Administrative Agent at least two Business Days’ prior irrevocable notice of such election. The Borrower may elect from time to time to convert ABR Loans to SOFR Loans by giving the Administrative Agent at least three U.S. Government Securities Business Days’ prior irrevocable notice of such election. Any such notice of conversion to SOFR Loans shall specify the length of the initial Interest Period therefor. Upon receipt of any such notice the Administrative Agent shall promptly notify each Lender thereof. All or any part of outstanding SOFR Loans and ABR Loans may be converted as provided herein, provided that (i) no Loan may be converted into a SOFR Loan when any Event of Default has occurred and is continuing and the Administrative Agent has or the Majority Lenders have determined that such a conversion is not appropriate and (ii) no Loan may be converted into a SOFR Loan after the date that is one month prior to the Termination Date. No Multicurrency Loan or CAF Advance may be converted into or continued as a Loan denominated in a different currency, but instead must be prepaid in the original currency of such Loan and reborrowed in the other currency.
(b)    Any SOFR Loans may be continued as such upon the expiration of the then current Interest Period with respect thereto by the Borrower giving notice to the Administrative Agent, in accordance with the applicable provisions of the term “Interest Period” set forth in subsection 1.1, of the length of the next Interest Period to be applicable to such Loans, provided that no SOFR Loan may be continued as such (i) when any Event of Default has occurred and is continuing and the Administrative Agent has or the Majority Lenders have determined that such a continuation is not appropriate or (ii) after the date that is one month prior to the Termination Date, and provided, further, that if the Borrower shall fail to give such notice or if such continuation is not permitted, SOFR Loans shall be automatically converted to ABR Loans on the last day of such then expiring Interest Period.
(c)    Any Multicurrency Loans may be continued as such upon the expiration of the then current Interest Period with respect thereto by the Borrower giving a Notice of Multicurrency Loan Continuation, provided, that if the Borrower shall fail to give such Notice of Multicurrency Loan Continuation by the deadline specified therefor in Schedule II, such Multicurrency Loans shall automatically be continued for an Interest Period of one month.
3.3.    Minimum Amounts and Maximum Number of Tranches
. All borrowings, conversions and continuations of Revolving Credit Loans and Multicurrency Loans hereunder and all selections of Interest Periods hereunder shall be in such amounts and be made pursuant to such elections so that, after giving effect thereto, (i) the aggregate principal amount of the SOFR Loans comprising each SOFR Tranche shall be equal to $5,000,000 or a whole multiple of $1,000,000 in excess thereof and (ii) the aggregate principal amount of the Multicurrency Loans comprising each Multicurrency Tranche shall be in an amount the Dollar Equivalent of which is at least $5,000,000. In no event shall there be more than ten Tranches outstanding at any time, unless the Borrower and the Administrative Agent shall so agree.
3.4.    Interest Rates and Payment Dates
.
(a)    Each SOFR Loan shall bear interest for each day during each Interest Period with respect thereto at a rate per annum equal to Adjusted Term SOFR determined for such Interest Period plus the Applicable Margin in effect for such day.
    - 50 -


(b)    Each ABR Loan shall bear interest at a rate per annum equal to the ABR plus the Applicable Margin.
(c)    Each Multicurrency Loan shall bear interest at a rate per annum equal to the Eurocurrency Rate plus the Applicable Margin in effect on the day such Multicurrency Loan is made.
(d)    Each CAF Advance shall bear interest at the rate determined in accordance with subsection 2.9.
(e)    If all or a portion of (i) any principal of any Loan, (ii) any interest payable thereon, (iii) any facility fee or (iv) any other amount payable hereunder shall not be paid when due (whether at the stated maturity, by acceleration or otherwise), the principal of the Loans and/or any such overdue interest, facility fee or other amount shall bear interest at a rate per annum which is (x) in the case of principal, the rate that would otherwise be applicable thereto pursuant to the foregoing provisions of this subsection plus 2% or (y) in the case of any such overdue interest, facility fee or other amount, the rate described in paragraph (b) of this subsection plus 2%, in each case from the date of such non-payment until such overdue principal, interest, facility fee or other amount is paid in full (as well after as before judgment).
(f)    Interest pursuant to this subsection shall be payable in arrears on each Interest Payment Date or CAF Advance Interest Payment Date, as the case may be, provided that interest accruing pursuant to paragraph (e) of this subsection shall be payable from time to time on demand.
3.5.    Computation of Interest and Fees
.
(a)    All interest and fees hereunder shall be computed on the basis of a year of 360 days, except that (i) interest computed by reference to the ABR when it is based on the Prime Rate shall be computed on the basis of a year of 365 days (or 366 days in a leap year) and (ii) interest computed with respect to Loans denominated in Australian Dollar, Canadian Dollar and Pounds Sterling shall be computed on the basis of a year of 365 days, and in each case shall be payable for the actual number of days elapsed (including the first day but excluding the last day). The applicable ABR, Adjusted Term SOFR or Eurocurrency Rate shall be determined by the Administrative Agent, and such determination shall be conclusive absent manifest error. The Administrative Agent shall as soon as practicable notify the Borrower and the Lenders of each determination of a Eurocurrency Rate or Adjusted Term SOFR. Any change in the interest rate on a Loan resulting from a change in the ABR, Adjusted Term SOFR or the Eurocurrency Reserve Requirements shall become effective as of the opening of business on the day on which such change becomes effective. The Administrative Agent shall as soon as practicable notify the Borrower and the relevant Lenders of the effective date and the amount of each such change in interest rate.
(b)    Each determination of an interest rate by the Administrative Agent pursuant to any provision of this Agreement shall be conclusive and binding on the Borrower and the Lenders in the absence of manifest error. The Administrative Agent shall, at the request of either of the Borrower, deliver to the Borrower a statement showing the quotations used by the Administrative Agent in determining any interest rate pursuant to subsections 3.4(a), (b) or (d).
3.6.    Changed Circumstances
.
    - 51 -


(a)    If prior to the first day of any Interest Period:
(i)    the Administrative Agent shall have determined (which determination shall be conclusive and binding upon the Borrower) that, by reason of circumstances affecting the relevant market, adequate and reasonable means do not exist for ascertaining Adjusted Term SOFR or the Eurocurrency Rate for any applicable Currency for such Interest Period, or
(ii)    the Administrative Agent shall have received notice from the Majority Lenders or the Majority Multicurrency Lenders, as the case may be, that Adjusted Term SOFR or the Eurocurrency Rate for any applicable Currency determined or to be determined for such Interest Period will not adequately and fairly reflect the cost to such Lenders (as conclusively certified by such Lenders) of making or maintaining their affected Loans during such Interest Period,
the Administrative Agent shall give telecopy or telephonic notice thereof to the Borrower and the Lenders as soon as practicable thereafter. If such notice is given (w) any SOFR Loans or Multicurrency Loans, as the case may be, in the affected Currency requested to be made on the first day of such Interest Period shall be made as ABR Loans (in the case of Multicurrency Loans, in an amount equal to the Dollar Equivalent of such requested Multicurrency Loans), provided, that, notwithstanding the provisions of subsection 2.2 or 2.14, the Borrower may cancel the request for such SOFR Loan or Multicurrency Loan, as the case may be, by written notice to the Administrative Agent one Business Day prior to the first day of such Interest Period and the Borrower shall not be subject to any liability pursuant to subsection 3.11 with respect to such cancelled request, (x) if the affected Currency is Dollars, any Loans that were to have been converted on the first day of such Interest Period to SOFR Loans shall be continued as ABR Loans, (y) if the affected Currency is Dollars, any outstanding SOFR Loans shall be converted, on the first day of such Interest Period, to ABR Loans and (z) any Multicurrency Loans in the affected Currency to which such Interest Period relates shall be repaid on the first day of such Interest Period. Until such notice has been withdrawn by the Administrative Agent, no further SOFR Loans or Multicurrency Loans in the applicable affected Currency shall be made or continued as such, nor (if the affected Currency is Dollars) shall the Borrower have the right to convert ABR Loans to SOFR Loans.
(b)    
(i)    Notwithstanding anything to the contrary herein or in any other Loan Document, upon the occurrence of a Benchmark Transition Event or an Early Opt-in Election with respect to any applicable then-current Benchmark, as applicable, the Administrative Agent and the Borrower may amend this Agreement to replace such Benchmark with one or more Benchmark Replacements (it being understood that all amounts denominated in a given currency for which a Benchmark is being replaced shall be subject to the same Benchmark Replacement). Any such amendment with respect to a Benchmark Transition Event will become effective at 5:00 p.m. on the fifth (5th) Business Day after the Administrative Agent has posted such proposed amendment to all affected Lenders and the Borrower so long as the Administrative Agent has not received, by such time, written notice of objection to such amendment from Lenders comprising the Majority Lenders. Any such amendment with respect to an Early Opt-in Election will become effective on the date that Lenders comprising the Majority Lenders have delivered to the Administrative Agent written notice that such Majority Lenders accept such amendment. No replacement of a Benchmark with a Benchmark Replacement pursuant to this Section 3.6(b)(i) will occur prior to the applicable Benchmark Transition Start Date.
    - 52 -


(ii)    In connection with the use, administration, adoption or implementation of a Benchmark Replacement, the Administrative Agent will have the right (in consultation with the Borrower) to make Benchmark Replacement Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Benchmark Replacement Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.
    (iii)    The Administrative Agent will promptly notify the Borrower and the Lenders of (i) any occurrence of a Benchmark Transition Event or an Early Opt-in Election, as applicable, and its related Benchmark Replacement Date and Benchmark Transition Start Date, (ii) the implementation of any Benchmark Replacement, (iii) the effectiveness of any Benchmark Replacement Conforming Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement and (iv) the commencement or conclusion of any Benchmark Unavailability Period. The Administrative Agent will promptly notify the Borrower of the removal or reinstatement of any tenor of a Benchmark pursuant to Section 3.6(b)(iv). Any determination, decision or election that may be made by the Administrative Agent or Lenders pursuant to this Section 3.6(b), including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this Section 3.6(b).

    (iv)    Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (A) if any then-current Benchmark is a term rate (including the Term SOFR Reference Rate, EURIBOR, BBSY or CDOR) and either (1) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (2) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Administrative Agent may modify the definition of “Interest Period” (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (B) if a tenor that was removed pursuant to clause (A) above either (1) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (2) is not, or is no longer, subject to an announcement that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the definition of “Interest Period” (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor

(v)    Upon the Borrower’s receipt of notice of the commencement of a Benchmark Unavailability Period with respect to a given Benchmark, (A) the Borrower may revoke any pending request for a borrowing of, conversion to or continuation of SOFR Loans or Multicurrency Loans, in each case, to be made, converted or continued during any Benchmark Unavailability Period denominated in the applicable Currency and, failing that, (I) in the case of any request for any affected SOFR Loans, if applicable, the Borrower will be deemed to have converted any such request into a request for a borrowing of or conversion to ABR Loans in the amount specified therein and (II) in the case of any request for any affected Multicurrency Loan,
    - 53 -


then such request shall be ineffective and (B)(I) any outstanding affected SOFR Loans, if applicable, will be deemed to have been converted into ABR Loans at the end of the applicable Interest Period and (II) any outstanding affected Multicurrency Loans, at the Borrower’s election, shall either (1) be converted into ABR Loans denominated in Dollars (in an amount equal to the Dollar Equivalent of such Available Foreign Currency) at the end of the applicable Interest Period or (2) be prepaid in full at the end of the applicable Interest Period; provided that if no election is made by the Borrower by the earlier of (x) the date that is three (3) Business Days after receipt by the Borrower of such notice and (y) the last day of the current Interest Period for the applicable Multicurrency Loan, the Borrower shall be deemed to have elected clause (1) above. Upon any such prepayment or conversion, the Borrower shall also pay accrued interest on the amount so prepaid or converted, together with any additional amounts required pursuant to Section 3.11. During a Benchmark Unavailability Period with respect to any Benchmark or at any time that a tenor for any then-current Benchmark is not an Available Tenor, the component of ABR based upon the then-current Benchmark that is the subject of such Benchmark Unavailability Period or such tenor for such Benchmark, as applicable, will not be used in any determination of Base Rate.

3.7.    Pro Rata Treatment and Payments
.
(a)    Each payment of principal and interest in respect of any optional prepayment of Revolving Credit Loans or Multicurrency Loans shall be made pro rata according to the amounts then due and owing to the respective Revolving Lender or Multicurrency Lender, as the case may be.
(b)    Except as provided in subsection 2.16, each borrowing by the Borrower of Revolving Credit Loans from the Revolving Lenders hereunder shall be made pro rata according to the Funding Commitment Percentages of the Revolving Lenders in effect on the date of such borrowing. Each payment by the Borrower on account of any facility fee hereunder and any reduction of the Revolving Credit Commitments of the Revolving Lenders shall be allocated by the Administrative Agent among the Revolving Lenders pro rata according to the Revolving Credit Commitment Percentages of the Lenders. Except as provided in subsection 2.16, each payment (including each prepayment) by the Borrower on account of principal on the Revolving Credit Loans shall be made pro rata according to the respective outstanding principal amounts of the Revolving Credit Loans then due and owing to the Revolving Lenders. Each payment by the Borrower of interest in respect of the Revolving Credit Loans shall be applied to the amounts of such obligations owing to the Revolving Lenders pro rata according to the respective amounts then due and owing to the Revolving Lenders. All payments (including prepayments) to be made by the Borrower hereunder in respect of amounts denominated in Dollars, whether on account of principal, interest, fees or otherwise, shall be made without set off or counterclaim and shall be made prior to 12:00 Noon, New York City time, on the due date thereof to the Administrative Agent, for the account of the relevant Lenders, at the Administrative Agent’s office specified in subsection 13.2, in Dollars and in immediately available funds. The Administrative Agent shall distribute such payments to the relevant Lenders promptly upon receipt in like funds as received. If any payment hereunder (other than payments on the SOFR Loans or Multicurrency Loans) becomes due and payable on a day other than a Business Day, such payment shall be extended to the next succeeding Business Day, and, with respect to payments of principal, interest thereon shall be payable at the then applicable rate during such extension. If any payment on a SOFR Loan or a Multicurrency Loan becomes due and payable on a day other than a Business Day, the maturity of such payment shall be extended to the next succeeding Business Day (and, with respect to payments of principal, interest thereon shall be payable at the then
    - 54 -


applicable rate during such extension) unless the result of such extension would be to extend such payment into another calendar month, in which event such payment shall be made on the immediately preceding Business Day.
(c)    Each borrowing of Multicurrency Loans by the Borrower shall be made, and any reduction of the Multicurrency Commitments shall be allocated by the Administrative Agent, pro rata according to the Multicurrency Commitment Percentages of the Multicurrency Lenders. Each payment (including each prepayment) by the Borrower on account of principal on Multicurrency Loans shall be allocated by the Administrative Agent pro rata according to the respective principal amounts of the Multicurrency Loans then due and owing by the Borrower to each Multicurrency Lender. Each payment by the Borrower of interest in respect of the Multicurrency Loans shall be allocated by the Administrative Agent to the amounts of such obligations owing to the Multicurrency Lenders pro rata according to the respective amounts then due and owing to the Multicurrency Lenders. All payments (including prepayments) to be made by the Borrower on account of Multicurrency Loans hereunder, whether on account of principal, interest, fees or otherwise, shall be made without set-off or counterclaim and shall be made at or before the payment time for the currency of such Multicurrency Loan prior to 3:00 PM (in the local time of the Borrower), on the due date thereof to the Administrative Agent, for the account of the Multicurrency Lenders, at the payment office for the currency of such Multicurrency Loan from time to time specified by the Administrative Agent by notice to the Multicurrency Lenders and the Borrower, in the currency of such Multicurrency Loan and in immediately available funds. The Administrative Agent shall distribute such payments to the Multicurrency Lenders entitled to receive the same promptly upon receipt in like funds as received; provided that the Administrative Agent will provide funds in the then applicable Dollar Equivalent thereof (including an exchange fee and other normal and customary fees for providing this service as determined by the Administrative Agent in its sole discretion) to those Multicurrency Lenders that had funded the Revolving Credit Loans with the Dollar Equivalent as provided in subsection 2.14.
(d)    Notwithstanding the foregoing, payments and Commitment reductions may be made on a non pro rata basis under this Agreement in order to give effect to subsections 2.19 and 2.20.
(e)    Unless the Administrative Agent shall have been notified in writing by any Lender prior to a borrowing that such Lender will not make the amount that would constitute its share of such borrowing available to the Administrative Agent, the Administrative Agent may assume that such Lender is making such amount available to the Administrative Agent, and the Administrative Agent may, in reliance upon such assumption, make available to the Borrower a corresponding amount. If such amount is not made available to the Administrative Agent by the required time on the Borrowing Date therefor, such Lender shall pay to the Administrative Agent, on demand, such amount with interest thereon at a rate equal to (i) the daily average NYFRB Rate (in the case of a borrowing of Revolving Credit Loans or CAF Advances denominated in Dollars) and (ii) the Administrative Agent’s reasonable estimate of its average daily cost of funds (in the case of a borrowing of Multicurrency Loans or CAF Advances denominated in a currency other than Dollars), in each case for the period until such Lender makes such amount immediately available to the Administrative Agent. A certificate of the Administrative Agent submitted to any Lender with respect to any amounts owing under this subsection 3.7 shall be conclusive in the absence of manifest error. If such Lender’s share of such borrowing is not made available to the Administrative Agent by such Lender within three Business Days of such Borrowing Date, the Administrative Agent shall also be entitled to recover such amount with interest thereon equal to (i) the rate per annum applicable to ABR Loans hereunder (in the case of a borrowing of Revolving Credit Loans or CAF Advances or CAF Advances denominated in Dollars) and (ii) the Administrative Agent’s reasonable estimate of its average daily cost of funds plus the Applicable Margin applicable to
    - 55 -


Multicurrency Loans (in the case of a borrowing of Multicurrency Loans or CAF Advances denominated in a currency other than Dollars), on demand, from the Borrower.
3.8.    Illegality
. Notwithstanding any other provision herein, if after the date hereof the adoption of or any change in any Requirement of Law or in the interpretation or application thereof shall make it unlawful for any Lender to make or maintain SOFR Loans or Multicurrency Loans as contemplated by this Agreement, (a) the commitment of such Lender hereunder to make SOFR Loans or Multicurrency Loans, continue SOFR Loans or Multicurrency Loans as such and convert ABR Loans to SOFR Loans shall forthwith be cancelled, (b) such Lender’s Loans then outstanding as SOFR Loans, if any, shall be converted automatically to ABR Loans on the respective last days of the then current Interest Periods with respect to such Loans or within such earlier period as required by law and (c) such Lender’s Multicurrency Loans shall be prepaid on the last day of the then current Interest Period with respect thereto. If any such conversion of a SOFR Loan occurs on a day which is not the last day of the then current Interest Period with respect thereto, the Borrower shall pay to such Lender such amounts, if any, as may be required pursuant to subsection 3.11. For all purposes of this Section 3.8, the term “Lenders” shall be deemed to include Issuing Lenders.
3.9.    Requirements of Law
.
(a)    If, due to either (i) the introduction of or any change in any law or regulation or in the interpretation or administration of any law or regulation by any Governmental Authority charged with the interpretation or administration thereof or (ii) the compliance with any guideline or request from any central bank or other Governmental Authority that would be complied with generally by similarly situated banks or lenders acting reasonably (whether or not having the force of law and for the avoidance of doubt, including any changes resulting from requests, rules, guidelines or directives concerning capital adequacy issued after the date hereof in connection with the Dodd-Frank Wall Street Reform and Consumer Protection Act or promulgated after the date hereof by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III), there shall be any increase in the cost to any Lender of agreeing to make or making, funding or maintaining SOFR Loans, Multicurrency Loans or Term Rate CAF Advances or issuing or participating in Letters of Credit (except any reserve or other requirement contemplated by subsection 3.9(b) or (c) other than as set forth below) by an amount deemed by such Lender to be material (except, for the avoidance of doubt, for Non-Excluded Taxes indemnified under subsection 3.10 and Excluded Taxes), then the Borrower shall from time to time, upon demand by such Lender (with a copy of such demand to the Administrative Agent), pay to the Administrative Agent for the account of such Lender additional amounts sufficient to compensate such Lender for such increased cost. A certificate as to the amount of such increased cost, submitted to the Borrower and the Administrative Agent by such Lender, shall be conclusive and binding for all purposes, absent manifest error.
(b)    If, due to either (i) the introduction of or any change in or interpretation of any law or regulation or (ii) compliance with any guideline or request from any central bank or other governmental or regulatory authority which becomes effective after the date hereof (for the avoidance of doubt, including any changes resulting from requests, rules, guidelines or directives concerning capital adequacy issued after the date hereof in connection with the Dodd-Frank Wall Street Reform and Consumer
    - 56 -


Protection Act or promulgated after the date hereof by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III), there shall be any increase in the amount of capital required or expected to be maintained by any Lender or any corporation controlling such Lender and the amount of such capital is increased by or based upon the existence of such Lender’s Loans or commitment to extend credit and other commitments of this type by an amount deemed by such Lender to be material, then, upon demand by such Lender (with a copy of such demand to the Administrative Agent), the Borrower shall pay to the Administrative Agent for the account of such Lender, from time to time as specified by such Lender, additional amounts sufficient to compensate such Lender or such corporation in the light of such circumstances, to the extent that such Lender reasonably determines such increase in capital to be allocable to the existence of such Lender’s Loans or commitment to extend credit hereunder. A certificate as to such amounts submitted to the Borrower and the Administrative Agent by such Lender shall be conclusive and binding for all purposes as to the calculations therein, absent manifest error. Such certificate shall be in reasonable detail and shall certify that the claim for additional amounts referred to therein is generally consistent with such Lender’s treatment of similarly situated customers of such Lender whose transactions with such Lender are similarly affected by the change in circumstances giving rise to such payment, but such Lender shall not be required to disclose any confidential or proprietary information therein. For all purposes of this Section 3.9(b), the term “Lenders” shall be deemed to include Issuing Lenders.
(c)    For purposes of the foregoing paragraphs (a) and (b), the amendments to 12 C.F.R. Part 327 set forth in the final rule attached to the Federal Deposit Insurance Corporation Financial Institution Letter FIL-8-2011, dated February 9, 2011, shall be deemed to have been introduced and adopted after the date of this Agreement.
3.10.    Taxes
.
(a)    All payments made by the Borrower under any Loan Document shall be made free and clear of, and without deduction or withholding for or on account of, any Taxes, excluding (i) all net income Taxes, franchise Taxes or other Taxes, including branch profits Taxes, in each case imposed on the Administrative Agent or any Lender as a result of a present or former connection between the Administrative Agent or such Lender and the jurisdiction of the Governmental Authority imposing such Tax or any political subdivision or taxing authority thereof or therein (other than any such connection arising solely from the Administrative Agent or such Lender having executed, delivered or performed its obligations or received a payment under, or enforced, any Loan Document), (ii) in the case of a Lender other than an assignee pursuant to a request by a Borrower under subsection 3.12, any U.S. federal withholding Tax that is imposed under a law in effect at the time such Lender becomes a party hereto (or designates a new lending office), except to the extent that such Lender (or its assignor, if any) was entitled, immediately prior to the time of designation of a new lending office (or assignment), to receive additional amounts from the Borrower with respect to such withholding Tax pursuant to this Section, (iii) any withholding Tax imposed as a result of a Lender failing to comply with subsection 3.10(c) and (iv) any U.S. federal Taxes that are imposed by reason of FATCA (Taxes in clauses (i) to (iv) being “Excluded Taxes”). If any Taxes are required to be withheld from any amounts payable to the Administrative Agent or any Lender hereunder or under any Loan Document as determined in good faith by the applicable withholding agent, (x) such amounts shall be paid to the relevant Governmental Authority in accordance with applicable law and (y) if such Taxes are not Excluded Taxes (“Non-Excluded Taxes”) the amounts so payable by the Borrower to the Administrative Agent or such Lender
    - 57 -


shall be increased to the extent necessary to yield to the Administrative Agent or such Lender (after payment of all Non-Excluded Taxes) interest or any such other amounts payable hereunder at the rates or in the amounts specified in such Loan Document as if such withholding or deduction had not been made. Whenever any Taxes are payable by the Borrower pursuant to this Section, as promptly as possible thereafter the Borrower shall send to the Administrative Agent for its own account or for the account of such Lender, as the case may be, a certified copy of an original official receipt received by the Borrower showing payment thereof or other evidence of such payment satisfactory to the Administrative Agent (in its reasonable discretion). If the Borrower fails to pay any Non-Excluded Taxes when due to the appropriate taxing authority or fails to remit to the Administrative Agent the required receipts or other required documentary evidence, the Borrower shall indemnify the Administrative Agent and the Lenders for any incremental Taxes that may become payable by the Administrative Agent or any Lender as a result of any such failure. The agreements in this subsection 3.10 shall survive the termination of this Agreement and each other Loan Document and the payment of the Loans and all other amounts payable hereunder and thereunder.
(b)    The Borrower shall indemnify and hold harmless the Administrative Agent and each Lender within 20 days after demand therefor, for the full amount of any Non-Excluded Taxes (including Non-Excluded Taxes imposed or asserted on or attributable to amounts payable under this subsection 3.10) payable by the Administrative Agent or such Lender and any penalties, interest and reasonable expenses arising therefrom or with respect thereto, whether or not such Non-Excluded Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority; provided that the Borrower and the Foreign Subsidiary Borrower, as applicable, shall not be obligated to indemnify the Administrative Agent or any such Lender pursuant to this subsection 3.10(b) in respect of penalties, interest or reasonable expenses if such penalties, interest or reasonable expenses are attributable to the gross negligence or willful misconduct of the person seeking indemnification.
(c)    Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in subsections 3.10(c)(A), (B) and (D) below) shall not be required if in the Lender's reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.
Without limiting the generality of the foregoing, in the event the Borrower is a U.S. Person,
(i)    any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed originals of IRS Form W-9 certifying that such Lender is exempt from U.S. Federal backup withholding tax;
    - 58 -


(ii)    any Non-U.S. Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Non-U.S. Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable:
(A)    in the case of a Non-U.S. Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed originals of IRS Form W-8BEN or W-8BEN-E, as applicable, establishing an exemption from, or reduction of, U.S. Federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or W-8BEN-E, as applicable, establishing an exemption from, or reduction of, U.S. Federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty;
(B)    executed originals of IRS Form W-8ECI;
(C)    in the case of a Non-U.S. Lender claiming the benefits of the exemption for portfolio interest under Section 871(h) or Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit J-1 to the effect that such Non-U.S. Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” related to the Borrower as described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (y) executed originals of IRS Form W-8BEN or W-8BEN-E, as applicable; or
(D)    to the extent a Non-U.S. Lender is not the beneficial owner, executed originals of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN or W-8BEN-E, as applicable, a U.S. Tax Compliance Certificate substantially in the form of Exhibit J-2 or Exhibit J-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Non-U.S. Lender is a partnership and one or more direct or indirect partners of such Non-U.S. Lender are claiming the portfolio interest exemption, such Non-U.S. Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit J-4 on behalf of each such direct and indirect partner;
(iii)    any Non-U.S. Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Non-U.S. Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed originals of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. Federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable
    - 59 -


law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and
(iv)    If a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and Administrative Agent, at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or Administrative Agent, such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or Administrative Agent as may be necessary for the Borrower and Administrative Agent to comply with their obligations under FATCA, to determine that such Lender has complied with such Lender's obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (D), “FATCA” shall include any amendments made to FATCA after the date of this Agreement.
Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so. Notwithstanding any other provision of this Section, a Lender shall not be required to deliver any form pursuant to this Section that such Lender is not legally able to deliver.
(d)    If the Borrower pays any additional amounts or makes an indemnity payment under this subsection 3.10 to any Lender or the Administrative Agent, and such Lender or the Administrative Agent determines in its sole discretion exercised in good faith that it has actually received in connection therewith any refund of the underlying Non-Excluded Taxes, such Lender or the Administrative Agent shall pay to the Borrower an amount equal to such refund which was obtained by such Lender or Administrative Agent (but only to the extent of indemnity payments made, or Additional Amounts paid by the Borrower under this subsection 3.10 with respect to the Non-Excluded Taxes giving rise to such refund) net of all reasonable out-of-pocket expenses of the Lender or the Administrative Agent with respect to such refund, and without interest (other than any interest paid by the relevant taxation authority); provided, however, that the Borrower, upon the request of the Lender or the Administrative Agent, agrees to repay the amount paid over to the Borrower to any Lender or the Administrative Agent in the event any Lender or the Administrative Agent is required to repay such refund, plus interest and penalties (excluding interest and penalties attributable to the negligence or willful misconduct of such Lender or the Administrative Agent). This paragraph shall not be construed to require any Lender or the Administrative Agent to disclose any confidential information to the Borrower or any other Person (including its Tax returns).
(e)    Each Lender shall indemnify the Administrative Agent for the full amount of any Taxes imposed by any Governmental Authority that are attributable to such Lender and that are payable or paid by the Administrative Agent, together with all interest, penalties, reasonable costs and expenses arising therefrom or with respect thereto (but only to the extent not already paid by the Borrower), as determined by the Administrative Agent in good faith. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to the
    - 60 -


Lender from any other source against any amount due to the Administrative Agent under this subsection 3.10(e).
For all purposes of this Section 3.10, the term “Lenders” shall be deemed to include Issuing Lenders.
3.11.    Indemnity
. The Borrower agrees to indemnify each Lender and to hold each such Lender harmless from any loss or expense which such Lender may sustain or incur as a consequence of (a) default by the Borrower in making a borrowing of, conversion into or continuation of SOFR Loans, Local Currency Loans, Multicurrency Loans or CAF Advances after the Borrower has given a notice requesting the same in accordance with the provisions of this Agreement, (b) default by the Borrower or any Foreign Subsidiary Borrower in making any prepayment after the Borrower or such Foreign Subsidiary Borrower has given a notice thereof in accordance with the provisions of this Agreement or any other Loan Document or (c) the making of a prepayment of SOFR Loans, Local Currency Loans, Multicurrency Loans or CAF Advances or the conversion of SOFR Loans to ABR Loans on a day which is not the last day of an Interest Period with respect thereto. Such indemnification may include an amount equal to the excess, if any, of (i) the amount of interest which would have accrued on the amount so prepaid, or not so borrowed, converted or continued, for the period from the date of such prepayment or of such failure to borrow, convert or continue to the last day of such Interest Period (or, in the case of a failure to borrow, convert or continue, the Interest Period that would have commenced on the date of such failure) or, in the case of CAF Advances, the applicable CAF Advance Maturity Date (or proposed CAF Advance Maturity Date), in each case at the applicable rate of interest for such Loans provided for herein (excluding, however, the Applicable Margin or any positive margin applicable to CAF Advances included therein, if any) over (ii) the amount of interest (as reasonably determined by such Lender) which would have accrued to such Lender on such amount by placing such amount on deposit for a comparable period with leading banks in the interbank eurodollar market. This covenant shall survive the termination of this Agreement and each other Loan Document and the payment of the Loans and all other amounts payable hereunder and thereunder. For all purposes of this Section 3.11, the term “Lenders” shall be deemed to include Issuing Lenders.
3.12.    Change of Lending Office; Removal of Lender
. Each Lender agrees that if it makes any demand for payment under subsection 3.9 or 3.10(a), or if any adoption or change of the type described in subsection 3.8 shall occur with respect to it, (i) it will use reasonable efforts (consistent with its internal policy and legal and regulatory restrictions and so long as such efforts would not be disadvantageous to it, as determined in its sole discretion) to designate a different lending office if the making of such a designation would reduce or obviate the need for the Borrower to make payments under subsection 3.9 or 3.10(a), or would eliminate or reduce the effect of any adoption or change described in subsection 3.8 or (ii) it will, upon at least five Business Days’ notice from the Borrower to such Lender and the Administrative Agent, assign, pursuant to and in accordance with the provisions of subsection 13.6(c) and 13.19, to one or more Assignees designated by the Borrower all, but not less than all, of such Lender’s rights and obligations hereunder (other than rights in respect of such Lender’s outstanding CAF Advance), without recourse to or warranty by, or expense to, such Lender, for a purchase price equal to the outstanding principal amount of each Loan (other than a CAF Advance) then owing to such Lender plus any accrued but unpaid interest thereon and any accrued but unpaid facility fees and utilization fees owing thereto and, in addition, all additional costs and reimbursements, expense reimbursements and indemnities, if any, owing in respect of such Lender’s Commitment hereunder at such time (including any amount that would be payable under subsection 3.11
    - 61 -


if such assignment were, instead, a prepayment in full of all amounts owing to such Lender) shall be paid to such Lender.
3.13.    Evidence of Debt
.
(a)    Each Lender shall maintain in accordance with its usual practice an account or accounts evidencing indebtedness of the Borrower to such Lender resulting from each Loan of such Lender from time to time, including the amounts of principal and interest payable and paid to such Lender from time to time under this Agreement.
(b)    The Administrative Agent shall maintain the Register pursuant to subsection 13.6(d), and a subaccount therein for each Lender, in which shall be recorded (i) in the case of Revolving Credit Loans, the amount of each Revolving Credit Loan made hereunder, the Type thereof and each Interest Period applicable thereto, (ii) in the case of Multicurrency Loans, the amount and currency of each Multicurrency Loans and each Interest Period applicable thereto, (iii) in the case of CAF Advances, the amount and currency of each CAF Advance made hereunder, the CAF Advance Maturity Date thereof, the interest rate applicable thereto and each CAF Advance Interest Payment Date applicable thereto, (iv) the amount of any principal or interest due and payable or to become due and payable from the Borrower to each Lender hereunder and (v) both the amount of any sum received by the Administrative Agent hereunder from the Borrower and each Lender’s share thereof.
(c)    The entries made in the Register and the accounts of each Lender maintained pursuant to subsection 3.13(a) shall, to the extent permitted by applicable law, be prima facie evidence of the existence and amounts of the obligations of the Borrower therein recorded; provided, however, that the failure of any Lender or the Administrative Agent to maintain the Register or any such account, or any error therein, shall not in any manner affect the obligation of the Borrower to repay (with applicable interest) the Loans made to the Borrower by such Lender in accordance with the terms of this Agreement.
(d)    The Borrower agrees that, upon the request to the Administrative Agent by any Revolving Lender, the Borrower will execute and deliver to such Revolving Lender a promissory note of the Borrower evidencing the Revolving Credit Loans of such Revolving Lender, substantially in the form of Exhibit A with appropriate insertions as to date and principal amount (a “Revolving Credit Note”).
(e)    The Borrower agrees that, upon the request to the Administrative Agent by any Lender, the Borrower will execute and deliver to such Lender a promissory note of the Borrower evidencing the CAF Advances of such Lender, substantially in the form of Exhibit B with appropriate insertions (a “CAF Advance Note”).
(f)    The Borrower agrees that, upon the request to the Administrative Agent by any Multicurrency Lender, the Borrower will execute and deliver to such Multicurrency Lender a promissory note of the Borrower evidencing the Multicurrency Loans of such Multicurrency Lender, substantially in the form of Exhibit L with appropriate insertions as to date and principal amount (a “Multicurrency Note”).
    - 62 -


SECTION 4    

LOCAL CURRENCY FACILITIES
4.1.    Terms of Local Currency Facilities.
(a)    Subject to the provisions of this Section 4, the Borrower may in its discretion from time to time designate any Subsidiary of the Borrower organized under the laws of any jurisdiction outside the United States as a “Foreign Subsidiary Borrower” and any Qualified Credit Facility to which such Foreign Subsidiary Borrower and any one or more Lenders (or its Affiliates, agencies or branches) is a party as a “Local Currency Facility”, with the consent of the Administrative Agent and each such Lender in its sole discretion, by delivering a Local Currency Facility Addendum to the Administrative Agent and the Lenders (through the Administrative Agent) executed by the Borrower, each such Foreign Subsidiary Borrower and each such Lender, provided, that on the effective date of such designation no Default or Event of Default shall have occurred and be continuing. Concurrently with the delivery of a Local Currency Facility Addendum, the Borrower or the relevant Foreign Subsidiary Borrower shall furnish to the Administrative Agent copies of all documentation executed and delivered by such Foreign Subsidiary Borrower in connection therewith, together with, if applicable, an English translation thereof, and any other information as any Lender may reasonably request for purposes of compliance with applicable “know your customer” and anti-money laundering rules and regulations, including the Patriot Act and the Beneficial Ownership Regulation, as reasonably requested by the Lenders. Except as otherwise provided in this Section 4 or in the definition of “Qualified Credit Facility” in subsection 1.1, the terms and conditions of each Local Currency Facility shall be determined by mutual agreement of the relevant Foreign Subsidiary Borrower(s), Local Currency Lender(s) and the Administrative Agent. The documentation governing each Local Currency Facility shall (i) contain an express acknowledgement that such Local Currency Facility shall be subject to the provisions of this Section 4, (ii) if more than one Lender is a party thereto, designate a Local Currency Facility Agent for such Local Currency Facility and (iii) include an opinion of counsel reasonably satisfactory to the Administrative Agent from the jurisdiction in which such Local Currency Facility is established that the documentation governing such Local Currency Facility is enforceable in accordance with its terms. Each of the Borrower and, by agreeing to any Local Currency Facility designation as contemplated hereby, each relevant Local Currency Lender (if any) party thereto which is an Affiliate, branch or agency of a Lender, acknowledges and agrees that each reference in this Agreement to any Lender shall, to the extent applicable, be deemed to be a reference to such Local Currency Lender. In the event of any inconsistency between the terms of this Agreement and the terms of any Local Currency Facility, the terms of this Agreement shall prevail.
(b)    The documentation governing each Local Currency Facility shall set forth (i) the maximum amount (expressed in Dollars) available to be borrowed from all Local Currency Lenders under such Local Currency Facility (as the same may be reduced from time to time, a “Local Currency Facility Maximum Borrowing Amount”) and (ii) with respect to each Local Currency Lender party to such Local Currency Facility, the maximum amount (expressed in Dollars) available to be borrowed from such Local Currency Lender thereunder (as the same may be reduced from time to time, a “Local Currency Lender Maximum Borrowing Amount”).
(c)    Except as otherwise required by applicable law, in no event shall the Local Currency Lenders party to a Local Currency Facility have the right to accelerate the Local Currency Loans outstanding thereunder, or to terminate their commitments (if any) to make such Local Currency Loans prior to the earlier of the stated termination date in respect thereof or the Termination Date, except, in each case, in connection with an acceleration of the Loans or a termination of the Commitments pursuant
    - 63 -


to Section 10 hereof, provided, that nothing in this paragraph (c) shall be deemed to require any Local Currency Lender to make a Local Currency Loan if the applicable conditions precedent to the making of such Local Currency Loan set forth in the documentation governing the relevant Local Currency Facility have not been satisfied. No Local Currency Loan may be made under a Local Currency Facility if (i) after giving effect thereto, the conditions precedent in subsection 7.2 hereof would not be satisfied or (ii) after giving effect to the making of such Local Currency Loan and the simultaneous application of the proceeds thereof, (A) the Aggregate Total Outstandings of all Lenders at any time exceeds the Aggregate Revolving Credit Commitments or (B) the Dollar Equivalent of the aggregate outstanding principal amount of Multicurrency Loans, Local Currency Loans and L/C Obligations attributable to Letters of Credit denominated in any currency other than Dollars would exceed the Multicurrency Sublimit.
(d)    The relevant Foreign Subsidiary Borrower shall furnish to the Administrative Agent copies of any amendment, supplement or other modification (including any change in commitment amounts or in the Local Currency Lenders participating in any Local Currency Facility) to the terms of any Local Currency Facility promptly after the effectiveness thereof (together with, if applicable, an English translation thereof). If any such amendment, supplement or other modification to a Local Currency Facility shall (i) add a Local Currency Lender as a Local Currency Lender thereunder or (ii) change the Local Currency Facility Maximum Borrowing Amount or any Local Currency Lender Maximum Borrowing Amount with respect thereto, the Borrower shall promptly furnish an appropriately revised Local Currency Facility Addendum, executed by the Borrower, the relevant Foreign Subsidiary Borrower and the affected Local Currency Lenders (or any agent acting on their behalf), to the Administrative Agent and the Lenders (through the Administrative Agent).
(e)    The Borrower may terminate its designation of a facility as a Local Currency Facility, with the consent of each Local Currency Lender party thereto in its sole discretion, by written notice to the Administrative Agent, which notice shall be executed by the Borrower, the relevant Foreign Subsidiary Borrower and each Local Currency Lender party to such Local Currency Facility (or any agent acting on their behalf). Once notice of such termination is received by the Administrative Agent, such Local Currency Facility and the loans and other obligations outstanding thereunder shall immediately cease to be subject to the terms of this Agreement.
4.2.    Reporting of Local Currency Outstandings
.
(a)    On the date of the making of any Local Currency Loan having a maturity of 30 or more days to a Foreign Subsidiary Borrower and on the last Business Day of each month on which a Foreign Subsidiary Borrower has any outstanding Local Currency Loans, the Local Currency Facility Agent for such Foreign Subsidiary Borrower, shall deliver to the Administrative Agent a Notice of Local Currency Outstandings and the Administrative Agent shall deliver a copy of such Notice of Local Currency Outstandings to the Lenders. The Administrative Agent will, at the request of any Local Currency Facility Agent, advise such Local Currency Facility Agent of the Exchange Rate used by the Administrative Agent in calculating the Dollar Equivalent of Local Currency Loans under the related Local Currency Facility on any date.
(b)    For purposes of any calculation under this Agreement in which the amount of the Aggregate Local Currency Outstandings of any Lender is a component, the Administrative Agent shall make such calculation on the basis of the Notices of Local Currency Outstanding received by it at least two Business Days prior to the date of such calculation.
    - 64 -


SECTION 5    

LETTERS OF CREDIT
5.1.    L/C Commitment
.
(a)    Subject to the terms and conditions hereof, each Issuing Lender, in reliance on the agreements set forth in this Agreement, agrees to issue letters of credit (provided that Barclays shall only be required to issue standby letters of credit) (“Letters of Credit”) for the account of the Borrower on any Business Day during the Commitment Period in such form as may be approved from time to time by the Issuing Lender; provided that the Issuing Lender shall not issue any Letter of Credit if, after giving effect to such issuance, (i) the L/C Obligations would exceed the L/C Commitment, (ii) the aggregate amount of the Available Revolving Credit Commitments would be less than zero, (iii) the Dollar Equivalent of the aggregate outstanding principal amount of Multicurrency Loans, Local Currency Loans and L/C Obligations attributable to Letters of Credit denominated in any currency other than Dollars would exceed the Multicurrency Sublimit, (iv) the L/C Obligations in respect of all Letters of Credit issued by such Issuing Lender would exceed its Issuing Lender Commitment or (v) any Lender is at that time a Defaulting Lender, unless the Issuing Lender has entered into arrangements, including the delivery of Cash Collateral, reasonably satisfactory to the Issuing Lender with the Borrower or such Lender to eliminate the Issuing Lender’s actual or potential Fronting Exposure (after giving effect to subsection 2.19(a)(iv)) with respect to the Defaulting Lender arising from either the Letter of Credit then proposed to be issued or that Letter of Credit and all other L/C Obligations as to which the Issuing Lender has actual or potential Fronting Exposure. Each Letter of Credit shall (i) be denominated in Dollars, any Available Foreign Currency, or any other currency acceptable to the Issuing Lender, (ii) have a face amount of at least $1,000,000 (unless otherwise agreed by the Issuing Lender) and (iii) expire (or be subject to termination by notice from the Issuing Lender to the beneficiary thereof) no later than the date that is five Business Days prior to the Termination Date.
(b)    The Issuing Lender shall not at any time be obligated to issue any Letter of Credit if such issuance would conflict with, or cause the Issuing Lender or any L/C Participant to exceed any limits imposed by, any applicable Requirement of Law.
(c)    Letters of Credit issued under the Existing Credit Facilities and outstanding on the Closing Date shall be deemed to be issued under this Agreement on the Closing Date.
5.2.    Procedure for Issuance of Letter of Credit
. The Borrower may from time to time request that the Issuing Lender issue a Letter of Credit by delivering to the Issuing Lender at its address for notices specified herein an Application therefor, completed to the satisfaction of the Issuing Lender, and such other certificates, documents and other papers and information as the Issuing Lender may request. Upon receipt of any Application, the Issuing Lender will process such Application and the certificates, documents and other papers and information delivered to it in connection therewith in accordance with its customary policies and procedures and shall promptly issue the Letter of Credit requested thereby (but in no event shall the Issuing Lender be required to issue any Letter of Credit earlier than three Business Days after its receipt of the Application therefor and all such other certificates, documents and other papers and information relating thereto) by issuing the original of such Letter of Credit to the beneficiary thereof or as otherwise may be agreed to by the Issuing
    - 65 -


Lender and the Borrower. The Issuing Lender shall furnish a copy of such Letter of Credit to the Borrower promptly following the issuance thereof. The Issuing Lender shall promptly furnish to the Administrative Agent, which shall in turn promptly furnish to the Lenders, notice of the issuance of each Letter of Credit (including the amount thereof). If the Borrower so requests, the applicable Issuing Lender may, in its sole and absolute discretion, agree to issue a Letter of Credit that has automatic extension provisions (each, an “Auto-Extension Letter of Credit”); provided, that any such Auto-Extension Letter of Credit must permit such Issuing Lender to prevent any such extension at least once in each 12-month period (or such longer period in the case of a Letter of Credit with an expiration in excess of 12 months) (commencing with the date of issuance of such Letter of Credit) by giving prior notice to the beneficiary thereof not later than a day (the “Non-Extension Notice Date”) in each such 12-month period (or such longer period in the case of a Letter of Credit with an expiration in excess of 12 months) to be agreed upon at the time such Letter of Credit is issued. Unless otherwise directed by the applicable Issuing Lender, the Borrower shall not be required to make a specific request to such Issuing Lender for any such extension. Once an Auto-Extension Letter of Credit has been issued, the Lenders shall be deemed to have authorized (but may not require) the applicable Issuing Lender to permit the extension of such Letter of Credit at any time to an expiry date not later than the Termination Date; provided, however, that such Issuing Lender shall not permit any such extension if (i) such Issuing Lender has determined that it would not be permitted, at such time to issue such Letter of Credit in its revised form (as extended) under the terms hereof, or (ii) it has received notice (which may be by telephone or in writing) on or before the day that is five Business Days before the Non-Extension Notice Date (A) from the Administrative Agent that the Majority Lenders have elected not to permit such extension or (B) from the Administrative Agent, any Lender or the Borrower that one or more of the applicable conditions specified in Section 7 are not then satisfied, and in each such case directing such Issuing Lender not to permit such extension.
5.3.    Fees and Other Charges
.
(a)    The Borrower will pay a fee on the actual daily undrawn amount of all outstanding Letters of Credit at a per annum rate equal to the Applicable Margin then in effect with respect to SOFR Loans, shared ratably among the Revolving Lenders and payable quarterly in arrears on each L/C Fee Payment Date after the issuance date; such fee with respect to each Letter of Credit denominated in any currency other than Dollars shall be payable in Dollars, and for purposes of calculating the amount of such fee applicable to each Letter of Credit denominated in any currency other than Dollars, the actual daily undrawn, outstanding amount of such Letter of Credit shall be the Dollar Equivalent of such amount calculated at the Exchange Rate as of the relevant L/C Fee Payment Date; provided, however, that any such fees otherwise payable for the account of a Defaulting Lender with respect to any Letter of Credit as to which such Defaulting Lender has not provided Cash Collateral satisfactory to the Issuing Lender pursuant to subsection 5.1 shall be payable, to the maximum extent permitted by applicable law, to the other Lenders in accordance with the upward adjustments in their respective Revolving Credit Commitment Percentages allocable to such Letter of Credit pursuant to subsection 2.19(a)(iv), with the balance of such fee, if any, payable to the Issuing Lender for its own account. In addition, the Borrower shall pay to the Issuing Lender for its own account a fronting fee in the amount separately agreed to by the Issuing Lender and the Borrower on the actual daily undrawn, outstanding amount of each Letter of Credit, payable quarterly in arrears on each L/C Fee Payment Date after the issuance date; such fee with respect to each Letter of Credit denominated in any currency other than Dollars shall be payable in Dollars, and for purposes of calculating the amount of such fee applicable to each Letter of Credit denominated in any currency other than Dollars, the actual daily undrawn, outstanding amount of such
    - 66 -


Letter of Credit shall be the Dollar Equivalent of such amount calculated at the Exchange Rate as of the relevant L/C Fee Payment Date.
(b)    In addition to the foregoing fees, the Borrower shall pay or reimburse the Issuing Lender for such normal and customary costs and expenses as are incurred or charged by the Issuing Lender in issuing, negotiating, examining documents under, effecting payment under, amending or otherwise administering any Letter of Credit.
5.4.    L/C Participations
.
(a)    The Issuing Lender irrevocably agrees to grant and hereby grants to each L/C Participant, and, to induce the Issuing Lender to issue Letters of Credit, each L/C Participant irrevocably agrees to accept and purchase and hereby accepts and purchases from the Issuing Lender, on the terms and conditions set forth below, for such L/C Participant’s own account and risk an undivided interest equal to such L/C Participant’s Revolving Credit Commitment Percentage in the Issuing Lender’s obligations and rights under and in respect of each Letter of Credit and the amount of each drawing paid by the Issuing Lender thereunder. Each L/C Participant unconditionally and irrevocably agrees with the Issuing Lender that, if a drawing is paid under any Letter of Credit for which the Issuing Lender is not reimbursed in full by the Borrower in accordance with the terms of this Agreement, such L/C Participant shall pay to the Issuing Lender through the Administrative Agent (or the Administrative Agent shall apply Cash Collateral provided for this purpose) upon demand at the Administrative Agent’s address for notices specified herein an amount equal to such L/C Participant’s Revolving Credit Commitment Percentage of the amount of such drawing, or any part thereof, that is not so reimbursed.
(b)    If any amount required to be paid by any L/C Participant to the Issuing Lender pursuant to subsection 5.4(a) in respect of any unreimbursed portion of any payment made by the Issuing Lender under any Letter of Credit is paid to the Issuing Lender within three Business Days after the date such payment is due, such L/C Participant shall pay to the Issuing Lender on demand an amount equal to the product of (i) such amount, times (ii) the daily average NYFRB Rate during the period from and including the date such payment is required to the date on which such payment is immediately available to the Issuing Lender, times (iii) a fraction the numerator of which is the number of days that elapse during such period and the denominator of which is 360. If any such amount required to be paid by any L/C Participant pursuant to subsection 5.4(a) is not made available to the Issuing Lender by such L/C Participant within three Business Days after the date such payment is due, the Issuing Lender shall be entitled to recover from such L/C Participant, on demand, such amount with interest thereon calculated from such due date at the rate per annum applicable to ABR Loans. A certificate of the Issuing Lender submitted through the Administrative Agent to any L/C Participant with respect to any amounts owing under this Section shall be conclusive in the absence of manifest error.
(c)    Whenever, at any time after the Issuing Lender has made payment under any Letter of Credit and has received from any L/C Participant its pro rata share of such payment in accordance with subsection 5.4(a), the Administrative Agent receives any payment related to such Letter of Credit (whether directly from the Borrower or otherwise, including proceeds of collateral applied thereto by the Issuing Lender), or any payment of interest on account thereof, the Administrative Agent will distribute to such L/C Participant its pro rata share thereof; provided, however, that in the event that any such payment received by the Issuing Lender shall be required to be returned by the Issuing Lender, such L/C
    - 67 -


Participant shall return to the Issuing Lender through the Administrative Agent the portion thereof previously distributed by the Issuing Lender to it.
5.5.    Reimbursement Obligation of the Borrower
. The Borrower agrees to reimburse the Issuing Lender through the Administrative Agent on the Business Day next succeeding the Business Day on which the Issuing Lender notifies the Borrower and the Administrative Agent of the date and amount of a drawing under any Letter of Credit paid by the Issuing Lender for the amount of (a) such drawing so paid and (b) any taxes, fees, charges or other costs or expenses incurred by the Issuing Lender in connection with such payment. Each such payment shall be made to the Issuing Lender in Dollars and in immediately available funds. Interest shall be payable on any such amounts from the date on which the relevant drawing is paid until payment in full at the rate set forth in (i) until the Business Day next succeeding the date of the relevant notice, subsection 3.4(b) and (ii) thereafter, subsection 3.4(e). Each drawing under any Letter of Credit shall (unless an event of the type described in clause (i) or (ii) of subsection 10(g) shall have occurred and be continuing with respect to the Borrower, in which case the procedures specified in subsection 5.4 for funding by L/C Participants shall apply) constitute a request by the Borrower to the Administrative Agent for a borrowing pursuant to subsection 2.2 of ABR Loans in the amount of such drawing (and the minimum borrowing amount in such subsection shall not apply to such borrowing). The Borrowing Date with respect to such borrowing shall be the first date on which a borrowing of Revolving Credit Loans could be made, pursuant to subsection 2.2, if the Administrative Agent had received a notice of such borrowing at the time the Administrative Agent receives notice from the relevant Issuing Lender of such drawing under such Letter of Credit.
5.6.    Obligations Absolute
. The Borrower’s obligations under this Section 5 shall be absolute and unconditional under any and all circumstances and irrespective of any setoff, counterclaim or defense to payment that the Borrower may have or have had against the Issuing Lender, any beneficiary of a Letter of Credit or any other Person. The Borrower also agrees with the Issuing Lender that the Issuing Lender shall not be responsible for, and the Borrower’s Reimbursement Obligations under subsection 5.5 shall not be affected by, among other things, the validity or genuineness of documents or of any endorsements thereon, even though such documents shall in fact prove to be invalid, fraudulent or forged, or any dispute between or among the Borrower and any beneficiary of any Letter of Credit or any other party to which such Letter of Credit may be transferred or any claims whatsoever of the Borrower against any beneficiary of such Letter of Credit or any such transferee. The Issuing Lender shall not be liable for any error, omission, interruption or delay in transmission, dispatch or delivery of any message or advice, however transmitted, in connection with any Letter of Credit, except for errors or omissions found by a final and nonappealable decision of a court of competent jurisdiction to have resulted from the gross negligence or willful misconduct of the Issuing Lender. The Borrower agrees that any action taken or omitted by the Issuing Lender under or in connection with any Letter of Credit or the related drafts or documents, if done in the absence of gross negligence or willful misconduct and in accordance with the standards of care specified in the Uniform Commercial Code of the State of New York, shall be binding on the Borrower and shall not result in any liability of the Issuing Lender to the Borrower.
5.7.    Letter of Credit Payments
. If any drawing shall be presented for payment under any Letter of Credit, the Issuing Lender shall, promptly following its receipt thereof, examine all documents purporting to represent a demand for
    - 68 -


payment under such Letter of Credit. Such Issuing Lender shall promptly after such examination notify the Administrative Agent and the Borrower in writing of such demand for payment and whether such Issuing Lender has made or will make payment thereunder; provided that any failure to give or delay in giving such notice shall not relieve the Borrower of its obligation to reimburse such Issuing Lender and L/C Participant with respect to any such payment under Letter of Credit. The responsibility of the Issuing Lender to the Borrower in connection with any drawing presented for payment under any Letter of Credit shall, in addition to any payment obligation expressly provided for in such Letter of Credit, be limited to determining that the documents (including each drawing) delivered under such Letter of Credit in connection with such presentment are substantially in conformity with such Letter of Credit.
5.8.    Applications
. To the extent that any provision of any Application related to any Letter of Credit is inconsistent with the provisions of this Section 5, the provisions of this Section 5 shall apply.
5.9.    Reimbursement Obligations for Certain Letters of Credit Denominated in Currencies Other Than Dollars
. Notwithstanding any other provision of this Section 5, in the event that any Letter of Credit is denominated in any currency other than Dollars, the amount of the Reimbursement Obligation of the Borrower pursuant to subsection 5.5 in respect of such Letter of Credit shall bear interest as provided in subsection 5.5 with respect to amounts owing in Dollars; provided, that (i) the interest rate on such amounts shall be the rate reasonably determined by the Issuing Lender to be the equivalent rate, in respect of the relevant non-Dollar currency, to the applicable rate provided in subsection 5.5 with respect to amounts denominated in Dollars and (ii) if the Borrower fails to pay any such Reimbursement Obligation required by subsection 5.5 on or prior to the third Business Day following the date of the drawing to which such Reimbursement Obligation relates, then, on the fourth Business Day following such date of drawing, the relevant Issuing Lender, in cooperation with the Administrative Agent, shall determine the Dollar Equivalent of the amount of such Reimbursement Obligation, and the Borrower’s obligation in respect of such Reimbursement Obligation shall be converted to such Dollar Equivalent, with interest thereon as provided in subsection 5.5 (provided, that if the Application in respect of such Letter of Credit provides for conversion of such amount into Dollars on any earlier date or at any other conversion rate, the provisions hereunder shall control with respect to such conversion).
5.10.    Replacement of Issuing Lenders
. An Issuing Lender may be replaced at any time by written agreement among the Borrower, the Administrative Agent, the replaced Issuing Lender and the successor Issuing Lender. The Administrative Agent shall notify the Lenders of any such replacement of an Issuing Lender. At the time any such replacement shall become effective, the Borrower shall pay all unpaid fees accrued for the account of the replaced Issuing Lender. From and after the effective date of any such replacement, (x) the successor Issuing Lender shall have all the rights and obligations of Issuing Lenders under this Agreement with respect to Letters of Credit to be issued thereafter and (y) references herein to the term “Issuing Lender” shall be deemed to refer to such successor or to any previous Issuing Lenders, or to such successor and all previous Issuing Lenders, as the context shall require. After the replacement of an Issuing Lender hereunder, the replaced Issuing Lender shall remain a party hereto and shall continue to have all the rights and obligations of an Issuing Lender under this Agreement with respect to Letters of Credit issued by it prior to such replacement, but shall not be required to issue additional Letters of Credit.
    - 69 -


SECTION 6    

REPRESENTATIONS AND WARRANTIES
To induce the Administrative Agent and the Lenders to enter into this Agreement and to make the Loans and issue or participate in the Letters of Credit, the Borrower hereby represents and warrants to the Administrative Agent, each Issuing Lender and each Lender that:
6.1.    Financial Condition
. The consolidated balance sheet of the Borrower and its consolidated Subsidiaries as at each of December 31, 20192022 and December 31, 20202023 and the related consolidated statements of operations and of cash flows for the fiscal years ended on such dates, reported on by Ernst & Young LLP, copies of which have heretofore been furnished to each Lender, are complete and correct and present fairly the consolidated financial condition of the Borrower and its consolidated Subsidiaries as at such dates, and the consolidated results of their operations and their consolidated cash flows for the fiscal years then ended. The unaudited consolidated balance sheet of the Borrower and its consolidated Subsidiaries as at the date of the Borrower’s most recent publicly available Form 10-Q and the related unaudited consolidated statements of operations and of cash flows for the fiscal period ended on such date, certified by a Responsible Officer, copies of which have heretofore been furnished to each Lender, are complete and materially correct and present fairly (subject to normal year-end audit adjustments) the consolidated financial condition of the Borrower and its consolidated Subsidiaries as at such date, and the consolidated results of their operations and their consolidated cash flows for the fiscal period then ended. All such annual financial statements, including the related schedules and notes thereto, were, as of the date prepared, prepared in accordance with GAAP applied consistently throughout the periods involved (except as approved by such accountants or Responsible Officer, as the case may be, and as disclosed therein). The quarterly financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Act of 1933. Accordingly, such quarterly financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of the Borrower, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Neither the Borrower nor any of its consolidated Subsidiaries had, at the date of the most recent balance sheet referred to above, any of the following except as disclosed in the Borrower’s Form 10-K and 10-Q filings: any material Guarantee Obligation, material contingent liability or material liability for taxes, or any material long-term lease or material unusual forward or long-term commitment, including, without limitation, any interest rate or foreign currency swap or exchange transaction, which is not reflected in the foregoing financial statements or in the notes thereto.
6.2.    Corporate Existence; Compliance with Law
. Each of the Borrower and its Subsidiaries (a) is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, (b) has the corporate power and authority, and the legal right, to own and operate its property, to lease the property it operates as lessee and to conduct the business in which it is currently engaged, (c) is duly qualified as a foreign corporation and in good standing under the laws of each jurisdiction where its ownership, lease or operation of property or the conduct of its business requires such qualification and (d) is in compliance with all Requirements of Law, except to the extent that the failure of the foregoing clauses (a) and (b) (in each such case, only with
    - 70 -


respect to Subsidiaries of the Borrower), (c) and (d) to be true and correct could not, in the aggregate, reasonably be expected to have a Material Adverse Effect.
6.3.    Corporate Power; Consents and Authorization; Enforceable Obligations
. The Borrower has the corporate power and authority, and the legal right, to make, deliver and perform the Loan Documents to which it is a party and to borrow hereunder and has taken all necessary corporate action to (i) authorize the borrowings on the terms and conditions of this Agreement, any Notes and any Applications, (ii) to authorize the execution, delivery and performance of the Loan Documents to which it is a party and (iii) in the case of the Borrower, to guarantee all Obligations of any Foreign Subsidiary Borrower hereunder. No consent or authorization of, filing with, notice to or other act by or in respect of, any Governmental Authority (including, without limitation, exchange control) or any other Person is required with respect to the Borrower or any of its Subsidiaries in connection with the borrowings or guarantee hereunder or with the execution, delivery, performance, validity or enforceability of the Loan Documents to which the Borrower is party. This Agreement and each other Loan Document to which the Borrower is, or is to become, a party has been or will be, duly executed and delivered on behalf of the Borrower. This Agreement and each other Loan Document to which the Borrower is, or is to become, a party constitutes or will constitute, a legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, subject to the effects of bankruptcy, examination, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.
6.4.    No Legal Bar
. The execution, delivery and performance of the Loan Documents, the borrowings hereunder and the use of the proceeds thereof will not violate any Requirement of Law or Contractual Obligation of the Borrower or of any of its Subsidiaries which could reasonably be expected to have a Material Adverse Effect and will not result in, or require, the creation or imposition of any Lien on any of its or their respective properties or revenues pursuant to any such Requirement of Law or Contractual Obligation which could reasonably be expected to have a Material Adverse Effect.
6.5.    No Default
. Neither the Borrower nor any of its Subsidiaries is in default under or with respect to any of its Contractual Obligations in any respect which could reasonably be expected to have a Material Adverse Effect. No Default or Event of Default has occurred and is continuing.
6.6.    Taxes
. Each of the Borrower and its Subsidiaries has filed or caused to be filed all tax returns which, to the knowledge of the Borrower, are required to be filed and has paid all taxes shown to be due and payable on said returns or on any assessments made against it (other than any the amount or validity of which are currently being contested in good faith by appropriate proceedings and with respect to which reserves in conformity with GAAP have been provided on the books of the Borrower or its Subsidiaries, as the case may be), except to the extent that the failure to do so could not reasonably be expected to result in a Material Adverse Effect.
6.7.    Federal Regulations
    - 71 -


. No part of the proceeds of any Loans will be used in any manner that would violate Regulation U of the Board as now and from time to time hereafter in effect.
6.8.    ERISA
. Neither a Reportable Event nor a failure to meet the minimum funding standards (within the meaning of Section 302 of ERISA), whether or not waived, has occurred during the five-year period prior to the date on which this representation is made or deemed made with respect to any Plan other than a Multiemployer Plan, and eachno Plan has failed to compliedy in all respects with the applicable provisions of ERISA and the Code, where the liability for such occurrence or failure to comply could be reasonably expected to result in a Material Adverse Effect; provided, however, that with respect to any Multiemployer Plan, such representation is made only to the knowledge of the Borrower. No termination of a Single Employer Plan pursuant to Section 4041(c) or 4042 of ERISA has occurred, and no Lien with respect to any Single Employer Plan in favor of the PBGC or a Plan has arisen, during such five-year period. There has been no determination that any Single Employer Plan is, or is reasonably expected to be, in “at risk” status (within the meaning of Section 430 of the Code or Section 303 of ERISA). Neither the Borrower nor any Commonly Controlled Entity has had a complete or partial withdrawal from any Multiemployer Plan that has resulted in liability and to the knowledge of the Borrower, neither the Borrower nor any Commonly Controlled Entity would become subject to any liability under ERISA if the Borrower or any such Commonly Controlled Entity were to withdraw completely from all Multiemployer Plans as of the valuation date most closely preceding the date on which this representation is made or deemed made which liability could be reasonably expected to result in a Material Adverse Effect. To the Borrower’s knowledge, no Multiemployer Plan with respect to which the Borrower or any Commonly Controlled Entity has any liability is in Insolvency or in “endangered” or “critical” status (within the meaning of Section 432 of the Code or Section 305 of ERISA).
6.9.    Investment Company Act; Other Regulations
. The Borrower is not required to be registered as an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Borrower is not subject to regulation under any Federal or State statute or regulation (other than Regulation X of the Board) which limits its ability to incur Indebtedness.
6.10.    Purpose of Loans
. The proceeds of the Loans shall be used to finance working capital and general corporate needs of the Borrower and its Subsidiaries, including but not limited to acquisitions.
6.11.    Environmental Matters
. Except to the extent that the failure of the following statements to be true and correct could not reasonably be expected to have a Material Adverse Effect:
(a)    The facilities and properties owned, leased or operated by the Borrower or any of its Subsidiaries (the “Properties”) do not contain, and have not previously contained, any Materials of Environmental Concern in amounts or concentrations which (i) constitute or constituted a violation of, or (ii) could reasonably be expected to give rise to liability under, any Environmental Law.
(b)    The Properties and all operations at the Properties are in compliance, and have in the last five years been in compliance, in all material respects with all applicable Environmental Laws, and there
    - 72 -


is no contamination at, under or about the Properties or violation of any Environmental Law with respect to the Properties or the business operated by the Borrower or any of its Subsidiaries (the “Business”) which could reasonably be expected to materially interfere with the continued operation of the Properties or Business or materially impair the fair saleable value thereof.
(c)    Neither the Borrower nor any of its Subsidiaries has received any notice of violation, alleged violation, non-compliance, liability or potential liability regarding environmental matters or compliance with Environmental Laws with regard to any of the Properties or the Business, nor does the Borrower have knowledge or reason to believe that any such notice will be received or is being threatened.
(d)    Materials of Environmental Concern have not been transported or disposed of from the Properties in violation of, or in a manner or to a location which could reasonably be expected to give rise to liability under, any Environmental Law, nor have any Materials of Environmental Concern been generated, treated, stored or disposed of at, on or under any of the Properties in violation of, or in a manner that could reasonably be expected to give rise to liability under, any applicable Environmental Law.
(e)    No judicial proceeding or governmental or administrative action is pending or, to the knowledge of the Borrower, threatened, under any Environmental Law to which the Borrower or any Subsidiary is or will be named as a party with respect to the Properties or the Business, nor are there any consent decrees or other decrees, consent orders, administrative orders or other orders, or other administrative or judicial requirements outstanding under any Environmental Law with respect to the Properties or the Business.
(f)    There has been no release or threat of release of Materials of Environmental Concern at or from the Properties, or arising from or related to the operations of the Borrower or any Subsidiary in connection with the Properties or otherwise in connection with the Business, in violation of, or in amounts or in a manner that could reasonably be expected to give rise to liability under, Environmental Laws.
6.12.    Disclosure
. The statements and information contained herein and in any of the information provided to the Administrative Agent or the Lenders in writing in connection with this Agreement, taken as a whole, do not contain any untrue statement of any material fact, or omit to state a fact necessary in order to make such statements or information not misleading in any material respect, in each case in light of the circumstances under which such statements were made or information provided as of the date so provided.
6.13.    No Change
. There has been no change, effect, event, occurrence, state of facts or development which individually or in the aggregate has had or would reasonably be expected to result in a Material Adverse Effect since the Form 10-Q or Form 10-K most recently filed by the Borrower with the Securities and Exchange Commission.
6.14.    No Material Litigation
. There are no actions, suits, proceedings, claims or disputes pending at law, in equity, in arbitration or before any Governmental Authority, by or against the Borrower or any of its Subsidiaries or
    - 73 -


against any of their properties or revenues that (a) purport to affect or pertain to this Agreement or any other Loan Document, or any of the transactions contemplated hereby, or (b) except as specifically disclosed on the Form 10-Q or Form 10-K most recently filed by the Borrower with the Securities and Exchange Commission, either individually or in the aggregate could reasonably be expected to have a Material Adverse Effect.
6.15.    Anti-Corruption Laws and Sanctions
. The Borrower has implemented and maintains in effect policies and procedures reasonably designed to promote compliance by the Borrower, its Subsidiaries and their respective directors, officers and employees with Anti-Corruption Laws and Sanctions applicable to the Borrower, its Subsidiaries and their respective directors, officers and employees, and the Borrower, its Subsidiaries and their respective officers and directors and to the knowledge of the Borrower its employees are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects. None of (a) the Borrower, any Subsidiary or, to the Borrower’s knowledge, any of their respective directors or officers or (b) to the Borrower’s knowledge, any of the Borrower’s or such Subsidiary’s respective employees is a Sanctioned Person or organized or resident in a Sanctioned Country. No Borrowing or Letter of Credit or use of proceeds contemplated by this Agreement will be used by the Borrower or any of its Subsidiaries directly or to its knowledge indirectly in violation of applicable Anti-Corruption Laws or applicable Sanctions.
SECTION 7    
CONDITIONS PRECEDENT
7.1.    Conditions to Closing
. The effectiveness of this Agreement is subject to the satisfaction on the Closing Date of the following conditions precedent:
(a)    Credit Agreement. The Administrative Agent shall have received this Agreement, executed and delivered by a duly authorized officer of each Lender and the Borrower, with a counterpart for each Lender and original Notes executed by the Borrower (in the case of Revolving Credit Notes, Multicurrency Notes or CAF Advance Notes), in favor of each Lender requesting a Note.
(b)    Closing Certificate. The Administrative Agent shall have received a certificate of the Borrower, dated the Closing Date, substantially in the form of Exhibit F, with appropriate insertions and attachments, satisfactory in form and substance to the Administrative Agent, executed by the President or any Vice President and the Secretary or any Assistant Secretary of the Borrower.
(c)    Representations and Warranties. Each of the representations and warranties made by the Borrower in or pursuant to the Loan Documents shall be true and correct in all material respects (other than any representation or warranty qualified as to “materiality”, “Material Adverse Effect” or similar language, which shall be true and correct in all respects) on and as of the Closing Date as if made on and as of the Closing Date.
(d)    Legal Opinions. The Administrative Agent shall have received, with a counterpart for each Lender, the executed legal opinion of counsel to the Borrower (which may be delivered in part by in-house counsel to the Borrower), covering the matters set forth in Exhibit G. Each such legal opinion shall cover such other matters incident to the transactions contemplated by this Agreement as the Administrative Agent may reasonably require.
    - 74 -


(e)    Fees. All accrued fees and reasonable out-of-pocket expenses (including the reasonable fees and expenses of counsel to the Arrangers) of the Arrangers through the Closing Date invoiced with reasonable detail at least three Business Days prior to the Closing Date in connection with the Loan Documents shall have been paid; provided that the Arrangers shall have provided an estimate and available reasonable detail five business days prior to the Closing Date.
(f)    Financial Statements. The Administrative Agent shall have received an unaudited consolidated balance sheet of the Borrower and its consolidated Subsidiaries and the related unaudited consolidated statements of operations and of cash flows for each fiscal quarter ended after December 31, 2020 (so long as such fiscal quarters have ended at least 40 days prior to the Closing Date). The Borrower’s filing of any required unaudited financial statements with respect to the Borrower on Form 10-Q will satisfy the requirements under this paragraph.
(g)    No Default. No Default or Event of Default shall have occurred and be continuing on such date or after giving effect to the Loans requested to be made, or Letters of Credit requested to be issued.
(h)    No conflicts. No law or regulation shall be applicable in the reasonable judgment of the Lenders that restrains, prevents or imposes material adverse conditions upon the Transactions or this Agreement. All requisite governmental authorities and third parties shall have approved or consented to the Transactions and the other transactions contemplated hereby to the extent required (without the imposition of any materially burdensome condition or qualification in the reasonable judgment of the Lenders) and all such approvals shall be in full force and effect. The Transactions shall be in compliance with all applicable laws and regulations.
(i)    Termination of Existing Credit Facilities. Evidence that all principal amounts, interest, fees and other amounts owed under the Borrower’s Existing Credit Facilities shall have been paid in full on or before the Closing Date and all commitments and agreements with respect thereto shall have been terminated.
(j)    Know Your Customer Information. The Administrative Agent shall have received at least three Business Days prior to the Closing Date all documentation and other information about the Borrower as has been reasonably requested by the Administrative Agent at least 10 Business Days prior to the Closing Date that is required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including without limitation the USA PATRIOT Act.
7.2.    Conditions to Each Loan and Letter of Credit
. The agreement of each Lender to make any Loan requested to be made by it on any date following the Closing Date, or to issue any Letter of Credit, is subject to the satisfaction of the following conditions precedent:
(a)    Representations and Warranties. Each of the representations and warranties (except for those made in subsection 6.13 and 6.14, which shall be made only on the Closing Date and on each Termination Date which a Borrower has requested be extended in accordance with subsection 2.20) made by the Borrower in or pursuant to the Loan Documents shall be true and correct in all material respects on and as of such date as if made on and as of such date.
    - 75 -


(b)    No Default. No Default or Event of Default shall have occurred and be continuing on such date or after giving effect to the Loans requested to be made, or Letters of Credit requested to be issued.
(c)    Each borrowing by the Borrower hereunder, and each request by the Borrower for the issuance of a Letter of Credit shall constitute a representation and warranty by the Borrower as of the date thereof that the conditions contained in this subsection have been satisfied.
SECTION 8    

AFFIRMATIVE COVENANTS
The Borrower hereby agrees that, so long as the Commitments (or any of them) remain in effect, any Letter of Credit is outstanding or any amount is owing to any Lender, and Issuing Lender or the Administrative Agent hereunder or under any other Loan Documents, the Borrower shall and (except in the case of delivery of financial information, reports and notices) shall cause each of its Subsidiaries to:
8.1.    Financial Statements
. Furnish to each Lender:
(a)    as soon as available, but in any event not later than 20 days after required to be filed with the Securities and Exchange Commission at the end of each fiscal year of the Borrower, a copy of the consolidated balance sheet of the Borrower and its consolidated Subsidiaries as at the end of such year and the related consolidated statements of operations and stockholders’ equity and of cash flows for such year, setting forth in each case in comparative form the figures for the previous year, reported on without a “going concern” or like qualification or exception, or qualification arising out of the scope of the audit, by Ernst & Young LLP or other independent certified public accountants of nationally recognized standing;
(b)    as soon as available, but in any event not later than 15 days after required to be filed with the Securities and Exchange Commission at the end of each of the first three quarterly periods of each fiscal year of the Borrower commencing with the fiscal quarter ending on or about March 31, 2021, the unaudited consolidated balance sheet of the Borrower and its consolidated Subsidiaries as at the end of such quarter and the related unaudited consolidated statements of operations for such quarter and the portion of the fiscal year through the end of such quarter and of cash flows of the Borrower and its consolidated Subsidiaries for the portion of the fiscal year through the end of such quarter, setting forth in each case in comparative form the figures for the previous year, certified by a Responsible Officer as being fairly stated in all material respects (subject to normal year-end audit adjustments); and
(c)    all such financial statements shall be complete and correct in all material respects and shall be prepared in reasonable detail and in accordance with GAAP applied consistently throughout the periods reflected therein and with prior periods (except as approved by such accountants or officer, as the case may be, and disclosed therein); provided, that it is hereby acknowledged that the quarterly financial statements delivered pursuant to paragraph (b) above may not include all of the information and footnotes required by GAAP for complete annual financial statements.
Any financial statement required to be furnished pursuant to this subsection 8.1 may be delivered electronically and if so delivered, shall be deemed to have been furnished on the earlier of the date (i) on which the Borrower posts such documents, or provides a link thereto on the Borrower’s website at the
    - 76 -


website address listed in subsection 13.2(a), (ii) on which such documents are posted on the Securities and Exchange Commission’s website (www.sec.gov), or (iii) on which such documents are posted on the Borrower’s behalf on any website to which each Lender and Administrative Agent have access (whether a commercial, third-party website such as Intralinks or DebtDomain or whether sponsored by the Administrative Agent); provided that the Borrower shall give notice (which may be in the form of facsimile or electronic mail) of any such posting to the Administrative Agent (who shall then give notice of any such posting to the Lenders). Notwithstanding the foregoing, the Borrower shall deliver paper copies of any financial statement referred to in this subsection 8.1 to the Administrative Agent if the Administrative Agent or any Lender requests the Borrower to furnish such paper copies until written notice to cease delivering such paper copies is given by the Administrative Agent.
8.2.    Certificates; Other Information
. Furnish to the Administrative Agent with sufficient copies for the Lenders:
(a)    concurrently with the delivery of the financial statements referred to in subsections 8.1(a) and 8.1(b), a certificate of a Responsible Officer stating that such Officer has obtained no knowledge of any Default or Event of Default that has occurred and is continuing except as specified in such certificate, and including calculations demonstrating compliance with subsection 9.1 (which delivery may, unless the Administrative Agent, or a Lender requests executed originals, be by electronic communication including fax or email and shall be deemed to be an original authentic counterpart thereof for all purposes);
(b)    within ten days after the same are sent, copies of all financial statements and reports which the Borrower sends to its stockholders, and within five days after the same are filed, copies of all financial statements and reports which the Borrower may make to, or file with, the Securities and Exchange Commission or any successor or analogous Governmental Authority, and promptly after the same are issued, copies of all press releases issued by the Borrower; and
(c)    promptly, such additional financial and other information as any Lender may from time to time reasonably request, including information for purposes of compliance with applicable “know your customer” and anti-money laundering rules and regulations, including the Patriot Act and the Beneficial Ownership Regulation, as reasonably requested by the Lenders.
The Borrower hereby acknowledges that (a) the Administrative Agent and/or the Arrangers may make available to the Lenders and the Issuing Lender materials and/or information provided by or on behalf of the Borrower hereunder (collectively, “Borrower Materials”) by posting the Borrower Materials on IntraLinks or another similar electronic system (the “Platform”) and (b) certain of the Lenders (each, a “Public Lender”) may have personnel who do not wish to receive material non-public information with respect to the Borrower or its Affiliates, or the respective securities of any of the foregoing, and who may be engaged in investment and other market-related activities with respect to such Persons’ securities. The Borrower hereby agrees that (a) all Borrower Materials that are to be made available to Public Lenders shall be clearly and conspicuously marked “PUBLIC” which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page thereof; (b) by marking Borrower Materials “PUBLIC,” the Borrower shall be deemed to have authorized the Administrative Agent, the Arrangers, the Issuing Lender and the Lenders to treat such Borrower Materials as not containing any material non-public information with respect to the Borrower or its securities for purposes of United States Federal and state securities laws (provided, however, that to the extent such Borrower Materials constitute Information (as defined in subsection 13.14), they shall be treated as set forth in subsection 13.14); (c) all Borrower Materials marked “PUBLIC” are permitted to be made available through a portion of the
    - 77 -


Platform designated “Public Side Information;” and (d) the Administrative Agent and the Arrangers shall be entitled to treat any Borrower Materials that are not marked “PUBLIC” as being suitable only for posting on a portion of the Platform not designated “Public Side Information.”
8.3.    Payment of Obligations
. Pay, discharge or otherwise satisfy at or before maturity or before they become delinquent, as the case may be, all its obligations of whatever nature, (other than where the amount or validity thereof is currently being contested in good faith by appropriate proceedings and reserves in conformity with GAAP with respect thereto have been provided on the books of the Borrower or its Subsidiaries, as the case may be) except to the extent that the failure to do so could not reasonably be expected to result in a Material Adverse Effect.
8.4.    Conduct of Business and Maintenance of Existence
. (a) Continue to engage in business of the same general type as conducted by it on the Closing Date; (b) preserve, renew and keep in full force and effect its corporate existence (except as could not in the aggregate be reasonably expected to have a Material Adverse Effect); (c) take all reasonable action to maintain all rights, privileges and franchises necessary or desirable in the normal conduct of its business except as otherwise permitted pursuant to subsection 9.4; and (d) comply with all Requirements of Law except to the extent that failure to comply therewith could not, in the aggregate, be reasonably expected to have a Material Adverse Effect.
8.5.    Maintenance of Property; Insurance
. Keep all property necessary in its business in good working order and condition except to the extent that failure to do so could not, in the aggregate, be reasonably expected to have a Material Adverse Effect; maintain with financially sound and reputable insurance companies insurance on all its property in at least such amounts and against at least such risks as are adequate for conducting its business; and furnish to each Lender, upon written request, full information as to the insurance carried.
8.6.    Inspection of Property; Books and Records; Discussions
. Keep proper books of records and account in which full, true and correct entries in conformity with GAAP and all Requirements of Law shall be made of all dealings and transactions in relation to its business and activities; and permit representatives of any Lender (upon reasonable advance notice coordinated through the Administrative Agent) to visit and inspect any of its properties and examine and make abstracts from any of its books and records at any reasonable time and as often as may reasonably be desired and to discuss the business, operations, properties and financial and other condition of the Borrower and its Subsidiaries with officers and employees of the Borrower and its Subsidiaries and with its independent certified public accountants.
8.7.    Notices
. Promptly give notice (unless available in the public filings or releases of the Borrower or its Subsidiaries) to the Administrative Agent and each Lender of:
(a)    the occurrence of any Default or Event of Default;
    - 78 -


(b)    any (i) default or event of default under any Contractual Obligation of the Borrower or any of its Subsidiaries or (ii) litigation, investigation or proceeding which may exist at any time involving the Borrower or any of its Subsidiaries, which in either case, could reasonably be expected to have a Material Adverse Effect; and
(c)    the following events, as soon as reasonably possible and in any event within 30 days after the Borrower knows of the event: (i) the occurrence or reasonably expected occurrence of any Reportable Event with respect to any Plan, a failure of the Borrower, its Subsidiaries or a Commonly Controlled Entity to make any required contribution to a Plan, the creation of any Lien in favor of the PBGC or a Plan, any determination that a Single Employer Plan is in “at risk” status (within the meaning of Section 430 of the Code or Section 303 of ERISA), or any withdrawal by the Borrower or a Commonly Controlled Entity from, or the termination or Insolvency of, any Multiemployer Plan or determination that any Multiemployer Plan is in “endangered” or “critical” status (within the meaning of Section 432 of the Code or Section 305 of ERISA); or (ii) the institution of proceedings or the taking of any other action by the PBGC, the Borrower, any Commonly Controlled Entity or any Multiemployer Plan with respect to the withdrawal by the Borrower or a Commonly Controlled Entity from, or the termination or Insolvency of, any Plan (other than the termination of any Single Employer Plan pursuant to Section 4041(b) of ERISA), or with respect to any determination that any Single Employer Plan is in “at risk” status or any such Multiemployer Plan is in “endangered” or “critical” status; where, in connection with any of the foregoing in clause (i) or (ii), only to the extent the amount of liability the Borrower or any Commonly Controlled Entity could reasonably be expected to have arising from an event has a Material Adverse Effect.
Each notice pursuant to this subsection 8.7 shall be accompanied by a statement of a Responsible Officer setting forth details of the occurrence referred to therein and stating what action the Borrower proposes to take with respect thereto.
SECTION 9    

NEGATIVE COVENANTS
The Borrower hereby agrees that, so long as the Commitments (or any of them) remain in effect, any Letter of Credit remains outstanding, or any amount is owing to any Lender, any Issuing Lender or the Administrative Agent hereunder or under any other Loan Documents, the Borrower shall not, and (except with respect to subsection 9.1) shall not permit any of its Subsidiaries to, directly or indirectly:
9.1.    Financial Covenant
. Consolidated Leverage Ratio. Permit the Consolidated Leverage Ratio as at the last day of any period of four consecutive fiscal quarters of the Borrower to exceed the Maximum Leverage Ratio.
9.2.    Limitation on Liens
. Create, incur, assume or suffer to exist any Lien upon any of its property, assets or revenues, whether now owned or hereafter acquired, except for:
(a)    Liens for taxes not yet due or which are being contested in good faith by appropriate proceedings, provided that adequate reserves with respect thereto are maintained on the books of the Borrower or its Subsidiaries, as the case may be, in conformity with GAAP;
    - 79 -


(b)    carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s or other like Liens arising in the ordinary course of business which are not overdue for a period of more than 60 days or which are being contested in good faith by appropriate proceedings;
(c)    pledges or deposits in connection with workers’ compensation, unemployment insurance and other social security legislation and deposits securing liability to insurance carriers under insurance or self-insurance arrangements;
(d)    deposits to secure the performance of bids, trade contracts (other than for borrowed money), leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of business;
(e)    easements, rights-of-way, restrictions and other similar encumbrances incurred in the ordinary course of business which, in the aggregate, are not substantial in amount and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of the Borrower or such Subsidiary;
(f)    Liens in existence on the date hereof listed on Schedule 9.2, provided that no such Lien is spread to cover any additional property after the Closing Date and that the amount of Indebtedness secured thereby is not increased;
(g)    Liens securing Indebtedness of the Borrower and its Subsidiaries incurred to finance the acquisition of fixed or capital assets, provided that (i) such Liens shall be created substantially simultaneously with the acquisition of such fixed or capital assets, (ii) such Liens do not at any time encumber any property other than the property financed by such Indebtedness and (iii) the amount of Indebtedness secured thereby is not increased;
(h)    Liens on the property or assets of a corporation which becomes a Subsidiary after the date hereof, provided that (i) such Liens existed at the time such corporation became a Subsidiary and were not created in anticipation thereof, (ii) any such Lien is not spread to cover any property or assets of such corporation after the time such corporation becomes a Subsidiary, and (iii) the amount of Indebtedness secured thereby is not increased;
(i)    Liens created pursuant to any Receivables Transaction permitted pursuant to subsection 9.3; and
(j)    Liens (not otherwise permitted hereunder) which secure obligations not exceeding (as to the Borrower and all Subsidiaries) the greater of (i) $500,000,000 and (ii) 7.5% of the Consolidated Tangible Assets, in aggregate amount at any time.
9.3.    Limitation on Indebtedness pursuant to Receivables Transactions
. Create, issue, incur, assume, become liable in respect of or suffer to exist any Indebtedness pursuant to any Receivables Transaction, except for Indebtedness pursuant to all Receivables Transactions in an aggregate principal amount not exceeding 20% of Consolidated Tangible Assets.
9.4.    Limitation on Fundamental Changes
. Enter into any merger, consolidation or amalgamation, or liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution), consummate a Division as the Dividing Person, or convey, sell,
    - 80 -


lease, assign, transfer or otherwise Dispose of, all or substantially all of its property, business or assets, except:
(a)    any Subsidiary of the Borrower may be merged or consolidated with or into the Borrower (provided that the Borrower shall be the continuing or surviving corporation) or with or into any one or more wholly owned Subsidiaries of the Borrower (provided that the wholly owned Subsidiary or Subsidiaries shall be the continuing or surviving corporation);
(b)    any Subsidiary of the Borrower that is inactive or no longer needed in the Borrower’s consolidated group structure may be liquidated, dissolved, or otherwise eliminated under applicable law, so long as any remaining significant assets of such Subsidiary are transferred to the Borrower or to another of Borrower’s wholly owned Subsidiaries (as a liquidation distribution or otherwise);
(c)    the Borrower or any wholly owned Subsidiary of the Borrower may sell, lease, transfer or otherwise dispose of any or all of its assets (upon voluntary liquidation or otherwise) to the Borrower or any other wholly owned Subsidiary, and, so long as no Default or Event of Default shall have occurred and be continuing or would occur as a result thereof, the Borrower or any Subsidiary of the Borrower may sell, lease, transfer or otherwise dispose of any or all of its assets (upon voluntary liquidation or otherwise) to any non-wholly owned Subsidiary of the Borrower for fair market value;
(d)    any non-wholly owned Subsidiary of the Borrower may sell, lease, transfer or otherwise dispose of any or all of its assets (upon voluntary liquidation or otherwise) to the Borrower or any wholly owned Subsidiary of the Borrower for fair market value or may sell, lease, transfer or otherwise dispose of any or all of its assets (upon voluntary liquidation or otherwise) to any other non-wholly owned Subsidiary of the Borrower; and
(e)    the Borrower or any Subsidiary of the Borrower may be merged or consolidated with or into another Person; provided that the Borrower or such Subsidiary shall be the continuing or surviving corporation and no Default or Event of Default shall have occurred and be continuing or would occur as a result thereof (and, in the case of any such transaction involving a Subsidiary, such Subsidiary shall continue to be a Subsidiary or the Borrower shall have received fair market value therefor as determined by the Board of Directors of the Borrower); and provided further that the Borrower may not be merged or consolidated with or into any Subsidiary.
9.5.    Limitation on Indebtedness of Subsidiaries
. Permit any Subsidiaries to, directly or indirectly, create, incur, assume or guaranty, or otherwise become or remain directly or indirectly liable with respect to, any Indebtedness in excess of 12.5% of Consolidated Tangible Assets in the aggregate at any time for all such Subsidiaries, except for (i) Indebtedness permitted by subsection 9.3 hereof, (ii) any Indebtedness of any Subsidiary of the Borrower owing to the Borrower or to any other Subsidiary of the Borrower, (iii) Indebtedness in existence on the date hereof listed on Schedule 9.5 and (iv) Indebtedness of American Medical Systems Europe B.V. for so long as American Medical Systems Europe B.V. is a foreign Subsidiary that owns no material assets (including no Capital Stock) and has no material operations.
SECTION 10    

EVENTS OF DEFAULT
If any of the following events shall occur and be continuing:
    - 81 -


(a)    The Borrower shall fail to pay any principal of any Loan or any Reimbursement Obligation when due in accordance with the terms thereof or hereof; or the Borrower shall fail to pay any interest on any Loan, or any fee or other amount payable hereunder, within five days after any such interest or other amount becomes due in accordance with the terms thereof or hereof; or
(b)    Any representation or warranty made or deemed made by the Borrower herein or in any other Loan Document or which is contained in any certificate, document or financial or other statement furnished by it at any time under or in connection with this Agreement shall prove to have been incorrect in any material respect on or as of the date made or deemed made; or
(c)    The Borrower shall default in the observance or performance of any covenant contained in subsections 8.4(b), 8.7(a) or in Section 9; or
(d)    The Borrower shall default in the observance or performance of any agreement contained in Section 12; or
(e)    The Borrower shall default in the observance or performance of any other agreement contained in this Agreement (other than as provided above in this Section), and such default described in this clause (e) shall continue unremedied for a period of 30 days; or
(f)    The Borrower or any of its Subsidiaries shall: (i) default in any payment of principal of or interest of any Indebtedness (other than the Loans) or in the payment of any Guarantee Obligation, beyond the period of grace, if any, provided in the instrument or agreement under which such Indebtedness or Guarantee Obligation was created; or (ii) default in the observance or performance of any other agreement or condition relating to any such Indebtedness or Guarantee Obligation or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event shall occur or condition exist, the effect of which default or other event or condition is to cause, or to permit the holder or holders of such Indebtedness or beneficiary or beneficiaries of such Guarantee Obligation (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, with the giving of notice if required, such Indebtedness to become due prior to its stated maturity or such Guarantee Obligation to become payable; provided, however, that no Default or Event of Default shall exist under this paragraph unless the aggregate amount of Indebtedness and/or Guarantee Obligations in respect of which any default or other event or condition referred to in this paragraph shall have occurred shall be equal to at least $250,000,000; or
(g)    (i) The Borrower or any of its Subsidiaries shall commence any case, proceeding or other action (A) under any existing or future law of any jurisdiction, domestic or foreign, relating to bankruptcy, insolvency, examinership, court protection, reorganization or relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it a bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition, examinership, court protection or other relief with respect to it or its debts, or (B) seeking appointment of an examiner, receiver, trustee, custodian, conservator or other similar official for it or for all or any substantial part of its assets, or the Borrower or any of its Subsidiaries shall make a general assignment for the benefit of its creditors; or (ii) there shall be commenced against the Borrower or any of its Subsidiaries any case, proceeding or other action of a nature referred to in clause (i) above which (A) results in the entry of an order for relief or any such adjudication or appointment or (B) remains undismissed, undischarged or unbonded for a period of 60 days; or (iii) there shall be commenced against the Borrower or any of its Subsidiaries any case, proceeding or other action seeking issuance of a warrant of attachment, execution, distraint or similar process against all or any substantial part of its assets which
    - 82 -


results in the entry of an order for any such relief which shall not have been vacated, discharged, or stayed or bonded pending appeal within 60 days from the entry thereof; or (iv) the Borrower or any of its Subsidiaries shall take any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth in clause (i), (ii), or (iii) above; or (v) the Borrower or any of its Subsidiaries shall generally not or shall admit in writing its inability to, pay its debts as they become due; or
(h)    (i) The Borrower, its Subsidiaries or any Commonly Controlled Entity engages in any “prohibited transaction” (as defined in Section 406 of ERISA or Section 4975 of the Code) involving any Plan, (ii) any Plan fails to meet the minimum funding standards described in Section 302 of ERISA or any Lien in favor of the PBGC or a Plan arises on the assets of the Borrower or any Commonly Controlled Entity, (iii) a Reportable Event occurs with respect to, or proceedings shall commence to have a trustee appointed, or a trustee shall be appointed, to administer or to terminate, any Single Employer Plan, which Reportable Event or commencement of proceedings or appointment of a trustee results in the termination of such Plan for purposes of Title IV of ERISA, (iv) any Single Employer Plan terminates for purposes of Title IV of ERISA, (v) a determination that any Single Employer Plan is, or is expected to be, in “at risk” status (within the meaning of Section 430 of the Code or Section 303 of ERISA), (vi) the Borrower or any Commonly Controlled Entity incurs any liability in connection with a withdrawal from, or the Insolvency of, a Multiemployer Plan, or a determination that any Multiemployer Plan is in “endangered” or “critical” status (within the meaning of Section 432 of the Code or Section 305 of ERISA), or (vii) any other event or condition occurs or exist with respect to a Plan; and in each case in clauses (i) through (vii) above, such event or condition, together with all other such events or conditions, if any, could reasonably be expected to have a Material Adverse Effect; or
(i)    Any one judgment or decree shall be entered against the Borrower or any of its Subsidiaries involving in the aggregate a liability (not paid or in excess of the amount recoverable by insurance) of $250,000,000 (net of any related tax benefit) or more, and such judgment or decree shall not have been vacated, discharged, stayed or appealed (as long as enforcement is effectively stayed during such appeal or such appeal is bonded, if required) within 60 days from the entry thereof; or
(j)    (i) Any Person or “group” (within the meaning of Section 13(d) or 14(d) of the Securities Exchange Act of 1934, as amended) (A) shall have acquired beneficial ownership of 40% or more of any outstanding class of Capital Stock having ordinary voting power in the election of directors of the Borrower (other than Peter M. Nicholas and John E. Abele or any of their affiliated trust holdings) or (B) shall obtain the power (whether or not exercised) to elect a majority of the Borrower’s directors; or (ii) the Board of Directors of the Borrower shall not consist of a majority of Continuing Directors; “Continuing Directors” shall mean the directors of the Borrower on the Closing Date and each other director, if such other director’s nomination for election to the Board of Directors of the Borrower is recommended by a majority of the then Continuing Directors;
then, and in any such event, (A) if such event is an Event of Default specified in clause (i) or (ii) of paragraph (g) above with respect to the Borrower, automatically the Commitments shall immediately terminate and the Loans hereunder (with accrued interest thereon) and all other amounts owing under this Agreement and the other Loan Documents (including, without limitation, all amounts of L/C Obligations, whether or not the beneficiaries of the then outstanding Letters of Credit shall have presented the documents required thereunder) shall immediately become due and payable, and (B) if such event is any other Event of Default, either or both of the following actions may be taken: (i) with the consent of the Majority Lenders, the Administrative Agent may, or upon the request of the Majority Lenders, the Administrative Agent shall, by notice to the Borrower declare the Commitments to be terminated
    - 83 -


forthwith, whereupon the Commitments shall immediately terminate; and (ii) with the consent of the Majority Lenders, the Administrative Agent may, or upon the request of the Majority Lenders, the Administrative Agent shall, by notice to the Borrower, declare the Loans hereunder (with accrued interest thereon) and all other amounts owing under this Agreement and the other Loan Documents (including, without limitation, all amounts of L/C Obligations, whether or not the beneficiaries of the then outstanding Letters of Credit shall have presented the documents required thereunder) to be due and payable forthwith, whereupon the same shall immediately become due and payable. In the case of each Letter of Credit with respect to which presentment for honor shall not have occurred at the time of an acceleration pursuant to this paragraph, the Borrower shall at such time Cash Collateralize the L/C Obligations in an amount (in the currency in which such Letter of Credit is denominated) equal to the then undrawn and unexpired amount of such Letter of Credit. Amounts held as Cash Collateral shall be applied by the Administrative Agent in accordance with subsection 2.18.
SECTION 11    

THE AGENTS
11.1.    Appointment
. Each Lender hereby irrevocably designates and appoints the Administrative Agent as the agent of such Lender under this Agreement and the other Loan Documents, and each Lender irrevocably authorizes the Administrative Agent, in such capacity, to take such action on its behalf under the provisions of this Agreement and the other Loan Documents and to exercise such powers and perform such duties as are expressly delegated to the Administrative Agent by the terms of this Agreement and the other Loan Documents, together with such other powers as are reasonably incidental thereto. Notwithstanding any provision to the contrary elsewhere in this Agreement, the Administrative Agent shall not have any duties or responsibilities, except those expressly set forth herein, or any fiduciary relationship with any Lender, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or any other Loan Document or otherwise exist against the Administrative Agent.
11.2.    Delegation of Duties
. The Administrative Agent may execute any of its duties under this Agreement and the other Loan Documents by or through agents or attorneys-in-fact and shall be entitled to advice of counsel concerning all matters pertaining to such duties. The Administrative Agent shall not be responsible for the negligence or misconduct of any agents or attorneys in-fact selected by it with reasonable care.
11.3.    Exculpatory Provisions
. Neither any Agent nor any of its officers, directors, employees, agents, attorneys-in-fact or Affiliates shall be (i) liable for any action lawfully taken or omitted to be taken by it or such Person under or in connection with this Agreement or any other Loan Document (except for its or such Person’s own gross negligence or willful misconduct) or (ii) responsible in any manner to any of the Lenders for any recitals, statements, representations or warranties made by the Borrower or any officer thereof contained in this Agreement or any other Loan Document or in any certificate, report, statement or other document referred to or provided for in, or received by such Agent under or in connection with, this Agreement or any other Loan Document or for the value, validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Loan Document or for any failure of the Borrower or any
    - 84 -


Foreign Subsidiary Borrower to perform its obligations hereunder or thereunder. No Agent shall be under any obligation to any Lender to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or conditions of, this Agreement or any other Loan Document, or to inspect the properties, books or records of the Borrower or any Foreign Subsidiary Borrower.
11.4.    Reliance by Administrative Agent
. The Administrative Agent shall be entitled to rely, and shall be fully protected in relying, upon any Note, writing, resolution, notice, consent, certificate, affidavit, letter, telecopy, telex or teletype message, statement, order or other document or conversation believed by it to be genuine and correct and to have been signed, sent or made by the proper Person or Persons and upon advice and statements of legal counsel (including, without limitation, counsel to the Borrower or any Foreign Subsidiary Borrower), independent accountants and other experts selected by the Administrative Agent. The Administrative Agent may deem and treat the payee of any Note as the owner thereof for all purposes unless a written notice of assignment, negotiation or transfer thereof shall have been filed with the Administrative Agent. The Administrative Agent shall be fully justified in failing or refusing to take any action under this Agreement or any other Loan Document unless it shall first receive such advice or concurrence of the Majority Lenders as it deems appropriate or it shall first be indemnified to its satisfaction by the Lenders against any and all liability and expense which may be incurred by it by reason of taking or continuing to take any such action. The Administrative Agent shall in all cases be fully protected in acting, or in refraining from acting, under this Agreement and the other Loan Documents in accordance with a request of the Majority Lenders, and such request and any action taken or failure to act pursuant thereto shall be binding upon all the Lenders and all future holders of the Loans.
11.5.    Notice of Default
. The Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event of Default hereunder unless the Administrative Agent has received notice from a Lender or the Borrower referring to this Agreement, describing such Default or Event of Default and stating that such notice is a “notice of default”. In the event that the Administrative Agent receives such a notice, the Administrative Agent shall give notice thereof to the Lenders. The Administrative Agent shall take such action with respect to such Default or Event of Default as shall be reasonably directed by the Majority Lenders; provided that unless and until the Administrative Agent shall have received such directions, the Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Default or Event of Default as it shall deem advisable in the best interests of the Lenders.
11.6.    Non-Reliance on Administrative Agent and Other Lenders
. Each Lender expressly acknowledges that neither the Administrative Agent nor any of its officers, directors, employees, agents, attorneys-in-fact or Affiliates has made any representations or warranties to it and that no act by the Administrative Agent hereafter taken, including any review of the affairs of the Borrower or any Foreign Subsidiary Borrower, shall be deemed to constitute any representation or warranty by the Administrative Agent to any Lender. Each Lender represents to the Administrative Agent that it has, independently and without reliance upon the Administrative Agent or any other Lender, and based on such documents and information as it has deemed appropriate, made its own appraisal of and investigation into the business, operations, property, financial and other condition and creditworthiness of the Borrower and the Foreign Subsidiary Borrowers, if any, and made its own decision to make its Loans hereunder and enter into this Agreement. Each Lender also represents that it
    - 85 -


will, independently and without reliance upon the Administrative Agent or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Loan Documents, and to make such investigation as it deems necessary to inform itself as to the business, operations, property, financial and other condition and creditworthiness of the Borrower. Except for notices, reports and other documents expressly required to be furnished to the Lenders by the Administrative Agent hereunder, the Administrative Agent shall not have any duty or responsibility to provide any Lender with any credit or other information concerning the business, operations, property, condition (financial or otherwise), prospects or creditworthiness of the Borrower or any Foreign Subsidiary Borrower which may come into the possession of the Administrative Agent or any of its officers, directors, employees, agents, attorneys-in-fact or Affiliates.
11.7.    Indemnification
. The Lenders agree to indemnify the Administrative Agent (or sub-agent), in its capacity, any Issuing Lender, in its capacity, and any Related Party acting for the Administrative Agent (or any sub-agent) or any Issuing Lender in connection with such capacity (to the extent not reimbursed by the Borrower and without limiting the obligation of the Borrower and the Foreign Subsidiary Borrowers, if any, to do so), ratably according to their respective Aggregate Exposure Percentages in effect on the date on which indemnification is sought (or, if indemnification is sought after the date upon which the Commitments shall have terminated and the Loans shall have been paid in full, ratably in accordance with such Aggregate Exposure Percentages immediately prior to such date), from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever which may at any time (including, without limitation, at any time following the payment of the Loans) be imposed on, incurred by or asserted against the Administrative Agent (or any sub-agent), any Issuing Lender or such Related Party in any way relating to or arising out of, the Commitments, this Agreement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by the Administrative Agent (or any sub-agent), any Issuing Lender or such Related Party under or in connection with any of the foregoing; provided that no Lender shall be liable for the payment of any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements which are found by a final and nonappealable decision of a court of competent jurisdiction to have resulted from the gross negligence or willful misconduct of the Administrative Agent (or sub-agent), any Issuing Lender or any Related Party acting for the Administrative Agent (or any sub-agent) or any Issuing Lender in connection with such capacity. The agreements in this subsection shall survive the payment of the Loans and all other amounts payable hereunder.
11.8.    Administrative Agent in Its Individual Capacity
. The Administrative Agent and its Affiliates may make loans to, accept deposits from and generally engage in any kind of business with the Borrower or the Foreign Subsidiary Borrower, if any, as though the Administrative Agent were not the Administrative Agent hereunder and under the other Loan Documents. With respect to the Loans made by it and with respect to any Letter of Credit issued or participated in by it, the Administrative Agent shall have the same rights and powers under this Agreement and the other Loan Documents as any Lender and may exercise the same as though it were not the Administrative Agent, and the terms “Lender” and “Lenders” shall include the Administrative Agent in its individual capacity.
11.9.    Successor Administrative Agent
    - 86 -


. The Administrative Agent may resign as Administrative Agent upon 10 days’ notice to the Lenders. If the Administrative Agent shall resign as Administrative Agent under this Agreement and the other Loan Documents, then the Majority Lenders shall appoint from among the Lenders a successor agent for the Lenders, which successor agent (provided that it shall have been approved by the Borrower), shall succeed to the rights, powers and duties of the Administrative Agent hereunder. Upon the earlier of (i) the 10 day period following the Administrative Agent’s notice of resignation to the Lenders and (ii) the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Administrative Agent, and the retiring Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged therefrom as provided above in this Section). The term “Administrative Agent” shall mean such successor agent, and the former Administrative Agent’s rights, powers and duties as Administrative Agent shall be terminated, without any other or further act or deed on the part of such former Administrative Agent or any of the parties to this Agreement or any holders of the Loans. After any retiring Administrative Agent’s resignation as Administrative Agent, the provisions of this Section 11 shall inure to its benefit as to any actions taken or omitted to be taken by it while it was Administrative Agent under this Agreement and the other Loan Documents.
Any resignation by Wells Fargo as Administrative Agent pursuant to this section shall also constitute its resignation as Issuing Lender. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, (a) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring Issuing Lender, (b) the retiring Issuing Lender shall be discharged from all of their respective duties and obligations hereunder or under the other Loan Documents, and (c) the successor Issuing Lender shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to the retiring Issuing Lender to effectively assume the obligations of the retiring Issuing Lender with respect to such Letters of Credit.
11.10.    The Arrangers, the Bookrunner and the Documentation Agents
. None of the Arrangers, the Bookrunner or the Documentation Agents shall have any right, power, obligation, liability, responsibility or duty under this Agreement other than those applicable to all Lenders as such. Without limiting the foregoing, none of the Arrangers, the Bookrunner or the Documentation Agents shall have or be deemed to have any fiduciary relationship with any Lender. Each Lender acknowledges that it has not relied, and will not rely, on the Arrangers, the Bookrunner or the Documentation Agents in deciding to enter into this Agreement or in taking or not taking any action hereunder.
11.11.    Certain ERISA Matters
.
(a)    Each Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of the Administrative Agent, the Arrangers, and the other Agents and their respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower, that at least one of the following is and will be true:
    - 87 -


(i)    such Lender is not using “plan assets” (within the meaning of the Plan Asset Regulations) of one or more Benefit Plans in connection with the Loans or the Commitments,
(ii)    the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement,
(iii)    (A) such Lender is an investment fund managed by a “Qualified Professional Asset Manager” (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement, or
(iv)    such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.
(b)    In addition, unless either (1) sub-clause (i) in the immediately preceding clause (a) is true with respect to a Lender or (2) a Lender has not provided another representation, warranty and covenant in accordance with sub-clause (iv) in the immediately preceding clause (a), such Lender further (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent, the Arrangers, and the other Agents and their respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower, that none of the Administrative Agent, or the Arrangers, or any other Agents or any of their respective Affiliates is a fiduciary with respect to the assets of such Lender involved in the Loans, the Commitments and this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Agreement, any Loan Document or any documents related to hereto or thereto).
11.12.    Accidental Payments
.
(a)    Each Lender, each Issuing Lender, each other Secured Party and any other party hereto hereby severally agrees that if (i) the Administrative Agent notifies (which such notice shall be conclusive absent manifest error) such Lender or Issuing Lender or any other Secured Party (or the Lender Affiliate of a Secured Party) or any other Person that the Administrative Agent has determined in its sole discretion that has received funds on behalf of a Lender, Issuing Lender, Secured Party or other Person (each such recipient, a “Payment Recipient”) from the Administrative Agent or any of its Affiliates were erroneously transmitted to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or
    - 88 -


not known to such Payment Recipient) or (ii) any Payment Recipient receives any payment from the Administrative Agent (or any of its Affiliates) (x) that is in a different amount than, or on a different date from, that specified in a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment, (y) that was not preceded or accompanied by a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment or (z) that such Payment Recipient otherwise becomes aware was transmitted or received in error or by mistake (in whole or in part) then, in each case, an error in payment shall be presumed to have been made (any such amounts specified in clauses (i) or (ii) of this Section 11.12(a), whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise; individually and collectively, an “Erroneous Payment”) then such Payment Recipient is deemed to have knowledge of such error at the time of its receipt of such Erroneous Payment; provided that nothing in this Section shall require the Administrative Agent to provide any of the notices specified in clauses (i) or (ii) above. Each Payment Recipient shall not assert any right or claim to the Erroneous Payment, and hereby waives any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Erroneous Payments, including without limitation waiver of any defense based on “discharge for value” or any similar doctrine.
(b)    Without limiting the immediately preceding clause (a), each Payment Recipient agrees that, in the case of clause (a)(ii) above, it shall promptly (and, in all events, within one Business Day of its knowledge (or deemed knowledge) of such error) notify the Administrative Agent in writing of such occurrence.
(c)    In the case of either clause (a)(i) or (a)(ii) above, such Erroneous Payment shall at all times remain the property of the Administrative Agent and shall be segregated by the Payment Recipient and held in trust for the benefit of the Administrative Agent, and upon demand from the Administrative Agent such Payment Recipient shall (or, with respect to any Payment Recipient who received such funds on its behalf shall cause such Payment Recipient to), promptly, but in all events no later than one Business Day thereafter, return to the Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made in same day funds and in the currency so received, together with interest thereon in respect of each day from and including the date such Erroneous Payment (or portion thereof) was received by such Payment Recipient to the date such amount is repaid to the Administrative Agent at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect.
(d)    In the event that an Erroneous Payment (or portion thereof) is not recovered by the Administrative Agent for any reason, after demand therefor by the Administrative Agent in accordance with immediately preceding clause (c), from any Lender or Issuing Lender that is a Payment Recipient (such unrecovered amount as to such Lender or Issuing Lender, an “Erroneous Payment Return Deficiency”), then at the sole discretion of the Administrative Agent and upon the Administrative Agent’s written notice to such Payment Recipient (i) such Payment Recipient shall be deemed to have assigned its Loans (but not its Commitments) to the Administrative Agent or, at the option of the Administrative Agent, the Administrative Agent’s lending affiliate, in a principal amount equal to the Erroneous Payment Return Deficiency (or such lesser amount as the Administrative Agent may specify) (such assignment of the Loans (but not Commitments), the “Erroneous Payment Deficiency Assignment”) at par plus any accrued and unpaid interest, without further consent or approval of any party hereto Without any further payment by the Administrative Agent or its lending affiliate as the assignee of such Erroneous Payment Deficiency Assignment, and the Administrative Agent may reflect in the Register its ownership interest in
    - 89 -


the Loans subject to the Erroneous Payment Deficiency Assignment. As to any Erroneous Payment Deficiency Assignment, the provisions of this clause (d) shall govern in the event of any conflict with the terms and conditions of Section 13.6. For the avoidance of doubt, no Erroneous Payment Deficiency Assignment will reduce the Commitments of any Lender or Issuing Bank and such Commitments shall remain available in accordance with the terms of this Agreement.
(e)    Each party hereto hereby agrees that (x) in the event an Erroneous Payment (or portion thereof) is not recovered from any Payment Recipient that has received such Erroneous Payment (or portion thereof) for any reason, the Administrative Agent shall be subrogated to all the rights of such Payment Recipient with respect to such amount, (y) the receipt of an Erroneous Payment by a Payment Recipient shall not for the purpose of this Agreement be treated as a payment, prepayment, repayment, discharge or other satisfaction any Obligations owed by the Borrower or any other Credit Party and (z) to the extent that an Erroneous Payment was in any way or at any time credited as payment or satisfaction of any of the Obligations, the Obligations or any part thereof that were so credited, and all rights of the Payment Recipient, as the case may be, shall be reinstated and continue in full force and effect as if such payment or satisfaction had never been received.
(f)    Each Payment Recipient hereby authorizes the Administrative Agent to set off, net and apply any and all amounts at any time owing to such Payment Recipient under any Loan Document, or otherwise payable or distributable by the Administrative Agent to such Payment Recipient from any source, against any amount due to the Administrative Agent under pursuant to this Section 11.12 or under the indemnification provisions of this Agreement.
(g)    Each party’s obligations under this Section 11.12 shall survive the resignation or replacement of the Administrative Agent or any transfer of right or obligations by, or the replacement of, a Lender, the termination of the Commitments or the repayment, satisfaction or discharge of all Obligations (or any portion thereof) under any Loan Document.


SECTION 12    

GUARANTEE
12.1.    Guarantee
.
(a)    The Borrower hereby unconditionally and irrevocably guarantees to the Administrative Agent, for the ratable benefit of the Administrative Agent and the Lenders and their respective successors, endorsees, transferees and assigns, the prompt and complete payment and performance by the Foreign Subsidiary Borrowers (if any) when due (whether at the stated maturity, by acceleration or otherwise) of the Obligations.
(b)    No payment or payments made by the Borrower or any other Person or received or collected by the Administrative Agent or any Lender from the Borrower or any other Person by virtue of any action or proceeding or any set-off or appropriation or application, at any time or from time to time, in reduction of or in payment of the Obligations shall be deemed to modify, reduce, release or otherwise affect the liability of the Borrower hereunder which shall, notwithstanding any such payment or
    - 90 -


payments, remain liable hereunder for the Obligations until the Obligations are paid in full and the Commitments are terminated.
(c)    The Borrower agrees that whenever, at any time, or from time to time, it shall make any payment to the Administrative Agent or any Lender on account of its liability hereunder, it will notify the Administrative Agent and such Lender in writing that such payment is made under this Section for such purpose.
12.2.    No Subrogation
. Notwithstanding any payment or payments made by the Borrower hereunder, or any set-off or application of funds of the Borrower by the Administrative Agent or any Lender, the Borrower shall not be entitled to be subrogated to any of the rights of the Administrative Agent or any Lender against the Foreign Subsidiary Borrowers or against any collateral security or guarantee or right of offset held by the Administrative Agent or any Lender for the payment of the Obligations, nor shall the Borrower seek or be entitled to seek any contribution or reimbursement from the Foreign Subsidiary Borrowers in respect of payments made by the Borrower hereunder, until all amounts owing to the Administrative Agent and the Local Currency Lenders by the Foreign Subsidiary Borrowers on account of the Obligations are paid in full and the Commitments are terminated. If any amount shall be paid to the Borrower on account of such subrogation rights at any time when all of the Obligations shall not have been paid in full, such amount shall be held by the Borrower in trust for the Administrative Agent and the Lenders, segregated from other funds of the Borrower, and shall, forthwith upon receipt by the Borrower, be turned over to the Administrative Agent in the exact form received by the Borrower (duly indorsed by the Borrower to the Administrative Agent, if required), to be applied against the Obligations, whether matured or unmatured, in such order as Administrative Agent may determine. The provisions of this paragraph shall continue to be effective after the termination of this Agreement, the payment in full of the Obligations and the termination of the Commitments.
12.3.    Amendments, etc. with respect to the Obligations; Waiver of Rights
. The Borrower shall remain obligated hereunder notwithstanding that, without any reservation of rights against the Borrower, and without notice to or further assent by the Borrower, any demand for payment of any of the Obligations made by the Administrative Agent or any Lender may be rescinded by the Administrative Agent or such Lender, and any of the Obligations continued, and the Obligations, or the liability of any other party upon or for any part thereof, or any collateral security or guarantee therefor or right of offset with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by the Administrative Agent or any Lender, and any Loan Documents and any other documents executed and delivered in connection therewith may be amended, modified, supplemented or terminated, in whole or in part, in accordance with the provisions thereof as the Administrative Agent (or the requisite Lenders, as the case may be) may deem advisable from time to time, and any collateral security, guarantee or right of offset at any time held by the Administrative Agent or any Lender for the payment of the Obligations may be sold, exchanged, waived, surrendered or released. None of the Administrative Agent or any Lender shall have any obligation to protect, secure, perfect or insure any Lien at any time held by it as security for the Obligations or for this Agreement or any property subject thereto. When making any demand hereunder against the Borrower, the Administrative Agent or any Lender may, but shall be under no obligation to, make a similar demand on the Foreign Subsidiary Borrowers or any other guarantor, and any failure by the Administrative Agent or any Lender to make any such demand or to collect any payments from a Foreign Subsidiary Borrower or any such other guarantor or any release of a Foreign Subsidiary Borrower
    - 91 -


or such other guarantor shall not relieve the Borrower of its obligations or liabilities hereunder, and shall not impair or affect the rights and remedies, express or implied, or as a matter of law, of the Administrative Agent or any Lender against the Borrower. For the purposes hereof “demand” shall include the commencement and continuance of any legal proceedings.
12.4.    Guarantee Absolute and Unconditional
. The Borrower waives any and all notice of the creation, renewal, extension or accrual of any of the Obligations and notice of or proof of reliance by the Administrative Agent or any Lender upon this Agreement or acceptance of this Agreement; the Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon this Agreement; and all dealings between the Foreign Subsidiary Borrowers and the Borrower, on the one hand, and the Administrative Agent and the Lenders, on the other, shall likewise be conclusively presumed to have been had or consummated in reliance upon this Agreement. The Borrower waives diligence, presentment, protest, demand for payment and notice of default or nonpayment to or upon the Foreign Subsidiary Borrowers and the Borrower with respect to the Obligations. This Section 12 shall be construed as a continuing, absolute and unconditional guarantee of payment without regard to (a) the validity, regularity or enforceability of this Agreement, any other Loan Document, any of the Obligations or any other collateral security therefor or guarantee or right of offset with respect thereto at any time or from time to time held by the Administrative Agent or any Lender, (b) any defense, set-off or counterclaim (other than a defense of payment or performance) which may at any time be available to or be asserted by the Foreign Subsidiary Borrowers against the Administrative Agent or any Lender, (c) any law, regulation, decree or order of any jurisdiction, or any other event, affecting the Obligations or any Lender’s rights with respect thereto, including, without limitation: (i) the application of any such law, regulation, decree or order, including any prior approval, that would prevent the exchange of a non-Dollar currency for Dollars or the remittance of funds outside of such jurisdiction or the unavailability of Dollars in any legal exchange market in such jurisdiction in accordance with normal commercial practice; or (ii) a declaration of banking moratorium or any suspension of payments by banks in such jurisdiction or the imposition by such jurisdiction or any governmental authority thereof of any moratorium on the required rescheduling or restructuring of, or required approval of payments on, any indebtedness in such jurisdiction; or (iii) any expropriation, confiscation, nationalization or requisition by such country or any governmental authority that directly or indirectly deprives the companies in such jurisdiction of any payment obligation under the Obligations; or (iv) any war (whether or not declared), insurrection, revolution, hostile act, civil strife or similar events occurring in such jurisdiction that has the same effect as the events described in clause (i), (ii) or (iii) above (in each of the cases contemplated in clauses (i) through (iv) above, to the extent occurring or existing on or at any time after the date of this Agreement), or (d) any other circumstance whatsoever (with or without notice to or knowledge of the Foreign Subsidiary Borrowers or the Borrower) which constitutes, or might be construed to constitute, an equitable or legal discharge of the Foreign Subsidiary Borrowers for the Obligations, or of the Borrower under this Section 12, in bankruptcy or in any other instance. When pursuing its rights and remedies hereunder against the Borrower, the Administrative Agent and any Lender may, but shall be under no obligation to, pursue such rights and remedies as it may have against the Foreign Subsidiary Borrowers or any other Person or against any collateral security or guarantee for the Obligations or any right of offset with respect thereto, and any failure by the Administrative Agent or any Lender to pursue such other rights or remedies or to collect any payments from the Borrower or any such other Person or to realize upon any such collateral security or guarantee or to exercise any such right of offset, or any release of the Foreign Subsidiary Borrowers or any such other Person or of any such collateral security, guarantee or right of offset, shall not relieve the Borrower of any liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of the Administrative Agent
    - 92 -


or any Lender against the Borrower. This Section 12 shall remain in full force and effect and be binding in accordance with and to the extent of its terms upon the Borrower and its successors and assigns, and shall inure to the benefit of the Administrative Agent and the Lenders, and their respective successors, endorsees, transferees and assigns, until all the Obligations and the obligations of the Borrower under this Agreement shall have been satisfied by payment in full and the Commitments shall be terminated, notwithstanding that from time to time during the term of this Agreement the Foreign Subsidiary Borrowers may be free from any Obligations.
12.5.    Reinstatement
. This Section 12 shall continue to be effective, or be reinstated, as the case may be, if at any time payment, or any part thereof, of any of the Obligations is rescinded or must otherwise be restored or returned by the Administrative Agent or any Lender upon the insolvency, bankruptcy, dissolution, liquidation or reorganization of the Borrower or upon or as a result of the appointment of a receiver, intervenor or conservator of, or trustee or similar officer for, the Borrower or any substantial part of its property, or otherwise, all as though such payments had not been made.
12.6.    Payments
. The Borrower hereby agrees that all payments required to be made by it hereunder will be made to the Administrative Agent without set-off or counterclaim in accordance with the terms of the Obligations, including, without limitation, in the currency in which payment is due, provided that if a payment is due in a currency other than Dollars and/or at a place other than the United States, and such payment is not made as and when agreed, the Borrower will, upon the Administrative Agent’s request, either (i) make payment in such non- Dollar currency and at the place where such payment is payable or (ii) pay the Administrative Agent in Dollars at the Administrative Agent’s office referred in Subsection 13.2. In the event of a payment pursuant to clause (ii) above, the Borrower will pay the Administrative Agent the Dollar Equivalent of the amount of such payment on the date the Borrower makes such payment.
12.7.    “Lenders”
. For all purposes of this Section 12, the term “Lenders” shall be deemed to include Local Currency Lenders.
SECTION 13    

MISCELLANEOUS
13.1.    Amendments and Waivers
.
(a)    Except as provided in paragraphs (b) and (d) of this subsection 13.1, neither this Agreement nor any other Loan Document, nor any terms hereof or thereof may be amended, supplemented or modified except in accordance with the provisions of this subsection. The Majority Lenders may, or, with the written consent of the Majority Lenders, the Administrative Agent may, from time to time, (a) enter into with the Borrower written amendments, supplements or modifications hereto and to the other Loan Documents for the purpose of adding any provisions to this Agreement or the other Loan Documents or changing in any manner the rights of the Lenders or of the Borrower hereunder or
    - 93 -


thereunder or (b) waive, on such terms and conditions as the Majority Lenders or the Administrative Agent, as the case may be, may specify in such instrument, any of the requirements of this Agreement or the other Loan Documents or any Default or Event of Default and its consequences; provided, however, that no such waiver and no such amendment, supplement or modification shall (i) reduce the amount or extend the scheduled date of maturity of any Loan or reduce the stated rate or amount of any interest or fee payable hereunder (except that any amendment or modification of defined terms used in the financial covenants in this Agreement shall not constitute a reduction in the rate of interest or fees for purposes of this clause (i)) or extend the scheduled date of any payment thereof or increase the amount or extend the expiration date of any Lender’s Multicurrency Commitment, Revolving Credit Commitment or Issuing Lender Commitment, in each case without the consent of each Lender or Issuing Lender, as applicable, directly affected thereby, (ii) amend, modify or waive any provision of this subsection or reduce the percentages specified in the definitions, of Majority Lenders or Majority Multicurrency Lenders, or consent to the assignment or transfer by the Borrower of any of its rights and obligations under this Agreement and the other Loan Documents or release, subordinate or otherwise materially limit the Borrower’s liability with respect to the guarantee set forth in Section 12, in each case without the written consent of all the Lenders, (iii) amend, modify or waive any provision of Section 11 without the written consent of the then Administrative Agent, (iv) waive any condition in subsection 7.2 without the written consent of the Majority Lenders, (v) modify the pro rata distribution of payments, proceeds or fees payable to the Lenders (except in connection with an amend and extend transaction offered ratably to all Lenders under a tranche of Commitments) without the consent of each Lender directly affected thereby or (vi) amend, modify or waive any provision of Section 5 without the written consent of each Lender directly adversely affected thereby. Any such waiver and any such amendment, supplement or modification shall apply equally to each of the Lenders and shall be binding upon the Borrower, the Lenders, the Administrative Agent and all future holders of the Loans. In the case of any waiver, the Borrower, the Lenders and the Administrative Agent shall be restored to their former positions and rights hereunder and under the other Loan Documents, and any Default or Event of Default waived shall be deemed to be cured and not continuing; no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereon.
(b)    In addition to amendments effected pursuant to the foregoing paragraph (a), (i) Schedule II may be amended to change administrative information contained therein with the approval of the Majority Multicurrency Lenders, upon execution and delivery by the Borrower and the Administrative Agent of a written amendment providing for such amendment, (ii) additional freely-convertible euro currencies may be added as Available Foreign Currencies, upon execution and delivery by the Borrower, the Administrative Agent and the Majority Multicurrency Lenders of an amendment providing for such addition and (iii) this Agreement may be amended by the Borrower and the Administrative Agent to implement increases in the Revolving Credit Commitments pursuant to subsection 2.17.
(c)    The Administrative Agent shall give prompt written notice to each Lender of any amendment effected pursuant to subsection 13.1(b).
(d)    Notwithstanding the provisions of this subsection 13.1, any Local Currency Facility may be amended, supplemented or otherwise modified in accordance with its terms so long as after giving effect thereto either (x) such Local Currency Facility ceases to be a “Local Currency Facility” and the Borrower so notifies the Administrative Agent or (y) the Local Currency Facility continues to meet the requirements of a Local Currency Facility set forth herein.
(e)    Notwithstanding the provisions of this subsection 13.1, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment,
    - 94 -


waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (x) the Commitment of any Defaulting Lender may not be increased or extended and the principal amount owed to such Lender may not be reduced other than pursuant to payments made by a Borrower with respect thereto without the consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such Defaulting Lender.
(f)    Notwithstanding the foregoing, the Administrative Agent, with the consent of the Borrower, may amend, modify or supplement any Loan Document without the consent of any Lender or the Majority Lenders in order to correct, amend or cure any ambiguity, inconsistency or defect or correct any typographical error or manifest error in any Loan Document.
(g)    If any Lender is a Non-Consenting Lender, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 13.6 and payment of amounts due to such Lender under this Agreement), all of its interests, rights (other than its existing rights to payments pursuant to Section 3.9 or Section 3.10) and obligations under this Agreement and the related Loan Documents to an assignee that shall assume such obligations (which assignee may be another Lender or an Affiliate of a Lender, if a Lender or such Affiliate accepts such assignment); provided that the applicable assignee shall have consented to the applicable amendment, waiver or consent.
13.2.    Notices
.
(a)    General. All notices, requests and demands to or upon the respective parties hereto to be effective shall be in writing (including by facsimile transmission) and, unless otherwise expressly provided herein, shall be deemed to have been duly given or made (a) in the case of delivery by hand, when delivered, (b) in the case of delivery by mail, three days after being deposited in the mails, postage prepaid, or (c) in the case of delivery by facsimile transmission, when sent and receipt has been confirmed, addressed as follows in the case of the Borrower and the Administrative Agent, and as set forth in Schedule I in the case of the other parties hereto, or to such other address as may be hereafter notified by the respective parties hereto:
If to the Borrower:
Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, Massachusetts 01752
Attention:    Daniel J. Brennan
    Executive Vice President and Chief Financial Officer
    and
    Robert J. Castagna
    Vice President and Treasurer
    
Fax: 508-683-4410
    www.bostonscientific.com
    - 95 -


with a copy to:
Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, Massachusetts 01752
Attention:    Vance Brown
    Vice President and Chief Corporate Counsel

    Fax: 508-683-5389
Email: legalnotices@bsci.com
If to the Administrative Agent (for payments and notices of borrowings, etc. in Dollars):
Wells Fargo Bank, National Association
MAC D01109-019
1525 W. W.T. Harris Blvd.
Charlotte, North Carolina 28262
Attention: Syndication Agency Services
Facsimile No.: 844-879-5899
E-mail: agencyservices.requests@wellsfargo.com

If to the Administrative Agent (for payments and notices of borrowings, etc. in non-Dollars):
Wells Fargo Bank, National Association
MAC D01109-019
1525 W. W.T. Harris Blvd.
Charlotte, North Carolina 28262
Attention: Syndication Agency Services
Facsimile No.: 844-879-5899
E-mail: agencyservices.requests@wellsfargo.com

If to the Administrative Agent (for other notices):
Wells Fargo Bank, National Association
301 S. College550 South Tryon Street, 142th Floor
Charlotte, NC 28202
Attn:
Telephone: (704) 715-4361
E-mail:

For Letters of Credit, to the address provided by the applicable Issuing Lender to the Borrower for such purpose.
provided that any notice, request or demand to or upon the Administrative Agent or the Lenders pursuant to subsection 2.2, 2.6, 2.9, 2.14, 2.15, or 3.2 shall not be effective until received.
(b)    Notices and other communications to the Lenders and the Issuing Lender hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, provided that the foregoing shall
    - 96 -


not apply to notices to any Lender or the Issuing Lender pursuant to Section 2, 3, 4 and 5 if such Lender or the Issuing Lender, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Section by electronic communication. The Administrative Agent or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, provided that approval of such procedures may be limited to particular notices or communications.
Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement), provided that if such notice or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient, and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that such notice or communication is available and identifying the website address therefor.
(c)    The Platform. THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE.” THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE BORROWER MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no event shall the Administrative Agent or any of its Affiliates (collectively, the “Agent Parties”) have any liability to the Borrower, any Lender, the Issuing Lender or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether in tort, contract or otherwise) arising out of the Borrower’s or the Administrative Agent’s transmission of Borrower Materials through the Internet, except to the extent that such losses, claims, damages, liabilities or expenses are determined by a court of competent jurisdiction by a final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Agent Party; provided, however, that in no event shall any Agent Party have any liability to the Borrower, any Lender, the Issuing Lender or any other Person for indirect, special, incidental, consequential or punitive damages (as opposed to direct or actual damages).
13.3.    No Waiver; Cumulative Remedies
. No failure to exercise and no delay in exercising, on the part of the Administrative Agent or any Lender, any right, remedy, power or privilege hereunder or under the other Loan Documents shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.
13.4.    Survival of Representations and Warranties
    - 97 -


. All representations and warranties made hereunder, in the other Loan Documents and in any document, certificate or statement delivered pursuant hereto or in connection herewith shall survive the execution and delivery of this Agreement and the making of the Loans hereunder.
13.5.    Payment of Expenses and Taxes
. The Borrower agrees (a) to pay or reimburse each of the Arrangers and the Administrative Agent for all their reasonable and documented out-of-pocket costs and expenses incurred in connection with the development, preparation and execution of, and any amendment, supplement or modification to, this Agreement and the other Loan Documents and any other documents prepared in connection herewith or therewith, and the consummation and administration of the transactions contemplated hereby and thereby, including, without limitation, the reasonable and documented fees and disbursements of outside counsel (including one local counsel in each applicable jurisdiction) to the Administrative Agent and the Arrangers, (b) to pay or reimburse each Lender, each Issuing Lender, the Arrangers and the Administrative Agent for all its costs and expenses incurred in connection with the enforcement or preservation of any rights under this Agreement, the other Loan Documents and any such other documents, including, without limitation, the documented fees and disbursements of counsel (including the allocated fees and expenses of in house counsel) to each Lender and Issuing Lender and of counsel to the Administrative Agent and the Arrangers, provided, that in connection with any workout or restructuring, the Borrower shall pay the fees and disbursements of (i) one U.S. counsel for the Administrative Agent, the Arrangers, the Issuing Lenders and the Lenders pursuant to this clause (b) and (ii) one counsel to the Administrative Agent, the Arrangers, the Issuing Lenders and the Lenders in the jurisdiction of each Foreign Subsidiary Borrower pursuant to this clause (b), and, in the case of an actual or perceived conflict of interest where the indemnified party affected by such conflict informs the Borrower of such conflict and thereafter, retains its own counsel, of another firm of counsel for such affected indemnified party, (c) to pay, indemnify, and hold each Lender, each Issuing Lender and the Administrative Agent and each of their affiliates and their respective officer, directors, employees, agents and advisors (each, an “indemnified party”) harmless from, any and all recording and filing fees and any and all liabilities with respect to, or resulting from any delay in paying, stamp, excise and other similar taxes, if any, which may be payable or determined to be payable in connection with the execution and delivery of, or consummation or administration of any of the transactions contemplated by, or any amendment, supplement or modification of, or any waiver or consent under or in respect of, this Agreement, the other Loan Documents and any such other documents, and (d) to pay, indemnify, and hold each indemnified party harmless from and against any and all other liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever incurred by any indemnified party or asserted against any indemnified party by any third party or by the Borrower or any of its Subsidiaries arising out of, in connection with or as a result of the Transactions (or any transactions related thereto), or the execution, delivery, enforcement, performance and administration of this Agreement, the other Loan Documents and such other documents, including, without limitation, any of the foregoing relating to the violation of, noncompliance with or liability under, any Environmental Law applicable to the operations of the Borrower, any of its Subsidiaries or any of the Properties (all the foregoing in this clause (d), collectively, the “indemnified liabilities”), provided that the Borrower shall have no obligation hereunder to any indemnified party with respect to indemnified liabilities arising from the gross negligence or willful misconduct of such indemnified party determined in a court of competent jurisdiction in a final non-appealable judgment. The agreements in this subsection shall survive repayment of the Loans and all other amounts payable hereunder and the termination of this Agreement.
13.6.    Successors and Assigns; Participations and Assignments
    - 98 -


.
(a)    This Agreement shall be binding upon and inure to the benefit of the Borrower, the Lenders, the Administrative Agent and their respective successors and assigns, except that the Borrower may not assign or transfer any of its rights or obligations under this Agreement without the prior written consent of each Lender.
(b)    Any Lender, other than a Conduit Lender, may, in the ordinary course of its commercial banking business and in accordance with applicable law, at any time sell to one or more banks or other entities (other than a Defaulting Lender, the Borrower or its Affiliates or Subsidiaries or any natural Person) (“Participants”) participating interests in any Loan owing to such Lender, any Commitment of such Lender or any other interest of such Lender hereunder and under the other Loan Documents. In the event of any such sale by a Lender of a participating interest to a Participant, such Lender’s obligations under this Agreement to the other parties to this Agreement shall remain unchanged, such Lender shall remain solely responsible for the performance thereof, such Lender shall remain the holder of any such Loan for all purposes under this Agreement and the other Loan Documents, and the Borrower and the Administrative Agent shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement and the other Loan Documents. No Lender shall be entitled to create in favor of any Participant, in the participation agreement pursuant to which such Participant’s participating interest shall be created or otherwise, any right to vote on, consent to or approve any matter relating to this Agreement or any other Loan Document except for those specified in clauses (i) and (ii) of the proviso to subsection 13.1(a). The Borrower agrees that if amounts outstanding under this Agreement are due or unpaid, or shall have been declared or shall have become due and payable upon the occurrence of an Event of Default, each Participant shall, to the maximum extent permitted by applicable law, be deemed to have the right of set-off in respect of its participating interest in amounts owing under this Agreement to the same extent as if the amount of its participating interest were owing directly to it as a Lender under this Agreement, provided that, in purchasing such participating interest, such Participant shall be deemed to have agreed to share with the Lenders the proceeds thereof as provided in subsection 13.7(a) as fully as if it were a Lender hereunder. The Borrower also agrees that each Participant shall be entitled to the benefits of subsections 3.9, 3.10 and 3.11 with respect to its participation in the Commitments and the Loans outstanding from time to time as if it was a Lender; provided that, in the case of subsection 3.10, such Participant shall have complied with the requirements of said subsection, and provided, further, that no Participant shall be entitled to receive any greater amount pursuant to any such subsection than the transferor Lender would have been entitled to receive in respect of the amount of the participation transferred by such transferor Lender to such Participant had no such transfer occurred. Each Lender that sells a participation, acting solely for this purpose as a non-fiduciary agent of the Borrower, shall maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under this Agreement (the “Participant Register”); provided, that no Lender shall have any obligation to disclose all or any portion of the Participant Register to any Person (including the identity of any Participant or any information relating to a Participant’s interest in any Commitments, Loans or its other Obligations under any Loan Document) except to the extent that such disclosure is necessary to establish that such Commitment, Loan or other Obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender, the Borrower and the Administrative Agent shall treat each person whose name is recorded in the Participant Register pursuant to the terms hereof as the owner of such participation for all purposes of this Agreement, notwithstanding notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.
    - 99 -


(c)    Any Lender, other than a Conduit Lender, may, in the ordinary course of its commercial banking business and in accordance with applicable law, at any time and from time to time, assign (i) to any Lender or any Lender Affiliate with the consent (in each case, not to be unreasonably withheld, delayed or conditioned) of the Administrative Agent and the Issuing Lender (in the case of assignments of Revolving Commitments) or (ii) with the consent of the Borrower (unless an Event of Default shall have occurred and be continuing), the Administrative Agent and Issuing Lender (which consent in each case shall not be unreasonably withheld, delayed or conditioned), to an additional bank, financial institution, or other entity (an “Assignee”) all or any part of its rights and obligations under this Agreement and the other Loan Documents pursuant to an Assignment and Assumption, substantially in the form of Exhibit H, executed by such Assignee, such assigning Lender (and, in the case of an Assignee that is not a Lender or a Lender Affiliate, by the Administrative Agent and the Issuing Lender) and delivered to the Administrative Agent for its acceptance and recording in the Register, provided that, except in the case of an assignment to a Lender or a Lender Affiliate or an assignment of the entire remaining amount of the assigning Lender’s Commitments or Loans, the amount of the Commitments or Loans of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent) shall not be less than $5,000,000 (or such lesser amount as may be agreed to by the Borrower and the Administrative Agent), and provided further that no such assignment shall be made to (A) any Defaulting Lender or any of its Subsidiaries, (B) the Borrower or any of its Affiliates or Subsidiaries or (C) any natural person. Upon such execution, delivery, acceptance and recording, from and after the effective date determined pursuant to such Assignment and Assumption, (x) the Assignee thereunder shall be a party hereto and, to the extent provided in such Assignment and Assumption, have the rights and obligations of a Lender hereunder with Commitments as set forth therein, and (y) the assigning Lender thereunder shall, to the extent provided in such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all or the remaining portion of an assigning Lender’s rights and obligations under this Agreement, such assigning Lender shall cease to be a party hereto but shall continue to be entitled to the indemnity and expense reimbursement provisions in the Loan Documents arising out of the period prior to the assignment). Each assignment by a Lender of any portion of its Revolving Credit Commitment shall be accompanied by assignment by such Lender to the same Assignee of the same percentage of such Lender’s Multicurrency Commitment. Notwithstanding the foregoing, any Conduit Lender may assign at any time to its designating Lender hereunder without the consent of the Borrower or the Administrative Agent any or all of the Loans it may have funded hereunder and pursuant to its designation agreement and without regard to the limitations set forth in the first sentence of this subsection 13.6(c).
(d)    The Administrative Agent, acting solely for this purpose as a non-fiduciary agent of the Borrower, shall maintain at the address of the Administrative Agent referred to in subsection 13.2 a copy of each Assignment and Assumption delivered to it and a register (the “Register”) for the recordation of the names and addresses of the Lenders and the Commitments of, and principal amount (and stated interest) of the Loans owing to, each Lender from time to time. The entries in the Register shall be conclusive, in the absence of manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register as the owner of a Loan or other obligation hereunder as the owner thereof for all purposes of this Agreement and the other Loan Documents, notwithstanding any notice to the contrary. Any assignment of any Loan or other obligation hereunder not evidenced by a Note shall be effective only upon appropriate entries with respect thereto being made in the Register. In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender. The Register shall be available for inspection by the Borrower or any Lender at any reasonable time and from time to time upon reasonable prior notice.
    - 100 -


(e)    Upon its receipt of an Assignment and Assumption executed by an assigning Lender and an Assignee (and, in the case of an Assignee that is not then a Lender or a Lender Affiliate, by the Borrower (if required) and the Administrative Agent) together with payment to the Administrative Agent of a registration and processing fee of $4,000, the Administrative Agent shall (i) promptly accept such Assignment and Assumption and (ii) on the effective date determined pursuant thereto record the information contained therein in the Register and give notice of such acceptance and recordation to the Lenders and the Borrower; provided that the Administrative Agent may, in its sole discretion, elect to waive such registration and processing fee in the case of any assignment.
(f)    The Borrower authorizes each Lender to disclose to any Participant or Assignee (each, a “Transferee”) and any prospective Transferee, subject to the provisions of subsection 13.14, any and all financial information in such Lender’s possession concerning the Borrower and its Affiliates which has been delivered to such Lender by or on behalf of the Borrower pursuant to this Agreement or which has been delivered to such Lender by or on behalf of the Borrower in connection with such Lender’s credit evaluation of the Borrower and its Affiliates prior to becoming a party to this Agreement.
(g)    Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank or any central bank having jurisdiction over such Lender in accordance with applicable law; provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.
(h)    In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall (unless otherwise agreed by the Borrower and the Administrative Agent) be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full pro rata share of all applicable Loans and participations in Letters of Credit in accordance with its Revolving Credit Commitment Percentage. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs.
13.7.    Adjustments; Set-off
.
(a)    If any Lender (a “benefited Lender”) shall at any time receive any payment of all or part of its Loans or the Reimbursement Obligations owing to it (or any participation therein arising pursuant to subsection 13.15) then due and owing, or interest thereon, or receive any collateral in respect thereof (whether voluntarily or involuntarily, by set-off, pursuant to events or proceedings of the nature referred to in subsection 10(g), or otherwise), in a greater proportion than any such payment to or collateral
    - 101 -


received by any other Lender (other than to the extent expressly provided herein or by court order), if any, in respect of such other Lender’s Loans or the Reimbursement Obligations owing to it (or any participation therein arising pursuant to subsection 13.15) then due and owing, or interest thereon, such benefited Lender shall purchase for cash from the other Lenders a participating interest in such portion of each such other Lender’s Loans or the Reimbursement Obligations owing to it, or shall provide such other Lenders with the benefits of any such collateral, or the proceeds thereof, as shall be necessary to cause such benefited Lender to share the excess payment or benefits of such collateral or proceeds ratably with each of the Lenders; provided, however, that if all or any portion of such excess payment or benefits is thereafter recovered from such benefited Lender, such purchase shall be rescinded, and the purchase price and benefits returned, to the extent of such recovery, but without interest; and provided further that in the event that any Defaulting Lender shall exercise any such right of setoff, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of subsection 2.19 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders, and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff.
(b)    In addition to any rights and remedies of the Lenders provided by law, each Lender shall have the right, without prior notice to the Borrower, any such notice being expressly waived by the Borrower to the extent permitted by applicable law, upon any amount becoming due and payable by the Borrower hereunder (whether at the stated maturity, by acceleration or otherwise) to set-off and appropriate and apply against such amount any and all deposits (general or special, time or demand, provisional or final), in any currency, and any other credits, indebtedness or claims, in any currency, in each case whether direct or indirect, absolute or contingent, matured or unmatured, at any time held or owing by such Lender or any Affiliate, branch or agency thereof to or for the credit or the account of the Borrower. Each Lender agrees promptly to notify the Borrower and the Administrative Agent after any such set-off and application made by such Lender, provided that the failure to give such notice shall not affect the validity of such set-off and application.
13.8.    Counterparts
. This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by facsimile transmission or in electronic (i.e., “pdf” or “tif”) format), and all of said counterparts taken together shall be deemed to constitute one and the same instrument. A set of the copies of this Agreement signed by all the parties shall be lodged with the Borrower and the Administrative Agent.
13.9.    Severability
. Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. Without limiting the foregoing provisions of this Section 13.9, if and to the extent that the enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by Debtor Relief Laws or a Bail-In Action, as determined in good faith by the Administrative Agent or the Issuing Lender, as applicable, then such provisions shall be deemed to be in effect only to the extent not so limited.
    - 102 -


13.10.    Integration
. This Agreement and the other Loan Documents represent the agreement of the Borrower, the Administrative Agent and the Lenders with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by the Administrative Agent or any Lender relative to subject matter hereof not expressly set forth or referred to herein or in the other Loan Documents.
13.11.    GOVERNING LAW
. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDERAND ANY CLAIM, CONTROVERSY, DISPUTE, PROCEEDING OR CAUSE OF ACTION (WHETHER IN CONTRACT, TORT OR OTHERWISE AND WHETHER AT LAW OR IN EQUITY) BASED UPON, ARISING OUT OF OR RELATING TO THIS AMENDMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.
13.12.    Submission To Jurisdiction and Waivers
. The Borrower hereby irrevocably and unconditionally:
(a)    submits for itself and its property in any legal action or proceeding (whether in contract, tort or otherwise and whether at law or in equity) relating to this Agreement and the other Loan Documents to which it is a party, or for recognition and enforcement of any judgment in respect thereof, to the exclusive general jurisdiction of the Courts of the State of New York sitting in New York County, Borough of Manhattan, the courts of the United States of America for the Southern District of New York, and appellate courts from any thereof;
(b)    consents that any such action or proceeding may be brought in such courts and waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same;
(c)    agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or any substantially similar form of mail), postage prepaid, to the Borrower at its address set forth in subsection 13.2 or at such other address of which the Administrative Agent shall have been notified pursuant thereto;
(d)    agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right to sue in any other jurisdiction; and
(e)    waives, to the maximum extent not prohibited by law, any right it may have to claim or recover in any legal action or proceeding referred to in this subsection any special, exemplary, punitive or consequential damages.
13.13.    Acknowledgements
. The Borrower hereby acknowledges that:
    - 103 -


(a)    it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Loan Documents;
(b)    neither the Administrative Agent nor any Lender has any fiduciary relationship with or duty to the Borrower arising out of or in connection with this Agreement or any of the other Loan Documents, and the relationship between the Administrative Agent and Lenders, on the one hand, and the Borrower, on the other hand, in connection herewith or therewith is solely that of debtor and creditor; and
(c)    no joint venture is created hereby or by the other Loan Documents or otherwise exists by virtue of the transactions contemplated hereby among the Lenders or among the Borrower and the Lenders.
13.14.    Confidentiality
. Each Lender agrees to keep confidential any Information (a) provided to it by or on behalf of the Borrower or any of its Subsidiaries pursuant to or in connection with this Agreement or (b) obtained by such Lender based on a review of the books and records of the Borrower or any of its Subsidiaries; provided that nothing herein shall prevent any Lender from disclosing any such Information (i) to the Administrative Agent, the Issuing Lender or any other Lender, (ii) to any Transferee or prospective Transferee which receives such Information having been made aware of the confidential nature thereof and having agreed to abide by the provisions of this subsection 13.14, (iii) to its employees, directors, agents, attorneys, accountants and other professional advisors, and to its and its Affiliates’ respective employees, officers, directors, agents, attorneys, accountants and other professional advisors who are directed to be bound by the provisions of this subsection 13.14 and who have a need for such Information in connection with this Agreement or other transactions or proposed transactions with the Borrower, (iv) upon the request or demand of any self-regulatory authority or any Governmental Authority having jurisdiction or oversight over such Lender or in connection with any assignment or pledge permitted under subsection 13.6(g), (v) in response to any order of any court, any self-regulatory authority or other Governmental Authority or as may otherwise be required pursuant to any Requirement of Law, (vi) subject to an agreement to comply with the provisions of this subsection, to any actual or prospective counter-party (or its advisors) to any Hedge Agreement, (vii) which has been publicly disclosed other than in breach of this Agreement, (viii) in connection with the exercise of any remedy hereunder, or (ix) with the written consent of either a Responsible Officer or the treasurer of the Borrower. or (x) to the extent required by a potential or actual insurer or reinsurer in connection with providing insurance, reinsurance or credit risk mitigation coverage under which payments are to be made or may be made by reference to this Agreement.
For purposes of this Section, “Information” means all information received from either Borrower or any Subsidiary relating to either Borrower or any Subsidiary or any of their respective businesses, other than any such information that is available to the Administrative Agent, any Lender or the Issuing Lender on a nonconfidential basis prior to disclosure by the Borrower or any Subsidiary and other than information pertaining to this Agreement routinely provided by arrangers to data service providers, including league table providers, that serve the lending industry, provided that, in the case of information received from the Borrower or any Subsidiary after the date hereof, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.
    - 104 -


Each of the Administrative Agent, the Lenders and the Issuing Lender acknowledges that (a) the Information may include material non-public information concerning the Borrower or a Subsidiary, as the case may be, (b) it has developed compliance procedures regarding the use of material non-public information and (c) it will handle such material non-public information in accordance with applicable Law, including Federal and state securities laws.
13.15.    Loan Conversion/Participations
.
(a)    (i) On any Conversion Date, to the extent not otherwise prohibited by a Requirement of Law or otherwise, all Loans (other than CAF Advances) outstanding in any currency other than Dollars (“Loans to be Converted”) shall be converted into Revolving Credit Loans denominated in Dollars (calculated on the basis of the relevant Exchange Rates as of the Business Day immediately preceding the Conversion Date) (“Converted Loans”) and (ii) on the Conversion Date (A) each Lender severally, unconditionally and irrevocably agrees that it shall purchase in Dollars a participating interest in such Converted Loans in an amount equal to its Conversion Sharing Percentage of the outstanding principal amount of the Converted Loans and (B) to the extent necessary to cause the Committed Outstandings Percentage of each Lender to equal its Revolving Credit Commitment Percentage (calculated immediately prior to the termination or expiration of the Revolving Credit Commitments), each Lender severally, unconditionally and irrevocably agrees that it shall purchase or sell a participating interest in Revolving Credit Loans then outstanding. Each Lender will immediately transfer to the Administrative Agent, in immediately available funds, the amounts of its participation(s), and the proceeds of such participation(s) shall be distributed by the Administrative Agent to each Lender from which a participating interest is being purchased in the amount(s) provided for in the preceding sentence. All Converted Loans shall bear interest at the rate which would otherwise be applicable to ABR Loans.
(b)    If, for any reason, the Loans to be Converted may not be converted into Dollars in the manner contemplated by paragraph (a) of this subsection 13.15, (i) effective on such Conversion Date, each Lender severally, unconditionally and irrevocably agrees that it shall purchase a participating interest in such Loans to be Converted, as the case may be, in an amount equal to its Conversion Sharing Percentage of such Loans to be Converted, and (ii) each Lender shall purchase or sell participating interests as provided in paragraph (a)(ii)(B) of this subsection 13.15. Each such Lender will immediately transfer to the appropriate Administrative Agent, in immediately available funds, the amount(s) of its participation(s), and the proceeds of such participation(s) shall be distributed by the Administrative Agent to each relevant Lender in the amount(s) provided for in the preceding sentence.
(c)    To the extent any Non-Excluded Taxes are required to be withheld from any amounts payable by a Lender to another Lender in connection with its participating interest in any Converted Loan, the Borrower shall be required to pay increased amounts to the Lender receiving such payments to the same extent they would be required under subsection 3.10 if the Borrower were making payments directly to such Lender.
(d)    Any time when the actions contemplated by paragraph (a) or (b) of this subsection 13.15 have been taken, upon the notice of any Lender to the Borrower the following shall occur (which notice shall not be required to be declared at any time an Event of Default under subsection 10(g) has occurred): (i) the Borrower (through the guarantee contained in Section 12) shall automatically be deemed to have assumed the Local Currency Loans which are Converted Loans in which such Lender holds a participation, and (ii) such Local Currency Loans shall be assigned by the relevant Lender holding such
    - 105 -


Local Currency Loans or obligations to the Lender who gave the notice requesting such assumption by the Borrower.
(e)    If a Defaulting Lender exists on the Conversion Date, the Administrative Agent may, in consultation with one or more other Revolving Lenders which are not Defaulting Lenders, revise this subsection 13.15 and related definitions in order to allocate payments for the benefit of such Defaulting Lender in a manner consistent with subsection 2.19.
13.16.    Judgment
.
(a)    If for the purpose of obtaining judgment in any court it is necessary to convert a sum due hereunder in one currency into another currency, the parties hereto agree, to the fullest extent that they may effectively do so, that the rate of exchange used shall be that at which in accordance with normal banking procedures the Administrative Agent could purchase the first currency with such other currency in the city in which it normally conducts its foreign exchange operation for the first currency on the Business Day preceding the day on which final judgment is given.
(b)    The obligation of the Borrower in respect of any sum due from it to any Lender hereunder shall, notwithstanding any judgment in a currency (the “Judgment Currency”) other than that in which such sum is denominated in accordance with the applicable provisions of this Agreement (the “Agreement Currency”), be discharged only to the extent that on the Business Day following receipt by such Lender of any sum adjudged to be so due in the Judgment Currency such Lender may in accordance with normal banking procedures purchase the Agreement Currency with the Judgment Currency; if the amount of Agreement Currency so purchased is less than the sum originally due to such Lender in the Agreement Currency, the Borrower agrees notwithstanding any such judgment to indemnify such Lender against such loss, and if the amount of the Agreement Currency so purchased exceeds the sum originally due to any Lender, such Lender agrees to remit to the Borrower such excess.
13.17.     WAIVERS OF JURY TRIAL
. THE BORROWER, THE ADMINISTRATIVE AGENT AND THE LENDERS HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING (WHETHER IN CONTRACT, TORT OR OTHERWISE AND WHETHER AT LAW OR IN EQUITY) RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AND FOR ANY COUNTERCLAIM THEREIN.
13.18.    USA Patriot Act Notice
. Each Lender that is subject to the requirements of the Patriot Act and the requirements of the Beneficial Ownership Regulation and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrower that pursuant to the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Patriot Act”) and the requirements of the Beneficial Ownership Regulation, it is required to obtain, verify and record information that identifies the Borrower and each Foreign Subsidiary Borrower, which information includes the name and address of the Borrower and each Foreign Subsidiary Borrower and other information that will allow such Lender or the Administrative Agent, as applicable, to identify the Borrower and each Foreign Subsidiary Borrower in accordance with the Patriot Act and the Beneficial Ownership Regulation.
    - 106 -


13.19.    No Advisory or Fiduciary Responsibility
. In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification hereof or of any other Loan Document), the Borrower acknowledges and agrees, and acknowledges its Affiliates’ understanding, that: (a) (i) the arranging and other services regarding this Agreement provided by the Administrative Agent and the Arrangers are arm’s-length commercial transactions between the Borrower and its Affiliates, on the one hand, and the Administrative Agent and the Arrangers, on the other hand, (ii) the Borrower has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (iii) the Borrower is capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents; (b) (i) the Administrative Agent and the Arrangers each is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary for the Borrower or any of its respective Affiliates, or any other Person and (ii) neither the Administrative Agent nor the Arrangers has any obligation to the Borrower or any of its respective Affiliates with respect to the transactions contemplated hereby except those obligations expressly set forth herein and in the other Loan Documents; and (c) the Administrative Agent and the Arrangers and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Borrower and its Affiliates, and neither the Administrative Agent nor the Arrangers has any obligation to disclose any of such interests to the Borrower or any of its Affiliates.
13.20.    Acknowledgement and Consent to Bail-In of Affected Financial Institutions
. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:
(a)    the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and
(b)    the effects of any Bail-In Action on any such liability, including, if applicable:
(i)    a reduction in full or in part or cancellation of any such liability;
(ii)    a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or
(iii)    the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution Authority.
13.21.    Acknowledgement Regarding Any Supported QFCs
. To the extent that the Loan Documents provide support, through a guarantee or otherwise, for Hedge Agreements or any other agreement or instrument that is a QFC (such support, “QFC Credit
    - 107 -


Support” and, each such QFC, a “Supported QFC”), the parties acknowledge and agree as follows with respect to the resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the “U.S. Special Resolution Regimes”) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States):
(a)    In the event a Covered Entity that is party to a Supported QFC (each, a “Covered Party”) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support.
(b)    As used in this Section 13.21, the following terms have the following meanings:
BHC Act Affiliate” of a party means an “affiliate” (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.
Covered Entity” means any of the following:
(i)    a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
(ii)    a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or
(iii)    a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).
Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.
QFC” has the meaning assigned to the term “qualified financial contract” in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D).     

[Signature Pages Follow]
    - 108 -



    - 109 -


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the day and year first above written.
BOSTON SCIENTIFIC CORPORATION



By:    _______________________________
Name:    
Title:    

Signature Page to
Boston Scientific Credit Agreement


WELLS FARGO BANK, NATIONAL ASSOCIATION,
as Administrative Agent



By: ________________________________
Name:    
Title:    
WELLS FARGO BANK, NATIONAL ASSOCIATION,
as a Lender



By:
            
Name:    
Title:    

Signature Page to
Boston Scientific Credit Agreement



Insert Lender’s Name, as a Lender [and as an Issuing Lender]



By:    _______________________________
Name:    
Title:    
Signature Page to
Boston Scientific Credit Agreement


SCHEDULE I
NAMES AND COMMITMENTS OF LENDERS
NameRevolving Credit CommitmentMulticurrency CommitmentIssuing Lender Commitment
Wells Fargo Bank, National Association
$275,000,000317,000,000
$80,000,00092,240,000
$83,333,333
Bank of America, N.A.
$275,000,000317,000,000
$80,000,00092,240,000
$83,333,333
Barclays Bank PLC
$275,000,000317,000,000
$80,000,00092,240,000
$83,333,333
Citibank, N.A.
$275,000,000317,000,000
$80,000,00092,240,000
$83,333,333
JPMorgan Chase Bank, N.A.
$275,000,000317,000,000
$80,000,00092,240,000
$83,333,333
Société Générale
$275,000,000317,000,000
$80,000,00092,240,000
$83,333,333
BNP Paribas$115,000,000$33,440,000
DNB Capital LLCDeutsche Bank AG New York Branch
$115,000,000$33,440,000
Goldman Sachs Bank USA$115,000,000$33,440,000
MUFGRoyal Bank, Ltd. of Canada
$115,000,000$33,440,000
RoyalStandard Chartered Bank of Canada
$115,000,000$33,440,000
The Bank of Nova Scotia$115,000,000$33,440,000
The Toronto-Dominion Bank, New York Branch$115,000,000$33,440,000
U.S Bank National Association$115,000,000$33,440,000
Allied IrishMUFG Banks, p.l.c, Ltd.
$45,000,00043,000,000
$13,120,00012,480,000
Deutsche Bank AG New York Branch$45,000,000$13,120,000
Intesa Sanpaolo S.p.A., New York Branch$45,000,000$13,120,000
Standard Chartered Bank$45,000,000$13,120,000
Total$2,750,000,000$800,000,000$500,000,000











EX-31.1 3 exhibit311-ceo302q22024.htm EX-31.1 Document

EXHIBIT 31.1
 
CERTIFICATIONS
 
I, Michael F. Mahoney, certify that:
1I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation;
2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:August 1, 2024 /s/ Michael F. Mahoney
  Michael F. Mahoney
  Chief Executive Officer

EX-31.2 4 exhibit312-cfo302q22024.htm EX-31.2 Document

EXHIBIT 31.2
 
CERTIFICATIONS
 
I, Daniel J. Brennan, certify that:


1I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation;
2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:August 1, 2024 /s/ Daniel J. Brennan
  Daniel J. Brennan
  Executive Vice President and Chief Financial Officer

EX-32.1 5 exhibit321-ceo906q22024.htm EX-32.1 Document

EXHIBIT 32.1
 
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Boston Scientific Corporation (the “Company”) for the period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 (1)   the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.
   
By:/s/ Michael F. Mahoney
 Michael F. Mahoney 
 Chief Executive Officer 
   
 August 1, 2024 
 


EX-32.2 6 exhibit322-cfo906q22024.htm EX-32.2 Document

EXHIBIT 32.2
 
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Boston Scientific Corporation (the “Company”) for the period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 (1)   the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.

   
By:/s/ Daniel J. Brennan
 Daniel J. Brennan 
 Executive Vice President and Chief Financial Officer 
   
 August 1, 2024 

EX-101.SCH 7 bsx-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Acquisitions, Divestitures and Strategic Investments link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Hedging Activities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Contractual Obligations and Commitments link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Weighted Average Shares Outstanding link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Changes in Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Acquisitions, Divestitures and Strategic Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Contractual Obligations and Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Weighted Average Shares Outstanding (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Changes in Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Assets and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Intangible Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Level 3 Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Hedging Activities and Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Hedging Activities and Fair Value Measurements - Notional Amounts (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Hedging Activities and Fair Value Measurements - Effect of Hedging Relationships on Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Hedging Activities and Fair Value Measurements - Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Hedging Activities and Fair Value Measurements - Location on Unaudited Consolidated Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Hedging Activities and Fair Value Measurements - Balance Sheet Location (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Hedging Activities and Fair Value Measurements - Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Hedging Activities and Fair Value Measurements - Licensing Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Hedging Activities and Fair Value Measurements - Change in Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Contractual Obligations and Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Weighted Average Shares Outstanding - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Revenue - Revenue by Geography (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 bsx-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 bsx-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 bsx-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Amount excluded from debt in leverage ratio Amount excluded from debt in leverage ratio Amount excluded from debt in leverage ratio Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax Pay vs Performance Disclosure [Line Items] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued expenses Accrued Liabilities, Current Accrued Liabilities, Current Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Range [Domain] Statistical Measurement [Domain] Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Preferred stock dividends Dividends, Preferred Stock, Stock Underlying Security Market Price Change Underlying Security Market Price Change, Percent Joseph M. Fitzgerald [Member] Joseph M. Fitzgerald Licensing Arrangements Accrued Royalties, Current Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Preferred Stock, Liquidation Preference Per Share Preferred Stock, Liquidation Preference Per Share All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Payments on short-term borrowings Repayments of Short-Term Debt Estimated Litigation Liability, Noncurrent Estimated Litigation Liability, Noncurrent the Offering the Offering - aggregate principal amount [Member] the Offering - aggregate principal amount CONTRACTUAL OBLIGATIONS AND COMMITMENTS Debt Disclosure [Text Block] Intangible asset impairment charges Impairment of Intangible Assets (Excluding Goodwill) Other Current Liabilities [Member] Other Current Liabilities [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Watchman Watchman [Member] Watchman Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Effect of foreign exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Deferred income taxes Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Restatement Determination Date: Restatement Determination Date [Axis] Derivatives Not Designated as Hedging Derivatives Not Designated as Hedging Instruments [Table Text Block] Other expense, net Nonoperating Income (Expense) Commitments and contingencies Commitments and Contingencies Goodwill and other intangible asset impairment charges Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Insider Trading Policies and Procedures [Line Items] Capital in progress Construction in Progress, Gross Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Derivative Asset, Current Derivative Asset, Current Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Deferred Revenue, Current Deferred Revenue, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] STOCKHOLDERS' EQUITY Equity [Text Block] Accrued expenses Accrued Liabilities, Current [Abstract] Schedule of Intangible Assets and Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans Proceeds from Stock Plans INCOME TAXES Income Tax Disclosure [Text Block] Other Accrued Liabilities, Noncurrent Other Accrued Liabilities, Noncurrent Ownership [Axis] Ownership [Axis] Other Current Assets [Abstract] Other Current Assets [Abstract] Other Current Assets [Abstract] Other Assets, Miscellaneous, Current Other Assets, Miscellaneous, Current Number of Interest Rate Derivatives Held Number of Interest Rate Derivatives Held Restricted cash equivalents included in Other long-term assets Restricted Cash Equivalents, Noncurrent Current liabilities: Liabilities, Current [Abstract] Qualified Acquisition Consideration Qualified Acquisition Consideration Qualified Acquisition Consideration Contingent consideration payments and other adjustments Payment of contingent consideration Payment of contingent consideration Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss AMS Europe AMS Europe [Member] AMS Europe Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of June 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Actual, Covenant [Member] Actual, Covenant [Member] Actual Covenant. Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Inventories Inventory, Net [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] MedSurg MedSurg [Member] MedSurg [Member] Payment of contingent consideration previously established in purchase accounting Payment for Contingent Consideration Liability, Financing Activities Net income (loss) per common share — diluted Earnings Per Share, Diluted Derivative Liability, Fair Value, Gross Liability Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Treasury stock, at cost - 263,289,848 shares as of June 30, 2024 and December 31, 2023 Treasury Stock, Value Land Land Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Goodwill [Roll Forward] Goodwill [Roll Forward] 0.625% Senior Notes due 2027 Senior Note due 2027 [Member] Senior Note due 2027 [Member] Business Acquisition, Share Price Business Acquisition, Share Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Treasury Stock, Common, Shares Treasury Stock, Common, Shares Other income (expense): Other Nonoperating Income (Expense) [Abstract] Trading Symbol Trading Symbol Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Schedule of Other Current Assets Schedule of Other Current Assets [Table Text Block] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Net Income (Loss) Net Income (Loss) Attributable to Parent Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Notional Amounts of Outstanding Derivative Positions Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Licensing arrangements Licensing arrangements Licensing arrangements Company Selected Measure Name Company Selected Measure Name Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Total debt Debt and Lease Obligation Cardiovascular Cardiovascular [Member] Cardiovascular [Member] Beginning Balance (Shares Issued) Ending Balance (Shares Issued) Shares, Issued LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Business Combination, Contingent Consideration, Liability [Roll Forward] Business Combination, Contingent Consideration, Liability [Roll Forward] Business Combination, Contingent Consideration, Liability Prepaid income taxes Prepaid Taxes Conversion of mandatory convertible preferred stock to common stock Stockholders' Equity, Period Increase (Decrease) Stockholders’ equity Equity, Attributable to Parent [Abstract] Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Contract with Customer, Liability Contract with Customer, Liability Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other intangible assets Other Intangible Assets [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Cost of products sold Cost of Goods and Services Sold Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Derivative, Remaining Maturity Derivative, Remaining Maturity Executive Category: Executive Category [Axis] Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] Schedule of Weighted Average Number of Shares Schedule of Weighted Average Number of Shares [Table Text Block] Urology [Member] Global Urology and Pelvic Health Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Peripheral Interventions [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Name Measure Name Patents Patents [Member] Name Forgone Recovery, Individual Name Goodwill Goodwill Beginning Balance Goodwill Ending Balance Goodwill Property, plant and equipment, net Property, Plant and Equipment [Table Text Block] Statement, Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Buildings and improvements Buildings and Improvements, Gross Hedging Relationship [Domain] Hedging Relationship [Domain] Apollo Apollo [Member] Apollo Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] CHANGES IN OTHER COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Trade accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Covenant [Axis] Covenant [Axis] Covenant. Legal Costs Legal Costs, Policy [Policy Text Block] Corporate expenses and currency exchange [Member] Corporate Expenses including hedging activities [Member] Corporate Expenses including hedging activities [Member] Derivative, Notional Amount Derivative, Notional Amount Measurement Frequency [Axis] Measurement Frequency [Axis] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Restricted cash and restricted cash equivalents included in Other current assets Restricted Cash and Cash Equivalents in Other current assets Restricted Cash and Cash Equivalents, Current March 2028 Notes [Member] March 2028 Notes [Member] March 2028 Notes [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation Depreciation Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Interventional Cardiology Therapies Interventional Cardiology Therapies [Member] Interventional Cardiology Therapies Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Changes to noncontrolling ownership interest Noncontrolling Interest, Period Increase (Decrease) Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Litigation payment exclusion from EBITDA Litigation payment exclusion from EBITDA Litigation payment exclusion from EBITDA Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Net effect of common stock equivalents Weighted Average Number of Shares Outstanding, Diluted, Adjustment Foreign Exchange Forward Foreign Exchange Forward [Member] Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Number Of Businesses Number Of Businesses Number Of Businesses Licensing arrangement liabilities [Member] Licensing arrangement liabilities [Member] Licensing arrangement liabilities [Member] Other Assets, Noncurrent [Abstract] Other Assets, Noncurrent [Abstract] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Rule Trading Arrangement Stock Appreciation Right [Member] Rule Trading Arrangement Stock Appreciation Right Product and Service [Domain] Product and Service [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Inventory step-up amortization Inventory step up amortization Inventory step up amortization Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Cash used to net share settle employee equity awards Payment to net share settle employee equity awards Payment to net share settle employee equity awards Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] contingent consideration liability, probability of payment contingent consideration liability, probability of payment contingent consideration liability, probability of payment Award Type Award Type [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Property, plant and equipment Property, Plant and Equipment, Gross Payments for Royalties Payments for Royalties Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Indemnification asset Indemnification asset Indemnification asset PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Covenant [Domain] Covenant [Domain] Covenant. Cardiology [Member] Global Cardiology Reporting Unit [Member] Global Cardiology Reporting Unit [Member] Derivative, Term of Contract (less than) Derivative, Term of Contract Schedule of Other Assets Schedule of Other Assets [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Amortization expense Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company Fair value of noncontrolling interest Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Average interest rate of de-recognized receivables Receivable with Imputed Interest, Effective Yield (Interest Rate) New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Fair value adjustment (expense) benefit Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Class of Stock Disclosures [Abstract] Class of Stock Disclosures [Abstract] Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization/ Write-offs Finite-Lived Intangible Assets, Accumulated Amortization Axonics Axonics [Member] Axonics Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure Subsequent Events Subsequent Events, Policy [Policy Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] foreign currency denominated in debt [Member] foreign currency denominated in debt [Member] foreign currency denominated in debt [Member] Common Stock, Shares, Issued Beginning Balance (Shares) Ending Balance (Shares) Common Stock, Shares, Issued Gross profit Gross Profit Security Exchange Name Security Exchange Name Assets, Fair Value Disclosure Assets, Fair Value Disclosure Long-term Debt Long-Term Debt Selling, general and administrative expenses Selling, General and Administrative Expense Accumulated other comprehensive income (loss), net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Maximum Maximum [Member] Comprehensive income attributable to Boston Scientific common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Property, plant and equipment, net Property, Plant and Equipment, Net [Abstract] June 2030 Notes [Member] June 2030 Notes [Member] June 2030 Notes Document Type Document Type Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Goodwill acquired Goodwill, Acquired During Period Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Tabular List, Table Tabular List [Table Text Block] EMEA [Member] EMEA [Member] Entity Address, Address Line One Entity Address, Address Line One Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method Stock-based compensation (Shares) Stock Issued During Period, Shares, Period Increase (Decrease) Intangible Assets and Goodwill [Line Items] Intangible Assets and Goodwill [Line Items] [Line Items] for Schedule of Intangible Assets and Goodwill [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA. Other, Other Long-term Assets Other, Other Long-term Assets Other, Other Long-term Assets Taxes Payable, Current Taxes Payable, Current Business Acquisition [Axis] Business Acquisition [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Less: allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current NEW ACCOUNTING PRONOUNCEMENTS New Accounting Pronouncements [Text Block] New Accounting Pronouncements Derivative [Table] Derivative [Table] Other current liabilities Other Liabilities, Current Other Liabilities, Current Preferred Stock, Convertible, Conversion Ratio Preferred Stock, Convertible, Conversion Ratio Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Inventory, Raw Materials, Net of Reserves Inventory, Raw Materials, Net of Reserves Payments for royalty rights Payments for royalty rights Payments for royalty rights Silk Medical Silk Medical [Member] Silk Medical Title of 12(b) Security Title of 12(b) Security Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Goodwill, Gross Goodwill, Gross Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Neuromodulation [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Trade accounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract] ACQUISITIONS AND STRATEGIC INVESTMENTS Business Combination Disclosure [Text Block] Other comprehensive income (loss) attributable to noncontrolling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Derivative Liability Derivative Liability Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Subsidiary, Ownership Percentage, Noncontrolling Owner Other Assets, Current Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Trade accounts receivable, net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Equity method investments Equity Method Investments Inventories Inventories Inventory, Net Renminbi Denominated Factoring Arrangements [Member] Renminbi Denominated Factoring Arrangements [Member] Renminbi Denominated Factoring Arrangements Range [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Other assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Segment operating income as percentage of net sales Segment operating income as percentage of net sales Segment operating income as percentage of net sales Segments [Domain] Segment [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Risk-Adjusted Discount Rates used in Purchase Price Allocation Discount Rate, Fair Value Input Discount Rate, Fair Value Input Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Pre-Judgement Interest Pre-Judgement Interest Pre-Judgement Interest Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Goodwill Goodwill [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Entity [Abstract] Entity [Abstract] Entity [Abstract] Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] PEO PEO [Member] Other, net Other Operating Activities, Cash Flow Statement AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Derivative Asset, Fair Value, Gross Asset Derivative Asset, Subject to Master Netting Arrangement, before Offset Non-cash impact of transferred royalty rights Non-cash impact of transferred royalty rights Non-cash impact of transferred royalty rights Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Legal reserves, current Estimated Litigation Liability, Current Cash provided by (used for) investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Equity Securities, FV-NI Equity Securities, FV-NI, Current Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Inventory Disclosure Schedule of Inventory, Current [Table Text Block] Net income (loss) attributable to Boston Scientific common stockholders Net Income (Loss) Available to Common Stockholders, Basic Payments for investments and acquisitions of certain technologies, net of investment proceeds Proceeds from (payments for) investments and acquisitions of certain technologies Proceeds from (payments for) investments and acquisitions of certain technologies Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate from continuing operations Effective Income Tax Rate Reconciliation, Percent Conversion of mandatory convertible preferred stock to common stock Conversion of Stock, Shares Converted Conversion of Stock, Shares Converted Credit Facility [Axis] Credit Facility [Axis] Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Deferred and prepaid income taxes Cash flow impact of deferred income tax expense (benefit) Cash flow impact of deferred income tax expense (benefit) Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Net increase (decrease) in commercial paper Proceeds from (Repayments of) Commercial Paper Accumulated other comprehensive income (loss), net of tax AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Charges to expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Impact of Foreign Currency Fluctuations on Net Sales Impact of Foreign Currency Fluctuations on Net Sales Impact of Foreign Currency Fluctuations on Net Sales Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Net Change in Defined Benefit Pensions and Other Items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] BSX Reportable Segments [Member] BSX Reportable Segments [Member] BSX Reportable Segments [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Number of reportable segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] November 2035 Notes [Member] November 2035 Notes [Member] November 2035 Notes [Member] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Proceeds from long-term borrowings, net of debt issuance costs Proceeds from Issuance of Senior Long-Term Debt Proceeds from Issuance of Senior Long-Term Debt Decrease in Unrecognized Tax Benefits is Reasonably Possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,734,329,744 shares as of June 30, 2024 and 1,729,000,224 shares as of December 31, 2023 Common Stock, Value, Issued Debt Instrument, Redemption Price, Percentage Debt Instrument, Redemption Price, Percentage Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes [Member] Senior Notes [Member] Total current assets Assets, Current Preferred stock Preferred Stock [Member] Payments for finance leases Finance Lease, Principal Payments Balance as of December 31, 2023 Balance as of June 30, 2024 Contingent Consideration Liability Business Combination, Contingent Consideration, Liability All Business Acquisitions All Business Acquisitions [Member] All Business Acquisitions Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Credit Rating A- or A3 Or Higher Credit Rating A- or A3 Or Higher [Member] Credit Rating A- or A3 Or Higher Supplemental Information Supplemental Cash Flow Information [Abstract] Other, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information. Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Requirement, seventh quarter following qualified acquisition Requirement, seventh quarter following qualified acquisition [Member] Requirement, seventh quarter following qualified acquisition Statement [Table] Statement [Table] Business Combination, Contingent Consideration, Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Requirement, four succeeding quarters following qualified acquisition Requirement, four succeeding quarters following qualified acquisition [Member] Requirement, four succeeding quarters following qualified acquisition Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Unrecognized Tax Benefits Unrecognized Tax Benefits PEO Name PEO Name Other Other Sundry Liabilities, Current APAC [Member] Asia Pacific [Member] Changes in Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Investments Investments Investments Schedule of Goodwill Schedule of Goodwill [Table Text Block] Impact of foreign currency fluctuations and purchase price and other adjustments Goodwill, Translation and Purchase Accounting Adjustments Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities Utilization of allowances SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Business Combination, Contingent Consideration, Liability, Current Business Combination, Contingent Consideration, Liability, Current Class of Stock [Axis] Class of Stock [Axis] Entities [Table] Entities [Table] Licensing arrangements, asset Licensing arrangements, asset Licensing arrangements, asset Licensing arrangements, asset Licensing arrangements, asset Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Cardiac Rhythm Management [Member] Cardiac Rhythm Management [Member] Cardiac Rhythm Management Other Other Accrued Liabilities, Current Depreciation and amortization Depreciation, Depletion and Amortization Litigation Settlement, Amount Awarded to Other Party Litigation Settlement, Amount Awarded to Other Party Other Operating Income (Expense), Net Other Operating Income (Expense), Net Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Information [Line Items] Entity Information [Line Items] Conditional Rating [Domain] Conditional Rating [Domain] Conditional Rating [Domain] Business Combination and Asset Acquisition [Abstract] Total stockholders’ equity Total stockholders’ equity Beginning Stockholders' Equity Ending Stockholders' Equity Equity, Attributable to Parent Commercial Paper [Member] Commercial Paper [Member] Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Conditional Rating [Axis] Conditional Rating [Axis] Conditional Rating Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized March 2049 Notes [Member] March 2049 Notes [Member] March 2049 Notes [Member] March 2039 Notes [Member] March 2039 Notes [Member] March 2039 Notes [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Net Change in Derivative Financial Instruments Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] March 2028 Senior Notes March 2028 Senior Notes [Member] March 2028 Senior Notes Long-term debt Long-term Debt and Capital Lease Obligations Long-Term Debt and Lease Obligation Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Measurement alternative investments(1, 2) Equity Securities without Readily Determinable Fair Value, Amount Fair Value Measurement Fair Value Measurement, Policy [Policy Text Block] Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred Stock, Shares Issued Operating Income Unallocated to Segment Operating Income Unallocated to Segment Operating Income Unallocated to Segment Hedging Designation [Domain] Hedging Designation [Domain] Liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Emerging Markets [Member] Emerging Markets [Member] Emerging Markets [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Net Investment Hedging [Member] Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Requirement, as of December 31, 2021 and through remaining term of facility Requirement, as of December 31, 2021 and through remaining term of facility [Member] Requirement, as of December 31, 2021 and through remaining term of facility Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Impact of stock-based compensation plans Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture Operating Income Allocated to Reportable Segments Operating Income Allocated to Reportable Segments Operating Income Allocated to Reportable Segments Derivative Instruments, Gain (Loss) Derivative Instruments, Gain (Loss) [Table Text Block] Proceeds from settlements of hedge contracts Payments for (Proceeds from) Hedge, Investing Activities Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Stock-based compensation expense Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] Requirement, sixth quarter following qualified acquisition Requirement, sixth quarter following qualified acquisition [Member] Requirement, sixth quarter following qualified acquisition Common Stock, par value $0.01 per share Common stock Common Stock [Member] Accrued income taxes Accrued Income Taxes, Noncurrent Net change in defined benefit pensions and other items Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Individual: Individual [Axis] Net proceeds from issuance of preferred stock in connection with public offering Proceeds from Issuance of Convertible Preferred Stock City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] WEIGHTED AVERAGE SHARES OUTSTANDING Earnings Per Share [Text Block] Rule Trading Arrangement, Common Stock [Member] Rule Trading Arrangement, Common Stock Income Statement Location [Domain] Income Statement Location [Domain] Revenues from contracts with customers, disaggregated - performance measurement Revenues from contracts with customers, disaggregated - performance measurement Revenues from contracts with customers, disaggregated - performance measurement - measures used by CODM to make business decisions, excludes impact of foreign currency fluctuations Discount Rate Valuation Technique, Discounted Cash Flow [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total equity Beginning Balance, Equity Ending Balance, Equity Equity, Including Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Minimum Minimum [Member] Licensing arrangement assets [Member] Licensing arrangement assets [Member] Licensing arrangement assets [Member] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Cash Cash Other comprehensive income (loss) Changes in other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Supplier Finance Program Obligation. current Supplier Finance Program, Obligation, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Financial and Nonfinancial Liabilities, Fair Value Disclosure Liabilities, Fair Value Disclosure Foreign Currency Transaction Gain (Loss), before Tax Gain (Loss), Foreign Currency Transaction, before Tax Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Cash provided by (used for) financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Fair value of contingent consideration recorded in purchase accounting Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Proceeds from royalty rights Payments for (Proceeds from) Other Investing Activities December 2027 Notes [Member] December 2027 Notes [Member] December 2027 Notes [Member] Business Acquisition, Percentage of Voting Interests Acquired Business Acquisition, Percentage of Voting Interests Acquired Retained earnings/(Accumulated deficit) Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] TOTAL LIABILITIES AND EQUITY Liabilities and Equity Other long-term assets Other Assets, Noncurrent Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Net change in derivative financial instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Net income (loss) per common share — basic Earnings Per Share, Basic Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] March 2026 Notes [Member] March 2026 Notes [Member] March 2026 Notes [Member] Arrangement Duration Trading Arrangement Duration IPR&D In Process Research and Development [Member] Yen Denominated Factoring Arrangements [Member] Yen Denominated Factoring Arrangements [Member] Yen denominated factoring arrangements. Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits Special Charges [Member] Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Restructuring net charges (credits) Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] June 2025 Notes [Member] June 2025 Notes [Member] June 2025 Notes Interest Expense [Member] Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Combinations [Abstract] Business Combinations [Abstract] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Technology-related Technology-Based Intangible Assets [Member] Termination Date Trading Arrangement Termination Date Derivative Instruments in Hedges, Assets, at Fair Value Derivative Instruments in Hedges, Assets, at Fair Value Common Stock, Shares Authorized Common Stock, Shares Authorized Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax March 2024 Notes [Member] March 2024 Notes [Member] March 2024 Notes [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-Lived Intangible Assets [Axis] Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity in Months Derivative Instrument [Axis] Derivative Instrument [Axis] Liability Class [Axis] Liability Class [Axis] All Trading Arrangements All Trading Arrangements [Member] Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Investment Investment Holdings, Schedule of Investments [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Acotec Acotec [Member] Acotec Award Timing Disclosures [Line Items] March 2031 Notes March 2031 Notes [Member] March 2031 Notes Compensation Amount Outstanding Recovery Compensation Amount Royalty expense Royalty Expense Comprehensive income (loss) attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Net loss (gain) on investments and notes receivable Gain (Loss) on Investments Other long-term liabilities Other Liabilities, Noncurrent [Abstract] Derivative Asset Derivative Asset Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Current debt obligations Debt, Current Debt, Current Other current assets Prepaid Expense and Other Assets, Current Electrophysiology [Member] Electrophysiology (EP) [Member] Electrophysiology (EP) Latin America and Canada [Member] Latin America and Canada [Member] Latin America and Canada [Member] Finance Lease Obligation Capital Lease Obligations [Member] Insider Trading Arrangements [Line Items] Deferred Revenue Deferred Revenue Net currency exchange gain (loss) Net currency exchange gain (loss) Net currency exchange gain (loss) Schedule of Intangible Assets and Goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Other Liabilities, Current [Abstract] Other Liabilities, Current [Abstract] Entity Registrant Name Entity Registrant Name Award Timing Method Award Timing Method [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Other assets Increase (Decrease) in Other Operating Assets Adjustment to Compensation, Amount Adjustment to Compensation Amount Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Cost of Sales [Member] Cost of Sales [Member] Contingent consideration net expense (benefit) Contingent consideration net expense (benefit) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Noncontrolling interests Equity, Attributable to Noncontrolling Interest Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary of term loan and revolving credit facility agreement compliance with debt covenants. Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Preferred Stock, Dividend Rate, Percentage Preferred Stock, Dividend Rate, Percentage Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Treasury stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Accrual for legal matters that are probable and estimable Loss Contingency Accrual Transfer of Financial Assets Accounted for as Sales Transfer of Financial Assets Accounted for as Sales [Table Text Block] Maximum Leverage Ratio Maximum Leverage Ratio Maximum leverage ratio permitted by revolving credit facility agreement. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Income tax expense (benefit) Income Tax Expense (Benefit) International [Member] Non-US [Member] Inventory, Finished Goods, Net of Reserves Inventory, Finished Goods, Net of Reserves Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Endoscopy [Member] Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Payroll and related liabilities Employee-related Liabilities, Current Requirement, eighth quarter following qualified acquisition and through remaining term of facility Requirement, eighth quarter following qualified acquisition and through remaining term of facility [Member] Requirement, eighth quarter following qualified acquisition and through remaining term of facility Entity Listing, Par Value Per Share Entity Listing, Par Value Per Share Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Preferred stock dividends Dividends, Preferred Stock, Cash Proceeds from royalty rights Proceeds from Royalties Received Revenue-based Payments and Milestones revenue-based payments [Member] revenue-based payments [Member] Name Trading Arrangement, Individual Name (Income) loss amounts reclassified from accumulated other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Net assets acquired Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Net sales Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag March 2032 Euro Senior Notes March 2032 Euro Senior Notes [Member] March 2032 Euro Senior Notes Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Payments for acquisitions of businesses, net of cash acquired Payment for acquisition, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Allowance for doubtful accounts SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Credit Facility [Domain] Credit Facility [Domain] Equipment, furniture and fixtures Equipment, furniture and fixtures Gross Equipment, furniture and fixtures Gross. Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Diluted Weighted average shares outstanding - diluted Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Total allocated to reportable segments [Member] Total allocated to reportable segments [Member] Total allocated to reportable segments [Member] Current Requirement [Member] Current Requirement [Member] Current Requirement. Interest Rate Contract [Member] Interest Rate Contract [Member] Amortizable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Other long-term liabilities Other Noncurrent Liabilities [Table Text Block] Licensing arrangements, liability Licensing arrangements, liability Licensing arrangements, liability Licensing arrangements, liability Licensing arrangements, liability Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Accrued Rebates, Current Accrued Rebates, Current Accrued Rebates, Current Operating expenses: Operating Expenses [Abstract] REVENUE Revenue from Contract with Customer [Text Block] Purchases of property, plant and equipment and internal use software Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock March 2029 Notes [Member] March 2029 Notes [Member] March 2029 Notes [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Additional paid-in capital Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] TOTAL ASSETS Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Uncapped Contingent Considertation Uncapped Contingent Considertation Uncapped Contingent Considertation United States UNITED STATES Fair Value, Measurements, Recurring [Member] Fair Value, Recurring [Member] Other Current Liabilities Other Current Liabilities [Table Text Block] Cash dividends paid on preferred stock Payments of Dividends Other long-term liabilities Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] CADE fine CADE fine CADE fine 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A Cash Flow Hedging [Member] Cash Flow Hedging [Member] Operating expenses Operating Expenses SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract] Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract] Non-PEO NEO Non-PEO NEO [Member] Derivative Instruments in Hedges, Liabilities, at Fair Value Derivative Instruments in Hedges, Liabilities, at Fair Value Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Inventory, Work in Process, Net of Reserves Inventory, Work in Process, Net of Reserves Trade accounts receivable, net Trade accounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic Weighted average shares outstanding — basic Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating income (loss) Operating income (loss) Operating Income (Loss) January 2040 Notes [Member] January 2040 Notes [Member] January 2040 Notes [Member] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] March 2025 Notes March 2025 Notes [Member] March 2025 Notes Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement, Business Segments [Axis] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Vance R. Brown [Member] Vance R. Brown March 2029 Euro Senior Notes March 2029 Euro Senior Notes [Member] March 2029 Euro Senior Notes Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] March 2034 Notes March 2034 Notes [Member] March 2034 Notes Customer relationships Customer Relationships [Member] Noncontrolling interests Noncontrolling Interest [Member] Schedule of Effective Income Tax Rate from Continuing Operations Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block] Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block] EX-101.PRE 11 bsx-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover Document - $ / shares
6 Months Ended
Jun. 30, 2024
Jul. 30, 2024
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2024  
Document Transition Report false  
Entity File Number 1-11083  
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 04-2695240  
Entity Address, Address Line One 300 Boston Scientific Way  
Entity Address, City or Town Marlborough  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 01752-1234  
City Area Code 508  
Local Phone Number 683-4000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Listing, Par Value Per Share $ 0.01  
Entity Common Stock, Shares Outstanding   1,472,626,135
Entity Central Index Key 0000885725  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Common Stock, par value $0.01 per share    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol BSX  
Security Exchange Name NYSE  
0.625% Senior Notes due 2027    
Entity Information [Line Items]    
Title of 12(b) Security 0.625% Senior Notes due 2027  
Trading Symbol BSX27  
Security Exchange Name NYSE  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Net sales $ 4,120 $ 3,599 $ 7,977 $ 6,988
Cost of products sold 1,270 1,058 2,479 2,098
Gross profit 2,850 2,542 5,498 4,891
Operating expenses:        
Selling, general and administrative expenses 1,446 1,354 2,810 2,570
Research and development expenses 383 359 749 695
Royalty expense 9 12 19 23
Amortization expense 213 210 427 412
Intangible asset impairment charges 276 57 276 57
Contingent consideration net expense (benefit) 2 19 18 31
Restructuring net charges (credits) 1 16 5 36
Operating expenses 2,330 2,028 4,303 3,825
Operating income (loss) 520 514 1,195 1,066
Other income (expense):        
Interest expense (77) (70) (146) (135)
Other, net (23) (18) (21) (61)
Income (loss) before income taxes 420 426 1,028 870
Income tax expense (benefit) 98 156 213 287
Net income (loss) 322 270 815 584
Preferred stock dividends 0 (9) 0 (23)
Net income (loss) attributable to noncontrolling interests (2) 0 (4) 0
Net income (loss) attributable to Boston Scientific common stockholders $ 324 $ 261 $ 819 $ 561
Net income (loss) per common share — basic $ 0.22 $ 0.18 $ 0.56 $ 0.39
Net income (loss) per common share — diluted $ 0.22 $ 0.18 $ 0.55 $ 0.39
Weighted-average shares outstanding        
Basic 1,470.6 1,446.2 1,469.5 1,441.0
Diluted 1,484.2 1,456.2 1,483.0 1,451.1
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ 322 $ 270 $ 815 $ 584
Other comprehensive income (loss), net of tax:        
Foreign currency translation adjustment 45 15 102 (28)
Net change in derivative financial instruments (16) 15 6 (28)
Net change in defined benefit pensions and other items 0 0 0 (5)
Other comprehensive income (loss) 30 30 108 (61)
Comprehensive income (loss) 352 300 924 523
Net income (loss) attributable to noncontrolling interests (2) 0 (4) 0
Other comprehensive income (loss) attributable to noncontrolling interests (1) 0 (6) 0
Comprehensive income (loss) attributable to noncontrolling interests (4) 0 (10) 0
Comprehensive income attributable to Boston Scientific common stockholders $ 356 $ 300 $ 933 $ 523
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 2,913 $ 865
Trade accounts receivable, net 2,400 2,228
Inventories 2,608 2,484
Prepaid income taxes 315 315
Other current assets 756 621
Total current assets 8,991 6,514
Property, plant and equipment, net 2,951 2,859
Goodwill 14,397 14,387
Other intangible assets, net 5,417 6,003
Deferred tax assets 3,801 3,841
Other long-term assets 1,551 1,531
TOTAL ASSETS 37,108 35,136
Current liabilities:    
Current debt obligations 1,580 531
Accounts payable 906 942
Accrued expenses 2,320 2,646
Other current liabilities 770 814
Total current liabilities 5,576 4,933
Long-term debt 8,991 8,571
Deferred income taxes 132 134
Other long-term liabilities 1,800 1,967
Commitments and contingencies
Stockholders’ equity    
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of June 30, 2024 and December 31, 2023 0 0
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,734,329,744 shares as of June 30, 2024 and 1,729,000,224 shares as of December 31, 2023 17 17
Treasury stock, at cost - 263,289,848 shares as of June 30, 2024 and December 31, 2023 (2,251) (2,251)
Additional paid-in capital 20,803 20,647
Retained earnings 1,639 819
Accumulated other comprehensive income (loss), net of tax 164 49
Total stockholders’ equity 20,371 19,282
Noncontrolling interests 238 248
Total equity 20,609 19,530
TOTAL LIABILITIES AND EQUITY $ 37,108 $ 35,136
Preferred Stock, Shares Issued 0 0
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2024
Dec. 31, 2023
Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]    
Preferred Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Preferred Stock, Shares Authorized 50,000,000 50,000,000
Preferred Stock, Shares Issued 0 0
Common Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Common Stock, Shares Authorized 2,000,000,000 2,000,000,000
Common Stock, Shares, Issued 1,734,329,744 1,729,000,224
Treasury Stock, Common, Shares 263,289,848 263,289,848
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Millions
Total
Preferred stock
Common stock
Treasury stock
Additional paid-in capital
Retained earnings/(Accumulated deficit)
Accumulated other comprehensive income (loss), net of tax
Noncontrolling interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total stockholders’ equity             $ 269  
Beginning Balance (Shares Issued) at Dec. 31, 2022   10,062,500            
Beginning Balance (Shares) at Dec. 31, 2022 1,696,633,993              
Beginning Balance, Equity at Dec. 31, 2022   $ 0 $ 17 $ (2,251) $ 20,289 $ (750) 269 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation (Shares)     5,339,246          
Conversion of mandatory convertible preferred stock to common stock   $ 0 $ 0          
Repurchase of common stock       0        
Impact of stock-based compensation plans     $ 0   153      
Net income (loss) $ 584         584    
Preferred stock dividends           (23)    
Conversion of mandatory convertible preferred stock to common stock   (10,062,500) 23,982,902          
Net income (loss) attributable to noncontrolling interests 0         0   0
Changes in other comprehensive income (loss) $ (61)           (61) 0
Changes to noncontrolling ownership interest               259
Ending Balance (Shares Issued) at Jun. 30, 2023   0            
Ending Balance (Shares) at Jun. 30, 2023 1,725,956,141   1,725,956,141          
Ending Balance, Equity at Jun. 30, 2023 $ 18,485 $ 0 $ 17 (2,251) 20,441 (189) 208 259
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total stockholders’ equity             178  
Beginning Balance (Shares Issued) at Mar. 31, 2023   10,062,500            
Beginning Balance (Shares) at Mar. 31, 2023     1,700,828,873          
Beginning Balance, Equity at Mar. 31, 2023   $ 0 $ 17 (2,251) 20,356 (450) 178 259
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation (Shares)     1,144,366          
Conversion of mandatory convertible preferred stock to common stock   $ 0 $ 0          
Repurchase of common stock       0        
Impact of stock-based compensation plans     $ 0   85      
Net income (loss) 270         270    
Preferred stock dividends           (9)    
Conversion of mandatory convertible preferred stock to common stock   (10,062,500) 23,982,902          
Net income (loss) attributable to noncontrolling interests 0         0   0
Changes in other comprehensive income (loss) $ 30           30 0
Changes to noncontrolling ownership interest               0
Ending Balance (Shares Issued) at Jun. 30, 2023   0            
Ending Balance (Shares) at Jun. 30, 2023 1,725,956,141   1,725,956,141          
Ending Balance, Equity at Jun. 30, 2023 $ 18,485 $ 0 $ 17 (2,251) 20,441 (189) 208 259
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total stockholders’ equity 18,226           208  
Total stockholders’ equity $ 19,282           49  
Beginning Balance (Shares Issued) at Dec. 31, 2023   0            
Beginning Balance (Shares) at Dec. 31, 2023 1,729,000,224              
Beginning Balance, Equity at Dec. 31, 2023 $ 19,530 $ 0 $ 17 (2,251) 20,647 819 49 248
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation (Shares)     5,329,520          
Conversion of mandatory convertible preferred stock to common stock   $ 0 $ 0          
Repurchase of common stock       0        
Impact of stock-based compensation plans     $ 0   156      
Net income (loss) 815         815    
Preferred stock dividends           0    
Conversion of mandatory convertible preferred stock to common stock   0 0          
Net income (loss) attributable to noncontrolling interests (4)         4   (4)
Changes in other comprehensive income (loss) $ 108           114 (6)
Changes to noncontrolling ownership interest               0
Ending Balance (Shares Issued) at Jun. 30, 2024   0            
Ending Balance (Shares) at Jun. 30, 2024 1,734,329,744   1,734,329,744          
Ending Balance, Equity at Jun. 30, 2024 $ 20,609 $ 0 $ 17 (2,251) 20,803 1,639 164 238
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total stockholders’ equity             132  
Beginning Balance (Shares Issued) at Mar. 31, 2024   0            
Beginning Balance (Shares) at Mar. 31, 2024     1,733,293,885          
Beginning Balance, Equity at Mar. 31, 2024   $ 0 $ 17 (2,251) 20,713 1,314 132 242
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation (Shares)     1,035,859          
Conversion of mandatory convertible preferred stock to common stock   $ 0 $ 0          
Repurchase of common stock       0        
Impact of stock-based compensation plans     $ 0   90      
Net income (loss) 322         322    
Preferred stock dividends           0    
Conversion of mandatory convertible preferred stock to common stock   0 0          
Net income (loss) attributable to noncontrolling interests (2)         2   (2)
Changes in other comprehensive income (loss) $ 30           31 (1)
Changes to noncontrolling ownership interest               0
Ending Balance (Shares Issued) at Jun. 30, 2024   0            
Ending Balance (Shares) at Jun. 30, 2024 1,734,329,744   1,734,329,744          
Ending Balance, Equity at Jun. 30, 2024 $ 20,609 $ 0 $ 17 $ (2,251) $ 20,803 $ 1,639 164 $ 238
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total stockholders’ equity $ 20,371           $ 164  
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash provided by (used for) operating activities    
Net income (loss) $ 815 $ 584
Depreciation and amortization 615 583
Deferred and prepaid income taxes 21 (45)
Stock-based compensation expense 129 115
Goodwill and other intangible asset impairment charges 276 57
Net loss (gain) on investments and notes receivable 46 35
Contingent consideration net expense (benefit) 18 31
Inventory step-up amortization 0 3
Other, net 8 23
Trade accounts receivable (228) (161)
Inventories (219) (399)
Other assets (126) (55)
Accounts payable, accrued expenses and other liabilities (379) 78
Cash provided by (used for) operating activities 977 848
Investing activities:    
Purchases of property, plant and equipment and internal use software (334) (254)
Proceeds from sale of property, plant and equipment 1 3
Payments for acquisitions of businesses, net of cash acquired (95) (1,018)
Payments for investments and acquisitions of certain technologies, net of investment proceeds (139) (73)
Proceeds from royalty rights 11 16
Proceeds from settlements of hedge contracts 0 (2)
Cash provided by (used for) investing activities (556) (1,324)
Financing activities:    
Payment of contingent consideration previously established in purchase accounting (34) (39)
Payments for royalty rights (15) (34)
Payments for finance leases (25) 0
Payments on short-term borrowings (504) 0
Net increase (decrease) in commercial paper 0 37
Proceeds from long-term borrowings, net of debt issuance costs 2,145 0
Cash dividends paid on preferred stock 0 (28)
Cash used to net share settle employee equity awards (80) (52)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans 106 90
Cash provided by (used for) financing activities 1,593 (26)
Effect of foreign exchange rates on cash (8) (3)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents 2,006 (506)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 1,055 1,126
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 3,062 620
Supplemental Information    
Stock-based compensation expense 129 115
Non-cash impact of transferred royalty rights (11) (16)
Cash and cash equivalents 2,913 426
Restricted cash and restricted cash equivalents included in Other current assets 75 135
Restricted cash equivalents included in Other long-term assets 74 60
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period $ 3,062 $ 620
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Basis of Presentation
6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION
NOTE A – BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation.

Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

Subsequent Events

We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure within our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.

Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note H – Commitments and Contingencies for further details.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisitions, Divestitures and Strategic Investments
6 Months Ended
Jun. 30, 2024
Business Combinations [Abstract]  
ACQUISITIONS AND STRATEGIC INVESTMENTS
NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.

On June 18, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Silk Road Medical, Inc. (Silk Road Medical), a publicly traded medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is $27.50 in cash per share, or approximately $1.260 billion for 100% of the fully diluted equity. The transaction is expected to be completed in the second half of 2024, subject to customary closing conditions. The Silk Road Medical business will be integrated into our Peripheral Interventions division.

On January 8, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $71.00 in cash per share, or approximately $3.670 billion for 100% of the fully diluted equity. On April 3, 2024, we and Axonics each received a request for additional information (Second Request) from the United States Federal Trade Commission (FTC) in connection with the FTC's review of the transaction. The issuance of the Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), until 30 days after both we and Axonics have substantially complied with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. We and Axonics are responding to the Second Request and continue to work cooperatively with the FTC in its review. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. The Axonics business will be integrated into our Urology division.
2023 Acquisitions

On April 4, 2023, we completed our acquisition of 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The transaction consisted of an upfront cash payment of $636 million, net of cash acquired. The Apollo business is being integrated into our Endoscopy division.

On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases. We consolidated this majority stake investment in Acotec based on the conclusion we control the entity, and recorded a noncontrolling interest for the portion we do not own. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.

Purchase Price Allocation

We accounted for these transactions as business combinations in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805). The final purchase prices were comprised of the amounts presented below:

(in millions)
Acotec(1)
Apollo
Payment for acquisition, net of cash acquired(2)
$381 $636 
$381 $636 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction
(2) Related to Acotec, represents our majority stake investment

We recorded the assets acquired, liabilities assumed and specific to Acotec, the noncontrolling interest, at their respective fair values as of the closing date of the transaction. The final purchase price allocations were comprised of the components presented below, with the excess of the purchase price over the fair value of net assets acquired recorded to goodwill:

(in millions)AcotecApollo
Goodwill$337 $378 
Amortizable intangible assets334 248 
Other assets acquired93 50 
Liabilities assumed(48)(33)
Net deferred tax liabilities(76)(5)
Fair value of noncontrolling interest(259)— 
$381 $636 

The fair value of Acotec's noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented in Stockholders' equity within our accompanying unaudited consolidated balance sheets. Goodwill was primarily established for Acotec due to opportunities for collaboration in research and development, manufacturing and commercial strategies, and for Apollo, due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.
We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Acotec:
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
Apollo:
Amortizable intangible assets:
Technology-related$222 1112%
Customer relationships26 1112%
$248 
Contingent Consideration
Changes in the fair value of our contingent consideration liability during the first six months of 2024 associated with prior period acquisitions were as follows:

(in millions)
Balance as of December 31, 2023$404 
Amount recorded related to current year acquisitions29 
Contingent consideration net expense (benefit)18 
Contingent consideration payments and other adjustments(158)
Balance as of June 30, 2024$293 

The payments made during the first six months of 2024 primarily related to our acquisition of Farapulse, Inc. (Farapulse) following the achievement of revenue-based earnouts as a result of over-performance. The maximum amount we could be required to pay for certain contingent consideration is not determinable as it is uncapped and based on a percent of certain sales. As of June 30, 2024, the fair value of such uncapped contingent consideration is estimated at $163 million. As of June 30, 2024, the maximum amount that we could be required to pay under our other contingent consideration arrangements (undiscounted) is approximately $320 million. Refer to Note B – Acquisitions and Strategic Investments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of June 30, 2024Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Revenue-based Payments and Milestones$293 millionDiscounted Cash FlowDiscount Rate6%-15%7%
Probability of Payment90%-100%99%
Projected Year of Payment2024-20292027
(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Projected contingent payment amounts related to our revenue-based payments and milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of June 30, 2024.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)June 30, 2024December 31, 2023
Equity method investments$207 $219 
Measurement alternative investments(1, 2)
243 194 
$450 $413 
(1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2) Includes publicly-held securities and convertible notes measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.

These investments are classified as Other long-term assets within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies.
As of June 30, 2024, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $233 million, which represents amortizable intangible assets, in-process research and development (IPR&D), goodwill and deferred tax liabilities.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Goodwill and Other Intangible Assets
6 Months Ended
Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS
NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
As of June 30, 2024As of December 31, 2023
(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs
Technology-related$12,846 $(8,372)$13,207 $(8,101)
Patents476 (380)480 (387)
Other intangible assets2,188 (1,555)2,130 (1,500)
Amortizable intangible assets$15,510 $(10,307)$15,817 $(9,988)
    
Goodwill$24,297 $(9,900)$24,287 $(9,900)
IPR&D$94 $54 
Technology-related120 120 
Indefinite-lived intangible assets$214 $174 
The following represents a roll-forward of our goodwill balance by reportable segment:
(in millions)MedSurgCardiovascularTotal
As of December 31, 2023$5,347 $9,041 $14,387 
Goodwill acquired24 46 71 
Impact of foreign currency fluctuations and purchase price and other adjustments(30)(30)(61)
As of June 30, 2024$5,341 $9,057 $14,397 

Goodwill and Other Intangible Asset Impairments

We did not record any goodwill impairment charges in the first six months of 2024 or 2023. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.

We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. We identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, Intangibles - Goodwill and Other (FASB ASC Topic 350), we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components of our Cardiology operating segment into a single Rhythm Management reporting unit.

In the second quarter of 2024, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. For the reporting units tested using the qualitative approach, after assessing the totality of events, it was determined that it was not more likely than not that the fair value of the reporting units was less than their carrying value, and it was not deemed necessary to proceed to the quantitative test. For the reporting units tested using the quantitative approach, we determined that the fair value of the reporting units exceeded the carrying value and concluded that goodwill was not impaired or at risk of impairment.

We recorded Intangible asset impairment charges of $276 million in the second quarter and first six months of 2024 and $57 million in the second quarter and first six months of 2023. The impairment charges recorded in 2024 were associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively. Intangible assets acquired from Cryterion were impaired due to strong commercial adoption of our Farapulse™ Pulsed Field Ablation System and the resulting lower revenue projections and cannibalization of our cryoablation business in major markets like the U.S. Intangible assets acquired from Devoro were impaired following management's decision to cancel the related program in the second quarter of 2024. We calculated the fair value of our Cryterion and Devoro intangible assets as the present value of estimated future cash flows we expect to generate from the assets based on estimates and assumptions about future revenue contributions, cost structures and the remaining useful lives of the assets.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist.

Refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements
and Supplementary Data of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements
6 Months Ended
Jun. 30, 2024
Fair Value Disclosures [Abstract]  
HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS
NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments

Risk Management Strategy

Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecasted transactions denominated primarily in euro, Chinese renminbi, Japanese yen, British pound sterling, Australian dollar and Swiss franc. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold within our unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within Accumulated other comprehensive income (loss), net of tax (AOCI) to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities within our unaudited consolidated statements of cash flows.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Chinese renminbi and Japanese yen. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the Foreign currency translation adjustment (CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within Interest expense within our unaudited consolidated statements of operations.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the euro. As of June 30, 2024 and December 31, 2023, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within
Other, net within our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net within our accompanying unaudited consolidated statements of operations.

Interest Rate Hedging Instruments

Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of June 30, 2024 or December 31, 2023. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of June 30, 2024 or December 31, 2023. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest-rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of
June 30, 2024December 31, 2023
Forward currency contractsCash flow hedge$1,969 $2,284 
Forward currency contractsNet investment hedge645 333 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,284 3,282 
Total Notional Outstanding$6,895 $6,896 
(1) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.

The remaining time to maturity as of June 30, 2024 is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and two years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 within our accompanying unaudited consolidated statements of operations. Refer to Note M – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss).
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended June 30, 2024
Forward currency contracts
Cash flow hedges$31 $(7)$24 Cost of products sold$1,270 $(52)$12 $(41)
Net investment hedges(2)
20 (5)16 Interest expense77 (4)(3)
Foreign currency-denominated debt
Net investment hedges(3)
(2)Other, net23 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense77 (0)

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended June 30, 2023
Forward currency contracts
Cash flow hedges$74 $(17)$58 Cost of products sold$1,058 $(55)$12 $(43)
Net investment hedges(2)
22 (5)17 Interest expense70 (2)(2)
Foreign currency-denominated debt
Net investment hedges(3)
— Other, net18 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest Expense70 (0)

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Six Months Ended June 30, 2024
Forward currency contracts
Cash flow hedges$108 $(24)$84 Cost of products sold$2,479 $(101)$23 $(79)
Net investment hedges(2)
48 (11)37 Interest expense146 (8)(6)
Foreign currency-denominated debt
Net investment hedges(3)
32 (7)25 Other, net21 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense146 (0)
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Six Months Ended June 30, 2023
Forward currency contracts
Cash flow hedges$87 $(20)$67 Cost of products sold$2,098 $(125)$28 $(97)
Net investment hedges(2)
28 (6)22 Interest expense135 (5)(4)
Foreign currency-denominated debt
Net investment hedges(3)
(18)(14)Other, net61 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense135 (0)
(1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.

As of June 30, 2024, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Designated Hedging Instrument
Forward currency contractsCash flow hedgeCost of products sold$163 
Forward currency contractsNet investment hedgeInterest expense11 
Interest rate derivative contractsCash flow hedgeInterest expense(1)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
Location on Unaudited Consolidated Statements of OperationsThree Months Ended June 30,Six Months Ended June 30,
(in millions)2024202320242023
Net gain (loss) on currency hedge contractsOther, net$30 $11 $45 $
Net gain (loss) on currency transaction exposuresOther, net(31)(20)(51)(26)
Net currency exchange gain (loss)$(1)$(9)$(6)$(24)
Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:

 
Location on Unaudited Consolidated Balance Sheets(1)
As of
(in millions)June 30, 2024December 31, 2023
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$236 $140 
Forward currency contractsOther long-term assets46 107 
  282 246 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets31 20 
Total Derivative and Nonderivative Assets $313 $266 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$$15 
Forward currency contractsOther long-term liabilities
Foreign currency-denominated debt(2)
Long-term debt957 988 
  960 1,012 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities14 38 
Total Derivative and Nonderivative Liabilities $974 $1,050 
(1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 June 30, 2024December 31, 2023
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$2,153 $— $— $2,153 $454 $— $— $454 
Publicly-held equity securities19 — — 19 18 — — 18 
Hedging instruments— 313 — 313 — 266 — 266 
Licensing arrangements— — 51 51 — — 77 77 
 $2,173 $313 $51 $2,536 $472 $266 $77 $816 
Liabilities        
Hedging instruments$— $974 $— $974 $— $1,050 $— $1,050 
Contingent consideration liability— — 293 293 — — 404 404 
Licensing arrangements— — 60 60 — — 90 90 
 $ $974 $353 $1,327 $ $1,050 $494 $1,545 

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents or Other current assets within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies. In addition to $2.153 billion invested in money market funds and time deposits as of June 30, 2024 and $454 million as of December 31, 2023, we held $793 million in interest-bearing and non-interest-bearing bank accounts as of June 30, 2024 and $411 million as of December 31, 2023.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability. In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We maintain a financial asset and associated liability for our licensing arrangements measured at fair value within our unaudited consolidated balance sheets in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Refer to Note D – Hedging Activities and Fair Value Measurements to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our licensing arrangements recognized within our accompanying unaudited consolidated balance sheet as of June 30, 2024 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of June 30, 2024Valuation TechniqueUnobservable InputRange
Weighted Average (1)
Financial Asset$51 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2024-20252025
Financial Liability$60 millionDiscounted Cash FlowDiscount Rate12 %-15%13%
Projected Year of Payment2024-20262025
(1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2023$77 
Proceeds from royalty rights(21)
Fair value adjustment (expense) benefit(5)
Balance as of June 30, 2024$51 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2023$90 
Payments for royalty rights(26)
Fair value adjustment expense (benefit)(4)
Balance as of June 30, 2024$60 

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations, excluding finance leases, was $10.073 billion as of June 30, 2024 and $8.735 billion as of December 31, 2023. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Contractual Obligations and Commitments
6 Months Ended
Jun. 30, 2024
Debt Disclosure [Abstract]  
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of $10.571 billion as of June 30, 2024 and $9.102 billion as of December 31, 2023, with current obligations of $1.580 billion as of June 30, 2024 and $531 million as of December 31, 2023. The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)Issuance DateMaturity DateAs of
Coupon Rate(1)
June 30,
2024
December 31,
2023
March 2025 Senior Notes(3)
March 2022March 2025— 1,105 0.750%
June 2025 Senior NotesMay 2020June 2025— 500 1.900%
March 2026 Senior NotesFebruary 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027963 995 0.625%
March 2028 Senior Notes(3)
March 2022March 2028802 829 1.375%
March 2028 Senior NotesFebruary 2018March 2028344 344 4.000%
March 2029 Senior NotesFebruary 2019March 2029272 272 4.000%
March 2029 Senior Notes(3)
February 2024March 2029802 — 3.375%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031802 829 1.625%
March 2032 Senior Notes(3)
February 2024March 20321,337 — 3.500%
March 2034 Senior Notes(3)
March 2022March 2034535 553 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.500%
March 2039 Senior NotesFebruary 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior NotesFebruary 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2024 - 2049(77)(65)
Finance Lease ObligationVarious
Long-term debt$8,991 $8,571 
(1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of June 30, 2024 and December 31, 2023, respectively.

Revolving Credit Facility

On May 10, 2021, we entered into a $2.750 billion revolving credit facility (as amended, supplemented or otherwise modified from time to time, the 2021 Revolving Credit Facility) with a global syndicate of commercial banks. On May 10, 2024, we entered into a third amendment to the 2021 Revolving Credit Facility credit agreement, which provided for, among other things, an extension of the scheduled maturity date to May 10, 2029, an amendment of the Ratings based pricing grid of the Applicable Margin, each as defined in the credit agreement, and reset the applicable date for purposes of determining the amounts of restructuring charges and restructuring-related expenses that may be excluded from consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the credit agreement, for purposes of our maximum leverage ratio covenant, from December 31, 2022 to March 31, 2024, as further discussed under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. We had no amounts outstanding under the 2021 Revolving Credit Facility as of June 30, 2024 or December 31, 2023.
Financial Covenant

As of June 30, 2024, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
Covenant RequirementActual
 as of June 30, 2024as of June 30, 2024
Maximum permitted leverage ratio(1)
3.75 times1.97 times
(1) Ratio of total debt to deemed consolidated EBITDA, as defined by the 2021 Revolving Credit Facility credit agreement, as amended.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The credit agreement provides for higher leverage ratios, at our election, for the period following a Qualified Acquisition, as defined by the agreement, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have elected to designate the Axonics acquisition as a Qualified Acquisition under the credit agreement, and upon closing, will increase the maximum permitted leverage ratio at that time. The agreement also provides for an exclusion of any debt incurred to fund a Qualified Acquisition, until the earlier of the acquisition close date or date of abandonment, termination or expiration of the acquisition agreement. As of June 30, 2024, we excluded from our leverage ratio calculation $2.120 billion of debt incurred in connection with the Axonics acquisition.

The financial covenant requirement, as amended on May 10, 2024, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions related to restructuring charges and restructuring-related expenses from December 31, 2022 to March 31, 2024. Permitted exclusions include up to $500 million in cash and non-cash restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of June 30, 2024, we had $453 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of June 30, 2024, we had $1.448 billion of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of June 30, 2024 or December 31, 2023.

Senior Notes

We had senior notes outstanding of $10.633 billion as of June 30, 2024 and $9.136 billion as of December 31, 2023. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (refer to Other Arrangements below).

In February 2024, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €2.000 billion in aggregate principal amount of euro-denominated senior notes comprised of €750 million of 3.375% Senior Notes due 2029 and €1.250 billion of 3.500% Senior Notes due 2032 (collectively, the 2024 Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the 2024 Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations.
AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $2.145 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering of the 2024 Eurobonds to fund the repayment at maturity of our 3.450% Senior Notes due March 2024 and to pay accrued and unpaid interest with respect to such notes. Additionally, we plan to use the remaining net proceeds from the Offering to fund a portion of the purchase price of the Axonics acquisition and to pay related fees and expenses, and for general corporate purposes. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. If (i) the Axonics acquisition is not consummated on or before the later of (x) January 8, 2025 (as such date may be extended in accordance with the merger agreement to no later than January 8, 2026) and (y) the date that is five business days after any later date to which we and Axonics may agree to extend the "Outside Date" in the merger agreement or (ii) AMS Europe notifies the trustee that we will not pursue consummation of the Axonics Acquisition, AMS Europe will be required to redeem each series of the notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of such series of notes, plus accrued and unpaid interest, if any, to, but excluding, the date on which the notes will be redeemed. Refer to Note B – Acquisitions and Strategic Investments for more information on the Axonics acquisition.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
Factoring ArrangementsAs of June 30, 2024As of December 31, 2023
Amount
De-recognized
Weighted Average
Interest Rate
Amount
De-recognized
Weighted Average
Interest Rate
Euro denominated$187 5.3 %$206 5.1 %
Yen denominated187 0.8 %214 0.6 %
Renminbi denominated
26 1.7 %14 2.9 %

Other Contractual Obligations and Commitments

We had outstanding letters of credit of $189 million as of June 30, 2024 and $174 million as of December 31, 2023, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of June 30, 2024 and December 31, 2023 we had not recognized a related liability for our outstanding letters of credit within our accompanying unaudited consolidated balance sheets.

We have a supplier financing program offered primarily in the U.S. that enables our suppliers to opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within Accounts Payable within our unaudited consolidated balance sheets and were $131 million as of June 30, 2024 and $152 million as of December 31, 2023.

Refer to Note E – Contractual Obligations and Commitments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Supplemental Balance Sheet Information
6 Months Ended
Jun. 30, 2024
Supplemental Balance Sheet Information [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION
NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions within our accompanying unaudited consolidated balance sheets are as follows:

Trade accounts receivable, net
 As of
(in millions)June 30, 2024December 31, 2023
Trade accounts receivable$2,505 $2,338 
Allowance for credit losses(105)(110)
 $2,400 $2,228 

The following is a roll forward of our Allowance for credit losses:
Three Months Ended June 30,Six Months Ended
June 30,
(in millions)2024202320242023
Beginning balance$109 $118 $110 $109 
Credit loss expense12 19 21 35 
Write-offs(16)(10)(26)(16)
Ending balance$105 $127 $105 $127 

Inventories
 As of
(in millions)June 30, 2024December 31, 2023
Finished goods$1,558 $1,537 
Work-in-process201 174 
Raw materials849 773 
 $2,608 $2,484 
Other current assets
 As of
(in millions)June 30, 2024December 31, 2023
Restricted cash and restricted cash equivalents$75 $130 
Derivative assets267 159 
Licensing arrangements38 47 
Other376 285 
 $756 $621 
Property, plant and equipment, net
 As of
(in millions)June 30, 2024December 31, 2023
Land$140 $140 
Buildings and improvements1,876 1,843 
Equipment, furniture and fixtures3,598 3,503 
Capital in progress897 857 
 6,512 6,343 
Less: accumulated depreciation3,561 3,484 
 $2,951 $2,859 

Depreciation expense was $98 million for the second quarter of 2024, $88 million for the second quarter of 2023, $188 million for the first six months of 2024 and $170 million for the first six months of 2023.

Other long-term assets

 As of
(in millions)June 30, 2024December 31, 2023
Restricted cash equivalents$74 $60 
Operating lease right-of-use assets416 439 
Derivative assets46 107 
Investments450 413 
Licensing arrangements13 30 
Indemnification asset172 176 
Other381 306 
 $1,551 $1,531 
Accrued expenses
 As of
(in millions)June 30, 2024December 31, 2023
Legal reserves$118 $206 
Payroll and related liabilities948 1,051 
Rebates412 389 
Contingent consideration175 304 
Other667 696 
 $2,320 $2,646 

Other current liabilities
 As of
(in millions)June 30, 2024December 31, 2023
Deferred revenue$284 $266 
Licensing arrangements40 49 
Taxes payable224 220 
Other222 278 
 $770 $814 
Other long-term liabilities
 As of
(in millions)June 30, 2024December 31, 2023
Accrued income taxes$356 $470 
Legal reserves133 172 
Contingent consideration118 100 
Licensing arrangements20 41 
Operating lease liabilities365 390 
Deferred revenue316 311 
Other491 484 
 $1,800 $1,967 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Income Taxes
6 Months Ended
Jun. 30, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE G – INCOME TAXES

Our effective tax rate from continuing operations is presented below:
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Effective tax rate from continuing operations23.4 %36.6 %20.7 %32.9 %

Our reported tax rate is affected by recurring items such as the amount of our earnings subject to differing tax rates in foreign jurisdictions and the impact of certain receipts and charges that are taxed at rates that differ from our effective tax rate.

The primary reasons for the difference between the statutory rate and our reported tax rate in the second quarter and first six months of 2024 relate to certain charges for acquisition expenses, as well as certain benefits for intangible asset impairment charges and integration costs, and discrete benefits primarily related to stock-based compensation. In the second quarter and first six months of 2023, the primary difference between the statutory tax rate and our reported tax rate relates to acquisition-related charges, as well as certain benefits for integration costs, and discrete tax items primarily related to unrecognized tax benefits.

As of June 30, 2024, we had $478 million of gross unrecognized tax benefits, of which a net $406 million, if recognized, would affect our effective tax rate. As of December 31, 2023, we had $467 million of gross unrecognized tax benefits, of which a net $395 million, if recognized, would affect our effective tax rate. The change in gross unrecognized tax benefit is primarily related to current year accruals for reserves and audits.

It is reasonably possible that within the next 12 months, we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $9 million.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Commitments and Contingencies
6 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE H – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. For additional information, refer to Note I – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations.

Our accrual for legal matters that are probable and estimable was $251 million as of June 30, 2024 and $377 million as of December 31, 2023 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund, which is included in restricted cash and restricted cash equivalents in Other current assets of $75 million as of June 30, 2024 and $130 million as of December 31, 2023. Refer to Note F – Supplemental Balance Sheet Information for additional information. We did not record any litigation-related net charges during the second quarter and first six months of 2024 or 2023.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or
otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against the Company in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT filed a motion seeking prejudgment interest and enhanced damages. The Company filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial. On June 5, 2024, the Court granted the Company’s motion for judgment as a matter of law of no willful infringement, but otherwise denied the Company’s motions. The Court also denied UT’s motion for enhanced damages, awarded approximately $7.4 million in pre-judgment interest, and awarded post-judgment interest. On July 3, 2024, UT and the Company each filed a notice of appeal.

Product Liability Litigation

Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand.

We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims, which we continue to vigorously contest. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission issued its decision on May 22, 2024, holding that BSB and a former employee should be held liable and setting a fine of $17 million. The Commission held that the three other current or former Company employees should be acquitted. BSB has filed a motion to clarify the proper calculation of the fine and, to the extent
any fine is upheld, the Company intends to appeal the decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.

Like many healthcare companies, the Company receives inquiries and has ongoing discussions with governmental agencies with respect to the Company’s operations, such as the Securities and Exchange Commission (SEC), the Department of Justice (DOJ) and foreign regulators, including its operations in Vietnam with respect to alleged Foreign Corrupt Practices Act (FCPA) violations the Company received in March 2022. The Company has received related subpoenas for documents from the DOJ and the SEC with respect to the Vietnam matter, and is cooperating with the government while investigating these allegations. From time to time, the Company also self-discloses potential concerns to regulators. In the course of Vietnam-related discussions with the DOJ and SEC, the Company has disclosed that it is investigating other potential concerns in Vietnam and other countries.

From time to time, the Company also receives U.S.-based subpoenas and DOJ Civil Investigative Demands (CID), including the following matters: in April 2023, the Company received a DOJ subpoena that seeks documents and information related to its ambulatory electrocardiography monitoring business; in December 2023, the Company received a DOJ CID related to the provision of peripheral intervention services through office-based labs. The Company is cooperating with the DOJ in these matters.

Other Proceedings

On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Union Asset Management Holding AG as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. On October 23, 2023, the Company reached an agreement in principle with the lead plaintiff to settle the case. The Court granted the motion for preliminary approval of the proposed settlement on December 27, 2023, and approved the settlement and dismissed the case on April 23, 2024.

On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to Section 220 of the Delaware General Corporation Law, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On April 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa. On May 8, 2023, the Court stayed the case until the conclusion of the consolidated class action case. On October 18, 2023, Frank Tripson filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware against the Company, Michael F. Mahoney, Daniel J. Brennan, Joseph M. Fitzgerald, Shawn McCarthy, Kevin Ballinger, Ian Meredith, Susan Vissers Lisa, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P. MacMillan, David Roux, John E. Sununu, and Ellen M. Zane. On December 15, 2023, the Court stayed that case until March 31, 2024. On March 26, 2024, the Company reached an agreement in principle with all of the plaintiffs to resolve the matters.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Stockholders' Equity
6 Months Ended
Jun. 30, 2024
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY
NOTE I – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses.

On June 1, 2023, (the Mandatory Conversion Date), all outstanding shares of MCPS automatically converted into shares of common stock. The conversion rate for each share of MCPS was 2.3834 shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS.

Refer to Note J – Stockholders' Equity to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for information on the pertinent rights and privileges of our outstanding common stock.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Weighted Average Shares Outstanding
6 Months Ended
Jun. 30, 2024
Earnings Per Share [Abstract]  
WEIGHTED AVERAGE SHARES OUTSTANDING
NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING

Three Months Ended June 30,Six Months Ended June 30,
(in millions)2024202320242023
Weighted average shares outstanding — basic1,470.6 1,446.2 1,469.5 1,441.0 
Net effect of common stock equivalents13.6 10.1 13.5 10.1 
Weighted average shares outstanding - diluted1,484.2 1,456.2 1,483.0 1,451.1 

The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:
Three Months Ended June 30,Six Months Ended June 30,
(in millions)2024202320242023
Stock options outstanding(1)
0
MCPS(2)
1620
(1)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2)    Represents common stock issuable upon the conversion of MCPS. Refer to Note I – Stockholders' Equity for additional information.

We base Net income (loss) per common share - diluted upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and, prior to the Mandatory Conversion Date, our MCPS, from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.
For the second quarter and first six months of 2023, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income (loss) was reduced by cumulative Preferred stock dividends, as presented within our accompanying unaudited consolidated statements of operations, for purposes of calculating Net income attributable to Boston Scientific common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.

We issued approximately one million shares of our common stock in the second quarter of 2024, approximately five million shares in the first six months of 2024, approximately 25 million shares in the second quarter of 2023 and approximately 29 million shares in the first six months of 2023. Shares were issued following the exercise of stock options, vesting of restricted stock units or purchases under our employee stock purchase plan and, specific to 2023, following the automatic conversion of the MCPS. We did not repurchase any shares of our common stock in the first six months of 2024 or 2023. On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of June 30, 2024, we had the full amount remaining available under the authorization.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Segment Reporting
6 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
SEGMENT REPORTING
NOTE K – SEGMENT REPORTING

We aggregate our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. Refer to Note L – Revenue for net sales by reportable segment presented in accordance with GAAP.
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation.

Three Months Ended
June 30,
Six Months Ended
June 30,
Net Sales2024202320242023
MedSurg$1,480 $1,346$2,882 $2,611
Cardiovascular2,632 2,2045,058 4,275
Total net sales of reportable segments4,112 3,5497,939 6,886
Impact of foreign currency fluctuations5137 102
$4,120 $3,599$7,977 $6,988
Income (loss) before income taxes
MedSurg$511 $458$986 $867
Cardiovascular761 5821,414 1,135
Total operating income of reportable segments1,272 1,0402,400 2,002
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(153)(75)(268)(173)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(386)(241)(510)(351)
Amortization expense(213)(210)(427)(412)
Operating income (loss)520 5141,195 1,066
Other income (expense), net(100)(88)(167)(195)
Income (loss) before income taxes$420 $426$1,028 $870

Three Months Ended June 30,Six Months Ended
June 30,
Operating income margin of reportable segments2024202320242023
MedSurg34.6 %34.0 %34.2 %33.2 %
Cardiovascular28.9 %26.4 %28.0 %26.6 %
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue
6 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE
NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.

Three Months Ended June 30,
20242023
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$415 $261 $676 $384 $246 $631 
Urology363 162 525 340 146 485 
Neuromodulation214 68 282 183 61 244 
MedSurg992 491 1,483 907 453 1,360 
   Interventional Cardiology Therapies201 464 665 189 440 629 
   Watchman342 36 379 286 30 317 
   Cardiac Rhythm Management352 224 576 356 209 566 
    Electrophysiology271 157 428 85 108 193 
Cardiology1,166 881 2,047 917 787 1,704 
Peripheral Interventions308 281 590 285 250 535 
Cardiovascular1,474 1,163 2,637 1,202 1,037 2,239 
Total Net Sales$2,466 $1,654 $4,120 $2,110 $1,490 $3,599 

Six Months Ended June 30,
20242023
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$810 $508 $1,318 $735 $472 $1,207 
Urology719 319 1,038 666 289 954 
Neuromodulation405 134 539 356 123 478 
MedSurg1,933 961 2,895 1,757 883 2,640 
   Interventional Cardiology Therapies396 921 1,316 372 848 1,220 
   Watchman653 70 723 552 55 607 
   Cardiac Rhythm Management706 446 1,151 702 412 1,114 
    Electrophysiology429 300 729 170 199 370 
Cardiology2,183 1,736 3,919 1,796 1,514 3,310 
Peripheral Interventions608 555 1,163 560 478 1,039 
Cardiovascular2,791 2,291 5,082 2,356 1,993 4,349 
Total Net Sales$4,724 $3,252 $7,977 $4,113 $2,876 $6,988 

Refer to Note K - Segment Reporting for information on our reportable segments.
Three Months Ended June 30,Six Months Ended June 30,
Geographic Regions2024202320242023
U.S.$2,466 $2,110 $4,724 $4,113 
Europe, Middle East and Africa822 723 1,625 1,435 
Asia-Pacific670 626 1,317 1,174 
Latin America and Canada162 140 311 267 
Total Net Sales$4,120 $3,599 $7,977 $6,988 
Emerging Markets(1)
$680 $592 $1,328 $1,121 
(1) Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $599 million as of June 30, 2024 and $577 million as of December 31, 2023. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $59 million in the second quarter and $120 million in the first six months of 2024 that was included in the above contract liability balance as of December 31, 2023. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration
For additional information on variable consideration, refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Changes in Other Comprehensive Income
6 Months Ended
Jun. 30, 2024
Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]  
CHANGES IN OTHER COMPREHENSIVE INCOME
NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax attributable to Boston Scientific common stockholders:
(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of March 31, 2024$(34)$175 $(8)$132 
Other comprehensive income (loss) before reclassifications50 24 75 
(Income) loss amounts reclassified from accumulated other comprehensive income(3)(40)(0)(44)
Total other comprehensive income (loss)47 (16)31 
Balance as of June 30, 2024$13 $159 $(8)$164 
(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of March 31, 2023$(43)$225 $(4)$178 
Other comprehensive income (loss) before reclassifications17 58 — 74 
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(42)(0)(44)
Total other comprehensive income (loss)15 15 (0)30 
Balance as of June 30, 2023$(28)$241 $(4)$208 

(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2023$(96)$154 $(8)$49 
Other comprehensive income (loss) before reclassifications115 84 199 
(Income) loss amounts reclassified from accumulated other comprehensive income(6)(78)(0)(84)
Total other comprehensive income (loss)108 114 
Balance as of June 30, 2024$13 $159 $(8)$164 

(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(24)67 (5)39 
(Income) loss amounts reclassified from accumulated other comprehensive income(4)(95)(1)(100)
Total other comprehensive income (loss)(28)(28)(5)(61)
Balance as of June 30, 2023$(28)$241 $(4)$208 

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustment and our cash flow hedges recorded in Net change in derivative financial instruments.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1
New Accounting Pronouncements
6 Months Ended
Jun. 30, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]  
NEW ACCOUNTING PRONOUNCEMENTS
NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first six months of 2024, we implemented the following standard on a prospective basis, which did not have a material impact on our unaudited consolidated financial statements:

ASC Update No. 2022-03

ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities.
Standards to be Implemented

In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. As this accounting standard update impacts disclosures only, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. As this accounting standard update impacts disclosures only, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Insider Trading Arrangements
3 Months Ended 6 Months Ended
Jun. 30, 2024
shares
Jun. 30, 2024
shares
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On May 23, 2024, Joseph M. Fitzgerald, our Executive Vice President and Group President, Cardiology, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Fitzgerald’s plan covers the sale of 553,370 shares of our common stock, including 492,532 shares to be acquired upon exercise of stock options. Transactions under Mr. Fitzgerald’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Fitzgerald’s plan will terminate on the earlier of May 20, 2026, or the date all shares subject to the plan have been sold.
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Joseph M. Fitzgerald [Member]    
Trading Arrangements, by Individual    
Name Joseph M. Fitzgerald  
Title Executive Vice President and Group President  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date May 23, 2024  
Vance R. Brown [Member]    
Trading Arrangements, by Individual    
Arrangement Duration 727 days  
Rule Trading Arrangement, Common Stock [Member] | Joseph M. Fitzgerald [Member]    
Trading Arrangements, by Individual    
Aggregate Available 553,370 553,370
Rule Trading Arrangement Stock Appreciation Right [Member] | Joseph M. Fitzgerald [Member]    
Trading Arrangements, by Individual    
Aggregate Available 492,532 492,532
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Basis of Presentation Basis of Presentation (Policies)
6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Subsequent Events
Subsequent Events

We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure within our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.

Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note H – Commitments and Contingencies for further details.
Fair Value Measurement FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures
Legal Costs In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations.
New Accounting Pronouncements
NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first six months of 2024, we implemented the following standard on a prospective basis, which did not have a material impact on our unaudited consolidated financial statements:

ASC Update No. 2022-03

ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities.
Standards to be Implemented

In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. As this accounting standard update impacts disclosures only, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. As this accounting standard update impacts disclosures only, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisitions, Divestitures and Strategic Investments (Tables)
6 Months Ended
Jun. 30, 2024
Business Acquisition [Line Items]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Changes in the fair value of our contingent consideration liability during the first six months of 2024 associated with prior period acquisitions were as follows:

(in millions)
Balance as of December 31, 2023$404 
Amount recorded related to current year acquisitions29 
Contingent consideration net expense (benefit)18 
Contingent consideration payments and other adjustments(158)
Balance as of June 30, 2024$293 
Fair Value Measurement Inputs and Valuation Techniques
The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of June 30, 2024Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Revenue-based Payments and Milestones$293 millionDiscounted Cash FlowDiscount Rate6%-15%7%
Probability of Payment90%-100%99%
Projected Year of Payment2024-20292027
(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Investment
The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)June 30, 2024December 31, 2023
Equity method investments$207 $219 
Measurement alternative investments(1, 2)
243 194 
$450 $413 
(1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2) Includes publicly-held securities and convertible notes measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.
Acotec  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition
(in millions)
Acotec(1)
Apollo
Payment for acquisition, net of cash acquired(2)
$381 $636 
$381 $636 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction
(2) Related to Acotec, represents our majority stake investment
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
(in millions)AcotecApollo
Goodwill$337 $378 
Amortizable intangible assets334 248 
Other assets acquired93 50 
Liabilities assumed(48)(33)
Net deferred tax liabilities(76)(5)
Fair value of noncontrolling interest(259)— 
$381 $636 
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination
We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Acotec:
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
Apollo:
Amortizable intangible assets:
Technology-related$222 1112%
Customer relationships26 1112%
$248 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Goodwill and Other Intangible Assets Goodwill (Tables)
6 Months Ended
Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets and Goodwill
The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
As of June 30, 2024As of December 31, 2023
(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs
Technology-related$12,846 $(8,372)$13,207 $(8,101)
Patents476 (380)480 (387)
Other intangible assets2,188 (1,555)2,130 (1,500)
Amortizable intangible assets$15,510 $(10,307)$15,817 $(9,988)
    
Goodwill$24,297 $(9,900)$24,287 $(9,900)
IPR&D$94 $54 
Technology-related120 120 
Indefinite-lived intangible assets$214 $174 
Schedule of Goodwill
The following represents a roll-forward of our goodwill balance by reportable segment:
(in millions)MedSurgCardiovascularTotal
As of December 31, 2023$5,347 $9,041 $14,387 
Goodwill acquired24 46 71 
Impact of foreign currency fluctuations and purchase price and other adjustments(30)(30)(61)
As of June 30, 2024$5,341 $9,057 $14,397 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Notional Amounts of Outstanding Derivative Positions
The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of
June 30, 2024December 31, 2023
Forward currency contractsCash flow hedge$1,969 $2,284 
Forward currency contractsNet investment hedge645 333 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,284 3,282 
Total Notional Outstanding$6,895 $6,896 
(1) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.
Derivative Instruments, Gain (Loss)
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended June 30, 2024
Forward currency contracts
Cash flow hedges$31 $(7)$24 Cost of products sold$1,270 $(52)$12 $(41)
Net investment hedges(2)
20 (5)16 Interest expense77 (4)(3)
Foreign currency-denominated debt
Net investment hedges(3)
(2)Other, net23 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense77 (0)

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended June 30, 2023
Forward currency contracts
Cash flow hedges$74 $(17)$58 Cost of products sold$1,058 $(55)$12 $(43)
Net investment hedges(2)
22 (5)17 Interest expense70 (2)(2)
Foreign currency-denominated debt
Net investment hedges(3)
— Other, net18 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest Expense70 (0)

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Six Months Ended June 30, 2024
Forward currency contracts
Cash flow hedges$108 $(24)$84 Cost of products sold$2,479 $(101)$23 $(79)
Net investment hedges(2)
48 (11)37 Interest expense146 (8)(6)
Foreign currency-denominated debt
Net investment hedges(3)
32 (7)25 Other, net21 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense146 (0)
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Six Months Ended June 30, 2023
Forward currency contracts
Cash flow hedges$87 $(20)$67 Cost of products sold$2,098 $(125)$28 $(97)
Net investment hedges(2)
28 (6)22 Interest expense135 (5)(4)
Foreign currency-denominated debt
Net investment hedges(3)
(18)(14)Other, net61 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense135 (0)
(1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.
Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months
As of June 30, 2024, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Designated Hedging Instrument
Forward currency contractsCash flow hedgeCost of products sold$163 
Forward currency contractsNet investment hedgeInterest expense11 
Interest rate derivative contractsCash flow hedgeInterest expense(1)
Derivatives Not Designated as Hedging
Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
Location on Unaudited Consolidated Statements of OperationsThree Months Ended June 30,Six Months Ended June 30,
(in millions)2024202320242023
Net gain (loss) on currency hedge contractsOther, net$30 $11 $45 $
Net gain (loss) on currency transaction exposuresOther, net(31)(20)(51)(26)
Net currency exchange gain (loss)$(1)$(9)$(6)$(24)
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value The following are the balances of our derivative and nonderivative assets and liabilities:
 
Location on Unaudited Consolidated Balance Sheets(1)
As of
(in millions)June 30, 2024December 31, 2023
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$236 $140 
Forward currency contractsOther long-term assets46 107 
  282 246 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets31 20 
Total Derivative and Nonderivative Assets $313 $266 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$$15 
Forward currency contractsOther long-term liabilities
Foreign currency-denominated debt(2)
Long-term debt957 988 
  960 1,012 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities14 38 
Total Derivative and Nonderivative Liabilities $974 $1,050 
(1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2) Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 June 30, 2024December 31, 2023
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$2,153 $— $— $2,153 $454 $— $— $454 
Publicly-held equity securities19 — — 19 18 — — 18 
Hedging instruments— 313 — 313 — 266 — 266 
Licensing arrangements— — 51 51 — — 77 77 
 $2,173 $313 $51 $2,536 $472 $266 $77 $816 
Liabilities        
Hedging instruments$— $974 $— $974 $— $1,050 $— $1,050 
Contingent consideration liability— — 293 293 — — 404 404 
Licensing arrangements— — 60 60 — — 90 90 
 $ $974 $353 $1,327 $ $1,050 $494 $1,545 
The recurring Level 3 fair value measurements of our licensing arrangements recognized within our accompanying unaudited consolidated balance sheet as of June 30, 2024 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of June 30, 2024Valuation TechniqueUnobservable InputRange
Weighted Average (1)
Financial Asset$51 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2024-20252025
Financial Liability$60 millionDiscounted Cash FlowDiscount Rate12 %-15%13%
Projected Year of Payment2024-20262025
(1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2023$77 
Proceeds from royalty rights(21)
Fair value adjustment (expense) benefit(5)
Balance as of June 30, 2024$51 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2023$90 
Payments for royalty rights(26)
Fair value adjustment expense (benefit)(4)
Balance as of June 30, 2024$60 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Contractual Obligations and Commitments (Tables)
6 Months Ended
Jun. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)Issuance DateMaturity DateAs of
Coupon Rate(1)
June 30,
2024
December 31,
2023
March 2025 Senior Notes(3)
March 2022March 2025— 1,105 0.750%
June 2025 Senior NotesMay 2020June 2025— 500 1.900%
March 2026 Senior NotesFebruary 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027963 995 0.625%
March 2028 Senior Notes(3)
March 2022March 2028802 829 1.375%
March 2028 Senior NotesFebruary 2018March 2028344 344 4.000%
March 2029 Senior NotesFebruary 2019March 2029272 272 4.000%
March 2029 Senior Notes(3)
February 2024March 2029802 — 3.375%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031802 829 1.625%
March 2032 Senior Notes(3)
February 2024March 20321,337 — 3.500%
March 2034 Senior Notes(3)
March 2022March 2034535 553 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.500%
March 2039 Senior NotesFebruary 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior NotesFebruary 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2024 - 2049(77)(65)
Finance Lease ObligationVarious
Long-term debt$8,991 $8,571 
(1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of June 30, 2024 and December 31, 2023, respectively.
Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants
As of June 30, 2024, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
Covenant RequirementActual
 as of June 30, 2024as of June 30, 2024
Maximum permitted leverage ratio(1)
3.75 times1.97 times
(1) Ratio of total debt to deemed consolidated EBITDA, as defined by the 2021 Revolving Credit Facility credit agreement, as amended.
Transfer of Financial Assets Accounted for as Sales Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
Factoring ArrangementsAs of June 30, 2024As of December 31, 2023
Amount
De-recognized
Weighted Average
Interest Rate
Amount
De-recognized
Weighted Average
Interest Rate
Euro denominated$187 5.3 %$206 5.1 %
Yen denominated187 0.8 %214 0.6 %
Renminbi denominated
26 1.7 %14 2.9 %
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Supplemental Balance Sheet Information (Tables)
6 Months Ended
Jun. 30, 2024
Supplemental Balance Sheet Information [Abstract]  
Trade accounts receivable, net
Trade accounts receivable, net
 As of
(in millions)June 30, 2024December 31, 2023
Trade accounts receivable$2,505 $2,338 
Allowance for credit losses(105)(110)
 $2,400 $2,228 

The following is a roll forward of our Allowance for credit losses:
Three Months Ended June 30,Six Months Ended
June 30,
(in millions)2024202320242023
Beginning balance$109 $118 $110 $109 
Credit loss expense12 19 21 35 
Write-offs(16)(10)(26)(16)
Ending balance$105 $127 $105 $127 
Inventory Disclosure
Inventories
 As of
(in millions)June 30, 2024December 31, 2023
Finished goods$1,558 $1,537 
Work-in-process201 174 
Raw materials849 773 
 $2,608 $2,484 
Schedule of Other Current Assets
Other current assets
 As of
(in millions)June 30, 2024December 31, 2023
Restricted cash and restricted cash equivalents$75 $130 
Derivative assets267 159 
Licensing arrangements38 47 
Other376 285 
 $756 $621 
Property, plant and equipment, net
Property, plant and equipment, net
 As of
(in millions)June 30, 2024December 31, 2023
Land$140 $140 
Buildings and improvements1,876 1,843 
Equipment, furniture and fixtures3,598 3,503 
Capital in progress897 857 
 6,512 6,343 
Less: accumulated depreciation3,561 3,484 
 $2,951 $2,859 
Schedule of Other Assets
Other long-term assets

 As of
(in millions)June 30, 2024December 31, 2023
Restricted cash equivalents$74 $60 
Operating lease right-of-use assets416 439 
Derivative assets46 107 
Investments450 413 
Licensing arrangements13 30 
Indemnification asset172 176 
Other381 306 
 $1,551 $1,531 
Schedule of Accrued Liabilities
Accrued expenses
 As of
(in millions)June 30, 2024December 31, 2023
Legal reserves$118 $206 
Payroll and related liabilities948 1,051 
Rebates412 389 
Contingent consideration175 304 
Other667 696 
 $2,320 $2,646 
Other Current Liabilities
Other current liabilities
 As of
(in millions)June 30, 2024December 31, 2023
Deferred revenue$284 $266 
Licensing arrangements40 49 
Taxes payable224 220 
Other222 278 
 $770 $814 
Other long-term liabilities
Other long-term liabilities
 As of
(in millions)June 30, 2024December 31, 2023
Accrued income taxes$356 $470 
Legal reserves133 172 
Contingent consideration118 100 
Licensing arrangements20 41 
Operating lease liabilities365 390 
Deferred revenue316 311 
Other491 484 
 $1,800 $1,967 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Income Taxes (Tables)
6 Months Ended
Jun. 30, 2024
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate from Continuing Operations
Our effective tax rate from continuing operations is presented below:
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Effective tax rate from continuing operations23.4 %36.6 %20.7 %32.9 %
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Weighted Average Shares Outstanding (Tables)
6 Months Ended
Jun. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares
NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING

Three Months Ended June 30,Six Months Ended June 30,
(in millions)2024202320242023
Weighted average shares outstanding — basic1,470.6 1,446.2 1,469.5 1,441.0 
Net effect of common stock equivalents13.6 10.1 13.5 10.1 
Weighted average shares outstanding - diluted1,484.2 1,456.2 1,483.0 1,451.1 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:
Three Months Ended June 30,Six Months Ended June 30,
(in millions)2024202320242023
Stock options outstanding(1)
0
MCPS(2)
1620
(1)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2)    Represents common stock issuable upon the conversion of MCPS. Refer to Note I – Stockholders' Equity for additional information.
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation.

Three Months Ended
June 30,
Six Months Ended
June 30,
Net Sales2024202320242023
MedSurg$1,480 $1,346$2,882 $2,611
Cardiovascular2,632 2,2045,058 4,275
Total net sales of reportable segments4,112 3,5497,939 6,886
Impact of foreign currency fluctuations5137 102
$4,120 $3,599$7,977 $6,988
Income (loss) before income taxes
MedSurg$511 $458$986 $867
Cardiovascular761 5821,414 1,135
Total operating income of reportable segments1,272 1,0402,400 2,002
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(153)(75)(268)(173)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(386)(241)(510)(351)
Amortization expense(213)(210)(427)(412)
Operating income (loss)520 5141,195 1,066
Other income (expense), net(100)(88)(167)(195)
Income (loss) before income taxes$420 $426$1,028 $870

Three Months Ended June 30,Six Months Ended
June 30,
Operating income margin of reportable segments2024202320242023
MedSurg34.6 %34.0 %34.2 %33.2 %
Cardiovascular28.9 %26.4 %28.0 %26.6 %
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue (Tables)
6 Months Ended
Jun. 30, 2024
Disaggregation of Revenue [Abstract]  
Disaggregation of Revenue The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.
Three Months Ended June 30,
20242023
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$415 $261 $676 $384 $246 $631 
Urology363 162 525 340 146 485 
Neuromodulation214 68 282 183 61 244 
MedSurg992 491 1,483 907 453 1,360 
   Interventional Cardiology Therapies201 464 665 189 440 629 
   Watchman342 36 379 286 30 317 
   Cardiac Rhythm Management352 224 576 356 209 566 
    Electrophysiology271 157 428 85 108 193 
Cardiology1,166 881 2,047 917 787 1,704 
Peripheral Interventions308 281 590 285 250 535 
Cardiovascular1,474 1,163 2,637 1,202 1,037 2,239 
Total Net Sales$2,466 $1,654 $4,120 $2,110 $1,490 $3,599 

Six Months Ended June 30,
20242023
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$810 $508 $1,318 $735 $472 $1,207 
Urology719 319 1,038 666 289 954 
Neuromodulation405 134 539 356 123 478 
MedSurg1,933 961 2,895 1,757 883 2,640 
   Interventional Cardiology Therapies396 921 1,316 372 848 1,220 
   Watchman653 70 723 552 55 607 
   Cardiac Rhythm Management706 446 1,151 702 412 1,114 
    Electrophysiology429 300 729 170 199 370 
Cardiology2,183 1,736 3,919 1,796 1,514 3,310 
Peripheral Interventions608 555 1,163 560 478 1,039 
Cardiovascular2,791 2,291 5,082 2,356 1,993 4,349 
Total Net Sales$4,724 $3,252 $7,977 $4,113 $2,876 $6,988 

Refer to Note K - Segment Reporting for information on our reportable segments.
Three Months Ended June 30,Six Months Ended June 30,
Geographic Regions2024202320242023
U.S.$2,466 $2,110 $4,724 $4,113 
Europe, Middle East and Africa822 723 1,625 1,435 
Asia-Pacific670 626 1,317 1,174 
Latin America and Canada162 140 311 267 
Total Net Sales$4,120 $3,599 $7,977 $6,988 
Emerging Markets(1)
$680 $592 $1,328 $1,121 
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Changes in Other Comprehensive Income (Tables)
6 Months Ended
Jun. 30, 2024
Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]  
Changes in Other Comprehensive Income
The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax attributable to Boston Scientific common stockholders:
(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of March 31, 2024$(34)$175 $(8)$132 
Other comprehensive income (loss) before reclassifications50 24 75 
(Income) loss amounts reclassified from accumulated other comprehensive income(3)(40)(0)(44)
Total other comprehensive income (loss)47 (16)31 
Balance as of June 30, 2024$13 $159 $(8)$164 
(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of March 31, 2023$(43)$225 $(4)$178 
Other comprehensive income (loss) before reclassifications17 58 — 74 
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(42)(0)(44)
Total other comprehensive income (loss)15 15 (0)30 
Balance as of June 30, 2023$(28)$241 $(4)$208 

(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2023$(96)$154 $(8)$49 
Other comprehensive income (loss) before reclassifications115 84 199 
(Income) loss amounts reclassified from accumulated other comprehensive income(6)(78)(0)(84)
Total other comprehensive income (loss)108 114 
Balance as of June 30, 2024$13 $159 $(8)$164 

(in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(24)67 (5)39 
(Income) loss amounts reclassified from accumulated other comprehensive income(4)(95)(1)(100)
Total other comprehensive income (loss)(28)(28)(5)(61)
Balance as of June 30, 2023$(28)$241 $(4)$208 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisitions, Divestitures and Strategic Investments - Narrative (Details)
$ / shares in Units, $ in Millions
Jun. 18, 2024
USD ($)
$ / shares
Jan. 08, 2024
USD ($)
$ / shares
Apr. 04, 2023
USD ($)
Feb. 20, 2023
USD ($)
Jun. 30, 2024
USD ($)
Feb. 20, 2023
$ / shares
Business Acquisition [Line Items]            
Uncapped Contingent Considertation         $ 163  
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity         233  
Acotec            
Business Acquisition [Line Items]            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners           35.00%
Silk Medical            
Business Acquisition [Line Items]            
Business Acquisition, Percentage of Voting Interests Acquired 100.00%          
Business Acquisition, Share Price | $ / shares $ 27.50          
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value $ 1,260          
Axonics            
Business Acquisition [Line Items]            
Business Acquisition, Percentage of Voting Interests Acquired   100.00%        
Business Acquisition, Share Price | $ / shares   $ 71.00        
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value   $ 3,670        
Apollo            
Business Acquisition [Line Items]            
Business Acquisition, Percentage of Voting Interests Acquired     100.00%      
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value     $ 636      
Acotec            
Business Acquisition [Line Items]            
Business Acquisition, Percentage of Voting Interests Acquired           65.00%
Business Acquisition, Share Price | $ / shares           $ 20.00
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value       $ 519    
All Business Acquisitions            
Business Acquisition [Line Items]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High         $ 320  
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisitions, Divestitures and Strategic Investments - Price Allocation (Details) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Feb. 20, 2023
Business Acquisition [Line Items]        
Payment for acquisition, net of cash acquired $ 95 $ 1,018    
Cash 793   $ 411  
Acotec        
Business Acquisition [Line Items]        
Payment for acquisition, net of cash acquired 381      
Net assets acquired 381      
Cash       $ 140
Apollo        
Business Acquisition [Line Items]        
Payment for acquisition, net of cash acquired 636      
Net assets acquired $ 636      
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisitions, Divestitures and Strategic Investments - Assets and Liabilities Assumed (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Business Acquisition [Line Items]    
Goodwill $ 14,397 $ 14,387
Acotec    
Business Acquisition [Line Items]    
Goodwill 337  
Amortizable intangible assets 334  
Other assets acquired 93  
Liabilities assumed (48)  
Net deferred tax liabilities (76)  
Fair value of noncontrolling interest (259)  
Net assets acquired 381  
Apollo    
Business Acquisition [Line Items]    
Goodwill 378  
Amortizable intangible assets 248  
Other assets acquired 50  
Liabilities assumed (33)  
Net deferred tax liabilities (5)  
Fair value of noncontrolling interest 0  
Net assets acquired $ 636  
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisitions, Divestitures and Strategic Investments - Intangible Assets Acquired (Details)
$ in Millions
6 Months Ended
Jun. 30, 2024
USD ($)
Acotec  
Business Acquisition [Line Items]  
Amortizable intangible assets $ 334
Acotec | Technology-related  
Business Acquisition [Line Items]  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles $ 308
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 11 years
Acotec | Technology-related | Weighted Average  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 14.00%
Acotec | Customer relationships  
Business Acquisition [Line Items]  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles $ 15
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 11 years
Acotec | Customer relationships | Weighted Average  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 14.00%
Acotec | Other intangible assets  
Business Acquisition [Line Items]  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles $ 11
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 13 years
Acotec | Other intangible assets | Weighted Average  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 14.00%
Apollo  
Business Acquisition [Line Items]  
Amortizable intangible assets $ 248
Apollo | Technology-related  
Business Acquisition [Line Items]  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles $ 222
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 11 years
Apollo | Technology-related | Weighted Average  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 12.00%
Apollo | Customer relationships  
Business Acquisition [Line Items]  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles $ 26
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 11 years
Apollo | Customer relationships | Weighted Average  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 12.00%
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Business Combination, Contingent Consideration, Liability [Roll Forward]        
Balance as of December 31, 2023     $ 404  
Fair value of contingent consideration recorded in purchase accounting     29  
Contingent consideration net expense (benefit) $ 2 $ 19 18 $ 31
Contingent consideration payments and other adjustments     (158)  
Balance as of June 30, 2024 $ 293   $ 293  
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisitions, Divestitures and Strategic Investments - Level 3 Contingent Consideration (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Business Acquisition [Line Items]    
Contingent Consideration Liability $ 293 $ 404
Revenue-based Payments and Milestones | Discount Rate    
Business Acquisition [Line Items]    
Contingent Consideration Liability $ 293  
contingent consideration liability, probability of payment 99.00%  
Revenue-based Payments and Milestones | Discount Rate | Minimum    
Business Acquisition [Line Items]    
contingent consideration liability, probability of payment 90.00%  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 6.00%  
Revenue-based Payments and Milestones | Discount Rate | Maximum    
Business Acquisition [Line Items]    
contingent consideration liability, probability of payment 100.00%  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 15.00%  
Revenue-based Payments and Milestones | Discount Rate | Weighted Average    
Business Acquisition [Line Items]    
Risk-Adjusted Discount Rates used in Purchase Price Allocation 7.00%  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]    
Equity method investments $ 207 $ 219
Measurement alternative investments(1, 2) 243 194
Investments $ 450 $ 413
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Intangible Assets and Goodwill [Line Items]    
Gross Carrying Amount $ 15,510 $ 15,817
Accumulated Amortization/ Write-offs (10,307) (9,988)
Indefinite-lived Intangible Assets (Excluding Goodwill) 214 174
Goodwill [Roll Forward]    
Goodwill Beginning Balance 14,387  
Goodwill acquired 71  
Impact of foreign currency fluctuations and purchase price and other adjustments (61)  
Goodwill Ending Balance 14,397  
MedSurg    
Goodwill [Roll Forward]    
Goodwill Beginning Balance 5,347  
Goodwill acquired 24  
Impact of foreign currency fluctuations and purchase price and other adjustments (30)  
Goodwill Ending Balance 5,341  
Cardiovascular    
Goodwill [Roll Forward]    
Goodwill Beginning Balance 9,041  
Goodwill acquired 46  
Impact of foreign currency fluctuations and purchase price and other adjustments (30)  
Goodwill Ending Balance 9,057  
Goodwill    
Intangible Assets and Goodwill [Line Items]    
Goodwill, Gross 24,297 24,287
Goodwill, Impaired, Accumulated Impairment Loss (9,900) (9,900)
IPR&D    
Intangible Assets and Goodwill [Line Items]    
Indefinite-lived Intangible Assets (Excluding Goodwill) 94 54
Technology-related    
Intangible Assets and Goodwill [Line Items]    
Indefinite-lived Intangible Assets (Excluding Goodwill) 120 120
Technology-related    
Intangible Assets and Goodwill [Line Items]    
Gross Carrying Amount 12,846 13,207
Accumulated Amortization/ Write-offs (8,372) (8,101)
Patents    
Intangible Assets and Goodwill [Line Items]    
Gross Carrying Amount 476 480
Accumulated Amortization/ Write-offs (380) (387)
Other intangible assets    
Intangible Assets and Goodwill [Line Items]    
Gross Carrying Amount 2,188 2,130
Accumulated Amortization/ Write-offs $ (1,555) $ (1,500)
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]        
Intangible asset impairment charges $ 276 $ 57 $ 276 $ 57
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements - Narrative (Details)
€ in Millions, $ in Millions
6 Months Ended
Jun. 30, 2024
USD ($)
derivative_instrument
Jun. 30, 2024
EUR (€)
derivative_instrument
Dec. 31, 2023
USD ($)
derivative_instrument
Dec. 31, 2023
EUR (€)
derivative_instrument
Derivative [Line Items]        
Cash $ 793   $ 411  
Debt Instrument, Fair Value Disclosure 10,073   8,735  
Fair Value, Measurements, Recurring [Member]        
Derivative [Line Items]        
Money Market Funds, at Carrying Value 2,153   454  
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]        
Derivative [Line Items]        
Money Market Funds, at Carrying Value $ 2,153   $ 454  
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member]        
Derivative [Line Items]        
Number of Interest Rate Derivatives Held | derivative_instrument 0 0 0 0
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Maximum        
Derivative [Line Items]        
Forward Currency Contracts, Time to Maturity 2 years      
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Minimum        
Derivative [Line Items]        
Forward Currency Contracts, Time to Maturity 1 year      
Foreign Exchange Forward | Not Designated as Hedging Instrument [Member]        
Derivative [Line Items]        
Derivative, Term of Contract (less than) 1 year      
Derivative, Remaining Maturity 1 year 1 year    
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member]        
Derivative [Line Items]        
Forward Currency Contracts, Time to Maturity 36 months      
December 2027 Notes [Member]        
Derivative [Line Items]        
Long-term Debt $ 963 € 900 $ 995 € 900
Debt Instrument, Interest Rate, Stated Percentage 0.625% 0.625%    
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements - Notional Amounts (Details)
€ in Millions, $ in Millions
Jun. 30, 2024
USD ($)
Jun. 30, 2024
EUR (€)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
EUR (€)
Derivative [Line Items]        
Derivative, Notional Amount $ 6,895   $ 6,896  
December 2027 Notes [Member]        
Derivative [Line Items]        
Long-term Debt 963 € 900 995 € 900
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]        
Derivative [Line Items]        
Derivative, Notional Amount 3,284   3,282  
Foreign Exchange Contract [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member]        
Derivative [Line Items]        
Derivative, Notional Amount 1,969   2,284  
Foreign Exchange Contract [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member]        
Derivative [Line Items]        
Derivative, Notional Amount 645   333  
foreign currency denominated in debt [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member]        
Derivative [Line Items]        
Derivative, Notional Amount $ 997   $ 997  
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements - Effect of Hedging Relationships on Accumulated Other Comprehensive Income (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Cost of products sold $ 1,270,000,000 $ 1,058,000,000 $ 2,479,000,000 $ 2,098,000,000
Interest Expense 77,000,000 70,000,000 146,000,000 135,000,000
Other Operating Income (Expense), Net 23,000,000 18,000,000 21,000,000 61,000,000
Foreign Currency Translation Adjustment        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 0 0 0 0
Foreign Exchange Contract [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Cost of Sales [Member]        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 31,000,000 74,000,000 108,000,000 87,000,000
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax (7,000,000) (17,000,000) (24,000,000) (20,000,000)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 24,000,000 58,000,000 84,000,000 67,000,000
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (52,000,000) (55,000,000) (101,000,000) (125,000,000)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 12,000,000 12,000,000 23,000,000 28,000,000
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (41,000,000) (43,000,000) (79,000,000) (97,000,000)
Foreign Exchange Contract [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Expense [Member]        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 20,000,000 22,000,000 48,000,000 28,000,000
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax (5,000,000) (5,000,000) (11,000,000) (6,000,000)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax 16,000,000 17,000,000 37,000,000 22,000,000
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax (4,000,000) (2,000,000) (8,000,000) (5,000,000)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax 1,000,000 1,000,000 2,000,000 1,000,000
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax (3,000,000) (2,000,000) (6,000,000) (4,000,000)
foreign currency denominated in debt [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Expense [Member]        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 9,000,000 1,000,000 32,000,000 (18,000,000)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax (2,000,000) 0 (7,000,000) 4,000,000
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax 7,000,000 1,000,000 25,000,000 (14,000,000)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax 0 0 0 0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax 0 0 0 0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax 0 0 0 0
Interest Rate Contract [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Expense [Member]        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 0 0 0 0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 0 0 0 0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 0 0 0 0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 0 1,000,000 1,000,000 1,000,000
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 0 0 0 0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax $ 0 $ 1,000,000 $ 1,000,000 $ 1,000,000
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements - Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings (Details)
$ in Millions
Jun. 30, 2024
USD ($)
Foreign Exchange Contract [Member] | Cash Flow Hedging [Member] | Cost of Sales [Member]  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months $ 163
Foreign Exchange Contract [Member] | Net Investment Hedging [Member] | Interest Expense [Member]  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net 11
Interest Rate Contract [Member] | Cash Flow Hedging [Member] | Interest Expense [Member]  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net $ (1)
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements - Location on Unaudited Consolidated Statements of Operations (Details) - Not Designated as Hedging Instrument [Member] - Other Nonoperating Income (Expense) [Member] - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]        
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments $ 30 $ 11 $ 45 $ 2
Foreign Currency Transaction Gain (Loss), before Tax (31) (20) (51) (26)
Net currency exchange gain (loss) $ (1) $ (9) $ (6) $ (24)
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements - Balance Sheet Location (Details)
€ in Millions, $ in Millions
Jun. 30, 2024
EUR (€)
Jun. 30, 2024
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2023
USD ($)
Derivatives, Fair Value [Line Items]        
Derivative Asset, Fair Value, Gross Asset   $ 313   $ 266
Derivative Liability, Fair Value, Gross Liability   974   1,050
December 2027 Notes [Member]        
Derivatives, Fair Value [Line Items]        
Long-term Debt € 900 963 € 900 995
Designated as Hedging Instrument [Member]        
Derivatives, Fair Value [Line Items]        
Derivative Instruments in Hedges, Assets, at Fair Value   282   246
Derivative Instruments in Hedges, Liabilities, at Fair Value   960   1,012
Prepaid Expenses and Other Current Assets [Member] | Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]        
Derivatives, Fair Value [Line Items]        
Derivative Instruments in Hedges, Assets, at Fair Value   236   140
Prepaid Expenses and Other Current Assets [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]        
Derivatives, Fair Value [Line Items]        
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value   31   20
Other Noncurrent Assets [Member] | Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]        
Derivatives, Fair Value [Line Items]        
Derivative Instruments in Hedges, Assets, at Fair Value   46   107
Other Current Liabilities [Member] | Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]        
Derivatives, Fair Value [Line Items]        
Derivative Instruments in Hedges, Liabilities, at Fair Value   3   15
Other Current Liabilities [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]        
Derivatives, Fair Value [Line Items]        
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value   14   38
Other Noncurrent Liabilities [Member] | Designated as Hedging Instrument [Member]        
Derivatives, Fair Value [Line Items]        
Derivative Instruments in Hedges, Liabilities, at Fair Value   957   988
Other Noncurrent Liabilities [Member] | Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]        
Derivatives, Fair Value [Line Items]        
Derivative Instruments in Hedges, Liabilities, at Fair Value   $ 0   $ 9
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements - Fair Value (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Asset $ 46 $ 107
Licensing arrangements, asset 13 30
Contingent Consideration Liability 293 404
Licensing arrangements, liability 20 41
Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money Market Funds, at Carrying Value 2,153 454
Equity Securities, FV-NI 19 18
Derivative Asset 313 266
Licensing arrangements, asset 51 77
Assets, Fair Value Disclosure 2,536 816
Derivative Liability 974 1,050
Contingent Consideration Liability 293 404
Licensing arrangements, liability 60 90
Financial and Nonfinancial Liabilities, Fair Value Disclosure 1,327 1,545
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money Market Funds, at Carrying Value 2,153 454
Equity Securities, FV-NI 19 18
Derivative Asset 0 0
Licensing arrangements, asset 0 0
Assets, Fair Value Disclosure 2,173 472
Derivative Liability 0 0
Contingent Consideration Liability 0 0
Licensing arrangements, liability 0 0
Financial and Nonfinancial Liabilities, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money Market Funds, at Carrying Value 0 0
Equity Securities, FV-NI 0 0
Derivative Asset 313 266
Licensing arrangements, asset 0 0
Assets, Fair Value Disclosure 313 266
Derivative Liability 974 1,050
Contingent Consideration Liability 0 0
Licensing arrangements, liability 0 0
Financial and Nonfinancial Liabilities, Fair Value Disclosure 974 1,050
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Licensing arrangements, asset 51  
Licensing arrangements, liability 60  
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money Market Funds, at Carrying Value 0 0
Equity Securities, FV-NI 0 0
Derivative Asset 0 0
Licensing arrangements, asset 51 77
Assets, Fair Value Disclosure 51 77
Derivative Liability 0 0
Contingent Consideration Liability 293 404
Licensing arrangements, liability 60 90
Financial and Nonfinancial Liabilities, Fair Value Disclosure $ 353 $ 494
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements - Licensing Arrangements (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Licensing arrangements, asset $ 13 $ 30
Licensing arrangements, liability $ 20 $ 41
Licensing arrangement assets [Member]    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Risk-Adjusted Discount Rates used in Purchase Price Allocation 15.00%  
Licensing arrangement assets [Member] | Weighted Average    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Risk-Adjusted Discount Rates used in Purchase Price Allocation 15.00%  
Licensing arrangement liabilities [Member] | Weighted Average    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Risk-Adjusted Discount Rates used in Purchase Price Allocation 13.00%  
Licensing arrangement liabilities [Member] | Minimum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Risk-Adjusted Discount Rates used in Purchase Price Allocation 12.00%  
Licensing arrangement liabilities [Member] | Maximum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Risk-Adjusted Discount Rates used in Purchase Price Allocation 15.00%  
Fair Value, Inputs, Level 3 [Member]    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Licensing arrangements, asset $ 51  
Licensing arrangements, liability $ 60  
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Hedging Activities and Fair Value Measurements - Change in Fair Value (Details)
$ in Millions
6 Months Ended
Jun. 30, 2024
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Licensing arrangements, asset $ 30
Licensing arrangements, liability 41
Licensing arrangements, asset 13
Licensing arrangements, liability 20
Licensing arrangement assets [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Proceeds from royalty rights (21)
Fair value adjustment (expense) benefit (5)
Licensing arrangement liabilities [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Payments for Royalties (26)
Fair value adjustment (expense) benefit (4)
Fair Value, Measurements, Recurring [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Licensing arrangements, asset 77
Licensing arrangements, liability 90
Licensing arrangements, asset 51
Licensing arrangements, liability 60
Fair Value, Inputs, Level 3 [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Licensing arrangements, asset 51
Licensing arrangements, liability 60
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Licensing arrangements, asset 77
Licensing arrangements, liability 90
Licensing arrangements, asset 51
Licensing arrangements, liability $ 60
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Contractual Obligations and Commitments (Details)
€ in Millions
3 Months Ended 6 Months Ended
Mar. 31, 2024
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
EUR (€)
Jun. 30, 2024
Jun. 30, 2024
Rate
Feb. 22, 2024
EUR (€)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
EUR (€)
May 10, 2021
USD ($)
Debt Instrument [Line Items]                    
Total debt   $ 10,571,000,000           $ 9,102,000,000    
Debt, Current   1,580,000,000           531,000,000    
Long-term Debt and Capital Lease Obligations   8,991,000,000           8,571,000,000    
Exclusion from EBITDA for Restructuring Charges   500,000,000                
Restructuring charges remaining to be excluded from calculation of consolidated EBITDA   453,000,000                
Amount excluded from debt in leverage ratio   2,120,000,000                
Legal payments remaining to be excluded from calculation of consolidated EBITDA   1,448,000,000                
Letters of Credit Outstanding, Amount   189,000,000           174,000,000    
Qualified Acquisition Consideration   1,000,000,000.000                
Proceeds from Issuance of Senior Long-Term Debt   2,145,000,000 $ 0              
Supplier Finance Program Obligation. current   131,000,000           152,000,000    
Litigation payment exclusion from EBITDA   $ 1,000,000,000.000                
AMS Europe                    
Debt Instrument [Line Items]                    
Debt Instrument, Redemption Price, Percentage   101.00%                
Commercial Paper [Member]                    
Debt Instrument [Line Items]                    
Debt, Current   $ 0           0    
Current Requirement [Member]                    
Debt Instrument [Line Items]                    
Maximum Leverage Ratio         3.75          
Actual, Covenant [Member]                    
Debt Instrument [Line Items]                    
Maximum Leverage Ratio         1.97          
Requirement, as of December 31, 2021 and through remaining term of facility                    
Debt Instrument [Line Items]                    
Maximum Leverage Ratio         3.75          
Requirement, four succeeding quarters following qualified acquisition                    
Debt Instrument [Line Items]                    
Maximum Leverage Ratio         4.75          
Requirement, fifth quarter following qualified acquisition [Member]                    
Debt Instrument [Line Items]                    
Maximum Leverage Ratio         4.50          
Requirement, sixth quarter following qualified acquisition                    
Debt Instrument [Line Items]                    
Maximum Leverage Ratio         4.25          
Requirement, seventh quarter following qualified acquisition                    
Debt Instrument [Line Items]                    
Maximum Leverage Ratio         4.00          
Requirement, eighth quarter following qualified acquisition and through remaining term of facility                    
Debt Instrument [Line Items]                    
Maximum Leverage Ratio         3.75          
Revolving Credit Facility [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   0           0    
Line of Credit Facility, Maximum Borrowing Capacity                   $ 2,750,000,000
March 2024 Notes [Member]                    
Debt Instrument [Line Items]                    
Debt Instrument, Interest Rate, Stated Percentage         3.45%          
March 2025 Notes                    
Debt Instrument [Line Items]                    
Long-term Debt   0           1,105,000,000    
Debt Instrument, Interest Rate, Stated Percentage         0.75%          
June 2025 Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   0           500,000,000    
Debt Instrument, Interest Rate, Stated Percentage         1.90%          
March 2026 Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   255,000,000           255,000,000    
Debt Instrument, Interest Rate, Stated Percentage         3.75%          
December 2027 Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   963,000,000   € 900       995,000,000 € 900  
Debt Instrument, Interest Rate, Stated Percentage         0.625%          
March 2028 Senior Notes                    
Debt Instrument [Line Items]                    
Long-term Debt   802,000,000           829,000,000    
Debt Instrument, Interest Rate, Stated Percentage         1.375%          
March 2028 Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   344,000,000           344,000,000    
Debt Instrument, Interest Rate, Stated Percentage         4.00%          
March 2029 Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   272,000,000           272,000,000    
Debt Instrument, Interest Rate, Stated Percentage         4.00%          
June 2030 Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   1,200,000,000           1,200,000,000    
Debt Instrument, Interest Rate, Stated Percentage         2.65%          
March 2031 Notes                    
Debt Instrument [Line Items]                    
Long-term Debt   802,000,000           829,000,000    
Debt Instrument, Interest Rate, Stated Percentage         1.625%          
March 2034 Notes                    
Debt Instrument [Line Items]                    
Long-term Debt   535,000,000           553,000,000    
Debt Instrument, Interest Rate, Stated Percentage         1.875%          
November 2035 Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   350,000,000           350,000,000    
Debt Instrument, Interest Rate, Stated Percentage         6.50%          
November 2035 Notes [Member] | Credit Rating A- or A3 Or Higher                    
Debt Instrument [Line Items]                    
Debt Instrument, Interest Rate, Stated Percentage         6.25%          
March 2039 Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   450,000,000           450,000,000    
Debt Instrument, Interest Rate, Stated Percentage         4.55%          
January 2040 Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   300,000,000           300,000,000    
Debt Instrument, Interest Rate, Stated Percentage         7.375%          
March 2049 Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   650,000,000           650,000,000    
Debt Instrument, Interest Rate, Stated Percentage         4.70%          
Senior Notes [Member]                    
Debt Instrument [Line Items]                    
Long-term Debt   10,633,000,000           9,136,000,000    
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net   (77,000,000)           (65,000,000)    
Finance Lease Obligation                    
Debt Instrument [Line Items]                    
Long-term Debt   4,000,000           5,000,000    
the Offering                    
Debt Instrument [Line Items]                    
Long-term Debt | €             € 2,000      
March 2029 Euro Senior Notes                    
Debt Instrument [Line Items]                    
Long-term Debt   802,000,000         750 0    
Debt Instrument, Interest Rate, Stated Percentage         3.375% 3.375%        
March 2032 Euro Senior Notes                    
Debt Instrument [Line Items]                    
Long-term Debt   1,337,000,000         € 1,250 0    
Debt Instrument, Interest Rate, Stated Percentage         3.50% 3.50%        
Euro Denominated Factoring Arrangements [Member]                    
Debt Instrument [Line Items]                    
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 187,000,000           206,000,000    
Average interest rate of de-recognized receivables 5.10% 5.30%                
Yen Denominated Factoring Arrangements [Member]                    
Debt Instrument [Line Items]                    
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 187,000,000           214,000,000    
Average interest rate of de-recognized receivables 0.60% 0.80%                
Renminbi Denominated Factoring Arrangements [Member]                    
Debt Instrument [Line Items]                    
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 26,000,000           $ 14,000,000    
Average interest rate of de-recognized receivables 2.90% 1.70%                
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]          
Depreciation $ 98 $ 88 $ 188 $ 170  
Trade accounts receivable, net          
Accounts receivable 2,505   2,505   $ 2,338
Less: allowance for doubtful accounts (105)   (105)   (110)
Trade accounts receivable, net 2,400   2,400   2,228
Allowance for doubtful accounts          
Beginning balance 109 118 110 109  
Charges to expenses 12 19 21 35  
Utilization of allowances (16) (10) (26) (16)  
Ending balance 105 127 105 127  
Inventories          
Inventory, Finished Goods, Net of Reserves 1,558   1,558   1,537
Inventory, Work in Process, Net of Reserves 201   201   174
Inventory, Raw Materials, Net of Reserves 849   849   773
Inventories 2,608   2,608   2,484
Other Current Assets [Abstract]          
Restricted Cash and Cash Equivalents in Other current assets 75 135 75 135 130
Derivative Asset, Current 267   267   159
Licensing arrangements 38   38   47
Other Assets, Miscellaneous, Current 376   376   285
Other Assets, Current 756   756   621
Property, plant and equipment, net          
Land 140   140   140
Buildings and improvements 1,876   1,876   1,843
Equipment, furniture and fixtures 3,598   3,598   3,503
Capital in progress 897   897   857
Property, plant and equipment 6,512   6,512   6,343
Less: accumulated depreciation 3,561   3,561   3,484
Property, plant and equipment, net 2,951   2,951   2,859
Other Assets, Noncurrent [Abstract]          
Restricted cash equivalents included in Other long-term assets 74 $ 60 74 $ 60 60
Operating Lease, Right-of-Use Asset 416   416   439
Derivative Asset 46   46   107
Investments 450   450   413
Licensing arrangements, asset 13   13   30
Indemnification asset 172   172   176
Other, Other Long-term Assets 381   381   306
Other Assets, Noncurrent 1,551   1,551   1,531
Accrued expenses          
Legal reserves, current 118   118   206
Payroll and related liabilities 948   948   1,051
Accrued Rebates, Current 412   412   389
Business Combination, Contingent Consideration, Liability, Current 175   175   304
Other 667   667   696
Accrued Liabilities, Current 2,320   2,320   2,646
Other Liabilities, Current [Abstract]          
Deferred Revenue, Current 284   284   266
Licensing Arrangements 40   40   49
Taxes Payable, Current 224   224   220
Other 222   222   278
Other Liabilities, Current 770   770   814
Other long-term liabilities          
Accrued income taxes 356   356   470
Estimated Litigation Liability, Noncurrent 133   133   172
Business Combination, Contingent Consideration, Liability, Noncurrent 118   118   100
Licensing arrangements, liability 20   20   41
Operating Lease, Liability, Noncurrent 365   365   390
Deferred Revenue 316   316   311
Other Accrued Liabilities, Noncurrent 491   491   484
Other long-term liabilities $ 1,800   $ 1,800   $ 1,967
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Income Taxes (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Effective Income Tax Rate Reconciliation, Percent [Abstract]          
Effective tax rate from continuing operations 23.40% 36.60% 20.70% 32.90%  
Unrecognized Tax Benefits $ 478   $ 478   $ 467
Unrecognized Tax Benefits that Would Impact Effective Tax Rate 406   406   $ 395
Decrease in Unrecognized Tax Benefits is Reasonably Possible $ 9   $ 9    
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Commitments and Contingencies (Details) - USD ($)
$ in Millions
Jan. 31, 2023
Jun. 30, 2024
Jun. 05, 2024
May 22, 2024
Dec. 31, 2023
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]            
Accrual for legal matters that are probable and estimable   $ 251.0     $ 377.0  
Restricted Cash and Cash Equivalents in Other current assets   $ 75.0     $ 130.0 $ 135.0
Litigation Settlement, Amount Awarded to Other Party $ 42.0          
Pre-Judgement Interest     $ 7.4      
CADE fine       $ 17.0    
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Stockholders' Equity (Details)
$ / shares in Units, $ in Millions
6 Months Ended
May 27, 2020
USD ($)
$ / shares
shares
Jun. 30, 2024
shares
Dec. 31, 2023
shares
Jun. 01, 2023
Class of Stock [Line Items]        
Preferred Stock, Shares Authorized   50,000,000 50,000,000  
Preferred Stock, Shares Issued   0 0  
5.50% MCPS, Series A [Member]        
Class of Stock [Line Items]        
Preferred Stock, Shares Issued 10,062,500      
Preferred Stock, Dividend Rate, Percentage 5.50%      
Preferred Stock, Liquidation Preference Per Share | $ / shares $ 100      
Net proceeds from issuance of preferred stock in connection with public offering | $ $ 975      
Preferred Stock, Convertible, Conversion Ratio       2.3834
Common Stock, par value $0.01 per share        
Class of Stock [Line Items]        
Conversion of Stock, Shares Converted   24,000,000    
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Weighted Average Shares Outstanding (Details) - shares
shares in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Weighted average shares outstanding — basic 1,470.6 1,446.2 1,469.5 1,441.0
Net effect of common stock equivalents 13.6 10.1 13.5 10.1
Weighted average shares outstanding - diluted 1,484.2 1,456.2 1,483.0 1,451.1
Share-based Payment Arrangement, Option        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0.0 0.0 0.0 0.0
5.50% MCPS, Series A [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0.0 16.0 0.0 20.0
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Weighted Average Shares Outstanding - Narrative (Details) - USD ($)
shares in Millions, $ in Billions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 14, 2020
Earnings Per Share [Abstract]          
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 1 25 5 29  
Stock Repurchase Program, Authorized Amount         $ 1.0
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Segment Reporting (Details)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
reportablesegments
Jun. 30, 2023
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | reportablesegments     2  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Amortization expense $ (213) $ (210) $ (427) $ (412)
Operating income (loss) 520 514 1,195 1,066
Other expense, net (100) (88) (167) (195)
Income (loss) before income taxes 420 426 1,028 870
Impact of Foreign Currency Fluctuations on Net Sales 8 51 37 102
Net sales 4,120 3,599 7,977 6,988
MedSurg        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Operating Income Allocated to Reportable Segments 511 458 986 867
Revenues from contracts with customers, disaggregated - performance measurement $ 1,480 $ 1,346 $ 2,882 $ 2,611
Segment operating income as percentage of net sales 34.60% 34.00% 34.20% 33.20%
Net sales $ 1,483 $ 1,360 $ 2,895 $ 2,640
Cardiovascular        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Operating Income Allocated to Reportable Segments 761 582 1,414 1,135
Revenues from contracts with customers, disaggregated - performance measurement $ 2,632 $ 2,204 $ 5,058 $ 4,275
Segment operating income as percentage of net sales 28.90% 26.40% 28.00% 26.60%
Net sales $ 2,637 $ 2,239 $ 5,082 $ 4,349
BSX Reportable Segments [Member]        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Revenues from contracts with customers, disaggregated - performance measurement 4,112 3,549 7,939 6,886
Total allocated to reportable segments [Member]        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Operating income (loss) 1,272 1,040 2,400 2,002
Corporate expenses and currency exchange [Member]        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Operating Income Unallocated to Segment (153) (75) (268) (173)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Operating Income Unallocated to Segment $ (386) $ (241) $ (510) $ (351)
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue - Narrative (Details)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
USD ($)
business
Jun. 30, 2024
USD ($)
business
Dec. 31, 2023
USD ($)
Revenue from Contract with Customer [Abstract]      
Contract with Customer, Liability $ 599 $ 599 $ 577
Contract with Customer, Liability, Revenue Recognized $ 59 $ 120  
Number Of Businesses | business 5 5  
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disaggregation of Revenue [Line Items]        
Net sales $ 4,120 $ 3,599 $ 7,977 $ 6,988
MedSurg        
Disaggregation of Revenue [Line Items]        
Net sales 1,483 1,360 2,895 2,640
Cardiovascular        
Disaggregation of Revenue [Line Items]        
Net sales 2,637 2,239 5,082 4,349
United States        
Disaggregation of Revenue [Line Items]        
Net sales 2,466 2,110 4,724 4,113
United States | MedSurg        
Disaggregation of Revenue [Line Items]        
Net sales 992 907 1,933 1,757
United States | Cardiovascular        
Disaggregation of Revenue [Line Items]        
Net sales 1,474 1,202 2,791 2,356
International [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 1,654 1,490 3,252 2,876
International [Member] | MedSurg        
Disaggregation of Revenue [Line Items]        
Net sales 491 453 961 883
International [Member] | Cardiovascular        
Disaggregation of Revenue [Line Items]        
Net sales 1,163 1,037 2,291 1,993
Endoscopy [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 676 631 1,318 1,207
Endoscopy [Member] | United States        
Disaggregation of Revenue [Line Items]        
Net sales 415 384 810 735
Endoscopy [Member] | International [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 261 246 508 472
Urology [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 525 485 1,038 954
Urology [Member] | United States        
Disaggregation of Revenue [Line Items]        
Net sales 363 340 719 666
Urology [Member] | International [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 162 146 319 289
Neuromodulation [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 282 244 539 478
Neuromodulation [Member] | United States        
Disaggregation of Revenue [Line Items]        
Net sales 214 183 405 356
Neuromodulation [Member] | International [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 68 61 134 123
Interventional Cardiology Therapies        
Disaggregation of Revenue [Line Items]        
Net sales 665 629 1,316 1,220
Interventional Cardiology Therapies | United States        
Disaggregation of Revenue [Line Items]        
Net sales 201 189 396 372
Interventional Cardiology Therapies | International [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 464 440 921 848
Watchman        
Disaggregation of Revenue [Line Items]        
Net sales 379 317 723 607
Watchman | United States        
Disaggregation of Revenue [Line Items]        
Net sales 342 286 653 552
Watchman | International [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 36 30 70 55
Cardiac Rhythm Management [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 576 566 1,151 1,114
Cardiac Rhythm Management [Member] | United States        
Disaggregation of Revenue [Line Items]        
Net sales 352 356 706 702
Cardiac Rhythm Management [Member] | International [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 224 209 446 412
Electrophysiology [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 428 193 729 370
Electrophysiology [Member] | United States        
Disaggregation of Revenue [Line Items]        
Net sales 271 85 429 170
Electrophysiology [Member] | International [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 157 108 300 199
Cardiology [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 2,047 1,704 3,919 3,310
Cardiology [Member] | United States        
Disaggregation of Revenue [Line Items]        
Net sales 1,166 917 2,183 1,796
Cardiology [Member] | International [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 881 787 1,736 1,514
Peripheral Interventions [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 590 535 1,163 1,039
Peripheral Interventions [Member] | United States        
Disaggregation of Revenue [Line Items]        
Net sales 308 285 608 560
Peripheral Interventions [Member] | International [Member]        
Disaggregation of Revenue [Line Items]        
Net sales $ 281 $ 250 $ 555 $ 478
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue - Revenue by Geography (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disaggregation of Revenue [Line Items]        
Net sales $ 4,120 $ 3,599 $ 7,977 $ 6,988
United States        
Disaggregation of Revenue [Line Items]        
Net sales 2,466 2,110 4,724 4,113
United States | BSX Reportable Segments [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 2,466 2,110 4,724 4,113
EMEA [Member] | BSX Reportable Segments [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 822 723 1,625 1,435
APAC [Member] | BSX Reportable Segments [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 670 626 1,317 1,174
Latin America and Canada [Member] | BSX Reportable Segments [Member]        
Disaggregation of Revenue [Line Items]        
Net sales 162 140 311 267
Emerging Markets [Member]        
Disaggregation of Revenue [Line Items]        
Net sales $ 680 $ 592 $ 1,328 $ 1,121
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]        
Beginning Stockholders' Equity     $ 19,282  
Other comprehensive income (loss) $ 30 $ 30 108 $ (61)
Ending Stockholders' Equity 20,371 18,226 20,371 18,226
Accumulated other comprehensive income (loss), net of tax        
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]        
Beginning Stockholders' Equity 132 178 49 269
Other comprehensive income (loss) before reclassifications 75 74 199 39
(Income) loss amounts reclassified from accumulated other comprehensive income (44) (44) (84) (100)
Other comprehensive income (loss) 31 30 114 (61)
Ending Stockholders' Equity 164 208 164 208
Foreign Currency Translation Adjustment        
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]        
Beginning Stockholders' Equity (34) (43) (96) (1)
Other comprehensive income (loss) before reclassifications 50 17 115 (24)
(Income) loss amounts reclassified from accumulated other comprehensive income (3) (2) (6) (4)
Other comprehensive income (loss) 47 15 108 (28)
Ending Stockholders' Equity 13 (28) 13 (28)
Net Change in Derivative Financial Instruments        
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]        
Beginning Stockholders' Equity 175 225 154 269
Other comprehensive income (loss) before reclassifications 24 58 84 67
(Income) loss amounts reclassified from accumulated other comprehensive income (40) (42) (78) (95)
Other comprehensive income (loss) (16) 15 6 (28)
Ending Stockholders' Equity 159 241 159 241
Net Change in Defined Benefit Pensions and Other Items        
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]        
Beginning Stockholders' Equity (8) (4) (8) 1
Other comprehensive income (loss) before reclassifications 0 0 0 (5)
(Income) loss amounts reclassified from accumulated other comprehensive income 0 0 0 (1)
Other comprehensive income (loss) 0 0 0 (5)
Ending Stockholders' Equity $ (8) $ (4) $ (8) $ (4)
EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 494 358 1 false 114 0 false 10 false false R1.htm 0000001 - Document - Cover Document Sheet http://www.bostonscientific.com/role/CoverDocument Cover Document Cover 1 false false R2.htm 0000002 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited Consolidated Balance Sheets (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation Sheet http://www.bostonscientific.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 0000009 - Disclosure - Acquisitions, Divestitures and Strategic Investments Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments Acquisitions, Divestitures and Strategic Investments Notes 9 false false R10.htm 0000010 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 10 false false R11.htm 0000011 - Disclosure - Hedging Activities and Fair Value Measurements Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements Hedging Activities and Fair Value Measurements Notes 11 false false R12.htm 0000012 - Disclosure - Contractual Obligations and Commitments Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitments Contractual Obligations and Commitments Notes 12 false false R13.htm 0000013 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 13 false false R14.htm 0000014 - Disclosure - Income Taxes Sheet http://www.bostonscientific.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 0000015 - Disclosure - Commitments and Contingencies Sheet http://www.bostonscientific.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 0000016 - Disclosure - Stockholders' Equity Sheet http://www.bostonscientific.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 0000017 - Disclosure - Weighted Average Shares Outstanding Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding Weighted Average Shares Outstanding Notes 17 false false R18.htm 0000018 - Disclosure - Segment Reporting Sheet http://www.bostonscientific.com/role/SegmentReporting Segment Reporting Notes 18 false false R19.htm 0000019 - Disclosure - Revenue Sheet http://www.bostonscientific.com/role/Revenue Revenue Notes 19 false false R20.htm 0000020 - Disclosure - Changes in Other Comprehensive Income Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome Changes in Other Comprehensive Income Notes 20 false false R21.htm 0000021 - Disclosure - New Accounting Pronouncements Sheet http://www.bostonscientific.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 9954471 - Disclosure - Basis of Presentation Basis of Presentation (Policies) Sheet http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies Basis of Presentation Basis of Presentation (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 23 false false R24.htm 9954472 - Disclosure - Acquisitions, Divestitures and Strategic Investments (Tables) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables Acquisitions, Divestitures and Strategic Investments (Tables) Tables http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments 24 false false R25.htm 9954473 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables Goodwill and Other Intangible Assets Goodwill (Tables) Tables http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets 25 false false R26.htm 9954474 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables Hedging Activities and Fair Value Measurements (Tables) Tables http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements 26 false false R27.htm 9954475 - Disclosure - Contractual Obligations and Commitments (Tables) Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables Contractual Obligations and Commitments (Tables) Tables http://www.bostonscientific.com/role/ContractualObligationsandCommitments 27 false false R28.htm 9954476 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation 28 false false R29.htm 9954477 - Disclosure - Income Taxes (Tables) Sheet http://www.bostonscientific.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.bostonscientific.com/role/IncomeTaxes 29 false false R30.htm 9954478 - Disclosure - Weighted Average Shares Outstanding (Tables) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables Weighted Average Shares Outstanding (Tables) Tables http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding 30 false false R31.htm 9954479 - Disclosure - Segment Reporting (Tables) Sheet http://www.bostonscientific.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.bostonscientific.com/role/SegmentReporting 31 false false R32.htm 9954480 - Disclosure - Revenue (Tables) Sheet http://www.bostonscientific.com/role/RevenueTables Revenue (Tables) Tables http://www.bostonscientific.com/role/Revenue 32 false false R33.htm 9954481 - Disclosure - Changes in Other Comprehensive Income (Tables) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables Changes in Other Comprehensive Income (Tables) Tables http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome 33 false false R34.htm 9954482 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Narrative (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails Acquisitions, Divestitures and Strategic Investments - Narrative (Details) Details http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables 34 false false R35.htm 9954483 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Price Allocation (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails Acquisitions, Divestitures and Strategic Investments - Price Allocation (Details) Details 35 false false R36.htm 9954484 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Assets and Liabilities Assumed (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails Acquisitions, Divestitures and Strategic Investments - Assets and Liabilities Assumed (Details) Details 36 false false R37.htm 9954485 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Intangible Assets Acquired (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails Acquisitions, Divestitures and Strategic Investments - Intangible Assets Acquired (Details) Details 37 false false R38.htm 9954486 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details) Details 38 false false R39.htm 9954487 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Level 3 Contingent Consideration (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails Acquisitions, Divestitures and Strategic Investments - Level 3 Contingent Consideration (Details) Details 39 false false R40.htm 9954488 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details) Details 40 false false R41.htm 9954489 - Disclosure - Goodwill and Other Intangible Assets (Details) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets (Details) Details http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables 41 false false R42.htm 9954490 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets - Narrative (Details) Details 42 false false R43.htm 9954491 - Disclosure - Hedging Activities and Fair Value Measurements - Narrative (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails Hedging Activities and Fair Value Measurements - Narrative (Details) Details 43 false false R44.htm 9954492 - Disclosure - Hedging Activities and Fair Value Measurements - Notional Amounts (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails Hedging Activities and Fair Value Measurements - Notional Amounts (Details) Details 44 false false R45.htm 9954493 - Disclosure - Hedging Activities and Fair Value Measurements - Effect of Hedging Relationships on Accumulated Other Comprehensive Income (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails Hedging Activities and Fair Value Measurements - Effect of Hedging Relationships on Accumulated Other Comprehensive Income (Details) Details 45 false false R46.htm 9954494 - Disclosure - Hedging Activities and Fair Value Measurements - Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails Hedging Activities and Fair Value Measurements - Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings (Details) Details 46 false false R47.htm 9954495 - Disclosure - Hedging Activities and Fair Value Measurements - Location on Unaudited Consolidated Statements of Operations (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails Hedging Activities and Fair Value Measurements - Location on Unaudited Consolidated Statements of Operations (Details) Details 47 false false R48.htm 9954496 - Disclosure - Hedging Activities and Fair Value Measurements - Balance Sheet Location (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails Hedging Activities and Fair Value Measurements - Balance Sheet Location (Details) Details 48 false false R49.htm 9954497 - Disclosure - Hedging Activities and Fair Value Measurements - Fair Value (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails Hedging Activities and Fair Value Measurements - Fair Value (Details) Details 49 false false R50.htm 9954498 - Disclosure - Hedging Activities and Fair Value Measurements - Licensing Arrangements (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails Hedging Activities and Fair Value Measurements - Licensing Arrangements (Details) Details 50 false false R51.htm 9954499 - Disclosure - Hedging Activities and Fair Value Measurements - Change in Fair Value (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails Hedging Activities and Fair Value Measurements - Change in Fair Value (Details) Details 51 false false R52.htm 9954500 - Disclosure - Contractual Obligations and Commitments (Details) Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails Contractual Obligations and Commitments (Details) Details http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables 52 false false R53.htm 9954501 - Disclosure - Supplemental Balance Sheet Information (Details) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails Supplemental Balance Sheet Information (Details) Details http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables 53 false false R54.htm 9954502 - Disclosure - Income Taxes (Details) Sheet http://www.bostonscientific.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.bostonscientific.com/role/IncomeTaxesTables 54 false false R55.htm 9954503 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.bostonscientific.com/role/CommitmentsandContingencies 55 false false R56.htm 9954504 - Disclosure - Stockholders' Equity (Details) Sheet http://www.bostonscientific.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.bostonscientific.com/role/StockholdersEquity 56 false false R57.htm 9954505 - Disclosure - Weighted Average Shares Outstanding (Details) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails Weighted Average Shares Outstanding (Details) Details http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables 57 false false R58.htm 9954506 - Disclosure - Weighted Average Shares Outstanding - Narrative (Details) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingNarrativeDetails Weighted Average Shares Outstanding - Narrative (Details) Details 58 false false R59.htm 9954507 - Disclosure - Segment Reporting (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.bostonscientific.com/role/SegmentReportingTables 59 false false R60.htm 9954508 - Disclosure - Revenue - Narrative (Details) Sheet http://www.bostonscientific.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 60 false false R61.htm 9954509 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 61 false false R62.htm 9954510 - Disclosure - Revenue - Revenue by Geography (Details) Sheet http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails Revenue - Revenue by Geography (Details) Details 62 false false R63.htm 9954511 - Disclosure - Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) Details http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables 63 false false All Reports Book All Reports bsx-20240630.htm bsx-20240630.xsd bsx-20240630_cal.xml bsx-20240630_def.xml bsx-20240630_lab.xml bsx-20240630_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bsx-20240630.htm": { "nsprefix": "bsx", "nsuri": "http://www.bostonscientific.com/20240630", "dts": { "inline": { "local": [ "bsx-20240630.htm" ] }, "schema": { "local": [ "bsx-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "bsx-20240630_cal.xml" ] }, "definitionLink": { "local": [ "bsx-20240630_def.xml" ] }, "labelLink": { "local": [ "bsx-20240630_lab.xml" ] }, "presentationLink": { "local": [ "bsx-20240630_pre.xml" ] } }, "keyStandard": 319, "keyCustom": 39, "axisStandard": 28, "axisCustom": 2, "memberStandard": 47, "memberCustom": 63, "hidden": { "total": 8, "http://xbrl.sec.gov/dei/2023": 5, "http://www.bostonscientific.com/20240630": 2, "http://xbrl.sec.gov/ecd/2023": 1 }, "contextCount": 494, "entityCount": 1, "segmentCount": 114, "elementCount": 699, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1313, "http://xbrl.sec.gov/dei/2023": 33, "http://xbrl.sec.gov/ecd/2023": 11 }, "report": { "R1": { "role": "http://www.bostonscientific.com/role/CoverDocument", "longName": "0000001 - Document - Cover Document", "shortName": "Cover Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "longName": "0000002 - Statement - Consolidated Statements of Operations (Unaudited)", "shortName": "Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R3": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "longName": "0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R4": { "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "longName": "0000004 - Statement - Consolidated Balance Sheets (Unaudited)", "shortName": "Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:PrepaidTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R5": { "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0000005 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-65", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R7": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000007 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R8": { "role": "http://www.bostonscientific.com/role/BasisofPresentation", "longName": "0000008 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments", "longName": "0000009 - Disclosure - Acquisitions, Divestitures and Strategic Investments", "shortName": "Acquisitions, Divestitures and Strategic Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets", "longName": "0000010 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements", "longName": "0000011 - Disclosure - Hedging Activities and Fair Value Measurements", "shortName": "Hedging Activities and Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitments", "longName": "0000012 - Disclosure - Contractual Obligations and Commitments", "shortName": "Contractual Obligations and Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation", "longName": "0000013 - Disclosure - Supplemental Balance Sheet Information", "shortName": "Supplemental Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bostonscientific.com/role/IncomeTaxes", "longName": "0000014 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bostonscientific.com/role/CommitmentsandContingencies", "longName": "0000015 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bostonscientific.com/role/StockholdersEquity", "longName": "0000016 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding", "longName": "0000017 - Disclosure - Weighted Average Shares Outstanding", "shortName": "Weighted Average Shares Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bostonscientific.com/role/SegmentReporting", "longName": "0000018 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bostonscientific.com/role/Revenue", "longName": "0000019 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome", "longName": "0000020 - Disclosure - Changes in Other Comprehensive Income", "shortName": "Changes in Other Comprehensive Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bostonscientific.com/role/NewAccountingPronouncements", "longName": "0000021 - Disclosure - New Accounting Pronouncements", "shortName": "New Accounting Pronouncements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "bsx:NewAccountingPronouncementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bsx:NewAccountingPronouncementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies", "longName": "9954471 - Disclosure - Basis of Presentation Basis of Presentation (Policies)", "shortName": "Basis of Presentation Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "longName": "9954472 - Disclosure - Acquisitions, Divestitures and Strategic Investments (Tables)", "shortName": "Acquisitions, Divestitures and Strategic Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables", "longName": "9954473 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables)", "shortName": "Goodwill and Other Intangible Assets Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables", "longName": "9954474 - Disclosure - Hedging Activities and Fair Value Measurements (Tables)", "shortName": "Hedging Activities and Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables", "longName": "9954475 - Disclosure - Contractual Obligations and Commitments (Tables)", "shortName": "Contractual Obligations and Commitments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables", "longName": "9954476 - Disclosure - Supplemental Balance Sheet Information (Tables)", "shortName": "Supplemental Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bostonscientific.com/role/IncomeTaxesTables", "longName": "9954477 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables", "longName": "9954478 - Disclosure - Weighted Average Shares Outstanding (Tables)", "shortName": "Weighted Average Shares Outstanding (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bostonscientific.com/role/SegmentReportingTables", "longName": "9954479 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bostonscientific.com/role/RevenueTables", "longName": "9954480 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables", "longName": "9954481 - Disclosure - Changes in Other Comprehensive Income (Tables)", "shortName": "Changes in Other Comprehensive Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails", "longName": "9954482 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Narrative (Details)", "shortName": "Acquisitions, Divestitures and Strategic Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-8", "name": "bsx:UncappedContingentConsidertation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "bsx:UncappedContingentConsidertation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails", "longName": "9954483 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Price Allocation (Details)", "shortName": "Acquisitions, Divestitures and Strategic Investments - Price Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-90", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R36": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails", "longName": "9954484 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Assets and Liabilities Assumed (Details)", "shortName": "Acquisitions, Divestitures and Strategic Investments - Assets and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R37": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "longName": "9954485 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Intangible Assets Acquired (Details)", "shortName": "Acquisitions, Divestitures and Strategic Investments - Intangible Assets Acquired (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-92", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-95", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R38": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "longName": "9954486 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details)", "shortName": "Acquisitions, Divestitures and Strategic Investments - Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R39": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails", "longName": "9954487 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Level 3 Contingent Consideration (Details)", "shortName": "Acquisitions, Divestitures and Strategic Investments - Level 3 Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-111", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R40": { "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails", "longName": "9954488 - Disclosure - Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details)", "shortName": "Acquisitions, Divestitures and Strategic Investments - Strategic Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "longName": "9954489 - Disclosure - Goodwill and Other Intangible Assets (Details)", "shortName": "Goodwill and Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "longName": "9954490 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)", "shortName": "Goodwill and Other Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "longName": "9954491 - Disclosure - Hedging Activities and Fair Value Measurements - Narrative (Details)", "shortName": "Hedging Activities and Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R44": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails", "longName": "9954492 - Disclosure - Hedging Activities and Fair Value Measurements - Notional Amounts (Details)", "shortName": "Hedging Activities and Fair Value Measurements - Notional Amounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "longName": "9954493 - Disclosure - Hedging Activities and Fair Value Measurements - Effect of Hedging Relationships on Accumulated Other Comprehensive Income (Details)", "shortName": "Hedging Activities and Fair Value Measurements - Effect of Hedging Relationships on Accumulated Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherOperatingIncomeExpenseNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R46": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "longName": "9954494 - Disclosure - Hedging Activities and Fair Value Measurements - Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings (Details)", "shortName": "Hedging Activities and Fair Value Measurements - Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-170", "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "bsx:DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-170", "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "bsx:DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails", "longName": "9954495 - Disclosure - Hedging Activities and Fair Value Measurements - Location on Unaudited Consolidated Statements of Operations (Details)", "shortName": "Hedging Activities and Fair Value Measurements - Location on Unaudited Consolidated Statements of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-173", "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-173", "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "longName": "9954496 - Disclosure - Hedging Activities and Fair Value Measurements - Balance Sheet Location (Details)", "shortName": "Hedging Activities and Fair Value Measurements - Balance Sheet Location (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "longName": "9954497 - Disclosure - Hedging Activities and Fair Value Measurements - Fair Value (Details)", "shortName": "Hedging Activities and Fair Value Measurements - Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-196", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R50": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails", "longName": "9954498 - Disclosure - Hedging Activities and Fair Value Measurements - Licensing Arrangements (Details)", "shortName": "Hedging Activities and Fair Value Measurements - Licensing Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-8", "name": "bsx:Licensingarrangementsasset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "bsx:DiscountRateFairValueInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R51": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "longName": "9954499 - Disclosure - Hedging Activities and Fair Value Measurements - Change in Fair Value (Details)", "shortName": "Hedging Activities and Fair Value Measurements - Change in Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-9", "name": "bsx:Licensingarrangementsasset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "us-gaap:ProceedsFromRoyaltiesReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R52": { "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "longName": "9954500 - Disclosure - Contractual Obligations and Commitments (Details)", "shortName": "Contractual Obligations and Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DebtAndCapitalLeaseObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:DebtAndCapitalLeaseObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails", "longName": "9954501 - Disclosure - Supplemental Balance Sheet Information (Details)", "shortName": "Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.bostonscientific.com/role/IncomeTaxesDetails", "longName": "9954502 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "longName": "9954503 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.bostonscientific.com/role/StockholdersEquityDetails", "longName": "9954504 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-279", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R57": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails", "longName": "9954505 - Disclosure - Weighted Average Shares Outstanding (Details)", "shortName": "Weighted Average Shares Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R58": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingNarrativeDetails", "longName": "9954506 - Disclosure - Weighted Average Shares Outstanding - Narrative (Details)", "shortName": "Weighted Average Shares Outstanding - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.bostonscientific.com/role/SegmentReportingDetails", "longName": "9954507 - Disclosure - Segment Reporting (Details)", "shortName": "Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "reportablesegments", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "reportablesegments", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.bostonscientific.com/role/RevenueNarrativeDetails", "longName": "9954508 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R61": { "role": "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "longName": "9954509 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "shortName": "Revenue - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-331", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R62": { "role": "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails", "longName": "9954510 - Disclosure - Revenue - Revenue by Geography (Details)", "shortName": "Revenue - Revenue by Geography (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-445", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } }, "R63": { "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "longName": "9954511 - Disclosure - Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details)", "shortName": "Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-66", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240630.htm", "unique": true } } }, "tag": { "bsx_A550MCPSSeriesAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "A550MCPSSeriesAMember", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.50% MCPS, Series A [Member]", "label": "5.50% MCPS, Series A [Member]", "documentation": "5.50% MCPS, Series A" } } }, "auth_ref": [] }, "bsx_AMSEuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "AMSEuropeMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AMS Europe", "label": "AMS Europe [Member]", "documentation": "AMS Europe" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts receivable, net", "totalLabel": "Trade accounts receivable, net", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable." } } }, "auth_ref": [ "r333", "r848" ] }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableNetCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts receivable, net", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r35", "r875" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r224", "r333", "r334", "r835" ] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued income taxes", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": [ "r139", "r190" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "totalLabel": "Accrued Liabilities, Current", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "bsx_AccruedRebatesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "AccruedRebatesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Rebates, Current", "label": "Accrued Rebates, Current", "documentation": "Accrued Rebates, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Arrangements", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39", "r838" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Change in Defined Benefit Pensions and Other Items", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r8", "r19", "r50", "r986", "r987", "r988" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r75", "r214", "r658" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Change in Derivative Financial Instruments", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r237", "r245", "r246", "r552", "r845", "r986" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r244", "r245", "r589", "r591", "r592", "r593", "r594", "r595" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive income (loss), net of tax", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r49", "r50", "r152", "r225", "r654", "r693", "r694" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r244", "r245", "r589", "r591", "r592", "r593", "r594", "r595" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss), net of tax", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r19", "r50", "r563", "r566", "r602", "r689", "r690", "r986", "r987", "r988", "r1000", "r1001", "r1002" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustment", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r7", "r19", "r50", "r245", "r246", "r591", "r592", "r593", "r594", "r595", "r986" ] }, "bsx_AcotecMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "AcotecMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Acotec", "label": "Acotec [Member]", "documentation": "Acotec" } } }, "auth_ref": [] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r170" ] }, "bsx_ActualCovenantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ActualCovenantMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual, Covenant [Member]", "label": "Actual, Covenant [Member]", "documentation": "Actual Covenant." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r926" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r142" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r522", "r523", "r524", "r706", "r1000", "r1001", "r1002", "r1039", "r1063" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r932" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r932" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r932" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r932" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r897", "r908", "r918", "r943" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r900", "r911", "r921", "r946" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r932" ] }, "bsx_AllBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "AllBusinessAcquisitionsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Business Acquisitions", "label": "All Business Acquisitions [Member]", "documentation": "All Business Acquisitions" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r939" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r904", "r912", "r922", "r939", "r947", "r951", "r959" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r957" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r226", "r335", "r372" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "negatedLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r16", "r68", "r73" ] }, "bsx_AmountExcludedFromDebtInLeverageRatio": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "AmountExcludedFromDebtInLeverageRatio", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount excluded from debt in leverage ratio", "label": "Amount excluded from debt in leverage ratio", "documentation": "Amount excluded from debt in leverage ratio" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r292" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r62" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r62" ] }, "bsx_ApolloMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ApolloMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Apollo", "label": "Apollo [Member]", "documentation": "Apollo" } } }, "auth_ref": [] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "APAC [Member]", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r1065", "r1066", "r1067", "r1068" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r188", "r218", "r259", "r303", "r318", "r324", "r369", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r548", "r553", "r583", "r647", "r750", "r875", "r888", "r1031", "r1032", "r1044" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r210", "r229", "r259", "r369", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r548", "r553", "r583", "r875", "r1031", "r1032", "r1044" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets, Fair Value Disclosure", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r127" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r954" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r955" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r950" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r950" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r950" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r950" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r950" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r950" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r953" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r952" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r951" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r951" ] }, "bsx_AxonicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "AxonicsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Axonics", "label": "Axonics [Member]", "documentation": "Axonics" } } }, "auth_ref": [] }, "bsx_BSXReportableSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "BSXReportableSegmentsMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSX Reportable Segments [Member]", "label": "BSX Reportable Segments [Member]", "documentation": "BSX Reportable Segments [Member]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r112", "r118" ] }, "us-gaap_BuildingsAndImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingsAndImprovementsGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and improvements", "label": "Buildings and Improvements, Gross", "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [ "r173" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r543", "r869", "r870" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r90", "r92", "r543", "r869", "r870" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r543" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r91" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Share Price", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Fair value of noncontrolling interest", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date." } } }, "auth_ref": [ "r95" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration net expense (benefit)", "terseLabel": "Contingent consideration net expense (benefit)", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r546", "r992" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r98" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance as of December 31, 2023", "periodEndLabel": "Balance as of June 30, 2024", "terseLabel": "Contingent Consideration Liability", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r2", "r97", "r545" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration, Liability, Current", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r97" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration, Liability, Noncurrent", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r97" ] }, "bsx_BusinessCombinationContingentConsiderationLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "BusinessCombinationContingentConsiderationLiabilityRollForward", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration, Liability [Roll Forward]", "label": "Business Combination, Contingent Consideration, Liability [Roll Forward]", "documentation": "Business Combination, Contingent Consideration, Liability" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments" ], "lang": { "en-us": { "role": { "verboseLabel": "ACQUISITIONS AND STRATEGIC INVESTMENTS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r181", "r544" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net deferred tax liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortizable intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r93", "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net assets acquired", "totalLabel": "Net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": [ "r24" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations [Abstract]", "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "bsx_CADEFine": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "CADEFine", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CADE fine", "label": "CADE fine", "documentation": "CADE fine" } } }, "auth_ref": [] }, "us-gaap_CapitalLeaseObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalLeaseObligationsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease Obligation", "label": "Capital Lease Obligations [Member]", "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time." } } }, "auth_ref": [ "r198" ] }, "bsx_CardiacRhythmManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "CardiacRhythmManagementMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiac Rhythm Management [Member]", "label": "Cardiac Rhythm Management [Member]", "documentation": "Cardiac Rhythm Management" } } }, "auth_ref": [] }, "bsx_CardiovascularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "CardiovascularMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiovascular", "label": "Cardiovascular [Member]", "documentation": "Cardiovascular [Member]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r200", "r651", "r717", "r745", "r875", "r888", "r979" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r57", "r212", "r833" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period", "periodEndLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r57", "r164", "r256" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease)\u00a0in cash, cash equivalents, restricted cash and restricted cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r164" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging [Member]", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r109" ] }, "bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "CashFlowImpactOfDeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred and prepaid income taxes", "label": "Cash flow impact of deferred income tax expense (benefit)", "documentation": "Cash flow impact of deferred income tax expense (benefit)" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r930" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDisclosuresAbstract", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock Disclosures [Abstract]", "label": "Class of Stock Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r205", "r221", "r222", "r223", "r259", "r285", "r286", "r289", "r291", "r297", "r298", "r369", "r417", "r419", "r420", "r421", "r424", "r425", "r456", "r457", "r461", "r464", "r471", "r583", "r698", "r699", "r700", "r701", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r718", "r737", "r759", "r779", "r808", "r809", "r810", "r811", "r812", "r966", "r996", "r1003" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r221", "r222", "r223", "r297", "r456", "r457", "r459", "r461", "r464", "r469", "r471", "r698", "r699", "r700", "r701", "r858", "r966", "r996" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r931" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r931" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper [Member]", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r176", "r882", "r883", "r884", "r885" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r44", "r134", "r650", "r736" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "verboseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r174", "r409", "r410", "r818", "r1027" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/CoverDocument", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, par value $0.01 per share", "verboseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r878", "r879", "r880", "r882", "r883", "r884", "r885", "r1000", "r1001", "r1039", "r1055", "r1063" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Par or Stated Value Per Share", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r141" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares Authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r141", "r737" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Issued", "periodStartLabel": "Beginning Balance (Shares)", "periodEndLabel": "Ending Balance (Shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r141" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,734,329,744 shares as of June\u00a030, 2024 and 1,729,000,224 shares as of December\u00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r141", "r653", "r875" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r936" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r935" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r937" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r934" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to Boston Scientific common stockholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r51", "r241", "r243", "r251", "r642", "r668" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss) attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r13", "r101", "r104", "r241", "r243", "r250", "r641", "r667" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r104", "r185", "r241", "r243", "r249", "r640", "r666" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "CHANGES IN OTHER COMPREHENSIVE INCOME", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r151", "r248", "r639", "r664" ] }, "bsx_CondensedConsolidatedBalanceSheetParentheticalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "CondensedConsolidatedBalanceSheetParentheticalAbstract", "lang": { "en-us": { "role": { "terseLabel": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]", "label": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]", "documentation": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]" } } }, "auth_ref": [] }, "bsx_ConditionalRatingAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ConditionalRatingAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional Rating [Axis]", "label": "Conditional Rating [Axis]", "documentation": "Conditional Rating" } } }, "auth_ref": [] }, "bsx_ConditionalRatingDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ConditionalRatingDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional Rating [Domain]", "label": "Conditional Rating [Domain]", "documentation": "Conditional Rating [Domain]" } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in progress", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r173" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "bsx_ContingentConsiderationLiabilityProbabilityOfPayment": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ContingentConsiderationLiabilityProbabilityOfPayment", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "contingent consideration liability, probability of payment", "label": "contingent consideration liability, probability of payment", "documentation": "contingent consideration liability, probability of payment" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Liability", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r473", "r474", "r485" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r486" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of mandatory convertible preferred stock to common stock", "verboseLabel": "Conversion of Stock, Shares Converted", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r58", "r59", "r60" ] }, "bsx_CorporateExpensesincludinghedgingactivitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "CorporateExpensesincludinghedgingactivitiesMember", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Corporate expenses and currency exchange [Member]", "label": "Corporate Expenses including hedging activities [Member]", "documentation": "Corporate Expenses including hedging activities [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r156", "r635" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales [Member]", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r261", "r262", "r430", "r459", "r603", "r842", "r844" ] }, "bsx_CovenantAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "CovenantAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant [Axis]", "label": "Covenant [Axis]", "documentation": "Covenant." } } }, "auth_ref": [] }, "bsx_CovenantDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "CovenantDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant [Domain]", "label": "Covenant [Domain]", "documentation": "Covenant." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "bsx_CreditRatingAOrA3OrHigherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "CreditRatingAOrA3OrHigherMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Rating A- or A3 Or Higher", "label": "Credit Rating A- or A3 Or Higher [Member]", "documentation": "Credit Rating A- or A3 Or Higher" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "bsx_CurrentRequirementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "CurrentRequirementMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current Requirement [Member]", "label": "Current Requirement [Member]", "documentation": "Current Requirement." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r96" ] }, "us-gaap_DebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total debt", "label": "Debt and Lease Obligation", "documentation": "Amount of short-term and long-term debt and lease obligation." } } }, "auth_ref": [ "r194" ] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current debt obligations", "terseLabel": "Debt, Current", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r220" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitments" ], "lang": { "en-us": { "role": { "verboseLabel": "CONTRACTUAL OBLIGATIONS AND COMMITMENTS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r175", "r257", "r426", "r432", "r433", "r434", "r435", "r436", "r437", "r442", "r449", "r450", "r452" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r33", "r137", "r138", "r189", "r191", "r263", "r427", "r428", "r429", "r430", "r431", "r433", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r597", "r853", "r854", "r855", "r856", "r857", "r997" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Fair Value Disclosure", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r440", "r582", "r854", "r855" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r41", "r428" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r263", "r427", "r428", "r429", "r430", "r431", "r433", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r451", "r597", "r853", "r854", "r855", "r856", "r857", "r997" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r42", "r263", "r427", "r428", "r429", "r430", "r431", "r433", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r597", "r853", "r854", "r855", "r856", "r857", "r997" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption Price, Percentage", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r26" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r42", "r81", "r84", "r130", "r131", "r133", "r135", "r178", "r179", "r263", "r427", "r428", "r429", "r430", "r431", "r433", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r451", "r597", "r853", "r854", "r855", "r856", "r857", "r997" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r132", "r438", "r453", "r854", "r855" ] }, "bsx_December2027NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "December2027NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2027 Notes [Member]", "label": "December 2027 Notes [Member]", "documentation": "December 2027 Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit." } } }, "auth_ref": [ "r89" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r527", "r528" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r527", "r528", "r648" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r984" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue, Current", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r983" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r16", "r74" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r16", "r308" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r231", "r232", "r582", "r719", "r720", "r721", "r722", "r723", "r725", "r726", "r727", "r728", "r729", "r743", "r744", "r795", "r798", "r801", "r802", "r803", "r804", "r844", "r880", "r1059" ] }, "us-gaap_DerivativeAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Current", "label": "Derivative Asset, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r231" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r727", "r729", "r742", "r743", "r744", "r746", "r747", "r748", "r749", "r751", "r752", "r753", "r754", "r766", "r767", "r768", "r769", "r772", "r773", "r774", "r775", "r795", "r796", "r801", "r803", "r878", "r880" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Fair Value, Gross Asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r30", "r115", "r150", "r230", "r844" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Fair Value, Gross Liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r30", "r115", "r150", "r230", "r844" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r113", "r116", "r119", "r121", "r727", "r729", "r742", "r743", "r744", "r746", "r747", "r748", "r749", "r751", "r752", "r753", "r754", "r766", "r767", "r768", "r769", "r772", "r773", "r774", "r775", "r795", "r796", "r801", "r803", "r844", "r878", "r880" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r21", "r113", "r119" ] }, "bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months", "label": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "documentation": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments in Hedges, Assets, at Fair Value", "label": "Derivative Instruments in Hedges, Assets, at Fair Value", "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "label": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset." } } }, "auth_ref": [ "r117" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability." } } }, "auth_ref": [ "r117" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r231", "r232", "r582", "r719", "r720", "r721", "r722", "r725", "r726", "r727", "r728", "r729", "r751", "r753", "r754", "r796", "r797", "r798", "r801", "r802", "r803", "r804", "r844", "r1059" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r568" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1037", "r1038" ] }, "us-gaap_DerivativeRemainingMaturity1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeRemainingMaturity1", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Remaining Maturity", "label": "Derivative, Remaining Maturity", "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r21", "r105", "r106", "r108", "r111", "r114", "r119", "r122", "r123", "r125", "r568" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Term of Contract (less than)", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "label": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "auth_ref": [] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument [Member]", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueAbstract", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Abstract]", "label": "Disaggregation of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r484", "r859", "r860", "r861", "r862", "r863", "r864", "r865" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r484", "r859", "r860", "r861", "r862", "r863", "r864", "r865" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1035" ] }, "bsx_DiscountRateFairValueInput": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "DiscountRateFairValueInput", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-Adjusted Discount Rates used in Purchase Price Allocation", "label": "Discount Rate, Fair Value Input", "documentation": "Discount Rate, Fair Value Input" } } }, "auth_ref": [] }, "us-gaap_DividendsPreferredStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStockCash", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Preferred stock dividends", "label": "Dividends, Preferred Stock, Cash", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r12", "r180" ] }, "us-gaap_DividendsPreferredStockStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStockStock", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Preferred stock dividends", "label": "Dividends, Preferred Stock, Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock." } } }, "auth_ref": [ "r12", "r180" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r892" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r925" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EMEAMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EMEA [Member]", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r1065", "r1066", "r1067", "r1068" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)\u00a0per common share \u2014 basic", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r252", "r273", "r274", "r275", "r276", "r277", "r282", "r285", "r289", "r290", "r291", "r295", "r571", "r572", "r643", "r669", "r846" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)\u00a0per common share \u2014 diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r252", "r273", "r274", "r275", "r276", "r277", "r285", "r289", "r290", "r291", "r295", "r571", "r572", "r643", "r669", "r846" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding" ], "lang": { "en-us": { "role": { "terseLabel": "WEIGHTED AVERAGE SHARES OUTSTANDING", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r281", "r292", "r293", "r294" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r588" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate from continuing operations", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r530" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "auth_ref": [] }, "bsx_ElectrophysiologyEPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ElectrophysiologyEPMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Electrophysiology [Member]", "label": "Electrophysiology (EP) [Member]", "documentation": "Electrophysiology (EP)" } } }, "auth_ref": [] }, "bsx_EmergingMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "EmergingMarketsMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Markets [Member]", "label": "Emerging Markets [Member]", "documentation": "Emerging Markets [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payroll and related liabilities", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "bsx_EntityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "EntityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Entity [Abstract]", "label": "Entity [Abstract]", "documentation": "Entity [Abstract]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r890" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r890" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r890" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r964" ] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingParValuePerShare", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listing, Par Value Per Share", "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r890" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r890" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r890" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r890" ] }, "bsx_EquipmentFurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "EquipmentFurnitureAndFixturesGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment, furniture and fixtures", "label": "Equipment, furniture and fixtures Gross", "documentation": "Equipment, furniture and fixtures Gross." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r20", "r206", "r244", "r245", "r246", "r268", "r269", "r270", "r272", "r278", "r280", "r296", "r370", "r371", "r472", "r522", "r523", "r524", "r536", "r537", "r562", "r563", "r564", "r565", "r566", "r567", "r570", "r589", "r591", "r592", "r593", "r594", "r595", "r602", "r689", "r690", "r691", "r706", "r779" ] }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee." } } }, "auth_ref": [ "r368" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r313", "r367", "r980", "r1010" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities, FV-NI", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r219", "r581", "r836" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement alternative investments(1, 2)", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r366" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r933" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r897", "r908", "r918", "r943" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r894", "r905", "r915", "r940" ] }, "bsx_EuroDenominatedFactoringArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "EuroDenominatedFactoringArrangementsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro Denominated Factoring Arrangements [Member]", "label": "Euro Denominated Factoring Arrangements [Member]", "documentation": "Euro Denominated Factoring Arrangements [Member]" } } }, "auth_ref": [] }, "bsx_ExclusionFromEbitdaForRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ExclusionFromEbitdaForRestructuringCharges", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exclusion from EBITDA for Restructuring Charges", "label": "Exclusion from EBITDA for Restructuring Charges", "documentation": "Exclusion from EBITDA for Restructuring Charges" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r939" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r574", "r575", "r579" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r574", "r575", "r579" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r22" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r440", "r489", "r490", "r491", "r492", "r493", "r494", "r575", "r607", "r608", "r609", "r854", "r855", "r866", "r867", "r868" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r129", "r187" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r574", "r575", "r576", "r577", "r580" ] }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r578" ] }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value." } } }, "auth_ref": [ "r578" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r573" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r440", "r489", "r494", "r575", "r607", "r866", "r867", "r868" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r440", "r489", "r494", "r575", "r608", "r854", "r855", "r866", "r867", "r868" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r440", "r489", "r490", "r491", "r492", "r493", "r494", "r575", "r609", "r854", "r855", "r866", "r867", "r868" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r23" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r23", "r129" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r23", "r129" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of contingent consideration recorded in purchase accounting", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r128" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r440", "r489", "r490", "r491", "r492", "r493", "r494", "r607", "r608", "r609", "r854", "r855", "r866", "r867", "r868" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring [Member]", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r573", "r580" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r112", "r114", "r124" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r600", "r601" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r451", "r469", "r568", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r665", "r850", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r1006", "r1007", "r1008", "r1009" ] }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization/ Write-offs", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r216", "r396" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "verboseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r393", "r395", "r396", "r398", "r636", "r637" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r171", "r637" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r69", "r72" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r126" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r584", "r585", "r586", "r587", "r776" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Contract [Member]", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r844", "r866", "r874" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Forward", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r743", "r748", "r753", "r768", "r774", "r799", "r800", "r801", "r880" ] }, "bsx_ForeigncurrencydenominatedindebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ForeigncurrencydenominatedindebtMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "foreign currency denominated in debt [Member]", "label": "foreign currency denominated in debt [Member]", "documentation": "foreign currency denominated in debt [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r901", "r912", "r922", "r947" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r901", "r912", "r922", "r947" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r901", "r912", "r922", "r947" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r901", "r912", "r922", "r947" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r901", "r912", "r922", "r947" ] }, "bsx_ForwardCurrencyContractsTimeToMaturity": { "xbrltype": "durationItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ForwardCurrencyContractsTimeToMaturity", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Currency Contracts, Time to Maturity", "label": "Forward Currency Contracts, Time to Maturity", "documentation": "Forward Currency Contracts, Time to Maturity in Months" } } }, "auth_ref": [] }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments." } } }, "auth_ref": [ "r113", "r120" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net loss (gain) on investments and notes receivable", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r159", "r965" ] }, "bsx_GlobalCardiologyReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "GlobalCardiologyReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiology [Member]", "label": "Global Cardiology Reporting Unit [Member]", "documentation": "Global Cardiology Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalEndoscopyEndoReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "GlobalEndoscopyEndoReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Endoscopy [Member]", "label": "Global Endoscopy (Endo) Reporting Unit [Member]", "documentation": "Global Endoscopy (Endo) Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalNeuromodulationNmReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "GlobalNeuromodulationNmReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Neuromodulation [Member]", "label": "Global Neuromodulation (NM) Reporting Unit [Member]", "documentation": "Global Neuromodulation (NM) Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalPeripheralInterventionsPiReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "GlobalPeripheralInterventionsPiReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Peripheral Interventions [Member]", "label": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "documentation": "Global Peripheral Interventions (PI) Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalUrologyandPelvicHealthReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "GlobalUrologyandPelvicHealthReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Urology [Member]", "label": "Global Urology and Pelvic Health Reporting Unit [Member]", "documentation": "Global Urology and Pelvic Health Reporting Unit [Member]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill Beginning Balance", "periodEndLabel": "Goodwill Ending Balance", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r215", "r381", "r638", "r852", "r875", "r1014", "r1021" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill acquired", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r384", "r852" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "verboseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r169" ] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Gross", "label": "Goodwill, Gross", "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r383", "r390", "r852" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Goodwill, Impaired, Accumulated Impairment Loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r383", "r390", "r852" ] }, "us-gaap_GoodwillMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill [Member]", "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of foreign currency fluctuations and purchase price and other adjustments", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r1", "r1013" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r155", "r259", "r303", "r317", "r323", "r326", "r369", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r583", "r847", "r1031" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r21", "r560" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r21" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r21" ] }, "bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ImpactOfForeignCurrencyFluctuationsOnNetSales", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of Foreign Currency Fluctuations on Net Sales", "label": "Impact of Foreign Currency Fluctuations on Net Sales", "documentation": "Impact of Foreign Currency Fluctuations on Net Sales" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset impairment charges", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r16", "r25" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and other intangible asset impairment charges", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r993", "r1024" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "IPR&D", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss)\u00a0before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r153", "r195", "r303", "r317", "r323", "r326", "r644", "r660", "r847" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r399", "r404", "r762" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r404", "r762" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r260", "r525", "r531", "r534", "r535", "r538", "r540", "r541", "r542", "r703" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r199", "r203", "r279", "r280", "r311", "r529", "r539", "r670" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued expenses and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Trade accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value adjustment (expense) benefit", "label": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option", "documentation": "Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks)." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r15" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r394", "r397" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r172" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r70", "r172" ] }, "bsx_IndemnificationAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "IndemnificationAsset", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification asset", "label": "Indemnification asset", "documentation": "Indemnification asset" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r904", "r912", "r922", "r939", "r947", "r951", "r959" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r957" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r893", "r963" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r893", "r963" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r893", "r963" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r67", "r71" ] }, "bsx_IntangibleAssetsandGoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "IntangibleAssetsandGoodwillLineItems", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets and Goodwill [Line Items]", "label": "Intangible Assets and Goodwill [Line Items]", "documentation": "[Line Items] for Schedule of Intangible Assets and Goodwill [Table]" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "terseLabel": "Interest Expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r132", "r197", "r247", "r307", "r596", "r763", "r886", "r1062" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense [Member]", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r29" ] }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months." } } }, "auth_ref": [ "r126" ] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateContractMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Contract [Member]", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r830", "r844", "r866" ] }, "bsx_InterventionalCardiologyTherapiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "InterventionalCardiologyTherapiesMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interventional Cardiology Therapies", "label": "Interventional Cardiology Therapies [Member]", "documentation": "Interventional Cardiology Therapies" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Finished Goods, Net of Reserves", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r168", "r839" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r227", "r834", "r875" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNetAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Raw Materials, Net of Reserves", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r168", "r841" ] }, "bsx_InventoryStepUpAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "InventoryStepUpAmortization", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory step-up amortization", "label": "Inventory step up amortization", "documentation": "Inventory step up amortization" } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Work in Process, Net of Reserves", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r168", "r840" ] }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Investment", "label": "Investment Holdings, Schedule of Investments [Table Text Block]", "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments." } } }, "auth_ref": [ "r1056", "r1057", "r1058", "r1059", "r1060", "r1061" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 4.0 }, "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Investments", "verboseLabel": "Investments", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r646" ] }, "bsx_January2040NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "January2040NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2040 Notes [Member]", "label": "January 2040 Notes [Member]", "documentation": "January 2040 Notes [Member]" } } }, "auth_ref": [] }, "bsx_JosephM.FitzgeraldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "JosephM.FitzgeraldMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Joseph M. Fitzgerald [Member]", "documentation": "Joseph M. Fitzgerald" } } }, "auth_ref": [] }, "bsx_June2025NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "June2025NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2025 Notes [Member]", "label": "June 2025 Notes [Member]", "documentation": "June 2025 Notes" } } }, "auth_ref": [] }, "bsx_June2030NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "June2030NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2030 Notes [Member]", "label": "June 2030 Notes [Member]", "documentation": "June 2030 Notes" } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r981" ] }, "bsx_LatinAmericaandCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "LatinAmericaandCanadaMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Latin America and Canada [Member]", "label": "Latin America and Canada [Member]", "documentation": "Latin America and Canada [Member]" } } }, "auth_ref": [] }, "us-gaap_LegalCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalCostsPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Costs", "label": "Legal Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights." } } }, "auth_ref": [ "r416" ] }, "bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "label": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "documentation": "Legal payments remaining to be excluded from calculation of consolidated EBITDA" } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of Credit Outstanding, Amount", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r146", "r193", "r657", "r875", "r998", "r1011", "r1041" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r40", "r211", "r259", "r369", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r549", "r553", "r554", "r583", "r875", "r1031", "r1044", "r1045" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r127" ] }, "bsx_LicensingarrangementassetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "LicensingarrangementassetsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangement assets [Member]", "label": "Licensing arrangement assets [Member]", "documentation": "Licensing arrangement assets [Member]" } } }, "auth_ref": [] }, "bsx_LicensingarrangementliabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "LicensingarrangementliabilitiesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangement liabilities [Member]", "label": "Licensing arrangement liabilities [Member]", "documentation": "Licensing arrangement liabilities [Member]" } } }, "auth_ref": [] }, "bsx_Licensingarrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "Licensingarrangements", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangements", "label": "Licensing arrangements", "documentation": "Licensing arrangements" } } }, "auth_ref": [] }, "bsx_Licensingarrangementsasset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "Licensingarrangementsasset", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangements, asset", "periodStartLabel": "Licensing arrangements, asset", "periodEndLabel": "Licensing arrangements, asset", "label": "Licensing arrangements, asset", "documentation": "Licensing arrangements, asset" } } }, "auth_ref": [] }, "bsx_Licensingarrangementsliability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "Licensingarrangementsliability", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 3.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangements, liability", "periodStartLabel": "Licensing arrangements, liability", "periodEndLabel": "Licensing arrangements, liability", "label": "Licensing arrangements, liability", "documentation": "Licensing arrangements, liability" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r36" ] }, "bsx_LitigationPaymentExclusionFromEBITDA": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "LitigationPaymentExclusionFromEBITDA", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation payment exclusion from EBITDA", "label": "Litigation payment exclusion from EBITDA", "documentation": "Litigation payment exclusion from EBITDA" } } }, "auth_ref": [] }, "us-gaap_LitigationReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserveCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal reserves, current", "label": "Estimated Litigation Liability, Current", "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position." } } }, "auth_ref": [ "r44", "r1028" ] }, "us-gaap_LitigationReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserveNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Litigation Liability, Noncurrent", "label": "Estimated Litigation Liability, Noncurrent", "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r44", "r1028" ] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Amount Awarded to Other Party", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r33", "r191", "r439", "r454", "r854", "r855", "r1052" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt", "terseLabel": "Long-term Debt and Capital Lease Obligations", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r33", "r649" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r42" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r42", "r77" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrual for legal matters that are probable and estimable", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r411", "r967" ] }, "bsx_March2024NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2024NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2024 Notes [Member]", "label": "March 2024 Notes [Member]", "documentation": "March 2024 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2025NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2025NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2025 Notes", "label": "March 2025 Notes [Member]", "documentation": "March 2025 Notes" } } }, "auth_ref": [] }, "bsx_March2026NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2026NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2026 Notes [Member]", "label": "March 2026 Notes [Member]", "documentation": "March 2026 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2028NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2028NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "March 2028 Notes [Member]", "label": "March 2028 Notes [Member]", "documentation": "March 2028 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2028SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2028SeniorNotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2028 Senior Notes", "label": "March 2028 Senior Notes [Member]", "documentation": "March 2028 Senior Notes" } } }, "auth_ref": [] }, "bsx_March2029EuroSeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2029EuroSeniorNotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2029 Euro Senior Notes", "label": "March 2029 Euro Senior Notes [Member]", "documentation": "March 2029 Euro Senior Notes" } } }, "auth_ref": [] }, "bsx_March2029NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2029NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2029 Notes [Member]", "label": "March 2029 Notes [Member]", "documentation": "March 2029 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2031NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2031NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2031 Notes", "label": "March 2031 Notes [Member]", "documentation": "March 2031 Notes" } } }, "auth_ref": [] }, "bsx_March2032EuroSeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2032EuroSeniorNotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2032 Euro Senior Notes", "label": "March 2032 Euro Senior Notes [Member]", "documentation": "March 2032 Euro Senior Notes" } } }, "auth_ref": [] }, "bsx_March2034NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2034NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2034 Notes", "label": "March 2034 Notes [Member]", "documentation": "March 2034 Notes" } } }, "auth_ref": [] }, "bsx_March2039NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2039NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2039 Notes [Member]", "label": "March 2039 Notes [Member]", "documentation": "March 2039 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2049NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "March2049NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2049 Notes [Member]", "label": "March 2049 Notes [Member]", "documentation": "March 2049 Notes [Member]" } } }, "auth_ref": [] }, "bsx_MaximumLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "MaximumLeverageRatio", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum Leverage Ratio", "label": "Maximum Leverage Ratio", "documentation": "Maximum leverage ratio permitted by revolving credit facility agreement." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r412", "r413", "r414", "r415", "r495", "r634", "r688", "r728", "r729", "r785", "r788", "r792", "r793", "r805", "r828", "r829", "r849", "r858", "r871", "r877", "r1033", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r931" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r931" ] }, "bsx_MedsurgMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "MedsurgMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MedSurg", "label": "MedSurg [Member]", "documentation": "MedSurg [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r412", "r413", "r414", "r415", "r495", "r634", "r688", "r728", "r729", "r785", "r788", "r792", "r793", "r805", "r828", "r829", "r849", "r858", "r871", "r877", "r1033", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r48", "r192", "r259", "r369", "r417", "r419", "r420", "r421", "r424", "r425", "r583", "r656", "r739" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestPeriodIncreaseDecrease", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes to noncontrolling ownership interest", "label": "Noncontrolling Interest, Period Increase (Decrease)", "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period." } } }, "auth_ref": [ "r100" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r950" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds, at Carrying Value", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Allowance for doubtful accounts", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r958" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r932" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided by (used for) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r255" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided by (used for) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r255" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided by (used for) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r164", "r165", "r166" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash provided by (used for) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r154", "r166", "r196", "r209", "r239", "r242", "r246", "r259", "r271", "r273", "r274", "r275", "r276", "r279", "r280", "r287", "r303", "r317", "r323", "r326", "r369", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r572", "r583", "r663", "r758", "r777", "r778", "r847", "r886", "r1031" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r103", "r186", "r239", "r242", "r279", "r280", "r662", "r988" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Boston Scientific common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r253", "r273", "r274", "r275", "r276", "r282", "r283", "r288", "r291", "r303", "r317", "r323", "r326", "r847" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsAmountofPreTaxGainLossthatmaybeReclassifiedtoEarningsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging [Member]", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r110" ] }, "bsx_Netcurrencyexchangegainloss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "Netcurrencyexchangegainloss", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net currency exchange gain (loss)", "label": "Net currency exchange gain (loss)", "documentation": "Net currency exchange gain (loss)" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "bsx_NewAccountingPronouncementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "NewAccountingPronouncementsTextBlock", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncements" ], "lang": { "en-us": { "role": { "terseLabel": "NEW ACCOUNTING PRONOUNCEMENTS", "label": "New Accounting Pronouncements [Text Block]", "documentation": "New Accounting Pronouncements" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r931" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r901", "r912", "r922", "r939", "r947" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r929" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r928" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r939" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r958" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r958" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International [Member]", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1065", "r1066", "r1067", "r1068" ] }, "bsx_Noncashimpactoftransferredroyaltyrights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "Noncashimpactoftransferredroyaltyrights", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash impact of transferred royalty rights", "label": "Non-cash impact of transferred royalty rights", "documentation": "Non-cash impact of transferred royalty rights" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r99", "r472", "r1000", "r1001", "r1002", "r1063" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNotionalAmountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument [Member]", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SegmentReportingDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r160" ] }, "bsx_November2035NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "November2035NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "November 2035 Notes [Member]", "label": "November 2035 Notes [Member]", "documentation": "November 2035 Notes [Member]" } } }, "auth_ref": [] }, "bsx_NumberOfBusinesses": { "xbrltype": "integerItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "NumberOfBusinesses", "presentation": [ "http://www.bostonscientific.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Businesses", "label": "Number Of Businesses", "documentation": "Number Of Businesses" } } }, "auth_ref": [] }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfInterestRateDerivativesHeld", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Interest Rate Derivatives Held", "label": "Number of Interest Rate Derivatives Held", "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date." } } }, "auth_ref": [ "r107", "r108" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1005" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "bsx_OperatingIncomeAllocatedToReportableSegments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "OperatingIncomeAllocatedToReportableSegments", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Income Allocated to Reportable Segments", "label": "Operating Income Allocated to Reportable Segments", "documentation": "Operating Income Allocated to Reportable Segments" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "terseLabel": "Operating income (loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r303", "r317", "r323", "r326", "r847" ] }, "bsx_OperatingIncomeUnallocatedToSegment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "OperatingIncomeUnallocatedToSegment", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating Income Unallocated to Segment", "label": "Operating Income Unallocated to Segment", "documentation": "Operating Income Unallocated to Segment" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r599" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r598" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/BasisofPresentation" ], "lang": { "en-us": { "role": { "verboseLabel": "BASIS OF PRESENTATION", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r136", "r184", "r695", "r696" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r39" ] }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Accrued Liabilities, Noncurrent", "label": "Other Accrued Liabilities, Noncurrent", "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r43" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Current", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r228", "r875" ] }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets, Miscellaneous, Current", "label": "Other Assets, Miscellaneous, Current", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term assets", "totalLabel": "Other Assets, Noncurrent", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r217" ] }, "us-gaap_OtherAssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets, Noncurrent [Abstract]", "label": "Other Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLocationAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income Location [Axis]", "label": "Other Comprehensive Income Location [Axis]", "documentation": "Information by location in other comprehensive income." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLocationDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income Location [Domain]", "label": "Other Comprehensive Income Location [Domain]", "documentation": "Location in other comprehensive income." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r32", "r50", "r245", "r589", "r592", "r595", "r986" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Net change in derivative financial instruments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r233", "r235" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r233", "r235" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r233", "r235", "r555", "r556", "r561" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r236" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r235", "r238" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r202", "r235", "r238" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r236" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax", "documentation": "Amount, after tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r234", "r235", "r238", "r558" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax", "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r234", "r235", "r238", "r558" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax", "documentation": "Amount of tax expense (benefit) for adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r234", "r235", "r238" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r234", "r235", "r557", "r561" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax", "documentation": "Amount, before adjustments, of tax expense (benefit) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r234", "r235", "r557", "r561" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r559" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "terseLabel": "Changes in other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r20", "r32", "r240", "r243", "r248", "r589", "r590", "r595", "r639", "r664", "r986", "r987" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]", "label": "Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) attributable to noncontrolling interests", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r13", "r18", "r185", "r240", "r243" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net change in defined benefit pensions and other items", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r9", "r152" ] }, "bsx_OtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "OtherCurrentAssetsAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets [Abstract]", "label": "Other Current Assets [Abstract]", "documentation": "Other Current Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities [Member]", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other current liabilities", "totalLabel": "Other Liabilities, Current", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r39", "r875" ] }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities, Current [Abstract]", "label": "Other Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "totalLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r43" ] }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Assets [Member]", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities [Member]", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "label": "Other Noncurrent Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r161" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other income (expense):", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLocationonUnauditedConsolidatedStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense) [Member]", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Operating Income (Expense), Net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "bsx_OtherOtherLongtermAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "OtherOtherLongtermAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, Other Long-term Assets", "label": "Other, Other Long-term Assets", "documentation": "Other, Other Long-term Assets" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r931" ] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": [ "r39", "r76" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r899", "r910", "r920", "r945" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r902", "r913", "r923", "r948" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r902", "r913", "r923", "r948" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r183" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r927" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of contingent consideration previously established in purchase accounting", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r11" ] }, "bsx_PaymentOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "PaymentOfContingentConsideration", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Contingent consideration payments and other adjustments", "label": "Payment of contingent consideration", "documentation": "Payment of contingent consideration" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromHedgeInvestingActivities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from settlements of hedge contracts", "label": "Payments for (Proceeds from) Hedge, Investing Activities", "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from royalty rights", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r968", "r989" ] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for Royalties", "label": "Payments for Royalties", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r14" ] }, "bsx_PaymentsForRoyaltyRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "PaymentsForRoyaltyRights", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for royalty rights", "label": "Payments for royalty rights", "documentation": "Payments for royalty rights" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash dividends paid on preferred stock", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r54" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for acquisitions of businesses, net of cash acquired", "terseLabel": "Payment for acquisition, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r52" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment and internal use software", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r163" ] }, "bsx_Paymenttonetsharesettleemployeeequityawards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "Paymenttonetsharesettleemployeeequityawards", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash used to net share settle employee equity awards", "label": "Payment to net share settle employee equity awards", "documentation": "Payment to net share settle employee equity awards" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r930" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r930" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r929" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r939" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r932" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r928" ] }, "bsx_PreJudgementInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "PreJudgementInterest", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-Judgement Interest", "label": "Pre-Judgement Interest", "documentation": "Pre-Judgement Interest" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionRatio", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Convertible, Conversion Ratio", "label": "Preferred Stock, Convertible, Conversion Ratio", "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted." } } }, "auth_ref": [ "r458" ] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Dividend Rate, Percentage", "label": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r457", "r786", "r789", "r791", "r806" ] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Liquidation Preference Per Share", "label": "Preferred Stock, Liquidation Preference Per Share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r81", "r82", "r140", "r996", "r1034" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r878", "r879", "r882", "r883", "r884", "r885", "r1055", "r1063" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Par or Stated Value Per Share", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r140", "r456" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r140", "r737" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred Stock, Shares Issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r140", "r456" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of June\u00a030, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r140", "r652", "r875" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r985" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets [Member]", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid income taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r837", "r851", "r1012" ] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from issuance of preferred stock in connection with public offering", "label": "Proceeds from Issuance of Convertible Preferred Stock", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from long-term borrowings, net of debt issuance costs", "verboseLabel": "Proceeds from Issuance of Senior Long-Term Debt", "label": "Proceeds from Issuance of Senior Long-Term Debt", "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)." } } }, "auth_ref": [ "r53" ] }, "bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for investments and acquisitions of certain technologies, net of investment proceeds", "label": "Proceeds from (payments for) investments and acquisitions of certain technologies", "documentation": "Proceeds from (payments for) investments and acquisitions of certain technologies" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfCommercialPaper", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net increase (decrease) in commercial paper", "label": "Proceeds from (Repayments of) Commercial Paper", "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper." } } }, "auth_ref": [ "r990", "r991", "r994" ] }, "us-gaap_ProceedsFromRoyaltiesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRoyaltiesReceived", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from royalty rights", "label": "Proceeds from Royalties Received", "documentation": "Cash received for royalties during the current period." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r162" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r10" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r328", "r635", "r682", "r683", "r684", "r685", "r686", "r687", "r831", "r859", "r876", "r970", "r1029", "r1030", "r1035", "r1053" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r328", "r635", "r682", "r683", "r684", "r685", "r686", "r687", "r831", "r859", "r876", "r970", "r1029", "r1030", "r1035", "r1053" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r209", "r239", "r242", "r254", "r259", "r271", "r279", "r280", "r303", "r317", "r323", "r326", "r369", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r547", "r550", "r551", "r572", "r583", "r644", "r661", "r705", "r758", "r777", "r778", "r847", "r872", "r873", "r887", "r988", "r1031" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r173", "r213", "r659" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r17", "r645", "r659", "r875" ] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNetAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r17" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r927" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r927" ] }, "bsx_QualifiedAcquisitionConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "QualifiedAcquisitionConsideration", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qualified Acquisition Consideration", "label": "Qualified Acquisition Consideration", "documentation": "Qualified Acquisition Consideration" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r412", "r413", "r414", "r415", "r488", "r495", "r518", "r519", "r520", "r610", "r634", "r688", "r728", "r729", "r785", "r788", "r792", "r793", "r805", "r828", "r829", "r849", "r858", "r871", "r877", "r880", "r1025", "r1033", "r1047", "r1048", "r1049", "r1050", "r1051" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsNarrativeDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r412", "r413", "r414", "r415", "r488", "r495", "r518", "r519", "r520", "r610", "r634", "r688", "r728", "r729", "r785", "r788", "r792", "r793", "r805", "r828", "r829", "r849", "r858", "r871", "r877", "r880", "r1025", "r1033", "r1047", "r1048", "r1049", "r1050", "r1051" ] }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Average interest rate of de-recognized receivables", "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)", "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable." } } }, "auth_ref": [ "r131", "r597" ] }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r246" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Income) loss amounts reclassified from accumulated other comprehensive income", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r32", "r50", "r245", "r589", "r594", "r595", "r986" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r32", "r50" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r246" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r64", "r65" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r63", "r65" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r894", "r905", "r915", "r940" ] }, "bsx_RenminbiDenominatedFactoringArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RenminbiDenominatedFactoringArrangementsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renminbi Denominated Factoring Arrangements [Member]", "label": "Renminbi Denominated Factoring Arrangements [Member]", "documentation": "Renminbi Denominated Factoring Arrangements" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on short-term borrowings", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r55" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r261", "r262", "r430", "r459", "r603", "r843", "r844" ] }, "bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, as of December 31, 2021 and through remaining term of facility", "label": "Requirement, as of December 31, 2021 and through remaining term of facility [Member]", "documentation": "Requirement, as of December 31, 2021 and through remaining term of facility" } } }, "auth_ref": [] }, "bsx_RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, eighth quarter following qualified acquisition and through remaining term of facility", "label": "Requirement, eighth quarter following qualified acquisition and through remaining term of facility [Member]", "documentation": "Requirement, eighth quarter following qualified acquisition and through remaining term of facility" } } }, "auth_ref": [] }, "bsx_RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, four succeeding quarters following qualified acquisition", "label": "Requirement, four succeeding quarters following qualified acquisition [Member]", "documentation": "Requirement, four succeeding quarters following qualified acquisition" } } }, "auth_ref": [] }, "bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RequirementSeventhQuarterFollowingQualifiedAcquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, seventh quarter following qualified acquisition", "label": "Requirement, seventh quarter following qualified acquisition [Member]", "documentation": "Requirement, seventh quarter following qualified acquisition" } } }, "auth_ref": [] }, "bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RequirementSixthQuarterFollowingQualifiedAcquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, sixth quarter following qualified acquisition", "label": "Requirement, sixth quarter following qualified acquisition [Member]", "documentation": "Requirement, sixth quarter following qualified acquisition" } } }, "auth_ref": [] }, "bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RequirementfifthquarterfollowingqualifiedacquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, fifth quarter following qualified acquisition [Member]", "label": "Requirement, fifth quarter following qualified acquisition [Member]", "documentation": "Requirement, fifth quarter following qualified acquisition [Member]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r1036" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r895", "r906", "r916", "r941" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r896", "r907", "r917", "r942" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r903", "r914", "r924", "r949" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash and restricted cash equivalents included in Other current assets", "terseLabel": "Restricted Cash and Cash Equivalents in Other current assets", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r57", "r212", "r256" ] }, "us-gaap_RestrictedCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash equivalents included in Other long-term assets", "label": "Restricted Cash Equivalents, Noncurrent", "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r201", "r816", "r817", "r982", "r995" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring net charges (credits)", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r16", "r406", "r407", "r1026" ] }, "bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA", "label": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA", "documentation": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r143", "r180", "r655", "r692", "r694", "r702", "r738", "r875" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings/(Accumulated deficit)", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r206", "r268", "r269", "r270", "r272", "r278", "r280", "r370", "r371", "r522", "r523", "r524", "r536", "r537", "r562", "r564", "r565", "r567", "r570", "r689", "r691", "r706", "r1063" ] }, "bsx_RevenueBasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RevenueBasedPaymentsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue-based Payments and Milestones", "label": "revenue-based payments [Member]", "documentation": "revenue-based payments [Member]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r304", "r305", "r316", "r321", "r322", "r328", "r330", "r332", "r483", "r484", "r635" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.bostonscientific.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r204", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r487" ] }, "bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from contracts with customers, disaggregated - performance measurement", "label": "Revenues from contracts with customers, disaggregated - performance measurement", "documentation": "Revenues from contracts with customers, disaggregated - performance measurement - measures used by CODM to make business decisions, excludes impact of foreign currency fluctuations" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility [Member]", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty expense", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r157" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r958" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r958" ] }, "bsx_RuleTradingArrangementCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RuleTradingArrangementCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule Trading Arrangement, Common Stock [Member]", "documentation": "Rule Trading Arrangement, Common Stock" } } }, "auth_ref": [] }, "bsx_RuleTradingArrangementStockAppreciationRightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "RuleTradingArrangementStockAppreciationRightMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule Trading Arrangement Stock Appreciation Right [Member]", "documentation": "Rule Trading Arrangement Stock Appreciation Right" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts receivable, net", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in Other Comprehensive Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r50", "r1042", "r1043" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsAssetsandLiabilitiesAssumedDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r90", "r92", "r543" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r90", "r92" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r42", "r81", "r84", "r130", "r131", "r133", "r135", "r178", "r179", "r854", "r856", "r999" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative Instruments, Gain (Loss)", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r113", "r119", "r560" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r114" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r574", "r575" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets and Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r852" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r852", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets and Goodwill", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r66" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r34", "r147", "r148", "r149" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Not Designated as Hedging", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r120", "r969" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r182" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r178", "r179", "r180", "r221", "r222", "r223", "r297", "r456", "r457", "r459", "r461", "r464", "r469", "r471", "r698", "r699", "r700", "r701", "r858", "r966", "r996" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted Average Number of Shares", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r61" ] }, "bsx_ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate from Continuing Operations", "label": "Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]", "documentation": "Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r889" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r891" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "verboseLabel": "Segment [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r300", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r332", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r405", "r408", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r852", "r970", "r1053" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r330", "r331", "r721", "r724", "r726", "r787", "r790", "r794", "r807", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r832", "r860", "r880", "r1035", "r1053" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT REPORTING", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r315", "r320", "r324", "r325", "r326", "r327", "r328", "r329", "r332" ] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "bsx_Segmentoperatingincomeaspercentageofnetsales": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "Segmentoperatingincomeaspercentageofnetsales", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment operating income as percentage of net sales", "label": "Segment operating income as percentage of net sales", "documentation": "Segment operating income as percentage of net sales" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r158" ] }, "bsx_SeniorNotedue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "SeniorNotedue2027Member", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "0.625% Senior Notes due 2027", "label": "Senior Note due 2027 [Member]", "documentation": "Senior Note due 2027 [Member]" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes [Member]", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance (Shares Issued)", "periodEndLabel": "Ending Balance (Shares Issued)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r35" ] }, "bsx_SilkMedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "SilkMedicalMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Silk Medical", "label": "Silk Medical [Member]", "documentation": "Silk Medical" } } }, "auth_ref": [] }, "bsx_SpecialChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "SpecialChargesMember", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits", "label": "Special Charges [Member]", "documentation": "Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Statement, Business Segments [Axis]", "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r208", "r300", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r332", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r400", "r405", "r408", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r852", "r970", "r1053" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r205", "r221", "r222", "r223", "r259", "r285", "r286", "r289", "r291", "r297", "r298", "r369", "r417", "r419", "r420", "r421", "r424", "r425", "r456", "r457", "r461", "r464", "r471", "r583", "r698", "r699", "r700", "r701", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r718", "r737", "r759", "r779", "r808", "r809", "r810", "r811", "r812", "r966", "r996", "r1003" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsEffectofHedgingRelationshipsonAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement, Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r20", "r46", "r206", "r244", "r245", "r246", "r268", "r269", "r270", "r272", "r278", "r280", "r296", "r370", "r371", "r472", "r522", "r523", "r524", "r536", "r537", "r562", "r563", "r564", "r565", "r566", "r567", "r570", "r589", "r591", "r592", "r593", "r594", "r595", "r602", "r689", "r690", "r691", "r706", "r779" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r330", "r331", "r721", "r724", "r726", "r787", "r790", "r794", "r807", "r815", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r832", "r860", "r880", "r1035", "r1053" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r268", "r269", "r270", "r296", "r635", "r697", "r718", "r730", "r731", "r732", "r733", "r734", "r735", "r737", "r740", "r741", "r742", "r743", "r744", "r746", "r747", "r748", "r749", "r751", "r752", "r753", "r754", "r755", "r757", "r760", "r761", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r779", "r881" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r268", "r269", "r270", "r296", "r635", "r697", "r718", "r730", "r731", "r732", "r733", "r734", "r735", "r737", "r740", "r741", "r742", "r743", "r744", "r746", "r747", "r748", "r749", "r751", "r752", "r753", "r754", "r755", "r757", "r760", "r761", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r779", "r881" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r898", "r909", "r919", "r944" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of stock-based compensation plans", "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r87", "r88" ] }, "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (Shares)", "label": "Stock Issued During Period, Shares, Period Increase (Decrease)", "documentation": "The increase (decrease) during the period in the number of shares issued." } } }, "auth_ref": [ "r20", "r1063", "r1064" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r20", "r140", "r141", "r180" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchase Program, Authorized Amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "terseLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning Stockholders' Equity", "periodEndLabel": "Ending Stockholders' Equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r141", "r144", "r145", "r167", "r739", "r756", "r781", "r782", "r875", "r888", "r998", "r1011", "r1041", "r1063" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning Balance, Equity", "periodEndLabel": "Ending Balance, Equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r99", "r100", "r102", "r206", "r207", "r245", "r268", "r269", "r270", "r272", "r278", "r370", "r371", "r472", "r522", "r523", "r524", "r536", "r537", "r562", "r563", "r564", "r565", "r566", "r567", "r570", "r589", "r591", "r595", "r602", "r690", "r691", "r704", "r739", "r756", "r781", "r782", "r813", "r887", "r998", "r1011", "r1041", "r1063" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r177", "r258", "r455", "r457", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r470", "r472", "r569", "r783", "r784", "r814" ] }, "us-gaap_StockholdersEquityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPeriodIncreaseDecrease", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of mandatory convertible preferred stock to common stock", "label": "Stockholders' Equity, Period Increase (Decrease)", "documentation": "The increase (decrease) in stockholders' equity during the period." } } }, "auth_ref": [ "r20", "r180", "r780", "r812", "r887", "r1054" ] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants", "label": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]", "documentation": "Summary of term loan and revolving credit facility agreement compliance with debt covenants." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r978" ] }, "bsx_SupplementalBalanceSheetInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "SupplementalBalanceSheetInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information [Abstract]", "label": "Supplemental Balance Sheet Information [Abstract]", "documentation": "Supplemental Balance Sheet Information." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Supplemental Information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplierFinanceProgramObligationCurrent", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program Obligation. current", "label": "Supplier Finance Program, Obligation, Current", "documentation": "Amount of obligation for supplier finance program, classified as current." } } }, "auth_ref": [ "r401", "r402", "r403" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r938" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes Payable, Current", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology-related", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r31" ] }, "bsx_TheOfferingAggregatePrincipalAmountMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "TheOfferingAggregatePrincipalAmountMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "the Offering", "label": "the Offering - aggregate principal amount [Member]", "documentation": "the Offering - aggregate principal amount" } } }, "auth_ref": [] }, "bsx_TotalAllocatedToReportableSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "TotalAllocatedToReportableSegmentsMember", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total allocated to reportable segments [Member]", "label": "Total allocated to reportable segments [Member]", "documentation": "Total allocated to reportable segments [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r930" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r937" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r957" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r959" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition." } } }, "auth_ref": [ "r28" ] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of Financial Assets Accounted for as Sales", "label": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]", "documentation": "Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction." } } }, "auth_ref": [ "r27" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsChangeinFairValueDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r451", "r469", "r568", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r665", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r1006", "r1007", "r1008", "r1009" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r960" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r961" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r959" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r959" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r962" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r960" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r85" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Common, Shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r85" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost - 263,289,848 shares as of June\u00a030, 2024 and December\u00a031, 2023", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r45", "r85", "r86" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r20", "r85", "r180" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails", "http://www.bostonscientific.com/role/RevenueRevenuebyGeographyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "bsx_UncappedContingentConsidertation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "UncappedContingentConsidertation", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncapped Contingent Considertation", "label": "Uncapped Contingent Considertation", "documentation": "Uncapped Contingent Considertation" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r956" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r526", "r532" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r533" ] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r264", "r267" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges to expenses", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": [ "r265" ] }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Utilization of allowances", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "documentation": "Amount of decrease in valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r266" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r1040" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r22" ] }, "bsx_VanceRBrownMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "VanceRBrownMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Vance R. Brown [Member]", "documentation": "Vance R. Brown" } } }, "auth_ref": [] }, "bsx_WatchmanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "WatchmanMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Watchman", "label": "Watchman [Member]", "documentation": "Watchman" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsIntangibleAssetsAcquiredDetails", "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsLevel3ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r828", "r829", "r1046", "r1048", "r1051" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net effect of common stock equivalents", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1004" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted", "totalLabel": "Weighted average shares outstanding - diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r284", "r291" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic", "terseLabel": "Weighted average shares outstanding \u2014 basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r282", "r291" ] }, "bsx_YenDenominatedFactoringArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240630", "localname": "YenDenominatedFactoringArrangementsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yen Denominated Factoring Arrangements [Member]", "label": "Yen Denominated Factoring Arrangements [Member]", "documentation": "Yen denominated factoring arrangements." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "30", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.13,16)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481161/840-30-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2E" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r965": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r966": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r967": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 84 0000885725-24-000068-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-24-000068-xbrl.zip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

K[]#QXN_2] M=TC!26?YK?Q^!*Z+3RSDJ_SYE8O4CQ_;%)26^ "208A=OAN;+T,OY0)@_JN* MNI#_F913,OC>[5%+149CG)#B0=PNF\QJ25=:2BE6C 75^B?)> #) #@EPBPM M@_>9&$]B%%-F&6(C$?ISN0"W[>L*4JB$77(=+"RH&=& V.%1%TFQ2M+%10M MQOOY-M24!*MT8RI5D,BN,;3BZ:.5*&F2IJJ+R()\ACHT?5>)=Z7FG8LREH:P MW 8W!6;%-SA3>6+)M;X61OT[+XB?HJL4.3#[00Y&5(8$924VFR37( *$$7 - M0>(,!S S2&F)8*T&B?EK"T+E!2[$4GZ"<7QI.?(]2??#HF%PMG5H[Y [L28T M5IP(A8I]:, .X+JJ=JE;F0R8JJGKA[RN;$N3B/HGSN<3S2+W!>"F(?DA,&;A M[:1^KT+8++LQ(/B=*1KU#<'?39TEC>0*P_*%CVA?9 (G>7!KM@&09&D;_N?-U9@,VC%UX)]= MS,^G 95'I1;2)E;!FU(Z\J-1BH'D)RWWJLB7&-/ TTPB<<\B\8GZBG]3?7U0 M<1F-;(#O!Y4>.Y^)?:+!1U$W)1:!X&3-Y;^H5?%J53/D0K, N58FK.!:X!XP^Y$-5KJ7IS^X%_U9WA4R93P&!*>#\9 MV@@H3U0.,O T#O,P@@YY&*Q*6U!TXQ%\*236NF0T&2=.ED@$W@<(&!E_ZN#Y M+O*BMGNT: 0%V?+FT<+.L[U:$66-LE5LU ]_#Y;QSOML" MF-,P>YX\Z"9K*O04Y.>;:H;Y&Q!1C1RX_VWDN('<0 MHJ43M!88=\&O1JU*M/HTLG;DE4-O,8Z8=Z;C7&B!!(8_' @RWK6:]@%O^5LZ M)$,-#8C'F[PA-IE5*Q-XFIUR2MV$;CO.MZQ@R@[Y)L.1[LVJN$UN#HNW$;)T M+WD*Z)G; OQ:0).1Z@$N_%M+K<,O5]^8+Z'7)4K[N!]RW,0^AS6OV-M7LCD.T^^\Q'XSCO47?,:O,18F1 M8(CH*24+0U]774[G9Z?_;J:O)S'YOF(RRDF7JW>OH16GV5BGRJ4[(_\+=X>? M7+V\G.TW]=)KBBOLLA[NRX%:'% /4_52F)N"^ MF-,(;++%]*+EH0KE\JZ'F+%CY8Q/8EF]]K@/^(C MF;W%3ZNTM-Y%/ZIHZX-M4%$M#D\?&%-TQ%L:^/>T!<#8 D$T&S=U4-][T &S M=JMQQ1H1#&"3-.AY:,1$5.V#.)C199[7YK,"ZE[-=H^SX,A.B;^IV]UF5;=L MFF5F/GR10-LSI]3QRN2Z20LJI=?Y P5)^.>3VU5"D_4EGJW$FXF+I!.T*%-Y M7?FO+?%V8L$")PK<6VUGY/OQBZJ4R4YPA%FDSD4@\B6F 9QV.XCP\[X/G)U1:L=V,2A\8',A+ MN!=B*8;G5D7E=FJ5QM69D M-/^GY\?:33OJ[A_[^_M?@C>;2>J>5@#(\P4 M_R<#_B]EE J"#F&R].W>OGG_X??@[&S^7,7;;ZXN@_^2P4)7O-N,5ONLSMB MJR('T @;LH$QVQ"X06ZA2KU%=+*FEM' Z"7-;Q)J(H(.LW5%Q(_J6V*YE!&* M7(H%-.>Y$.*_N=>9NB6^RW'P(4'?Q)'.T1P&")#'X+6O\^L,),OERR!D?.'V MXFCN,06P"(DG*68I0T2JUM;2/#N3JO:=CY,P?@=AS(4"2?"V"8]&*KM3U]=2 MZG+_JKDZ[6]\3KX8@L&DYS.F2=-T WL_.06[]RZ0>&@B_^)X'&3K.*>5@>VZ M7,LK1\)&>L($-WX@A G_=9'?)B*K5W1J*[9I:-5&J"4T@)2+? 66-&74$6D@ MUXNOHF&>+."=!6Z_=OH1B*(%!0ZS:M*.)1NR3RXV'Y,',SZ?!MWK@NU9C_I6 M>J05\ 6#/)K3^)TT=\"K:E-JE0E(MG2$F8R*1C*^8()4_@72ZHI)%=4$$D+$ M>EI!@2?*$,),N0/@KY_VC0E0)Q1R:L4,4&=MW3/T,427CX^PM1*M-H!F$WR/=!+&VVBVVK8..Q67LS/B#<]EO\\;SF3JZ6N2$8_[X-.63^ (]EYLLQ4[*JZ2$ M?IUH3),=1Z8HTIN _M.3E[.3-$VGXOT=USQNF([_3;*L"M[(W1NJ\WQ?_;#6 MA*G>,/@5UPTPTB;2.T99&+?*JN*4.M:LBEW%L!1;@/;#1C"?=!;%- M%W-G&[Q^?>FM7=!,Q2T^7JP>+S*/AS1+IAC5=YEN7.FT@N:%W$Z1+3/M%*Y->) M&GY=4YNC(>W:47X)5-4'R:-$5%/!L*K+!E,OM#"531*U=651IA6D0&%UN,TU M]1Z7R'&E6=3-%](<9L.0%BRT$].M]!GF1)B MU?<8*38T8:]R@MWZX#T XDM0@GK(O\34Q)Q\2M9QOQ__:3$ F=RA@@,5 MH(9^K'FD.5'"05>1XZ9[:=U0+S4O)0R:4IZDDH9'ZF13*2SV;?!K49/%0)ME MHA+#KA$7$>D\S2.4J@'L"=/$9X MR9FX!_$-<=2QH<%*4C024?BQ<"@0:1%UY?(DPFC/,4709_.#)IKHO;6W''R= M;#OMXYUJ5 6/\M0@Z)88ANT#@7TK:#W29P*UA- UUNQ._7QY^?XHC]BHUXQ\ M@F"K*&,]'T>]!*$J*UB_376M 434^@-NCOTWNB"$:#1TC613TEEWSMEAZM7V MF!4 B]VNBHRF"N%ELH<*FI$"NFM)OGJ5*MI=^P)D#KD:$EJH$:$.O_ 3K[^L MTD5:VR2SX"5W%]3TNB9'*2#QH(!XE,+QN/@,TK@'"/LFS94-/5D@W2]UM\!S@8.,ED3.$1G< (^/B"MD24"*O0V;@-8,C![,.T*G\)DB7PU M4E&)Y5"HKLI+G9\^?G)Z',K3$.YQ\*C9I%/SP]!S8 M$:M&/LF;9%$V$%#"9Q%XM[?Q>=SONR^XO.@-+C_8;6?WT'4%7NZ!Q'K^("?Y M"T3PWNUO=&.CNMC\Y.< @(V!% Y:;?W4!S$8%^P4WXJR M!'6$,#/"_BO0XFZK,YU=9 C@>^BVP$=-"JB5, PQZTHX :"ZC=+FT.FTYE_) MPW MM57]:(.E _*)G1A;BQK&]ZVDT1#DHH\U+;3_Z>-*I5=Q:/Q#DO;K8:X"1^%\^NA5PD[7NU\I M#2XTA/T EPXW&4KC(L^T476<4+@%>X M#J[0]ZGF0=!K=U5RXM*::%+I$&70H(,4BP6@!DE^+;D!K12Z ELC/#'0D[:7SK@H(H9J5=).WPQM'GR3 M '3E?L"FT_-615-&M)%27VY2^/<0A"[:UTK/EMG/&-Z_<;<[*3NH913!] 2* M5GX@+ZQSMK5CM&9"!?-5D%"[0:2H(3D6:W&=:'/^6?IU]H$0IV6B2DKT[Y"B M2I$!Z!H\'8B0_ ("VXB,E"6O@".51A7Y#C P@,S265%5]'J2+YLD1Q]=G3NP M<3(H#YUBEHEG,8[GCT*Y2=S2RM!*U5MY;BAV%?DJ2)[;FJ".+))MI=GX=OD= MS51]3?-0XQ>Z(F9)V#RX#X0K3UYX;^<_O9K<-X7=N"# MR?]=OOOM]U\_!9>_O@H^O?[P[F/PVYO@ZK=W[]Y^>O?ZUT\?CS#8.I^?]0=; M;00)"\IO*L#H LS3J0!SMX+J,:+I#514/S:+/ZRF$CH$N84E3LE+4,&4/SU,QB'^_4V;J]37%3 MJIE!8_@4Y:]%)(/:W$X?Z@B6/'/#1#Y@5.& ]PN(]*:D8"#,'[+-@/.A:$#^ MF93DFYZDZF;7\L, =1!\*L"E^:VI*T@S8KH9G CIARG8U;C T!2&U:@#P/KV MD/V?!Z\&MB=T]Q8\70"OA5\.710D(?)TV-C;"._CMK5] MP5-_&^3[LHB2&&#V(*;O[.9+=38=X6,/8NQ_ER*0XUG0,6\U8@^Z&(->'7-$ MNGP$.IVBQ^GU[4D=H((_<':5X,53Q9ZGN4^H*YM_6C<5U@: ST!^;9A,2^O0 MR9=N3[M]4)^=*C+,R_F[>8B[__>B_!Q<8=)-OA%*'6^[E]''N[R*NLC[GHN8 M@01B0+P[^R$U"_VC20CE1ND%&@4DC.#6=-68HIJRS7=Z?!IN,@'0:LCS87SE M8GE#WIQAK_M7H--WLU;VD[I3T#]5;C[U'_!=22ZA-4I[YOUW(2_*KE]I[Y5; MX!?(%V&_8L<-\SI@'!?<:'H=ST4)X2';JO;_;-N^C_5DJID$,$_A![+[C)&2 M)?DU\#73K7C3V[#GM#1I$^?!:]A*LZ(]%?BDX"V".W>^/LZ3W74+S[PD49-? M^'^?S9\=AUJ@\WEV@A: &CE,;;RWYZ%KH[RM1]>L\\>BN X+@!ZX01X[8G M4Z(7\'[O@_+L/@[*\UT'9:A.&M?R6T="*SKN2Q9B+1RS@QX)A2KAFP93/2WW M1M''JI&F$FI>&_DM8]D'LBQFE71H*,8(JFB[3R2TR Z%]'HVD'KAU/U-;H!< MK6*Y3".]:K]XZ $6R 6!LR%7,N1#\;(LYJ%E W!)Z7HM'UD^ B1B]WD(>801 MR).PNU:UOW@,'>6'/HW80)EC',6[AJ9F'66V7X66D:&73 ESY>KW29G. @IM M<=7@)[>2^I?@O24OIZVQ"A(VR%*IM"1JHMK+W3_.H'B@?3.!@K/))%_16W[X1QKW:[AS.7V<+A.S2FV#-X"2#PE,SM/K;:^4' >\ETK; QP M3W'<0+6@F,Y5<#*/+18Y/!>YW%MT]&5$74I1R+:8"RKE<0^@,/2V,U'5!-?+ M2O1.E-$J#/Z[R>7+^"@C0D*X@>N]DFX^_."\)(K %2@&7&;T+^=B_N*P<:(P MK)<=@Z(PX.5+RE+%A>E@*0]FSRC!9&@%;<51F!@$JAPA!BBM8IF6E;$U,791 M ^1+%#6E4PN55WR4_23CE%DX[B(Z2GY)8+3J*(]K%+"$6O_M=(2E!21Q58)G M>[U2G^P\_[BEKL]-?][KIMO:CZ5U(.OA_OBO:ED>[S:,J-+>AG> SX5! VE^ M:" TQ0>J SO%7NB_/'OQDTWAVB/W89??==!R0\VDT[>&%R&XM5;M+?GQ;D.UBWI['W324!W".@X MMV;9E""6AU==JP1+AZG!J&HWY^)X8DW*Y7X3XD[=*PUXBYNV4N8<8%.K!L\N M+#4Q=TA=VZGNI+&NS?.4T#/UV;.JD\5VCV,D((OD]!B9,J%K.[ W1B%0TC/! M X(V5O*2%>+/!)=Z\*YKY?S- CLJZ':'CL+IP1,+;*: @;ZL74[R6!0LE$'Y M'1]IWC]L:G6J^=,^5%Y7>\N62K./<*FJ4[5OC8"FAT3CWSO+<-""Y\BGG_K< M\1<#A225CN)^L,G1_B9'&^R"-')-KLT1=BZ"?@)J[[WF>G'^!0'$\HU(8V]7 M2.N;=C>XRGVH:>V>[,S)5Z1GR.-;),18U21.;NYXP#/.3@_:T-9*/[!HL3?2 MRD:DJD^37^. 2 R\L>X046'RW>;\L))B 2!A92:G#=TXU )"YR/E0DI%SR,% M(6_682<1$KJ9D'&*A9-/?3H=0W<^AG[H/8:N+M](8W@# V+3 717:=AGA-D# MZ]&)%W@4PWX7/HO0G;)PQC+,MU5@3=5!:B"?$] .E@F=&W'D(-]D0>FCV)[W M11\\$[?2N 2)#;YD;3''*A0 NJRE*H!81L M!"V3$B7(D%G4*?R,7 HQ266(;<5&VCB%_XO4.F0HD-NW *KO.$%Y"=;(]TG] MV_^9>Y5$S*QC3B!U1_ M@[IWYZGS0"4B$-LR^%_#SY>EZ]0MC[2FN:5%P/2C\1+:W=SV?K1L6]>&&6L' MS![@/]',.;9)!WGB&L'C+,'\N.=PHVVPCWJN<=1KOG,CE:=\H^334?W%5B'5 M(TB:\SH_\!<&2S98_S$Y:VN@XEUPTC-.T1H]$72H^VZM(+'R(G]"AWF@SNY0 M64JX["Q8PIH&I@QE"+U!K//MIS-,^A99&DF[*\^+JJW?5=_0!^= M17W MA8VMC"@=<-> 5'W'(2EW0YSET7A*RP<46F(":WCPE3J#3?(VY8>SG,.$/Q>\ M5DB2^"R4NI!N8T^^UQ[!$I59+YVS-(*U$GC,@2"MBS*QRZ<6P*'S(M\!ASA( M%&QZ1>%][]_QY25M6=!I:QV'FR-1S6:J+=9XB!YA4KQ== EU49B$=>O!+Z!3 M"O+II?64%\]/Z=>F3Z8E4&HIG=?=)_\\9NO>_.+TWN_NMPT,P*,68.R"+R/6 MO:K41.MJ._/X@R-P>E .4CTB0LS4A'Q2@TFL7*1:%28[GM MG3TTE;,=:?$G7S=KR]-P$H,\+<1T5E:(P_N,>UP2Q[/>-V#OQ*P@U MW"P2G#9EUBVTB(S,8H8_MT[?]CCME%/<_N&P7=J\74^9[5_O"0+ BXIN4P3_-Y#[[ 0[VQ@X_0&J CKI]GL#N [HW[NDXWN3* MV*%/6L^#M_TH%-H#C\1&1$0B(=VCMOHIFKS=7CLC?&Q[UA8"OTC__GH>%&[4 M?437(3M[]GU>Q%'&B_V$?YUX<3A#]S@#1D&YH8+?W']H^T.3T?T>GOZW@D_O?49&.G7QPE_TQN(JG>[N*D_=W1^_O MQ[V=O\?DS_7S\[YTHI.!L]]?RK;WV8'WVU%(N$.INR<3NN]:'C8/.EP7N,N. M4)WT[DGC^UC8CBJ[VR&DE5DE-1R%1DW]4WB $>Q1UAN7P,[R_&>OWUU+Z[A9 M0:1ASWG)(U*Q&Q;E(]G%_FVTMLF[&SU;=V(C6$KKOTS+-8DSQT'#8R,=@W%% MEZ#"=6\U>1:<7,Z.'-WD?/[C27)@DE,F++9C;#[(,;BM=%#KG2%V2 94V^7X M!V5:[^"P1+.6:1G7+@6M;8H.+:J=CB:*VD]>0@\]V@&B4UT+:68 ,L>5X$E2 MOUU2CV.;QB>I1QFK)'MU^>I<"QTEQ!C=\G*Y!10H;A7@1CU3$*?Q/LTG!@PB#Y_BN.Y/MUHC:]X M$M2=&*AO!:KIN',KS(H^^EC'S?3O\VYW-/[<][OM+4/L\0KU>H>EH7I4KWKX M73L#H[#5*NXA%[$S<*"28OVJM'/VP,P1<$"E7F3GDTZ*C#O@L7/0D\QX;$6+ MF][7EK:Y.?"-5?A:5!6:7A\FII'0S'VK"P'9.,AT9UNJ?LNMC[@Z2L;:.VO0 M;1-DQ#D-+93*HS,%=!U15P7P*%,D DN^+70@W0TXI&J35/B-K,(.)H7%@,4.YHXF)\5V %YUF/:>XQT MDU%?"5X!'@6(O[BD E[3@"\RZV6C7165NX=3)4A7@GX\ MDDK0@8XSRI"#55LD26ZR#&00J05V+^+5@:*0&R]X[0OU[GFY?Y&L-51P"$JC MF9.X7Z>-!G>U^]MT>@ 9Q/!"XU,RSVPO=ZZ QF- 8H1 640U6T-U(,0@<)\SRX]%^/8G6T'>WYF!V>WN"!J$AZ=]:-Z!]Q+UX/Y=UR$9WHU- 4^MT>U[/#G/D.4/#N5)[SY#ZR M('QYBS;V[J'/8E3B*110W5//G1%Z)* M"= 3@+.> "#+-A%C M41<,#Q$3/26QRI9)_W2O8[2!AKIW=BVGM8_'7-<(:$L\[6\P%80?L#NACF+,. MH-1')5,Q92)]:&K9BG_#((WZ0 M>2[49'4??5R6!ZG%)V>*R_3@IWU^[^4D")_,K9WE9:UGLMZPK_ M\:]/7_QT%?RVR-)K[C<2M?12%DVMD@;$(8O^'\_MWRUS&)JF)^ZI-%7-W45, M^(0K1=)48GL4/6G4IGG<#44?%U^'/3\/7@VHJX<,H^&Q[-YC$ASTA?)N&$9> MW<"C.D2:!_T[-.B[$64=,NR\=1EXUIZ.AX%SA6!5O)8!GB42\#30-.M;6+A3K"YWU4:;?>K)M7 MO?;)E_F^;3/H>2_4FD?=@VS]"9<@4^8F+;U5K [MJV8%>T#*09_KH0L\\I+L% Y3$+IL@ZI+2+$.3FR##Y,? M/,(339[@3_L5'0M@&C/Q5DV%[ MCF[]FIEO1X=@0:/=@O[0ST\>3C\,Y91V1LPZ:2. !T7(S;-Z>:E+>6E<%A/Z M[LX?26-;.LWL%L4->ASP)^URS.;![RV44]TJW[>O)M7?(1K?V2Z@V^GLOH$^ M?XTBWE^[3"UVTY:O:MKN8>CT@ R\NWOK"C$]'-R]X%>-@42QU6#3):[O1OFN M]D3RO](W4J?RGHD_:[1R=__A?FT_AJ5$SSOM:M$9T>MI4RP-+(W=^H$>I6EF M:8^9I5!:9C1?.$>JYTL&C K&4+> KQA+1SC"=-M EHR?E'NO^ 6CG;5,2-=\ MGT@%RAK*S>*PA;1&4K^6"8=ZZ#GG1;D&'8/D75-)OT&46_@(553ISG3:P;!4 M4MZ 1(JJA<'<^[Q^+,J9[2!G:=(HI3?*; *K8)%G]1C?PJT\.<\\8H[L@>R M&6>HXJ22[X'UH4XH_JB*UL;7BL5,GPE40#F!$5S.6".I*LG, ;!0MWN-N^Q<&,Y;Q(V>-)C:$1XD#O/U\H4*AL'F6O1@TC(@U5[8E=R[ MUYGRZLYS]9K2&8ZOURPCNZIO$ MU7#V\ HVIMMK*!R\VV=%]9L;S@L>X72TN MM1;KJ'@#G\ VK'09#O8_<#\8M92JNHH&>B$#K4(-^ U]'>0KUD2?T%:S?P]% MKPOH&?B&S@F+L<+SI$[\KV,PA&-V8!0"P<5?>TR7/]8[E0R;HZI_*-*PKR*7 M#Y)M=V@'.B1P1=RO2;YWR/+F6DH*Y)-]UOXG"U MJNG9A66MTSEC/"EP(.SAX :#%++VV$(!YPSZ<_:U=;Y-7<$W/#!)Q--2OG@D>$,[42EZR@J_,^^MVX_5=I /WO->!TXF>RL4, MX7X;T\3T(3$QSO%6Q:>RJRZ[GAU)V74L/?4G8FC87Y4O6@PGRKPYMFLEG.SK M5]523N!KH^X3_J"?<*"CYC Z02W#X2/!"=P3R;.OBC_XGK@MLVKU9>Y3G.HI M)9SP2'XK>J"S68J[@O&S.K(PBZ-K%M@!894L.JT/XU0'!U;C[/F! 35\KP;; ME1Z+4@QKA;=DZZ87<(,X?)-"94)(NQ'?U3"C%4-]RZK_^=P[STD=6GTU\!%K MY*+5)( /9]>ZR)S!IN0P9(ED>3*@P9YTJK\-V#/KXO/@4Z%V8W@;PN#DRXS2 MU:;?PX43"@,OO5N/?'Z5;/84!7OU:4?O0TI(L)"2<*;"1V^ SR[FYP0HJ)O MUC8B@[-Z0B*F&_9HS.KNCBS92?#OM;KED M5>$2 K:R@0T6IMQN F=^\NX!3(^1MYPPM]^JZWW%) 36 M5118-L)_Z2DPMU>A) E)>]%W)M_QSJ:+IOL4;W 4E8T!ZE". V\ZOX^8(42T MT$")\SK!##GAA4L!4E]5R!U'!1MY,3\[._1YX@56T5L^[CZ,GIAVT1O2MN * M;+H"((HT7A@P$ OL/4.P8^K\:IU1;WC^$QN3=Z0UA>Z-E$NH4GEBE]N^/&?[ M*&PE.;TGY3%E.7T/,(8T)[>_B[[WW,)I&GJA<'#UO$8X7& &JMZW=GYWX>\'(3;2P$^1=,NV+[Q-Z:^XWA]GC>DY)S0=-:DJ'"6@P MW3/6%2;LK?@*\ P=BHP#V('Z73JH#GH:Q9_Y'$1U" F\8L 5'M;@L']"IG_? M]@;74 H^9+,PP^'T /4G<._7>##T!]O"J?*L*\_G1U)Y/I"CMT=Q IMLJ#81 M)U4D[0B9B"A#7! X?\6BN$F&*Q>^<'B?RD47V=JR1D-*<[_GYG1&WENEPR)N MH5?9 ?.\>RVA/UE[T&+"5R;L!L5ZE.6$H17OY7T/5!2J[U52T+)R#RY$GP/G M?>7X%"U<*K^+]$BJ'D/*/Q4^'GWAHU,^&*4MO6OYH^>9A^HA0XN[YXJ(=W^^ MH22R5_Y&%Q[TH//0-[ZI*.'A\G3+$[L7/)4LII+%5+(XVI)%--0RC;B46IO[ MIP]2*T4ZJ?M=WX&7(YDQ67H-.@\PRYOG26F-33N4:NY+.@)W[_RPWEZ(L<2& MZ2IQ?^7. ^V]T0(='!X5FMF!-]8(-<0WEAO&QY=\!LT2BD:U?]^M:,^0>S_J MP@V9XT-;J7&?;KUS=2]ZY^K>YA$@JB1>\9FP$!X0"P$AL]3NNV&()Z7=Q99J M!V"=5!+8&4 ](%/Q;\\8EC M)&_W]:B+1<7:!D> DDX*E$^ODJ4 +&XI8J]O.->A?H=U[.1+RCC@JAZ< @^V MG5?: =^ )5\%S858!1LIDY"0Y73O#A\ M:M %\M7I/TK28LGE51$U!@JREI$\RB!6:N0[3D6FF!01@8KS,BJ<=P1/H6:* M_+/!D%^FN9#"+"!A4-5IW>#6G%CE/L$"9W-!ENI?EYIMP."A(4G+7KI=69JE MT-O0%.HC)^M%)690W +R45L/(K#1WJ(BK_6KAE,3R D&M* M]W>P/4?0* U9MN=S=V'Q4I7?3;Z *E:*4LB"-G6SC^H442!D*9Z,06 =PX ?^BGF135 M2HI&AJ5>D8WZ\8[QE=P9I..RQH.8CA,XF+A+N4STV0J.LO:P+8_&(?'Z(&KJ M,."DJ/1\H:S_\3_^]>*'G]Z['506H6>_@>,"W=NJ:LQS>5/## 0UZ%NU9-O%3*L: M: 5(&0PV*N!B<.$WI7Q[>X ;C=^M<'6@Y'(!R?K71ML5&1*Y@:LM9F-;16*&>^)[9#.B>EO=SKRV@G4Z@CRVQ]'$NU;%7M/ M&>TH \_^Z>R!C3[[$?[? R[K4NYRV_>RT_<,R5LU&[# [(\H>PZ3!-AX7)GY M\CC!S.C,[B=/K:'RA70C/B=Q:#H,%XE ^B[^IFH2K11=D,\%4J[Q$%BQ?+NA9W/A MZO""1 9=R@Q!CM?GOY 4 %534L)="K.G I "3#2IS!J5"$/5JLZ\&+K+O!4' M8#MZ95:O-M!F-79'S]N"JIP('O/9T[P^L$[MGR+XX20:2@\\N.[/@[=+)VCJ M#7BLZIJF)ZKHZ.ND>AQK )Q9ZDV&893(NO&9(;9R190E%YJ" -3T@H"VVQF MW> *QHA"PWN$_2%QLH:;#;1UA-AQKVFD=A0ZC0=_A[Q< HX0DG+@WL4)_6WL M%#5W[C,^I +^VDJ42+V K,6U<_! JL"!97'KI6%_G!]V?-%?-1@C8T8$ST1'#*LEB M7=IR&V!TM'QJH>' A MG/>HX?]H 97?CP7?8&FBS\B:EEDV9ZUF9 ED,%HD\-I<]LZ_. M:1HWI>IBB/!X;/"8P3Q6=\0",\CF7+(],IM@6,7QXWR;(XK(E<]JF-U54.!! MV1CG;HXC_)J%&AT%1)GSK_T=.*H>T>YR(8>,7;407X_5S-^^BE^EB->]JA,1 M4["']54J,>WI@^+[5N%D[0"=R(LW.81Z0.$(U2 "6I%*2M6L<6

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end XML 85 bsx-20240630_htm.xml IDEA: XBRL DOCUMENT 0000885725 2024-01-01 2024-06-30 0000885725 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0000885725 bsx:SeniorNotedue2027Member 2024-01-01 2024-06-30 0000885725 2024-07-30 0000885725 2024-04-01 2024-06-30 0000885725 2023-04-01 2023-06-30 0000885725 2023-01-01 2023-06-30 0000885725 2024-06-30 0000885725 2023-12-31 0000885725 us-gaap:CommonStockMember 2024-06-30 0000885725 us-gaap:PreferredStockMember 2024-03-31 0000885725 us-gaap:PreferredStockMember 2023-03-31 0000885725 us-gaap:PreferredStockMember 2023-12-31 0000885725 us-gaap:PreferredStockMember 2022-12-31 0000885725 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000885725 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000885725 us-gaap:PreferredStockMember 2024-01-01 2024-06-30 0000885725 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0000885725 us-gaap:PreferredStockMember 2024-06-30 0000885725 us-gaap:PreferredStockMember 2023-06-30 0000885725 us-gaap:CommonStockMember 2024-03-31 0000885725 us-gaap:CommonStockMember 2023-03-31 0000885725 2022-12-31 0000885725 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000885725 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000885725 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0000885725 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0000885725 us-gaap:CommonStockMember 2023-06-30 0000885725 2023-06-30 0000885725 us-gaap:CommonStockMember 2023-12-31 0000885725 us-gaap:CommonStockMember 2022-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2024-03-31 0000885725 us-gaap:TreasuryStockCommonMember 2023-03-31 0000885725 us-gaap:TreasuryStockCommonMember 2023-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2022-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0000885725 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000885725 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-06-30 0000885725 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0000885725 us-gaap:TreasuryStockCommonMember 2024-06-30 0000885725 us-gaap:TreasuryStockCommonMember 2023-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000885725 us-gaap:RetainedEarningsMember 2024-03-31 0000885725 us-gaap:RetainedEarningsMember 2023-03-31 0000885725 us-gaap:RetainedEarningsMember 2023-12-31 0000885725 us-gaap:RetainedEarningsMember 2022-12-31 0000885725 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000885725 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000885725 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0000885725 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0000885725 us-gaap:RetainedEarningsMember 2024-06-30 0000885725 us-gaap:RetainedEarningsMember 2023-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000885725 us-gaap:NoncontrollingInterestMember 2024-03-31 0000885725 us-gaap:NoncontrollingInterestMember 2023-03-31 0000885725 us-gaap:NoncontrollingInterestMember 2023-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2022-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0000885725 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0000885725 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-06-30 0000885725 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-06-30 0000885725 us-gaap:NoncontrollingInterestMember 2024-06-30 0000885725 us-gaap:NoncontrollingInterestMember 2023-06-30 0000885725 bsx:SilkMedicalMember 2024-06-18 0000885725 bsx:SilkMedicalMember 2024-06-18 2024-06-18 0000885725 bsx:AxonicsMember 2024-01-08 0000885725 bsx:AxonicsMember 2024-01-08 2024-01-08 0000885725 bsx:ApolloMember 2023-04-04 0000885725 bsx:ApolloMember 2023-04-04 2023-04-04 0000885725 bsx:AcotecMember 2023-02-20 0000885725 bsx:AcotecMember 2023-02-20 2023-02-20 0000885725 bsx:AcotecMember 2024-01-01 2024-06-30 0000885725 bsx:ApolloMember 2024-01-01 2024-06-30 0000885725 bsx:AcotecMember 2024-06-30 0000885725 bsx:ApolloMember 2024-06-30 0000885725 bsx:AcotecMember 2023-02-20 0000885725 bsx:AcotecMember us-gaap:TechnologyBasedIntangibleAssetsMember 2024-06-30 0000885725 bsx:AcotecMember us-gaap:TechnologyBasedIntangibleAssetsMember 2024-01-01 2024-06-30 0000885725 srt:WeightedAverageMember bsx:AcotecMember us-gaap:TechnologyBasedIntangibleAssetsMember 2024-06-30 0000885725 bsx:AcotecMember us-gaap:CustomerRelationshipsMember 2024-06-30 0000885725 bsx:AcotecMember us-gaap:CustomerRelationshipsMember 2024-01-01 2024-06-30 0000885725 srt:WeightedAverageMember bsx:AcotecMember us-gaap:CustomerRelationshipsMember 2024-06-30 0000885725 bsx:AcotecMember us-gaap:OtherIntangibleAssetsMember 2024-06-30 0000885725 bsx:AcotecMember us-gaap:OtherIntangibleAssetsMember 2024-01-01 2024-06-30 0000885725 srt:WeightedAverageMember bsx:AcotecMember us-gaap:OtherIntangibleAssetsMember 2024-06-30 0000885725 bsx:ApolloMember us-gaap:TechnologyBasedIntangibleAssetsMember 2024-06-30 0000885725 bsx:ApolloMember us-gaap:TechnologyBasedIntangibleAssetsMember 2024-01-01 2024-06-30 0000885725 srt:WeightedAverageMember bsx:ApolloMember us-gaap:TechnologyBasedIntangibleAssetsMember 2024-06-30 0000885725 bsx:ApolloMember us-gaap:CustomerRelationshipsMember 2024-06-30 0000885725 bsx:ApolloMember us-gaap:CustomerRelationshipsMember 2024-01-01 2024-06-30 0000885725 srt:WeightedAverageMember bsx:ApolloMember us-gaap:CustomerRelationshipsMember 2024-06-30 0000885725 bsx:AllBusinessAcquisitionsMember 2024-06-30 0000885725 bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-06-30 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-06-30 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-06-30 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-06-30 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-06-30 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000885725 us-gaap:PatentsMember 2024-06-30 0000885725 us-gaap:PatentsMember 2023-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2024-06-30 0000885725 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000885725 us-gaap:GoodwillMember 2024-06-30 0000885725 us-gaap:GoodwillMember 2023-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2024-06-30 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-06-30 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000885725 bsx:MedsurgMember 2023-12-31 0000885725 bsx:CardiovascularMember 2023-12-31 0000885725 bsx:MedsurgMember 2024-01-01 2024-06-30 0000885725 bsx:CardiovascularMember 2024-01-01 2024-06-30 0000885725 bsx:MedsurgMember 2024-06-30 0000885725 bsx:CardiovascularMember 2024-06-30 0000885725 bsx:December2027NotesMember 2023-12-31 0000885725 bsx:December2027NotesMember 2024-06-30 0000885725 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-01-01 2024-06-30 0000885725 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-06-30 0000885725 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-06-30 0000885725 srt:MinimumMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-06-30 0000885725 srt:MaximumMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2024-04-01 2024-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-04-01 2024-06-30 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-04-01 2024-06-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-04-01 2024-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-04-01 2023-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-04-01 2023-06-30 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-04-01 2023-06-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-04-01 2023-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2024-01-01 2024-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-01-01 2024-06-30 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-01-01 2024-06-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-01-01 2024-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-01-01 2023-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-06-30 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-06-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-06-30 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2024-04-01 2024-06-30 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-06-30 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 2023-06-30 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-06-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:InterestExpenseMember 2024-06-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2024-06-30 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-04-01 2024-06-30 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-04-01 2023-06-30 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-06-30 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-06-30 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-06-30 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-06-30 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2024-06-30 0000885725 bsx:LicensingarrangementassetsMember 2024-06-30 0000885725 srt:WeightedAverageMember bsx:LicensingarrangementassetsMember 2024-06-30 0000885725 srt:MinimumMember bsx:LicensingarrangementliabilitiesMember 2024-06-30 0000885725 srt:MaximumMember bsx:LicensingarrangementliabilitiesMember 2024-06-30 0000885725 srt:WeightedAverageMember bsx:LicensingarrangementliabilitiesMember 2024-06-30 0000885725 bsx:LicensingarrangementassetsMember 2024-01-01 2024-06-30 0000885725 bsx:LicensingarrangementliabilitiesMember 2024-01-01 2024-06-30 0000885725 bsx:March2025NotesMember 2024-06-30 0000885725 bsx:March2025NotesMember 2023-12-31 0000885725 bsx:June2025NotesMember 2024-06-30 0000885725 bsx:June2025NotesMember 2023-12-31 0000885725 bsx:March2026NotesMember 2024-06-30 0000885725 bsx:March2026NotesMember 2023-12-31 0000885725 bsx:March2028SeniorNotesMember 2024-06-30 0000885725 bsx:March2028SeniorNotesMember 2023-12-31 0000885725 bsx:March2028NotesMember 2024-06-30 0000885725 bsx:March2028NotesMember 2023-12-31 0000885725 bsx:March2029NotesMember 2024-06-30 0000885725 bsx:March2029NotesMember 2023-12-31 0000885725 bsx:March2029EuroSeniorNotesMember 2024-06-30 0000885725 bsx:March2029EuroSeniorNotesMember 2023-12-31 0000885725 bsx:June2030NotesMember 2024-06-30 0000885725 bsx:June2030NotesMember 2023-12-31 0000885725 bsx:March2031NotesMember 2024-06-30 0000885725 bsx:March2031NotesMember 2023-12-31 0000885725 bsx:March2032EuroSeniorNotesMember 2024-06-30 0000885725 bsx:March2032EuroSeniorNotesMember 2023-12-31 0000885725 bsx:March2034NotesMember 2024-06-30 0000885725 bsx:March2034NotesMember 2023-12-31 0000885725 bsx:November2035NotesMember 2024-06-30 0000885725 bsx:November2035NotesMember 2023-12-31 0000885725 bsx:March2039NotesMember 2024-06-30 0000885725 bsx:March2039NotesMember 2023-12-31 0000885725 bsx:January2040NotesMember 2024-06-30 0000885725 bsx:January2040NotesMember 2023-12-31 0000885725 bsx:March2049NotesMember 2024-06-30 0000885725 bsx:March2049NotesMember 2023-12-31 0000885725 us-gaap:SeniorNotesMember 2024-06-30 0000885725 us-gaap:SeniorNotesMember 2023-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2024-06-30 0000885725 us-gaap:CapitalLeaseObligationsMember 2023-12-31 0000885725 bsx:November2035NotesMember bsx:CreditRatingAOrA3OrHigherMember 2024-06-30 0000885725 us-gaap:RevolvingCreditFacilityMember 2021-05-10 0000885725 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0000885725 us-gaap:RevolvingCreditFacilityMember 2024-06-30 0000885725 bsx:CurrentRequirementMember 2024-06-30 0000885725 bsx:ActualCovenantMember 2024-06-30 0000885725 bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember 2024-06-30 0000885725 bsx:RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember 2024-06-30 0000885725 bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember 2024-06-30 0000885725 bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember 2024-06-30 0000885725 bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember 2024-06-30 0000885725 bsx:RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember 2024-06-30 0000885725 us-gaap:CommercialPaperMember 2024-06-30 0000885725 us-gaap:CommercialPaperMember 2023-12-31 0000885725 bsx:TheOfferingAggregatePrincipalAmountMember 2024-02-22 0000885725 bsx:March2029EuroSeniorNotesMember 2024-02-22 0000885725 bsx:March2032EuroSeniorNotesMember 2024-02-22 0000885725 bsx:March2024NotesMember 2024-06-30 0000885725 bsx:AMSEuropeMember 2024-01-01 2024-06-30 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2024-06-30 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2024-01-01 2024-06-30 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2023-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2024-01-01 2024-03-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2024-06-30 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2024-01-01 2024-06-30 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2023-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2024-01-01 2024-03-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2024-06-30 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2024-01-01 2024-06-30 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2023-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2024-01-01 2024-03-31 0000885725 2024-03-31 0000885725 2023-03-31 0000885725 2023-01-31 2023-01-31 0000885725 2024-06-05 0000885725 2024-05-22 0000885725 bsx:A550MCPSSeriesAMember 2020-05-27 0000885725 bsx:A550MCPSSeriesAMember 2020-05-27 2020-05-27 0000885725 bsx:A550MCPSSeriesAMember 2023-06-01 0000885725 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0000885725 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0000885725 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0000885725 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0000885725 bsx:A550MCPSSeriesAMember 2024-04-01 2024-06-30 0000885725 bsx:A550MCPSSeriesAMember 2023-04-01 2023-06-30 0000885725 bsx:A550MCPSSeriesAMember 2024-01-01 2024-06-30 0000885725 bsx:A550MCPSSeriesAMember 2023-01-01 2023-06-30 0000885725 2020-12-14 0000885725 bsx:MedsurgMember 2024-04-01 2024-06-30 0000885725 bsx:MedsurgMember 2023-04-01 2023-06-30 0000885725 bsx:MedsurgMember 2023-01-01 2023-06-30 0000885725 bsx:CardiovascularMember 2024-04-01 2024-06-30 0000885725 bsx:CardiovascularMember 2023-04-01 2023-06-30 0000885725 bsx:CardiovascularMember 2023-01-01 2023-06-30 0000885725 bsx:BSXReportableSegmentsMember 2024-04-01 2024-06-30 0000885725 bsx:BSXReportableSegmentsMember 2023-04-01 2023-06-30 0000885725 bsx:BSXReportableSegmentsMember 2024-01-01 2024-06-30 0000885725 bsx:BSXReportableSegmentsMember 2023-01-01 2023-06-30 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2024-04-01 2024-06-30 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2023-04-01 2023-06-30 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2024-01-01 2024-06-30 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2023-01-01 2023-06-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2024-04-01 2024-06-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2023-04-01 2023-06-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2024-01-01 2024-06-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2023-01-01 2023-06-30 0000885725 bsx:SpecialChargesMember 2024-04-01 2024-06-30 0000885725 bsx:SpecialChargesMember 2023-04-01 2023-06-30 0000885725 bsx:SpecialChargesMember 2024-01-01 2024-06-30 0000885725 bsx:SpecialChargesMember 2023-01-01 2023-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2024-04-01 2024-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2024-04-01 2024-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2024-04-01 2024-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2023-04-01 2023-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2023-04-01 2023-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2024-04-01 2024-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2024-04-01 2024-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2024-04-01 2024-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2023-04-01 2023-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2023-04-01 2023-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2024-04-01 2024-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2024-04-01 2024-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2024-04-01 2024-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2023-04-01 2023-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2023-04-01 2023-06-30 0000885725 country:US bsx:MedsurgMember 2024-04-01 2024-06-30 0000885725 us-gaap:NonUsMember bsx:MedsurgMember 2024-04-01 2024-06-30 0000885725 country:US bsx:MedsurgMember 2023-04-01 2023-06-30 0000885725 us-gaap:NonUsMember bsx:MedsurgMember 2023-04-01 2023-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember country:US 2024-04-01 2024-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2024-04-01 2024-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember 2024-04-01 2024-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember country:US 2023-04-01 2023-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember 2023-04-01 2023-06-30 0000885725 bsx:WatchmanMember country:US 2024-04-01 2024-06-30 0000885725 bsx:WatchmanMember us-gaap:NonUsMember 2024-04-01 2024-06-30 0000885725 bsx:WatchmanMember 2024-04-01 2024-06-30 0000885725 bsx:WatchmanMember country:US 2023-04-01 2023-06-30 0000885725 bsx:WatchmanMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0000885725 bsx:WatchmanMember 2023-04-01 2023-06-30 0000885725 bsx:CardiacRhythmManagementMember country:US 2024-04-01 2024-06-30 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2024-04-01 2024-06-30 0000885725 bsx:CardiacRhythmManagementMember 2024-04-01 2024-06-30 0000885725 bsx:CardiacRhythmManagementMember country:US 2023-04-01 2023-06-30 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0000885725 bsx:CardiacRhythmManagementMember 2023-04-01 2023-06-30 0000885725 bsx:ElectrophysiologyEPMember country:US 2024-04-01 2024-06-30 0000885725 bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2024-04-01 2024-06-30 0000885725 bsx:ElectrophysiologyEPMember 2024-04-01 2024-06-30 0000885725 bsx:ElectrophysiologyEPMember country:US 2023-04-01 2023-06-30 0000885725 bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0000885725 bsx:ElectrophysiologyEPMember 2023-04-01 2023-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember country:US 2024-04-01 2024-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2024-04-01 2024-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember 2024-04-01 2024-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember country:US 2023-04-01 2023-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember 2023-04-01 2023-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2024-04-01 2024-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2024-04-01 2024-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2024-04-01 2024-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2023-04-01 2023-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2023-04-01 2023-06-30 0000885725 country:US bsx:CardiovascularMember 2024-04-01 2024-06-30 0000885725 us-gaap:NonUsMember bsx:CardiovascularMember 2024-04-01 2024-06-30 0000885725 country:US bsx:CardiovascularMember 2023-04-01 2023-06-30 0000885725 us-gaap:NonUsMember bsx:CardiovascularMember 2023-04-01 2023-06-30 0000885725 country:US 2024-04-01 2024-06-30 0000885725 us-gaap:NonUsMember 2024-04-01 2024-06-30 0000885725 country:US 2023-04-01 2023-06-30 0000885725 us-gaap:NonUsMember 2023-04-01 2023-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2024-01-01 2024-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2024-01-01 2024-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2024-01-01 2024-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2023-01-01 2023-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2023-01-01 2023-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2024-01-01 2024-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2024-01-01 2024-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2024-01-01 2024-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2023-01-01 2023-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2023-01-01 2023-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2024-01-01 2024-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2024-01-01 2024-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2024-01-01 2024-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2023-01-01 2023-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2023-01-01 2023-06-30 0000885725 country:US bsx:MedsurgMember 2024-01-01 2024-06-30 0000885725 us-gaap:NonUsMember bsx:MedsurgMember 2024-01-01 2024-06-30 0000885725 country:US bsx:MedsurgMember 2023-01-01 2023-06-30 0000885725 us-gaap:NonUsMember bsx:MedsurgMember 2023-01-01 2023-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember country:US 2024-01-01 2024-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2024-01-01 2024-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember 2024-01-01 2024-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember country:US 2023-01-01 2023-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0000885725 bsx:InterventionalCardiologyTherapiesMember 2023-01-01 2023-06-30 0000885725 bsx:WatchmanMember country:US 2024-01-01 2024-06-30 0000885725 bsx:WatchmanMember us-gaap:NonUsMember 2024-01-01 2024-06-30 0000885725 bsx:WatchmanMember 2024-01-01 2024-06-30 0000885725 bsx:WatchmanMember country:US 2023-01-01 2023-06-30 0000885725 bsx:WatchmanMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0000885725 bsx:WatchmanMember 2023-01-01 2023-06-30 0000885725 bsx:CardiacRhythmManagementMember country:US 2024-01-01 2024-06-30 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2024-01-01 2024-06-30 0000885725 bsx:CardiacRhythmManagementMember 2024-01-01 2024-06-30 0000885725 bsx:CardiacRhythmManagementMember country:US 2023-01-01 2023-06-30 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0000885725 bsx:CardiacRhythmManagementMember 2023-01-01 2023-06-30 0000885725 bsx:ElectrophysiologyEPMember country:US 2024-01-01 2024-06-30 0000885725 bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2024-01-01 2024-06-30 0000885725 bsx:ElectrophysiologyEPMember 2024-01-01 2024-06-30 0000885725 bsx:ElectrophysiologyEPMember country:US 2023-01-01 2023-06-30 0000885725 bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0000885725 bsx:ElectrophysiologyEPMember 2023-01-01 2023-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember country:US 2024-01-01 2024-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2024-01-01 2024-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember 2024-01-01 2024-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember country:US 2023-01-01 2023-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0000885725 bsx:GlobalCardiologyReportingUnitMember 2023-01-01 2023-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2024-01-01 2024-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2024-01-01 2024-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2024-01-01 2024-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2023-01-01 2023-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2023-01-01 2023-06-30 0000885725 country:US bsx:CardiovascularMember 2024-01-01 2024-06-30 0000885725 us-gaap:NonUsMember bsx:CardiovascularMember 2024-01-01 2024-06-30 0000885725 country:US bsx:CardiovascularMember 2023-01-01 2023-06-30 0000885725 us-gaap:NonUsMember bsx:CardiovascularMember 2023-01-01 2023-06-30 0000885725 country:US 2024-01-01 2024-06-30 0000885725 us-gaap:NonUsMember 2024-01-01 2024-06-30 0000885725 country:US 2023-01-01 2023-06-30 0000885725 us-gaap:NonUsMember 2023-01-01 2023-06-30 0000885725 country:US bsx:BSXReportableSegmentsMember 2024-04-01 2024-06-30 0000885725 country:US bsx:BSXReportableSegmentsMember 2023-04-01 2023-06-30 0000885725 country:US bsx:BSXReportableSegmentsMember 2024-01-01 2024-06-30 0000885725 country:US bsx:BSXReportableSegmentsMember 2023-01-01 2023-06-30 0000885725 us-gaap:EMEAMember bsx:BSXReportableSegmentsMember 2024-04-01 2024-06-30 0000885725 us-gaap:EMEAMember bsx:BSXReportableSegmentsMember 2023-04-01 2023-06-30 0000885725 us-gaap:EMEAMember bsx:BSXReportableSegmentsMember 2024-01-01 2024-06-30 0000885725 us-gaap:EMEAMember bsx:BSXReportableSegmentsMember 2023-01-01 2023-06-30 0000885725 srt:AsiaPacificMember bsx:BSXReportableSegmentsMember 2024-04-01 2024-06-30 0000885725 srt:AsiaPacificMember bsx:BSXReportableSegmentsMember 2023-04-01 2023-06-30 0000885725 srt:AsiaPacificMember bsx:BSXReportableSegmentsMember 2024-01-01 2024-06-30 0000885725 srt:AsiaPacificMember bsx:BSXReportableSegmentsMember 2023-01-01 2023-06-30 0000885725 bsx:LatinAmericaandCanadaMember bsx:BSXReportableSegmentsMember 2024-04-01 2024-06-30 0000885725 bsx:LatinAmericaandCanadaMember bsx:BSXReportableSegmentsMember 2023-04-01 2023-06-30 0000885725 bsx:LatinAmericaandCanadaMember bsx:BSXReportableSegmentsMember 2024-01-01 2024-06-30 0000885725 bsx:LatinAmericaandCanadaMember bsx:BSXReportableSegmentsMember 2023-01-01 2023-06-30 0000885725 bsx:EmergingMarketsMember 2024-04-01 2024-06-30 0000885725 bsx:EmergingMarketsMember 2023-04-01 2023-06-30 0000885725 bsx:EmergingMarketsMember 2024-01-01 2024-06-30 0000885725 bsx:EmergingMarketsMember 2023-01-01 2023-06-30 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-31 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-03-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-04-01 2024-06-30 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-04-01 2024-06-30 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-06-30 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-06-30 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-03-31 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-03-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-01 2023-06-30 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-01 2023-06-30 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-06-30 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-06-30 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-06-30 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-06-30 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-06-30 0000885725 bsx:JosephM.FitzgeraldMember 2024-04-01 2024-06-30 0000885725 bsx:JosephM.FitzgeraldMember bsx:RuleTradingArrangementCommonStockMember 2024-06-30 0000885725 bsx:JosephM.FitzgeraldMember bsx:RuleTradingArrangementStockAppreciationRightMember 2024-06-30 0000885725 bsx:VanceRBrownMember 2024-04-01 2024-06-30 iso4217:USD shares shares iso4217:USD pure iso4217:HKD shares utr:Rate iso4217:EUR bsx:derivative_instrument bsx:reportablesegments bsx:business 0000885725 --12-31 2024 Q2 false P1Y P2Y P727D 10-Q true 2024-06-30 false 1-11083 BOSTON SCIENTIFIC CORPORATION DE 04-2695240 300 Boston Scientific Way Marlborough MA 01752-1234 508 683-4000 Common Stock, par value $0.01 per share BSX NYSE 0.625% Senior Notes due 2027 BSX27 NYSE Yes Yes Large Accelerated Filer false false false 0.01 1472626135 4120000000 3599000000 7977000000 6988000000 1270000000 1058000000 2479000000 2098000000 2850000000 2542000000 5498000000 4891000000 1446000000 1354000000 2810000000 2570000000 383000000 359000000 749000000 695000000 9000000 12000000 19000000 23000000 213000000 210000000 427000000 412000000 276000000 57000000 276000000 57000000 2000000 19000000 18000000 31000000 1000000 16000000 5000000 36000000 2330000000 2028000000 4303000000 3825000000 520000000 514000000 1195000000 1066000000 77000000 70000000 146000000 135000000 -23000000 -18000000 -21000000 -61000000 420000000 426000000 1028000000 870000000 98000000 156000000 213000000 287000000 322000000 270000000 815000000 584000000 0 9000000 0 23000000 -2000000 0 -4000000 0 324000000 261000000 819000000 561000000 0.22 0.18 0.56 0.39 0.22 0.18 0.55 0.39 1470600000 1446200000 1469500000 1441000000 1484200000 1456200000 1483000000 1451100000 322000000 270000000 815000000 584000000 45000000 15000000 102000000 -28000000 -16000000 15000000 6000000 -28000000 0 0 0 5000000 30000000 30000000 108000000 -61000000 352000000 300000000 924000000 523000000 -2000000 0 -4000000 0 -1000000 0 -6000000 0 -4000000 0 -10000000 0 356000000 300000000 933000000 523000000 2913000000 865000000 2400000000 2228000000 2608000000 2484000000 315000000 315000000 756000000 621000000 8991000000 6514000000 2951000000 2859000000 14397000000 14387000000 5417000000 6003000000 3801000000 3841000000 1551000000 1531000000 37108000000 35136000000 1580000000 531000000 906000000 942000000 2320000000 2646000000 770000000 814000000 5576000000 4933000000 8991000000 8571000000 132000000 134000000 1800000000 1967000000 0.01 0.01 50000000 50000000 0 0 0 0 0.01 0.01 2000000000 2000000000 1734329744 1729000224 17000000 17000000 263289848 263289848 2251000000 2251000000 20803000000 20647000000 1639000000 819000000 164000000 49000000 20371000000 19282000000 238000000 248000000 20609000000 19530000000 37108000000 35136000000 0 10062500 0 10062500 0 -10062500 0 -10062500 0 0 0 0 1733293885 1700828873 1729000224 1696633993 1035859 1144366 5329520 5339246 0 23982902 0 23982902 1734329744 1725956141 1734329744 1725956141 0 0 0 0 0 0 0 0 0 0 0 0 17000000 17000000 17000000 17000000 0 0 0 0 0 0 0 0 17000000 17000000 17000000 17000000 -2251000000 -2251000000 -2251000000 -2251000000 0 0 0 0 -2251000000 -2251000000 -2251000000 -2251000000 20713000000 20356000000 20647000000 20289000000 90000000 85000000 156000000 153000000 20803000000 20441000000 20803000000 20441000000 1314000000 -450000000 819000000 -750000000 322000000 270000000 815000000 584000000 2000000 0 4000000 0 0 9000000 0 23000000 1639000000 -189000000 1639000000 -189000000 132000000 178000000 49000000 269000000 31000000 30000000 114000000 -61000000 164000000 208000000 164000000 208000000 20371000000 18226000000 20371000000 18226000000 242000000 259000000 248000000 0 -2000000 0 -4000000 0 -1000000 0 -6000000 0 0 0 0 259000000 238000000 259000000 238000000 259000000 20609000000 18485000000 20609000000 18485000000 815000000 584000000 615000000 583000000 21000000 -45000000 129000000 115000000 276000000 57000000 -46000000 -35000000 18000000 31000000 0 3000000 8000000 23000000 228000000 161000000 219000000 399000000 126000000 55000000 -379000000 78000000 977000000 848000000 334000000 254000000 1000000 3000000 95000000 1018000000 139000000 73000000 -11000000 -16000000 0 -2000000 -556000000 -1324000000 34000000 39000000 15000000 34000000 25000000 0 504000000 0 0 37000000 2145000000 0 0 28000000 80000000 52000000 106000000 90000000 1593000000 -26000000 -8000000 -3000000 2006000000 -506000000 1055000000 1126000000 3062000000 620000000 129000000 115000000 -11000000 -16000000 2913000000 426000000 75000000 135000000 74000000 60000000 3062000000 620000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE A – BASIS OF PRESENTATION </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure within our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note H – Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure within our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note H – Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Silk Road Medical, Inc. (Silk Road Medical), a publicly traded medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is $27.50 in cash per share, or approximately $1.260 billion for 100% of the fully diluted equity. The transaction is expected to be completed in the second half of 2024, subject to customary closing conditions. The Silk Road Medical business will be integrated into our Peripheral Interventions division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $71.00 in cash per share, or approximately $3.670 billion for 100% of the fully diluted equity. On April 3, 2024, we and Axonics each received a request for additional information (Second Request) from the United States Federal Trade Commission (FTC) in connection with the FTC's review of the transaction. The issuance of the Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), until 30 days after both we and Axonics have substantially complied with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. We and Axonics are responding to the Second Request and continue to work cooperatively with the FTC in its review. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. The Axonics business will be integrated into our Urology division.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Acquisitions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2023, we completed our acquisition of 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The transaction consisted of an upfront cash payment of $636 million, net of cash acquired. The Apollo business is being integrated into our Endoscopy division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases. We consolidated this majority stake investment in Acotec based on the conclusion we control the entity, and recorded a noncontrolling interest for the portion we do not own. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We accounted for these transactions as business combinations in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(FASB ASC Topic 805). The final purchase prices were comprised of the amounts presented below: </span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acotec</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apollo</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Excludes approximately $140 million of cash on hand at the closing of the transaction</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Related to Acotec, represents our majority stake investment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded the assets acquired, liabilities assumed and specific to Acotec, the noncontrolling interest, at their respective fair values as of the closing date of the transaction. The final purchase price allocations were comprised of the components presented below, with the excess of the purchase price over the fair value of net assets acquired recorded to goodwill:</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acotec</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apollo</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Acotec's noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Stockholders' equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated balance sheets. Goodwill was primarily established for Acotec due to opportunities for collaboration in research and development, manufacturing and commercial strategies, and for Apollo, due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Acotec:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Apollo:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration liability during the first six months of 2024 associated with prior period acquisitions were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:84.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded related to current year acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments made during the first six months of 2024 primarily related to our acquisition of Farapulse, Inc. (Farapulse) following the achievement of revenue-based earnouts as a result of over-performance. The maximum amount we could be required to pay for certain contingent consideration is not determinable as it is uncapped and based on a percent of certain sales. As of June 30, 2024, the fair value of such uncapped contingent consideration is estimated at $163 million. As of June 30, 2024, the maximum amount that we could be required to pay under our other contingent consideration arrangements (undiscounted) is approximately $320 million. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:19.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.064%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June 30, 2024</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments and Milestones</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$293 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected contingent payment amounts related to our revenue-based payments and milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of June 30, 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Strategic Investments</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1, 2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes publicly-held securities and convertible notes measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies. </span></div>As of June 30, 2024, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $233 million, which represents amortizable intangible assets, in-process research and development (IPR&amp;D), goodwill and deferred tax liabilities. 1 27.50 1260000000 1 1 71.00 3670000000 1 1 636000000 0.65 20.00 519000000 <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acotec</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apollo</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Excludes approximately $140 million of cash on hand at the closing of the transaction</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Related to Acotec, represents our majority stake investment</span></div> 381000000 636000000 381000000 636000000 140000000 <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acotec</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apollo</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> 337000000 378000000 334000000 248000000 93000000 50000000 48000000 33000000 76000000 5000000 259000000 0 381000000 636000000 0.35 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Acotec:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Apollo:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 308000000 P11Y 0.14 15000000 P11Y 0.14 11000000 P13Y 0.14 334000000 222000000 P11Y 0.12 26000000 P11Y 0.12 248000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration liability during the first six months of 2024 associated with prior period acquisitions were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:84.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded related to current year acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 404000000 29000000 18000000 158000000 293000000 163000000 320000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:19.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.064%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June 30, 2024</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments and Milestones</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$293 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div> 293000000 0.06 0.15 0.07 0.90 1 0.99 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1, 2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes publicly-held securities and convertible notes measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div> 207000000 219000000 243000000 194000000 450000000 413000000 233000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization/ Write-offs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization/ Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,372)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,555)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,510</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,307)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,988)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following represents a roll-forward of our goodwill balance by reportable segment:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations and purchase price and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,057</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Asset Impairments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any goodwill impairment charges in the first six months of 2024 or 2023. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. We identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(FASB ASC Topic 350), we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components of our Cardiology operating segment into a single Rhythm Management reporting unit. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. For the reporting units tested using the qualitative approach, after assessing the totality of events, it was determined that it was not more likely than not that the fair value of the reporting units was less than their carrying value, and it was not deemed necessary to proceed to the quantitative test. For the reporting units tested using the quantitative approach, we determined that the fair value of the reporting units exceeded the carrying value and concluded that goodwill was not impaired or at risk of impairment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible asset impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $276 million in the second quarter and first six months of 2024 and $57 million in the second quarter and first six months of 2023. The impairment charges recorded in 2024 were associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively. Intangible assets acquired from Cryterion were impaired due to strong commercial adoption of our Farapulse™ Pulsed Field Ablation System and the resulting lower revenue projections and cannibalization of our cryoablation business in major markets like the U.S. Intangible assets acquired from Devoro were impaired following management's decision to cancel the related program in the second quarter of 2024. We calculated the fair value of our Cryterion and Devoro intangible assets as the present value of estimated future cash flows we expect to generate from the assets based on estimates and assumptions about future revenue contributions, cost structures and the remaining useful lives of the assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A – Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8. Financial Statements </span></div>and Supplementary Data of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization/ Write-offs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization/ Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,372)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,555)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,510</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,307)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,988)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 12846000000 8372000000 13207000000 8101000000 476000000 380000000 480000000 387000000 2188000000 1555000000 2130000000 1500000000 15510000000 10307000000 15817000000 9988000000 24297000000 9900000000 24287000000 9900000000 94000000 54000000 120000000 120000000 214000000 174000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following represents a roll-forward of our goodwill balance by reportable segment:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations and purchase price and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,057</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5347000000 9041000000 14387000000 24000000 46000000 46000000 71000000 -30000000 -30000000 -61000000 5341000000 9057000000 14397000000 276000000 57000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Currency Hedging Instruments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our currency risk management program depends, in part, on forecasted transactions denominated primarily in euro, Chinese renminbi, Japanese yen, British pound sterling, Australian dollar and Swiss franc. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Designations and Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(OCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (AOCI) to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities within our unaudited consolidated statements of cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Chinese renminbi and Japanese yen. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our unaudited consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the euro. As of June 30, 2024 and December 31, 2023, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CTA component of OCI. We reclassify these gains and losses to current period earnings within </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Hedging Instruments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Designations and Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as cash flow hedges outstanding as of June 30, 2024 or December 31, 2023. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as fair value hedges outstanding as of June 30, 2024 or December 31, 2023. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest-rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which generally offset.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.430%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,896</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining time to maturity as of June 30, 2024 is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between <span style="-sec-ix-hidden:f-614">one</span> and <span style="-sec-ix-hidden:f-615">two</span> years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 within our accompanying unaudited consolidated statements of operations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note M – Changes in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2024</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2024</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:28.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.663%"></td><td style="width:0.1%"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.117%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.911%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recurring Fair Value Measurements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">816</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,545</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies. In addition to $2.153 billion invested in money market funds and time deposits as of June 30, 2024 and $454 million as of December 31, 2023, we held $793 million in interest-bearing and non-interest-bearing bank accounts as of June 30, 2024 and $411 million as of December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of the changes in the fair value of our contingent consideration liability. In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We maintain a financial asset and associated liability for our licensing arrangements measured at fair value within our unaudited consolidated balance sheets in accordance with FASB ASC Topic 825, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D – Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized within our accompanying unaudited consolidated balance sheet as of June 30, 2024 include the following significant unobservable inputs:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:19.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June 30, 2024</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$51 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our strategic investments and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of the fair values of our intangible assets including goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our outstanding debt obligations, excluding finance leases, was $10.073 billion as of June 30, 2024 and $8.735 billion as of December 31, 2023. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E – Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our debt obligations.</span></div> 900000000 900000000 0.00625 P1Y 0 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.430%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,896</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.</span></div> 1969000000 2284000000 645000000 333000000 997000000 997000000 3284000000 3282000000 6895000000 6896000000 900000000 900000000 P36M P1Y <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2024</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2024</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.</span></div> 31000000 -7000000 24000000 1270000000 -52000000 12000000 -41000000 20000000 -5000000 16000000 77000000 -4000000 1000000 -3000000 9000000 -2000000 7000000 23000000 0 0 0 0 0 0 77000000 0 0 0 74000000 -17000000 58000000 1058000000 -55000000 12000000 -43000000 22000000 -5000000 17000000 70000000 -2000000 1000000 -2000000 1000000 0 1000000 18000000 0 0 0 0 0 0 70000000 1000000 0 1000000 108000000 -24000000 84000000 2479000000 -101000000 23000000 -79000000 48000000 -11000000 37000000 146000000 -8000000 2000000 -6000000 32000000 -7000000 25000000 21000000 0 0 0 0 0 0 146000000 1000000 0 1000000 87000000 -20000000 67000000 2098000000 -125000000 28000000 -97000000 28000000 -6000000 22000000 135000000 -5000000 1000000 -4000000 -18000000 4000000 -14000000 61000000 0 0 0 0 0 0 135000000 1000000 0 1000000 0 0 0 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:28.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.663%"></td><td style="width:0.1%"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 163000000 11000000 -1000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.117%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 30000000 11000000 45000000 2000000 -31000000 -20000000 -51000000 -26000000 -1000000 -9000000 -6000000 -24000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span> The following are the balances of our derivative and nonderivative assets and liabilities:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.911%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div> 236000000 140000000 46000000 107000000 282000000 246000000 31000000 20000000 313000000 266000000 3000000 15000000 0 9000000 957000000 988000000 960000000 1012000000 14000000 38000000 974000000 1050000000 900000000 900000000 <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">816</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">974</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,545</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized within our accompanying unaudited consolidated balance sheet as of June 30, 2024 include the following significant unobservable inputs:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:19.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June 30, 2024</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$51 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2153000000 0 0 2153000000 454000000 0 0 454000000 19000000 0 0 19000000 18000000 0 0 18000000 0 313000000 0 313000000 0 266000000 0 266000000 0 0 51000000 51000000 0 0 77000000 77000000 2173000000 313000000 51000000 2536000000 472000000 266000000 77000000 816000000 0 974000000 0 974000000 0 1050000000 0 1050000000 0 0 293000000 293000000 0 0 404000000 404000000 0 0 60000000 60000000 0 0 90000000 90000000 0 974000000 353000000 1327000000 0 1050000000 494000000 1545000000 2153000000 454000000 793000000 411000000 51000000 0.15 0.15 60000000 0.12 0.15 0.13 77000000 21000000 -5000000 51000000 90000000 26000000 -4000000 60000000 10073000000.000 8735000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings and Credit Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total debt outstanding of $10.571 billion as of June 30, 2024 and $9.102 billion as of December 31, 2023, with current obligations of $1.580 billion as of June 30, 2024 and $531 million as of December 31, 2023. The debt maturity schedule for our long-term debt obligations is presented below: </span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.847%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, <br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.900%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.750%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.650%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2032 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.500%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.500%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.375%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.700%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,991</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of June 30, 2024 and December 31, 2023, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2021, we entered into a $2.750 billion revolving credit facility (as amended, supplemented or otherwise modified from time to time, the 2021 Revolving Credit Facility) with a global syndicate of commercial banks. On May 10, 2024, we entered into a third amendment to the 2021 Revolving Credit Facility credit agreement, which provided for, among other things, an extension of the scheduled maturity date to May 10, 2029, an amendment of the Ratings based pricing grid of the Applicable Margin, each as defined in the credit agreement, and reset the applicable date for purposes of determining the amounts of restructuring charges and restructuring-related expenses that may be excluded from consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the credit agreement, for purposes of our maximum leverage ratio covenant, from December 31, 2022 to March 31, 2024, as further discussed under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Covenant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. We had no amounts outstanding under the 2021 Revolving Credit Facility as of June 30, 2024 or December 31, 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Covenant</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:32.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">as of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">as of June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75 times</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 times</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ratio of total debt to deemed consolidated EBITDA, as defined by the 2021 Revolving Credit Facility credit agreement, as amended.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The credit agreement provides for higher leverage ratios, at our election, for the period following a Qualified Acquisition, as defined by the agreement, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have elected to designate the Axonics acquisition as a Qualified Acquisition under the credit agreement, and upon closing, will increase the maximum permitted leverage ratio at that time. The agreement also provides for an exclusion of any debt incurred to fund a Qualified Acquisition, until the earlier of the acquisition close date or date of abandonment, termination or expiration of the acquisition agreement. As of June 30, 2024, we excluded from our leverage ratio calculation $2.120 billion of debt incurred in connection with the Axonics acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenant requirement, as amended on May 10, 2024, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions related to restructuring charges and restructuring-related expenses from December 31, 2022 to March 31, 2024. Permitted exclusions include up to $500 million in cash and non-cash restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of June 30, 2024, we had $453 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of June 30, 2024, we had $1.448 billion of the litigation exclusion remaining.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to maintain compliance with this covenant could require us to seek to renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable</span><span style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of June 30, 2024 or December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had senior notes outstanding of $10.633 billion as of June 30, 2024 and $9.136 billion as of December 31, 2023. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €2.000 billion in aggregate principal amount of euro-denominated senior notes comprised of €750 million of 3.375% Senior Notes due 2029 and €1.250 billion of 3.500% Senior Notes due 2032 (collectively, the 2024 Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the 2024 Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $2.145 billion, net of investor discounts and issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the net proceeds from the Offering of the 2024 Eurobonds to fund the repayment at maturity of our 3.450% Senior Notes due March 2024 and to pay accrued and unpaid interest with respect to such notes. Additionally, we plan to use the remaining net proceeds from the Offering to fund a portion of the purchase price of the Axonics acquisition and to pay related fees and expenses, and for general corporate purposes. The transaction is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. If (i) the Axonics acquisition is not consummated on or before the later of (x) January 8, 2025 (as such date may be extended in accordance with the merger agreement to no later than January 8, 2026) and (y) the date that is five business days after any later date to which we and Axonics may agree to extend the "Outside Date" in the merger agreement or (ii) AMS Europe notifies the trustee that we will not pursue consummation of the Axonics Acquisition, AMS Europe will be required to redeem each series of the notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of such series of notes, plus accrued and unpaid interest, if any, to, but excluding, the date on which the notes will be redeemed. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on the Axonics acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Arrangements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfers and Servicing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.912%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Renminbi denominated</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Obligations and Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had outstanding letters of credit of $189 million as of June 30, 2024 and $174 million as of December 31, 2023, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of June 30, 2024 and December 31, 2023 we had not recognized a related liability for our outstanding letters of credit within our accompanying unaudited consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a supplier financing program offered primarily in the U.S. that enables our suppliers to opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our unaudited consolidated balance sheets and were $131 million as of June 30, 2024 and $152 million as of December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E – Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.</span></div> 10571000000 9102000000 1580000000 531000000 The debt maturity schedule for our long-term debt obligations is presented below: <div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.847%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, <br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.900%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.750%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.650%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2032 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.500%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.500%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.375%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.700%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,991</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of June 30, 2024 and December 31, 2023, respectively.</span></div> 0 1105000000 0.00750 0 500000000 0.01900 255000000 255000000 0.03750 963000000 995000000 0.00625 802000000 829000000 0.01375 344000000 344000000 0.04000 272000000 272000000 0.04000 802000000 0 0.03375 1200000000 1200000000 0.02650 802000000 829000000 0.01625 1337000000 0 0.03500 535000000 553000000 0.01875 350000000 350000000 0.06500 450000000 450000000 0.04550 300000000 300000000 0.07375 650000000 650000000 0.04700 -77000000 -65000000 4000000 5000000 8991000000 8571000000 0.0625 2750000000 0 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:32.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">as of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">as of June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75 times</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 times</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ratio of total debt to deemed consolidated EBITDA, as defined by the 2021 Revolving Credit Facility credit agreement, as amended.</span></div> 3.75 1.97 3.75 1000000000.000 4.75 4.50 4.25 4.00 3.75 2120000000 500000000 453000000 1000000000.000 1448000000 0 0 10633000000 9136000000 2000000000.000 750000000 0.03375 1250000000 0.03500 2145000000 0.03450 1.01 Amounts de-recognized for accounts and notes receivable, which are excluded from <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):</span><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.912%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Renminbi denominated</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 187000000 0.053 206000000 0.051 187000000 0.008 214000000 0.006 26000000 0.017 14000000 0.029 189000000 174000000 131000000 152000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions within our accompanying unaudited consolidated balance sheets are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trade accounts receivable, net</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll forward of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">756</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">621</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, plant and equipment, net</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,859</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $98 million for the second quarter of 2024, $88 million for the second quarter of 2023, $188 million for the first six months of 2024 and $170 million for the first six months of 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued expenses</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;margin-top:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current liabilities</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">814</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term liabilities</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,967</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trade accounts receivable, net</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll forward of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2505000000 2338000000 105000000 110000000 2400000000 2228000000 109000000 118000000 110000000 109000000 12000000 19000000 21000000 35000000 16000000 10000000 26000000 16000000 105000000 127000000 105000000 127000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1558000000 1537000000 201000000 174000000 849000000 773000000 2608000000 2484000000 <div style="margin-bottom:1pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">756</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">621</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 75000000 130000000 267000000 159000000 38000000 47000000 376000000 285000000 756000000 621000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, plant and equipment, net</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,859</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 140000000 140000000 1876000000 1843000000 3598000000 3503000000 897000000 857000000 6512000000 6343000000 3561000000 3484000000 2951000000 2859000000 98000000 88000000 188000000 170000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 74000000 60000000 416000000 439000000 46000000 107000000 450000000 413000000 13000000 30000000 172000000 176000000 381000000 306000000 1551000000 1531000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued expenses</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 118000000 206000000 948000000 1051000000 412000000 389000000 175000000 304000000 667000000 696000000 2320000000 2646000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current liabilities</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">814</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 284000000 266000000 40000000 49000000 224000000 220000000 222000000 278000000 770000000 814000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term liabilities</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,967</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 356000000 470000000 133000000 172000000 118000000 100000000 20000000 41000000 365000000 390000000 316000000 311000000 491000000 484000000 1800000000 1967000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE G – INCOME TAXES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate from continuing operations is presented below:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.713%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reported tax rate is affected by recurring items such as the amount of our earnings subject to differing tax rates in foreign jurisdictions and the impact of certain receipts and charges that are taxed at rates that differ from our effective tax rate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary reasons for the difference between the statutory rate and our reported tax rate in the second quarter and first six months of 2024 relate to certain charges for acquisition expenses, as well as certain benefits for intangible asset impairment charges and integration costs, and discrete benefits primarily related to stock-based compensation. In the second quarter and first six months of 2023, the primary difference between the statutory tax rate and our reported tax rate relates to acquisition-related charges, as well as certain benefits for integration costs, and discrete tax items primarily related to unrecognized tax benefits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, we had $478 million of gross unrecognized tax benefits, of which a net $406 million, if recognized, would affect our effective tax rate. As of December 31, 2023, we had $467 million of gross unrecognized tax benefits, of which a net $395 million, if recognized, would affect our effective tax rate. The change in gross unrecognized tax benefit is primarily related to current year accruals for reserves and audits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that within the next 12 months, we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $9 million.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate from continuing operations is presented below:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.713%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.234 0.366 0.207 0.329 478000000 406000000 467000000 395000000 9000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE H – COMMITMENTS AND CONTINGENCIES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. For additional information, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I – Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our accompanying unaudited consolidated statements of operations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accrual for legal matters that are probable and estimable was $251 million as of June 30, 2024 and $377 million as of December 31, 2023 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund, which is included in restricted cash and restricted cash equivalents in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $75 million as of June 30, 2024 and $130 million as of December 31, 2023. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note F – Supplemental Balance Sheet Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information. We did not record any litigation-related net charges during the second quarter and first six months of 2024 or 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against the Company in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT filed a motion seeking prejudgment interest and enhanced damages. The Company filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial. On June 5, 2024, the Court granted the Company’s motion for judgment as a matter of law of no willful infringement, but otherwise denied the Company’s motions. The Court also denied UT’s motion for enhanced damages, awarded approximately $7.4 million in pre-judgment interest, and awarded post-judgment interest. On July 3, 2024, UT and the Company each filed a notice of appeal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims, which we continue to vigorously contest. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Investigations and Qui Tam Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission issued its decision on May 22, 2024, holding that BSB and a former employee should be held liable and setting a fine of $17 million. The Commission held that the three other current or former Company employees should be acquitted. BSB has filed a motion to clarify the proper calculation of the fine and, to the extent </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any fine is upheld, the Company intends to appeal the decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like many healthcare companies, the Company receives inquiries and has ongoing discussions with governmental agencies with respect to the Company’s operations, such as the Securities and Exchange Commission (SEC), the Department of Justice (DOJ) and foreign regulators, including its operations in Vietnam with respect to alleged Foreign Corrupt Practices Act (FCPA) violations the Company received in March 2022. The Company has received related subpoenas for documents from the DOJ and the SEC with respect to the Vietnam matter, and is cooperating with the government while investigating these allegations. From time to time, the Company also self-discloses potential concerns to regulators. In the course of Vietnam-related discussions with the DOJ and SEC, the Company has disclosed that it is investigating other potential concerns in Vietnam and other countries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company also receives U.S.-based subpoenas and DOJ Civil Investigative Demands (CID), including the following matters: in April 2023, the Company received a DOJ subpoena that seeks documents and information related to its ambulatory electrocardiography monitoring business; in December 2023, the Company received a DOJ CID related to the provision of peripheral intervention services through office-based labs. The Company is cooperating with the DOJ in these matters.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Union Asset Management Holding AG as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. On October 23, 2023, the Company reached an agreement in principle with the lead plaintiff to settle the case. The Court granted the motion for preliminary approval of the proposed settlement on December 27, 2023, and approved the settlement and dismissed the case on April 23, 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to Section 220 of the Delaware General Corporation Law, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On April 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa. On May 8, 2023, the Court stayed the case until the conclusion of the consolidated class action case. On October 18, 2023, Frank Tripson filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware against the Company, Michael F. Mahoney, Daniel J. Brennan, Joseph M. Fitzgerald, Shawn McCarthy, Kevin Ballinger, Ian Meredith, Susan Vissers Lisa, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P. MacMillan, David Roux, John E. Sununu, and Ellen M. Zane. On December 15, 2023, the Court stayed that case until March 31, 2024. On March 26, 2024, the Company reached an agreement in principle with all of the plaintiffs to resolve the matters.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span>within our accompanying unaudited consolidated statements of operations. 251000000 377000000 75000000 130000000 42000000 7400000 17000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE I – STOCKHOLDERS' EQUITY</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2023, (the Mandatory Conversion Date), all outstanding shares of MCPS automatically converted into shares of common stock. The conversion rate for each share of MCPS was 2.3834 shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note J – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for information on the pertinent rights and privileges of our outstanding common stock.</span></div> 50000000 10062500 0.0550 100 975000000 2.3834 24000000 <div style="margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding — basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,484.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,456.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,483.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,451.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note I – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and, prior to the Mandatory Conversion Date, our MCPS, from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the second quarter and first six months of 2023, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was reduced by cumulative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred stock dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as presented within our accompanying unaudited consolidated statements of operations, for purposes of calculating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Boston Scientific common stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued approximately one million shares of our common stock in the second quarter of 2024, approximately five million shares in the first six months of 2024, approximately 25 million shares in the second quarter of 2023 and approximately 29 million shares in the first six months of 2023. Shares were issued following the exercise of stock options, vesting of restricted stock units or purchases under our employee stock purchase plan and, specific to 2023, following the automatic conversion of the MCPS. We did not repurchase any shares of our common stock in the first six months of 2024 or 2023. On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of June 30, 2024, we had the full amount remaining available under the authorization.</span></div> <div style="margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding — basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,484.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,456.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,483.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,451.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1470600000 1446200000 1469500000 1441000000 13600000 10100000 13500000 10100000 1484200000 1456200000 1483000000 1451100000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note I – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div> 0 0 0 0 0 16000000 0 20000000 1000000 5000000 25000000 29000000 1000000000.000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE K – SEGMENT REPORTING </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aggregate our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note L – Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for net sales by reportable segment presented in accordance with GAAP.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,275</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,939 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,886</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,599</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,988</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,002</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">426</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">870</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income margin of reportable segments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 2 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,275</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,939 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,886</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,599</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,988</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,002</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">426</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">870</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income margin of reportable segments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 1480000000 1346000000 2882000000 2611000000 2632000000 2204000000 5058000000 4275000000 4112000000 3549000000 7939000000 6886000000 8000000 51000000 37000000 102000000 4120000000 3599000000 7977000000 6988000000 511000000 458000000 986000000 867000000 761000000 582000000 1414000000 1135000000 1272000000 1040000000 2400000000 2002000000 153000000 75000000 268000000 173000000 386000000 241000000 510000000 351000000 213000000 210000000 427000000 412000000 520000000 514000000 1195000000 1066000000 -100000000 -88000000 -167000000 -195000000 420000000 426000000 1028000000 870000000 0.346 0.340 0.342 0.332 0.289 0.264 0.280 0.266 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE L – REVENUE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">907</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">    Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,474</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,637</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,466</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,654</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,490</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">    Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,291</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,082</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,724</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note K - Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for information on our reportable segments.</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,466 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">592</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $599 million as of June 30, 2024 and $577 million as of December 31, 2023. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $59 million in the second quarter and $120 million in the first six months of 2024 that was included in the above contract liability balance as of December 31, 2023. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Variable Consideration</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on variable consideration, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A – Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K.</span> 5 The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">907</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">    Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,474</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,637</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,466</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,654</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,490</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">    Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,791</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,291</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,082</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,724</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note K - Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for information on our reportable segments.</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,466 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">592</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 415000000 261000000 676000000 384000000 246000000 631000000 363000000 162000000 525000000 340000000 146000000 485000000 214000000 68000000 282000000 183000000 61000000 244000000 992000000 491000000 1483000000 907000000 453000000 1360000000 201000000 464000000 665000000 189000000 440000000 629000000 342000000 36000000 379000000 286000000 30000000 317000000 352000000 224000000 576000000 356000000 209000000 566000000 271000000 157000000 428000000 85000000 108000000 193000000 1166000000 881000000 2047000000 917000000 787000000 1704000000 308000000 281000000 590000000 285000000 250000000 535000000 1474000000 1163000000 2637000000 1202000000 1037000000 2239000000 2466000000 1654000000 4120000000 2110000000 1490000000 3599000000 810000000 508000000 1318000000 735000000 472000000 1207000000 719000000 319000000 1038000000 666000000 289000000 954000000 405000000 134000000 539000000 356000000 123000000 478000000 1933000000 961000000 2895000000 1757000000 883000000 2640000000 396000000 921000000 1316000000 372000000 848000000 1220000000 653000000 70000000 723000000 552000000 55000000 607000000 706000000 446000000 1151000000 702000000 412000000 1114000000 429000000 300000000 729000000 170000000 199000000 370000000 2183000000 1736000000 3919000000 1796000000 1514000000 3310000000 608000000 555000000 1163000000 560000000 478000000 1039000000 2791000000 2291000000 5082000000 2356000000 1993000000 4349000000 4724000000 3252000000 7977000000 4113000000 2876000000 6988000000 2466000000 2110000000 4724000000 4113000000 822000000 723000000 1625000000 1435000000 670000000 626000000 1317000000 1174000000 162000000 140000000 311000000 267000000 4120000000 3599000000 7977000000 6988000000 6988000000 680000000 592000000 1328000000 1121000000 599000000 577000000 59000000 120000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to Boston Scientific common stockholders:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:46.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D – Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail on our net investment hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our cash flow hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to Boston Scientific common stockholders:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:46.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -34000000 175000000 -8000000 132000000 50000000 24000000 0 75000000 3000000 40000000 0 44000000 47000000 -16000000 0 31000000 13000000 159000000 -8000000 164000000 -43000000 225000000 -4000000 178000000 17000000 58000000 0 74000000 2000000 42000000 0 44000000 15000000 15000000 0 30000000 -28000000 241000000 -4000000 208000000 -96000000 154000000 -8000000 49000000 115000000 84000000 0 199000000 6000000 78000000 0 84000000 108000000 6000000 0 114000000 13000000 159000000 -8000000 164000000 -1000000 269000000 1000000 269000000 -24000000 67000000 -5000000 39000000 4000000 95000000 1000000 100000000 -28000000 -28000000 -5000000 -61000000 -28000000 241000000 -4000000 208000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE N – NEW ACCOUNTING PRONOUNCEMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first six months of 2024, we implemented the following standard on a prospective basis, which did not have a material impact on our unaudited consolidated financial statements:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-03</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Standards to be Implemented</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. As this accounting standard update impacts disclosures only, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. As this accounting standard update impacts disclosures only, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE N – NEW ACCOUNTING PRONOUNCEMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first six months of 2024, we implemented the following standard on a prospective basis, which did not have a material impact on our unaudited consolidated financial statements:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-03</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Standards to be Implemented</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. As this accounting standard update impacts disclosures only, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. As this accounting standard update impacts disclosures only, we do not expect the adoption to have a material impact on our unaudited consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.</span></div> false false false <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2024, Joseph M. Fitzgerald, our Executive Vice President and Group President, Cardiology, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Fitzgerald’s plan covers the sale of 553,370 shares of our common stock, including 492,532 shares to be acquired upon exercise of stock options. Transactions under Mr. Fitzgerald’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Fitzgerald’s plan will terminate on the earlier of May 20, 2026, or the date all shares subject to the plan have been sold.</span></div> May 23, 2024 Joseph M. Fitzgerald Executive Vice President and Group President true 553370 492532